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Malaria remains one of the most important infectious diseases causing significant burden 
worldwide, and an effective vaccine will be indispensable to fight this disease. However, 
in order to design and develop such a vaccine we need to improve our understanding of 
protective immunity. This thesis describes work that was carried out on a unique model 
for studying Plasmodium falciparum infections: the Controlled Human Malaria Infection 
(CHMI) model. In this model healthy volunteers are infected with malaria under controlled 
circumstances, providing for an effective methodology to investigate protection and immune 
responses. When CHMI is applied in conjunction with antimalarial prophylaxis, this becomes 
a highly efficient protocol to induce sterile protection: Chemoprophylaxis and Sporozoites 
(CPS) immunization. 
This general introduction provides a brief historical overview of the fight against 
malaria, the current strategies and challenges in malaria control, and the status of malaria 
vaccine development. The chapter concludes with a description of the aims and outline of 
this thesis.
An estimated 198 million cases and 584.000 deaths were caused by malaria in 2013, 
mainly amongst young children in sub-Saharan Africa (1). Malaria is caused by Plasmodium 
parasites, which are transmitted by mosquitoes. Six species of the Plasmodium parasite are 
known to cause malaria in humans: P. falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi, 
Figure 1 The Plasmodium falciparum life cycle. Vaccines are being developed against all 
life cycle stages of the malaria parasite: sporozoites, liver stages, asexual blood stages and 
sexual forms. Figure reprinted from reference (9) with permission from Nature Publishing 
Group.
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and P. cynomolgi (2, 3). Plasmodium parasites are transmitted to humans through the bites of 
infected female Anopheles mosquitoes. The injected sporozoites move to the liver where they 
invade hepatocytes, then mature and multiply. The liver stage of the Plasmodium life cycle is 
clinically silent. P. vivax and P. ovale can form dormant liver forms called hypnozoites, which 
can reactivate after several months or even years (4). Once the infected hepatocytes burst 
open, merosomes containing merozoites are released into the blood stream and symptoms 
may occur.  If not treated promptly and adequately, P. falciparum and to a lesser extent P. vivax 
infections may result in severe anemia, cerebral malaria, acute respiratory distress syndrome, 
organ failure, or death. Some blood-stage parasites develop into gametocytes, which cause 
infection of a mosquito when it takes a blood meal from the human host. Subsequently, 
sporozoites develop in the salivary glands of the infected mosquito, completing the life cycle 
of the Plasmodium parasite (Figure 1). While 40% of the world’s population is at risk from 
P. vivax and 21-27% of severe malaria cases in Southeast-Asia and India are caused by it 
(5-8), P. falciparum remains responsible for the vast majority of the morbidity and mortality 
worldwide and is therefore the focus of this thesis.
The battle against malaria: a historical perspective1
In 1955, the WHO launched the ‘Global malaria eradication program’, a campaign based 
on the use of dichloride-diphenyl-trichlorethane (DDT) to combat malaria mosquitoes, and 
the drug chloroquine for treatment and prevention of infections in humans. With this dual 
strategy, malaria was successfully eradicated in Europe and in large areas of subtropical 
Asia and Latin America (10). In the Netherlands the last case of endemic malaria occurred 
in 1959, after which the WHO in 1970 officially declared the country ‘malaria free’ (11). 
In Sub-Saharan Africa, this campaign was only implemented in Ethiopia, South Africa 
and Zimbabwe. It was not expected that the campaign would yield results in other areas 
because of high entomological inoculation rates and poor infrastructures (12). In 1969, global 
malaria-eradication was concluded to be unrealistic: the campaign was halted, and treatment 
of individual cases became the new focus (13). 
In the following years, the global situation rapidly deteriorated. The number of malaria-
related hospital admissions in Africa increased two to three-fold in the 1980s, and infection 
with P. falciparum was the cause of mortality in 30% of the children in sub-Saharan Africa at 
that time (14). An important cause for the worsening of the situation was the emergence and 
1 Parts of this introduction were previously published in 1) Bijker EM, Sauerwein RW. Malariavac-
cins: de huidige stand van zaken. [Malariavaccines: an update. In Dutch]. Tijdschrift voor infectieziek-
ten, 2014; 2) Bijker EM, Sauerwein RW. Plasmodium falciparum whole-parasite malaria vaccines. In: 
Malaria Vaccine Development: Over 40 Years of Trials and Tribulations. Corradin G, Engers H (Eds). 
Future Science Group, London, UK, 149–162 (2014) and 3) Bastiaens GJ, Bijker EM, Sauerwein RW. 
On the way to eradicating malaria. Ned Tijdschr Geneeskd 2012; 156:A4095.
10
Chapter 1
spread of chloroquine-resistant parasites and DDT-resistant mosquitoes. In addition, political 
instability in the areas where malaria was endemic (15), the emerging HIV-epidemic (16, 17) 
and possibly climate change (18) resulted in a crisis in the control of malaria by the end of 
the 1990s (19).
By the beginning of the new millennium, political interest and willingness to combat 
malaria were again renewed, probably strengthened by an increased understanding of its 
significant socio-economic effects (20). This resulted in an international funding impulse: 
funds available for malaria control increased to 2.7 billion dollars in 2013 (1). Although 
still significantly less than the estimated 5.1 billion dollars considered to be annually needed 
for adequate control (1), this was an important step forward. Implementation of WHO-
recommended control measures over the past 10-15 years resulted in a decrease of malaria 
morbidity and mortality: the number of clinical malaria cases decreased from 226 million in 
2000 to 198 million in 2013 and the number of deaths decreased from 881.000 to 584.000 
(1). However, it is evident that malaria remains a major burden in the poorest countries of the 
world, keeping millions of people in vicious cycles of disease, reduced productivity, income 
loss and poverty (20). 
Current cornerstones and future challenges of malaria control
Adequate diagnosis and prompt treatment with effective drugs is the first cornerstone of 
malaria control and elimination. However, treatment of fever episodes with antimalarials 
without confirming the diagnosis often occurs, and this can accelerate the emergence of drug-
resistant parasites (19). Hence adequate diagnostic tools are crucial. Microscopy is the gold 
standard, but implementation can be problematic, especially in rural clinics, because it requires 
well-trained staff, good quality microscopes and reagents and, usually, a power-source for 
the microscope. Alternatively, there are a number of user-friendly, sufficiently sensitive and 
specific rapid diagnostic tests (RDTs) available, which are based on the detection of either P. 
falciparum or P. vivax specific or pan-malaria antigens (21). Quantification of parasitemia is 
however not possible with RDTs, and the vulnerability of the tests to high temperatures and 
humidity is a concern. 
Artemisinin-combination therapy is the first-line treatment of choice for uncomplicated 
P. falciparum malaria, and intravenous or intramuscular artesunate is the recommended 
therapy for severe malaria (22). Yet, an important problem is the progressive development 
of Plasmodium-resistance against existent drugs. Its urgency is emphasized by reports 
demonstrating clinical artemisinin-resistance in Southeast Asia (23, 24). Resistance to both 
chloroquine and sulfadoxine–pyrimethamine has emerged in this area and subsequently 
spread to Africa (25). Continuous investment in drug discovery and development will be 
crucial to increase the portfolio of effective and affordable drugs and overcome this threat. 
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The second cornerstone of malaria control is targeting the vector, i.e. the mosquito, 
by indoor insecticide spraying and the use of insecticide-treated mosquito nets (ITNs). 
Per 1000 children, approximately 5.5 lives can be saved annually if ITNs are adequately 
used (26). Approximately half of the population at risk had access to an ITN in 2013 and 
90% of them slept under it, indicating that the efforts to encourage ITN use have been 
effective and continuous supply of new nets is needed (1). Indoor spraying of walls with 
DDT is an adequate way to kill Anopheles mosquitoes and an effective intervention that 
significantly reduces malaria incidence, partially because of the longevity (6-12 months) of 
the effect after spraying (27). Other insecticides work for a significantly shorter period, 2 
to 6 months, requiring these compounds to be sprayed more than twice every year. Until an 
alternative with similar efficacy and cost-effectiveness becomes available, the WHO accepts 
DDT despite its negative environmental effects (27). However, the emerging resistance of 
Anopheles mosquitoes poses a serious threat to the effectiveness of both ITNs and insecticide 
spraying (28). Furthermore, there is increasing evidence of the change in feeding behavior 
of Anopheles mosquitoes from mainly indoors to mainly outdoors (29), which would render 
these interventions fruitless. 
A number of novel methods are being evaluated to handle the changes in Anopheles 
behavior and the development of insecticide resistance: (a) application of fungi that are 
pathogenic for mosquitoes but harmless for humans (30); (b) microbial larvicides combined 
with existing interventions such as ITNs (31); (c) odor traps containing synthetically 
fabricated odors that attract female Anopheles mosquitoes (32). In addition, research 
efforts are being directed towards the generation of genetically modified mosquitoes that 
cannot transmit Plasmodium parasites (33). Although conceptually attractive, this remains 
a complex approach with considerable risks inherent to the introduction of a genetically 
modified organism into the environment, which need careful evaluation. 
The third cornerstone of malaria control that is currently pursued is intermittent 
preventive treatment. Approximately 28% of pregnant women in sub-Saharan Africa are 
infected with P. falciparum. They are at a high risk of developing severe complications such 
as maternal anemia and low birth weight of the baby (34). When all pregnant women in an 
endemic area were preventively treated with sulfadoxine–pyrimethamine during the 2nd and 
3rd trimester, the risk of infections and complications was reduced significantly (35). In infants, 
preventive treatment with long-acting antimalarials such as sulfadoxine–pyrimethamine 
resulted in a reduced incidence of malaria episodes (36). Resistance against sulfadoxine–
pyrimethamine is however widespread (37), which implies that these drugs should not be 
used for this purpose any longer. Artemisinin-combination drugs might be good and safe 
alternatives, but the search for other drugs and drug-combinations remains a priority.
Bearing these three cornerstones in mind, effective malaria control and elimination 
require a tailor-made approach for each endemic area by using specific interventions that take 
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local transmission characteristics into account. The efficiency of Plasmodium transmission 
between humans and mosquitoes varies per area and is dependent, amongst other things, 
on population density, climate and geographic factors (38), making malaria transmission a 
highly dynamic process (39). 
A crucial element of any elimination strategy will be a vaccine, since current 
interventions appear insufficient to eliminate malaria. 
Vaccine strategies 
Vaccination is one of the most cost-effective interventions in public health: it resulted in the 
eradication of smallpox and substantial reduction in morbidity and mortality by several other 
infectious diseases (40, 41). For malaria, however, no vaccine is licensed yet, although a 
partially effective first-generation vaccine is expected to become available in the near future 
(42). Design and development of an effective malaria vaccine are hampered by the complexity 
of the parasite lifecycle, the high degree of antigenic variation and polymorphism, the lack of 
correlates of protection and poor understanding of mechanisms of protective immunity and 
host-parasite interactions. This underlines the need for models to study and explain protection 
against malaria and then to improve rational vaccine design and development. 
Malaria vaccines are categorized by the different stages of the parasite life cycle that 
are targeted (43):
1. Pre-erythrocytic stage vaccines are directed against sporozoites that are injected by 
mosquitoes and/or against the subsequent liver stages 
2. Blood-stage vaccines are directed against the asexual blood stages that cause the 
symptoms and complications of malaria. 
3. Transmission blocking vaccines target sexual and/or sporogonic stages that cause 
transmission of the parasite from the human host to the mosquito.
Vaccines may be composed of attenuated whole organisms or subunits based on single 
antigens or combinations of antigens. After the discovery of smallpox inoculation by Jenner 
in 1796, the concept of whole organism immunization was adopted for clinical vaccine 
development against a number of viral and bacterial pathogens, including measles virus, 
mumps virus, yellow fever virus, poliovirus, varicella-zoster virus, rotavirus, rubella virus, 
adenovirus, Mycobacterium tuberculosis, Salmonella typhi and Vibrio cholera. Presently, 
the majority of effective and licensed vaccines is based on live-attenuated or killed whole 
organisms. 
The emerging technical feasibility to generate recombinant malaria proteins in 1983 
(44, 45) raised expectations for the rapid development of subunit vaccines. Advantages of 
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such vaccines are the relatively easy production, up-scaling, storage and transportation, 
consistency of the end product and detailed knowledge and characterization of the immune 
epitope. Disadvantages, however, include (i) poor immunogenicity of individual antigens, ii) 
antigenic diversity of target proteins and (iii) insufficient breadth and coverage of the induced 
immune response based on a single or limited number of antigens. Induction of a strong and 
long-lasting immune response against soluble protein is dependent on an adjuvant. For use 
in humans only alum, Adjuvant System (AS) from GlaxoSmithKline Biologicals (GSK) and 
MF59 (Novartis) are available. Expression of the antigen by viral vectors is an alternative 
approach to induce strong, mainly cellular, immune responses.
Attenuated live whole organism vaccination has several advantages over subunit 
vaccination. These include natural invasion of the host and expression of (almost) all antigens 
and pathogen-associated molecular patterns to stimulate the innate and adaptive immune 
system (46). Critical for successful whole organism vaccination is the separation of virulence 
from the induction of protective immunity, i.e. sufficient attenuation of the pathogen to not 
cause illness while still inducing protective immune responses. 
Testing vaccines: Controlled Human Malaria Infection trials
Vaccine candidates that show promising results in pre-clinical testing can progress in the 
developmental pipeline. Before testing these products in malaria-endemic areas, the CHMI 
model offers a unique possibility to efficiently test efficacy in a small group of healthy malaria-
naïve volunteers. These volunteers are exposed to infectious P. falciparum sporozoites by 
the bites of Anopheles mosquitoes or to an inoculum of blood-stage parasites. This enables 
investigators not only to assess a vaccine’s efficacy at early stages of clinical testing but also 
to study immune responses and identify immune correlates of protection (47). 
Already in 1917 Julius Wagner-Jauregg performed deliberate infections of humans 
with Plasmodium parasites for the treatment of neurosyphilis (48). To induce malaria, he 
drew blood from a patient with parasites, injected this blood under the skin of the back 
of a paretic patient and rubbed some drops upon scarifications that he made on the upper 
arm (48). The patients benefited from the induced fever, Wagner-Jauregg received the Nobel 
Prize for his invention in 1927 and this ‘malaria treatment’ was used for neurosyphilis 
until antibiotics were discovered (49, 50). Since the 1960s, experimental human malaria 
infections are again performed, but now mainly in order to assess novel vaccines and drugs. 
In a number of immunization studies performed by the University of Maryland in the 1970’s 
volunteers were immunized and challenged by bites from infected mosquitoes (51-53). These 
mosquitoes had fed on volunteers who served as ‘gametocyte donors’: after inoculation with 
the malaria parasite, they received small doses of quinine to avoid complications and induce 
sexual parasite stages. This method of generating gametocytes and infected mosquitoes 
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was complex and unpredictable, resulting in irregular availability of infected mosquitoes 
for immunizations (52). After it became possible to culture P. falciparum in vitro in 1986, 
mosquitoes could be infected by feeding on gametocyte-containing blood through so-called 
membrane feeders (54-56). This significantly increased the feasibility and reproducibility of 
experimental infections. 
In addition to the application of CHMI as a testing platform for new vaccines and 
therapies, this model can also be used to study clinical responses to a first or second malaria 
infection (57-59), and to investigate more fundamental questions. These questions can 
comprise immunological issues, such as complement activation (60), systemic cytokine 
responses (61) and the association of immune responses with parasite growth (62), but 
also pathophysiological topics including iron homeostasis (63), thrombocytopenia and 
endothelial cell activation (64). Moreover, parasitological questions concerning transcription 
of P. falciparum variant surface antigens (65) and gametocyte commitment and maturation 
(66) can be addressed by using CHMI. 
In the Netherlands, CHMI studies have been performed at the Radboud university 
medical center with more than 300 subjects since 1998. Extensive expertise has been built 
on all aspects of these trials. The first CHMI studies were used to optimize the model, i.e. 
the number of infected bites (58), the clinical follow-up protocol, thick smear diagnostics 
(67) and polymerase chain reaction for quantification of parasitemia (68). Consequently, 
bites from 5 mosquitoes infected with the NF54 strain of P. falciparum was established as 
consistently inducing 100% infection in malaria-naïve volunteers (69). In the following years, 
newly isolated P. falciparum strains were investigated for CHMI, establishing NF135.C10 
as a heterologous strain that can be used to investigate protection after immunization with 
NF54 (70). The variety of opportunities offered by the CHMI model is exploited in this thesis 
in order to improve our understanding of protection against malaria. These include i) the 
availability of both sporozoite and blood-stage challenge, ii) the availability of heterologous 
strains, iii) the possibility to vary the number of infected bites, iv) the possibility to investigate 
immune responses in exposed subjects, and v) the opportunity to follow these subjects during 
their illness and recovery. 
Pre-erythrocytic vaccine strategies
Pre-erythrocytic stage vaccines are directed against sporozoites and/or against the subsequent 
liver stages. Theoretically, an effective pre-erythrocytic vaccine has the potential to prevent 
both clinical disease and transmission. The parasite load in this stage is relatively low, i.e. 
tens to hundreds of parasites, in contrast to the parasite load in the asexual blood stage, which 
can be several million parasites. This makes the pre-erythrocytic stage an attractive target in 
the life cycle and these vaccines have shown the most promising results in both experimental 
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and field settings until today. Pre-erythrocytic vaccines based on whole sporozoites have 
shown superior efficacy in experimental settings and are the focus of this thesis.
Pre-erythrocytic subunit vaccine approaches
Remarkable few of the more than 2000 antigens that are expressed in the pre-erythrocytic 
stage have been investigated as subunit vaccines. Most research has been performed on 
the circumsporozoite protein (CSP), which is dominantly expressed on the surface of the 
sporozoite and crucial for binding to hepatocytes (71, 72). Antibodies against CSP reduce 
sporozoite mobility and prevent traversal and invasion of hepatocytes (73). Moreover, 
CSP is expressed in infected hepatocytes, and can thereby serve as a target for cytotoxic T 
cells (74). The candidate vaccine that is tested most extensively, and the only vaccine that 
has progressed to a phase-III trial is RTS,S, which consists of recombinant P. falciparum 
CSP fused with hepatitis B surface antigen formulated in the AS01 adjuvant from GSK. 
RTS,S induces both CD4 T cells and antibodies and protects 50% of vaccinated subjects 
from developing blood-stage infection after CHMI (75). Protection in phase-II studies 
is consistently approximately 50% and a large phase-III trial was started in May 2009 in 
11 research centers in seven African countries (76). The inclusion of 15,460 infants was 
completed in January 2011, and preliminary results from the first 12 months of follow-up 
show 26-50% protection against developing clinical disease (77, 78). Analysis of pooled data 
from phase II studies indicates that vaccine efficacy wanes quickly to zero after 3 years (76). 
Moreover, efficacy appears to be inversely related to transmission-intensity, with almost no 
efficacy in areas with high transmission (76). In summary, RTS,S does not yet fulfill the goal 
set in the Malaria Vaccine Technology Roadmap to license a first-generation vaccine with at 
least 50% protective efficacy during at least 3 years in 2015 (79). But the immense efforts 
that were put in this phase-III trial are monumental in malaria vaccine development. Since 
the studies have shown that vaccination can induce a certain degree of protection in endemic 
countries, this is an important milestone that will enable future vaccine studies in endemic 
areas (80). In 2015 all analyses from the RTS,S phase-III trial will be completed, and policy 
will be developed on possible implementation. Amongst other things, cost-effectiveness will 
be an important issue in this decision process.
In addition to soluble Plasmodium protein-adjuvant combinations, viral vectors are 
currently investigated as antigen delivery platform. Antigens presented by a viral vector are 
expressed in host cells, often leading to a strong T cell response. Such a T cell response 
will presumably be important against the intracellular liver stages. Multiple studies indeed 
show a strong specific T cell response after heterologous prime-boost immunizations, in 
which different viral vectors are combined with each other, with DNA or with recombinant 
protein vaccines (81, 82). When human adenovirus strains are used as vectors, the vaccine 
is neutralized by pre-existing antibodies, and loses its immunogenicity (83). Therefore, a 
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chimpanzee adenovirus (ChAd63) has been developed, in which thrombospondin related 
adhesion protein (TRAP) was incorporated next to other multiple epitopes (ME). Vaccination 
of healthy volunteers with this ChAd63 ME-TRAP vaccine followed by a modified vaccinia 
virus Ankara (MVA) boost with the same antigen, resulted in 21% protection against CHMI, 
correlating with a CD8 T cell response (84). Clinical trials with this vaccine in Africa are 
currently ongoing.
Whole sporozoite approaches 
Several regimes of attenuated sporozoite immunization have been tested in humans and 
animals under controlled clinical or laboratory conditions and repeatedly proven to induce 
(almost) complete protection. In order to attenuate sporozoites for immunization purposes, 
several approaches have been applied, including attenuation by radiation, genetic modification 
and concomitant administration of antimalarial drugs. 
RADIATION ATTENUATED SPOROZOITES (RAS)
In 1941 it was shown for the first time that immunity against the pre-erythrocytic stages of 
Plasmodium can be induced; repeated infection with UV radiation-attenuated P. gallinaceum 
sporozoites induced partial protective immunity (i.e. reduced mortality) to sporozoite 
challenge in chickens (85). Radiation of Plasmodium-infected mosquitoes induces DNA 
damage in sporozoites to such a degree that they are able to invade the host hepatocytes, 
but fail to mature and multiply, thereby preventing the onset of blood-stage parasitemia. 
In contrast, dead sporozoites did not induce protection, demonstrating the critical balance 
between radiation dose for sufficient attenuation and persistence of sporozoite infectivity. 
Efficacy of this protocol using gamma-irradiation of sporozoites was subsequently confirmed 
in a number of animal models including rodents (86) and non-human primates (87, 88). 
Administration of radiation attenuated live sporozoites became the proof of concept of 
immunization against malaria.
In humans, sterile protection after administration of irradiated P. falciparum sporozoites 
by mosquito bites was first demonstrated in a small number of volunteers at the University 
of Maryland, the US Navy and the Stateville Correctional Center, Joliet, IL, USA in the 
1970s (89, 90) and subsequently in studies carried out by the Biomedical Research Institute/
Naval Medical Research Center and the Walter Reed Army Institute for Research. Systematic 
analysis of studies performed in the period between 1970-1990 showed that protection 
against a homologous challenge infection could be induced in 93% of volunteers by bites 
of >1,000 P. falciparum-infected and irradiated mosquitoes (i.e. in 33 of 35 challenges in 14 
volunteers) (91). Usage of <1,000 infected mosquitoes resulted in only 40% protection. In 
a small number of volunteers (i.e. 6), longevity of protection was shown for up to 42 weeks 
after immunization (91). 
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RAS-induced protection appears to be cross-strain but species-specific as tested in only 
4 subjects; while P. falciparum RAS immunization protected against a heterologous strain, 2 
subjects challenged with P. vivax were not protected (91). While antibody responses seem to 
contribute to RAS-induced protection (92, 93), rodent and non-human primate studies have 
shown the requirement of CD8 T cell responses for recognition and clearance of infected 
hepatocytes (Figure 1) (94). In humans, the exact immune mechanism of protection against 
malaria induced by whole parasite immunization remains to be elucidated, but most likely a 
combination of several effectors is required, including CD4 T cells (95) and CD8 T cells (96) 
in addition to humoral immunity.
GENETICALLY ATTENUATED PARASITES (GAP) 
Sporozoites can be genetically attenuated using reverse-genetic methods. When one or 
more liver-stage specific genes are deleted, the parasite is programmed to die at a specific 
point during liver-stage development. A Genetically Attenuated Parasite (GAP) preparation 
consists of a uniform, homogenous population of parasites with a characterized attenuation 
phenotype, which is an advantage over RAS. While in theory a risk of GAP vaccination could 
be a reversal of the knockout parasite to wild type and thereby breakthrough blood-stage 
infection, this is virtually impossible since P. falciparum is a haploid organism in the pre-
erythrocytic and blood stages, excluding the occurrence of recombination in the human host. 
A number of different GAPs arrested at the liver stage have been developed in rodent 
malaria models, including parasites that lack genes which are crucial for the parasitophorous 
vacuole, genes involved in fatty acid synthesis and a gene involved in (post-) transcriptional 
regulation of early pre-erythrocytic genes (97, 98). Immunization of mice with these GAPs 
showed arrest at different stages of development in the liver. A comprehensive analysis of 
attenuation approaches for sporozoite immunization in rodent models showed a relationship 
between the degree of liver-stage development and protection; in order to reach similar levels 
of protection, immunization approaches with late liver-stage arresting parasites required 
lower doses than early and mid liver-stage arrest (Figure 2) (99). In these rodent models, 
occurrence of blood-stage parasitemia during immunization appeared to have a negative 
effect on the induction of immunity, stressing the need for a balanced and targeted arrest of 
the parasite (99). 
In human volunteers, only one GAP candidate vaccine, that lacks both p52 and p36, 
genes essential for the formation of the parasitophorous vacuole, has been tested in a Phase 
I trial, showing a breakthrough infection in one out of six volunteers (100). This emphasizes 
the need for thorough preclinical evaluation of any GAP candidate, including (i) evaluation 
in both P. yoelii and P. berghei for breakthrough and protective efficacy in different murine 
strains including outbred mice; and (ii) in vitro evaluation of liver-stage development of the 
P. falciparum equivalent GAP in human hepatocytes (98). Probably, removal of multiple 
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genes required for independent cellular processes essential to liver-stage development will 
be needed to ensure complete liver-stage arrest. 
CHEMOPROPHYLAXIS AND SPOROZOITES (CPS)
An alternative strategy to induce sterile protection in humans is the use of an immunization 
protocol combining chemoprophylaxis and live wild-type sporozoites (CPS). In a proof of 
concept study published in 2009, ten subjects received a standard prophylactic regimen of 
chloroquine for three months, during which period they were exposed to 12-15 P. falciparum 
infected mosquito bites three times, at monthly intervals. When subsequently exposed to a 
Figure 2 Developmental arrest of parasites in different whole sporozoite immunization 
methods. Radiation Attenuated Sporozoites (RAS) arrest early in the liver stage, before the 
establishment of a parasitophorous vacuole (PV). In genetically attenuated parasites (GAP) 
one or more specific genes are removed, resulting in arrest of the parasite at the point 
where this gene becomes essential, which can be anywhere in the liver stage, depending on 
the selected gene (98). In ChemoProphylaxis and Sporozoites (CPS) immunization, wild 
type sporozoites are administered. The moment of arrest therefore depends on the selected 
prophylactic drug. Azithromycin, for example, targets the apicoplast: not affecting liver-
stage load, but preventing blood-stage parasitemia to occur (101). Chloroquine does not 
affect sporozoites, nor liver stages: the parasite fully develops in the liver and only arrests 
in the first blood-stage cycle, where chloroquine kills the trophozoites (102). As illustrated 
by the triangle on the right, later developmental arrest results in exposure to a broader 




standard challenge infection of five P. falciparum-infected mosquito bites, 10/10 subjects 
were sterilely protected (102). In a subset of the volunteers this immunity was shown to be 
long lasting (103). CPS-immunization, requiring only a total of 45 infected mosquito bites, is 
therefore more than 20 times more efficient than RAS where >1,000 P. falciparum-infected 
mosquitoes are needed. This may be explained by: i) increased breadth and magnitude of 
the induced immune response, due to higher antigenic load and broader antigenic repertoire 
including late liver-stage and early blood-stage antigens; ii) known immune modulating 
effects of chloroquine.
The striking efficiency of CPS-immunization raises a number of questions and opens 
numerous exciting avenues for further research. For example, this approach could be 
developed into an implementable vaccination strategy if sporozoites could be administered 
by needle and syringe. And, possibly even more important, CPS-immunization can be used 
as a model to investigate a number of issues related to anti-malarial protection. These include 
the lifecycle-stage specificity of the protective immune responses, the induction of immune 
responses and their association with protection, the role of chloroquine, and protection 
against heterologous strains. This thesis aims to address a number of these important issues 
in order to improve our understanding of protection and immune responses against malaria 
induced by whole sporozoite immunization. 
Blood-stage vaccine strategies
Blood-stage vaccines target asexual stages that appear in the blood after the liver stage. These 
products aim to reduce clinical disease and control parasitemia. Clinical studies of blood-stage 
vaccines have mainly focused on subunit vaccines, but the development of such vaccines is 
hampered by the high degree of polymorphism of target antigens and a great diversity of P. 
falciparum strains in malaria-endemic areas (80). As a result of this, an immune response 
against a specific protein of one strain often does not protect against other strains.
Vaccines have been developed against antigens on the surface of infected erythrocytes 
and merozoites. Eight antigens have been investigated in clinical trials: Apical Membrane 
Antigen 1 (AMA-1), Merozoite Surface Protein 1, 2 and 3 (MSP1-3), Glutamate rich Protein 
(GLURP), Erythrocyte-Binding Antigen 175 (EBA 175), Ring-infected Erythrocyte Surface 
Antigen (RESA) and Serine Repeat Antigen (SERA). In residents of malaria-endemic areas, 
antibodies against these antigens are associated with clinical protection. However, clinical 
vaccine trials have until now only shown partial protection at best (104). Strain-specific 
efficacy, however, can be up to 64% (105). 
Asexual blood-stage parasites multiply exponentially in the blood and escape from 
the immune system in several ways. Development of a sterilely protective blood-stage 
subunit vaccine is therefore unlikely to be successful. In the search for an effective vaccine 
it will be important to identify new blood-stage antigens that are sufficiently immunogenic, 
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but little polymorphic. The recently discovered reticulocyte-binding protein Homologue 5 
(PfRH5) appears to fulfill these criteria. Anti-PfRH5 antibodies efficiently inhibit blood-
stage multiplication of heterologous strains in vitro (106). Alternatively, combining different 
variants in a polyvalent vaccine would be a sensible strategy.
Transmission blocking vaccines
Transmission blocking vaccines (TBVs) are directed against sexual and/or sporogonic stages 
and thus aim to prevent transmission of the parasite to the mosquito and subsequent spread 
into the human population. Since 2007, malaria elimination is back on the global agenda and 
this resulted particularly in an increased interest in TBVs (107, 108). Biological efficacy of 
induced antibodies can be tested in the laboratory by adding test or control antibodies to an 
infected blood meal for Anopheles mosquitoes that feed on a glass membrane feeder (109). 
The transmission-blocking effect of the antibodies is determined by comparing parasite 
development in test and control mosquitoes. Only subunit TBVs have been developed. Target 
proteins on the surface of sexual and sporogonic stages for transmission-blocking antibodies 
are Pfs25, Pfs28, Pfs230 and Pfs48/45 (110, 111). Initial clinical studies with soluble Pfs25 
show that it is difficult to find an appropriate antigen-adjuvant combination that induces 
robust transmission blocking immunity without causing too many side effects (110). Up until 
now, no TBVs have progressed to phase-II trials. 
Aims & outline of this thesis
The overall aim of this thesis is to improve our understanding of protection and immune 
responses against malaria using the chemoprophylaxis and sporozoites (CPS) immunization 
model. Inoculating malaria naïve individuals under chloroquine prophylaxis with live 
sporozoites has been shown to induce higher levels of protection than any other vaccination 
method in an experimental setting. We now use this model to advance our understanding of 
anti-malarial immunity induced by whole sporozoite immunization. The possibilities offered 
by the CHMI model allow us to explore and test a diverse range of issues including life 
cycle stage specificity of protective immunity, the minimum immunization dose that still 
induces protection, induction of cellular immune responses and correlates of protection, 
protection against a heterologous P. falciparum strain, the possibility of using alternative 
chemoprophylactic drugs for CPS, and an alternative way of administering sporozoites in 
order to replace the mosquito as method of inoculation—all of these together will aid the 
development of an effective vaccine. 
The objective of Chapter 2 is to provide a detailed description of the complex CHMI 
trials. This will help to understand the context and the work processes described in the other 
chapters of this thesis, and it shows how these CHMI studies are designed and carried out to 
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produce valuable scientific knowledge. The heuristics used in this chapter are from Science 
Technology and Society studies (STS), an interdisciplinary field that combines anthropology, 
philosophy, history and sociology to study the production of scientific knowledge and the 
role of science and technology in society. More precisely, the CHMI studies will serve as a 
strategic research site to study the role of trust and control and their interaction in clinical 
trials. 
The highly efficient induction of protection by CPS-immunization, compared to 
naturally acquired immunity and other immunization or vaccination protocols, raises many 
questions, one of which concerns the role of the administrated chloroquine. Chloroquine is 
a highly versatile drug, known not only for its antimalarial activity, but also for a number 
of immune-modulating effects including improvement of cross-presentation (112-114). 
The objective of Chapter 3 is to review and reflect on the use of chloroquine to modulate 
the immune system in order to potentially increase protection. In a next step, we will use 
P. berghei rodent models to investigate a potentially beneficial effect of chloroquine on 
sporozoite immunization; this is described in Chapter 4. In Chapter 5, we explore the option 
of translating chemoprophylaxis and parasite exposure into a field intervention with the aim 
of inducing protective immune responses.
In Chapters 6, 7, 8, 9, and 10 results from four clinical CPS trials are presented. 
Since individuals are exposed to pre-erythrocytic as well as blood-stage parasites during 
CPS-immunization, the protective immune responses could be directed against either of 
these stages. Resolving this question is important because of the traditional lifecycle stage-
specific distinction between vaccines designed to induce blood-stage versus pre-erythrocytic 
protection (115). The objective of Chapter 6 is to explore the Plasmodium lifecycle stage-
specificity of the CPS-induced protective immune responses. 
Immune mechanisms and correlates of protection against malaria are elusive, and their 
identification would greatly facilitate clinical development of new vaccines (116, 117). Both 
cellular and humoral immune responses are induced by whole sporozoite immunization 
(102, 118), but animal studies indicate that especially T cells are crucial (119-121). In CPS-
immunized human volunteers, P. falciparum specific pluripotent CD4 T cells were previously 
identified as possible correlate of protection, but it remained unclear whether these responses 
were rather a marker of parasite exposure (102). To address this issue, a dose-titration CPS-
immunization study is conducted in Chapter 7, to generate a differentially protected cohort 
allowing for the analysis of immune memory responses and their association with protection. 
Chapter 8 further explores the induction and differentiation of cellular immune responses 
using ex vivo analysis of lymphocytes directly after sporozoite immunization. 
So far CPS-immunization trials and most RAS studies have investigated homologous 
protection only, i.e. protection against the same P. falciparum strain that was used for 
immunization. In endemic areas however, infections are caused by multiple, genetically and 
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antigenically different strains (122-124). This huge diversity in strains is considered one of 
the main reasons why immunity develops only slowly in the field (125). In order for CPS to 
remain valuable as an immunization strategy, heterologous protection needs to be present, 
and this is studied in Chapter 9.
The unprecedented efficiency of CPS may be related to or dependent on the anti-malarial 
drug used during immunization. Chapter 10 therefore investigates safety, immunogenicity 
and protective efficacy of CPS-immunization with mefloquine compared to chloroquine.
The complex infrastructure, advanced skills and expertise required for parasite 
culture, mosquito breeding and infection of mosquitoes through membrane feeding restricts 
the availability of CHMI and CPS-immunization by mosquito bites to a few specialized 
centers. Replacing the infected mosquito as method of inoculation would greatly extend the 
implementability of CHMI and CPS-immunization worldwide. Therefore, we will investigate 
an alternative approach to infect healthy volunteers in Chapter 11: administration of aseptic, 
purified and cryopreserved sporozoites by needle and syringe. 
Chapter 12 explores tolerance as an alternative protection mechanism against primary 
parasite infection. There are three conceptually distinct ways for a host to protect itself 
against invading pathogens: i) resistance (i.e. limiting pathogen load), ii) tolerance (i.e. 
limiting the damage caused by the pathogen) and iii) avoidance (126, 127). For semi-immune 
adults in malaria-endemic areas, the first two mechanisms appear to go hand in hand: parasite 
density as well as symptoms and complications are controlled and limited (125, 128). Their 
individual contribution, however, is hard to disentangle. Therefore, innovative approaches 
are required. Cross-sectional data from residents from malaria-endemic areas suggest that so 
called “disease maps” may be a useful tool. Since longitudinal datasets are obtained in CHMI 
trials, we use these in Chapter 12 to assess tolerance in healthy malaria-naïve subjects using 
disease space. 
Finally, the findings of this thesis are placed in context in Chapter 13, and future 
directions and avenues for further research are discussed.
The cover of this book depicts the wall of a house in Tirana, Albania. When Edi Rama 
was elected major of this city in 2000, he decided to paint a large number of Tirana houses 
in bright colors and bold geometric designs. “It is not a matter of what color you may want 
this or that building, because that would be a question of trying to add up all the tastes and 
find the golden mean, which would be a grey”, he said. I believe that the same is fruitful for 
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Controlled Human Malaria Infections (CHMIs) are clinical trials in which healthy volunteers 
are deliberately infected with malaria under controlled conditions. CHMIs are complex 
clinical trials: many different groups and institutions are involved, and several complex 
technologies are required to function together. This functioning together of technologies, 
people and institutions is under special pressure because of potential risks to the volunteers. 
In this paper two medical researchers and an STS scholar use CHMIs as a strategic 
research site to study the use of control, the role of trust and the interactions between trust 
and control in the construction of scientific knowledge. The authors argue that tandems of 
trust and control play a central role in the successful execution of clinical trials and the 
construction of scientific knowledge. More specifically, two aspects of tandems of trust and 
control will be highlighted: tandems are sites where trust and control coproduce each other; 
and tandems link the personal, the technical and the institutional domains. 
Understanding how tandems of trust and control make scientific experiments work and 
enable the construction of scientific knowledge, results in setting an agenda for both clinical 
trial research and social studies of science.
33
CHMIs: tandems of trust and control construct scientific knowledge
Introduction 
In this paper we will explore how trust and control play a central role in the production of 
scientific knowledge, using the example of Controlled Human Malaria Infections (CHMIs).1 
CHMIs are clinical trials in which healthy volunteers are deliberately infected with 
malaria under controlled conditions, for example to test the efficacy of potential vaccines 
or to investigate immunological questions (1). Clinical trials are similar to other scientific 
experiments, but for one crucial characteristic—they involve people as objects of research. This 
makes them into a strategic research site for studying the particular aspects of experimenting 
that we want to focus on: the use of control and the role of trust in the production of credible 
knowledge. This analysis will, we hope, contribute to the understanding that science-studies 
scholars have of scientific experiments in general. 
Clinical trials have been studied from a social science and STS (science, technology 
& society studies) perspective since the 1990s. The first line in this body of research 
investigates the role of the pharmaceutical industry in clinical trials. Research and industry are 
increasingly intertwined—in almost all domains of research, but certainly and perhaps mostly 
in medicine—resulting in a potential problem of introducing a bias in trial design, conduct of 
clinical trials, interpretation of results and publication strategies (2-7). Some of this research 
broadens its scope to analyze the resulting political economy of the health care system and 
the implications of a globalizing clinical trial ‘industry’ (8, 9). This industrialization and 
commercialization of medical research is particularly visible in the increasingly prominent 
role of contract research organizations, or CROs, in the conduct of clinical trials (10-12). 
A second line of research focuses on the participants or subjects, often called ‘volunteers’, 
in clinical trials, and asks questions about volunteers’ motivation to participate, the effects 
of participation on their health, and the economic and educational background of these 
volunteers (13-18). The third line of social science research on clinical trials addresses issues 
of risk and vulnerability—mostly relating to the volunteers, but also about the trials’ scientific 
quality as potentially compromised by their complex and industrialized organization (18-21). 
Almost all of this research concerns drug trials: the testing of drugs on patients or healthy 
volunteers. These trials are often distinguished in three types: phase-I trials are to test the 
drug’s safety on healthy volunteers (often a small number of tens to hundreds); phase-II trials 
are for testing the efficacy of the drug on patients (usually some hundreds); and phase-III 
trials test the drug’s therapeutic effect (with generally thousands of patients). 
The clinical trials that we investigate in this article are of a different character than 
those studied in the literature we reviewed above. Instead of administering a drug that has 
never been tested on humans to healthy volunteers (Phase-I trials), or assessing the efficacy 
of such a new drug on patients (Phase-II and III trials), in CHMI trials healthy volunteers are 
1 See list of abbreviations at the end of the chapter.
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made into patients, by infecting them with the malaria parasite that also causes millions of 
natural infections every year. Hereby, pathophysiological and immunological mechanisms of 
the infection can be studied. Most CHMI trials are not (yet) interesting for pharmaceutical 
industry, and the trials are carried out by university researchers in university hospitals.2 The 
trial subjects are mostly, but not necessarily, medical students, who receive a fee of some 
1000-2000 euros; the numbers are typically small—10-40 volunteers per trial. Though most 
of the world’s malaria patients are in Africa and South-East Asia, it is crucial that CHMIs are 
done with ‘malaria-naive’ volunteers, and thus in a country like The Netherlands.3 
Not only are CHMIs different from the trials reported in the existing STS literature, also 
the questions we ask in this article are different. We ask how trust and control play a role in 
the construction of scientific knowledge and the execution of scientific experiments, and we 
consider CHMIs as a particularly good research site to ask that question. If the previously 
reviewed literature brings STS to clinical trial research, our article brings CHMI trials to 
STS. 
In CHMI trials, volunteers are made ill as part of the trial design. Their being infected 
with malaria, a potentially lethal disease, does demand very high levels of trust and control. 
This was the starting point for our research—CHMIs seem to present a ‘hard case’ for 
studying trust and control in Harry Collins’ (22: 142) sense: “if one wants to prove a general 
thesis, you endeavor to prove it for the case where the thesis seems least likely to hold.” 
But, even though this formed the starting point of our project, we will not exclusively focus 
on the relations between the volunteers and the researchers. We will argue that ‘tandems of 
trust & control’ play a central role in the construction of scientific knowledge much more 
generally—also in the relations between researchers themselves, in the relations between 
researchers and instruments, in the relations between researchers and institutions, and in 
other scientific experiments than clinical trials.
Trust has been a central concept in understanding the construction of scientific 
knowledge, as well as in analyzing the social functioning of science in society. Without 
scientists trusting each other, there would be no positive production of knowledge, since they 
would get stuck in an experimenters’ regress, as Collins (23: 130) describes: “the competence 
of experimenters and the integrity of experiments can only be ascertained by examining results, 
but the appropriate results can only be known from competently performed experiments, and 
so forth. Other ways of testing for the competence and integrity of experiments, such as ‘tests 
of tests’, turn out to need ‘tests of tests of tests’—and so on” (emphasis in the original). This 
is closely related to the key role of tacit knowledge and the scientist’s skills in performing an 
2 The CHMIs that are reported on in this article are investigator-initiated and have been funded by 
the Netherlands Organization of Scientific Research (NWO), the European Union, and the Bill & 
Melinda Gates Foundation.
3 ‘Malaria-naive’ is a term widely used in malaria research to indicate that a subject was never 
infected with malaria (1). 
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experiment. Independent replication of an experiment cannot resolve an issue, since no two 
experiments can ever be exactly the same in all details and so the status of an experiment as 
replication has to be negotiated. Thus, “for any finding to be accepted, scientists cannot be 
utter skeptics. (…) At any given moment, some knowledge must be taken on faith, if science 
is to proceed as a social institution.” (24: 15) For the functioning of science in society, it is 
crucial that non-scientists trust scientists and the results of their scientific work. Much recent 
work in STS relates to this issue: research about different forms of expertise, about new forms 
of scientific and technological democracy, and about participation of citizens, consumers and 
patients in science and technology. All these studies contribute, in different ways and with 
different foci, to our understanding how societal trust in scientists, scientific institutions and 
scientific knowledge is crucial for the functioning of science in society (25-29). In this paper 
we do not address these trust issues at the societal scale, but rather focus on the role of trust 
at the micro level of the clinical trial.
It is an almost trivial statement to say that control is crucial for the production of 
scientific knowledge through experiments. It is the proper and clever control of experimental 
circumstances that creates the laboratory conditions in which new knowledge can be 
generated; and, vice versa, scientific controversies are often about whether the experimental 
variables have been properly controlled. In the case of clinical trials, a textbook even states 
explicitly: “you must maintain control of the study at all times” (30: 249). As we will explore 
in our detailed analysis of CHMIs, in practice this is less straightforward than it may seem 
in theory. Explicating the various meanings of control will, we think, be fruitful to help trial 
researchers reflect on their practices and possibly improve them, and to yield insights in the 
construction of scientific knowledge more generally. 
After our analysis of CHMIs in terms of trust and control, we will conclude this article 
by arguing more specifically that it is the interplay of trust and control that makes the CHMIs 
work; these ‘tandems of trust & control’ make the social construction of scientific knowledge 
happen. Tandems of trust & control are specific combinations of these two, in which they 
work together, coproduce each other or partly substitute each other. 
The empirical research for this paper is a participant-observation study, and was carried 
out in two research hospitals—Radboud university medical center in Nijmegen and Leiden 
University Medical Center, both in The Netherlands—where the first and second author 
conduct(ed) CHMIs. Unlike most anthropological lab studies, where an anthropologist first 
gains access to the lab and then gradually picks up some tasks and adds ‘participation’ to 
‘observation’, it was the other way around in this study. The first author of this paper is a 
clinical researcher, who became interested in science-studies questions: so, gradually she 
added ‘observation’ to ‘participation’ in her way of being in the lab. She has a degree in 
medicine and is being trained as a researcher in clinical trials, parasitology and immunology. 
The last author was trained as a physicist and now is professor of sociology of science and 
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technology. His field is indeed the study of social processes in science and technology, but 
he has no direct experience with medical research or clinical trials. The second author is 
medical specialist in microbiology and professor of medical parasitology and one of the 
internationally leading experts in malaria vaccine research. His being fully socialized in the 
CHMI community provided a crucial role in the CHMI design and check on the observations 
and interpretations that our participant-observer made. He is the principal investigator of the 
CHMIs. 
The first author’s being a young medical researcher allowed her to approach questions 
about clinical trials with fresh curiosity, since she was not yet completely socialized into 
the CHMI community. The approach she followed is similar to Leon Anderson’s ‘analytic 
autoethnography’, for which he proposes five key features: “(1) complete member researcher 
(CMR) status, (2) analytic reflexivity, (3) narrative visibility of the researcher’s self, (4) 
dialogue with informants beyond the self, and (5) commitment to theoretical analysis” (31: 
378). For the particular questions we are addressing in this paper we consider the third 
characteristic of “narrative visibility of the researcher’s self” less important and thus have 
minimized such self-presence in the text.
Control
Different forms of control seem to play a crucial role in the making of scientific knowledge. 
We will distinguish two types of control—methodological and institutional—and we will 
show that both types can play out in three ‘locations’: control of people, of machines, and 
of institutions. The ‘methodological’ type is primarily internal to the trial and exerted by the 
researchers (and, we shall argue, by many other actors within the trial), the ‘institutional’ 
is external and exerted by actors in the institutional environment of the trials. Examples 
of methodological control are the use of a control group, inclusion-exclusion criteria for 
research subjects, processes of blinding and randomization, and sophisticated biostatistics. 
Institutional control is, for example, the requirement for a data monitoring system or GCP 
training of trial staff.
Methodological control is at the core of doing scientific experiments, and indeed of 
doing any scientific work. The more precisely a research question is formulated, the better the 
design of experiments or the selection of observational data can be controlled. All standard 
scientific methodologies—from interviewing to statistical analysis, from hermeneutical 
text analysis to coding of interviews, and from thick smear analysis to Polymerase Chain 
Reaction (PCR) analysis (which we will both describe below)—are meant to control the 
otherwise unruly world in the laboratory or in ‘the wild’. The better the control, the more 
trustworthy (although less surprising) the knowledge that is produced. 
The standard account in medical textbooks about the history of clinical trials is that 
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methodological improvements were introduced to reduce the subjectivity of the interpretation 
of the results, and to increase the scientific validity of clinical trial results (32, 33). In the first 
half of the 20th century, increasing distrust in the personal judgments of medical professionals 
was one of the factors that led to stepping-up standardization and regulation of clinical trials 
(34, 35). Moreover, a number of detrimental cases during clinical trials led to further increased 
control. For example, the death of a 24-year old healthy volunteer in an asthma trial in 2001 
at the Johns Hopkins University led to changes including “more resources; new procedures; 
Figure 1 Increasing control, 
1998-2013, A: Number of pages 
of Clinical Trial Protocol. B: 
Number of in- and exclusion 




more training for investigators and for IRB members, chairs, and staff; and the appointment 
of a vice dean for clinical investigation to oversee the process” (36: 719). It seems fair to say 
that by this kind of methodological and institutional interventions, clinical trials have become 
one of the most controlled ways of doing scientific research.
The design of a clinical trial, with all its stipulated methods and procedures, can be seen 
as a framework or recipe that has to be executed during the trial. Over the past decades both 
the overall trial designs and the included procedures and methods have become more and 
more detailed, in order to exert more control. To illustrate this: the clinical trial protocol for 
the first CHMI study, which was performed at Radboudumc in 1999, was only 4 pages long, 
while the protocol for the 2013 study is 60 pages long (see Figure 1A). At the same time, the 
numbers of in- and exclusion criteria have increased from 2 and 4, to 16 and 29 respectively 
(Figure 1B), and the volunteer information sheet was expanded from 1 to 14 pages (Figure 
1C). 
As stated in the previously cited textbook on clinical trial medicine: “There are several 
key aspects of ‘good clinical practice’. The first is the concept of being in control.” And 
further specified: “You must have systems in place to detect problems when they occur. You 
must have, in other words, the quality systems and standard operating procedures (SOPs). 
(…) [And] if problems are detected, you must take corrective action to ensure that the problem 
is abated and that the way you do business (processes) is modified as is reasonable to avoid 
the problem in the future.” (30: 243). Such ‘Standard operating procedures’ (SOPs) thus are 
increasingly used to explicate methodologies. As illustration of the kind of procedures that 
are described in these documents, supplementary table 1 provides a list with the SOPs from 
the parasite lab. Similar sets of SOPs are available for mosquito-related activities (46 SOPs), 
general procedures (e.g. good documentation practices; 8 SOPs), clinical activities (18 SOPs) 
and immunological and molecular methods (17 SOPs).
But who is exerting control? Evidently the textbook requires the researcher to be in 
control. But we will describe that many other actors have opportunities (and are sometimes 
expected) to control the conduct and outcome of the trials. Lab technicians are crucial in 
controlling the growth of mosquitos and the timely infection with parasites. Trial subjects 
or volunteers are supposed to be controlled by the trial design and the researchers, but 
sometimes take over and control the outcome of the trial in unintended ways, as we will 
describe below. And there is the Data and Safety Monitoring Board (DSMB) as a form of 
institutional control that is mandatory for some trials. Such a DSMB assesses safety and 
efficacy data while the trial is ongoing and can advise the sponsor about terminating a trial 
based on these data. As we will discuss, CHMIs are not legally required to have a DSMB; 
but the researchers decided to have one in order to increase trust by the ethical review board 
and the scientific community.
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Trust
If a variety of social groups exert some control and if, as we will show below, sometimes 
control measures have unintended consequences, why then is there no stalemate of conflicting 
control efforts? We will argue that trust—of different actors in each other, but also by 
actors in instruments, various elements of the clinical trial machinery and in the institutions 
involved—is crucial, and makes the trial succeed, in alliance with control. 
It may seem that trust is thus invoked as a residual explanation—as what is left when 
control cannot explain what is happening.4 We do want, however, to propose a more positive—
say, stand-alone—concept of trust, so that in the final section of this article we can develop 
a tandem of trust & control that is conceptually symmetrical. As a general starting point we 
consider, with McEvily et al. (37), trust as the willingness to accept vulnerability, based 
on positive expectations about another’s intentions and behavior (if about persons), about 
the regular functioning of organizational structures and rules (if about social institutions), 
and about the truth of the laws of science and the regularity of natural phenomena (if about 
machines, instruments and the natural world). Trust is thus partly a positive expectation that 
the world will ‘act’ in certain predictable ways, and it also involves a willingness to contribute 
to the relationship by being vulnerable, by a “leap of faith” (37: 93). Humans cannot function 
in this world without trust: not in the social world, and not in the physical world. 
As we mentioned previously, the concept of trust has been used in explaining the social 
construction of scientific knowledge, though mostly at what we will call the macro level 
of the society and the meso level of the scientific community. Steven Shapin (38) answers 
questions at a macro level about societal trust in science by showing how this was generated 
at a meso level by trust relations between gentlemen scientists in the 17th century. Harry 
Collins (39) analyzed how trust allows scientists to continue their work without questioning 
everything all the time (see also Collins (40)). Collins’ work is almost exclusively focused 
on the meso level, describing the role of trust between scientists in the scientific community. 
Our analysis of clinical trials is primarily based on an analysis of trust at the micro level, of 
actors within the experiment of the trial. 
Shapin first cites the generally acknowledged distinction between amoral trust and 
morally consequential trust. Amoral trust is trust “in the fulfillment of inductively generated 
expectations about events in the world” (38: 8). We, for example, trust the sun to rise every 
day, and malaria researchers almost as much trust the mosquitoes to bite when they are put 
in a cage on the skin of the volunteers. This is trust that the world will continue to ‘behave’ 
as it always has behaved. In the case of morally consequential trust, a breach of that trust 
could lead to blaming the one who made the breach. After citing this distinction, Shapin’s 
key argument is that the two types of trust are not that radically distinct in the construction 
4 We thank one of the (anonymous) reviewers for highlighting this point.
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of scientific knowledge. After all, the trust in the mosquitoes’ biting is built on other people 
saying that mosquitoes always bite in such circumstances: “insofar as our factual knowledge 
is built up through assent to what we have been told, the two, allegedly distinct, notions of 
trust both belong within the same moral frame, the second routinely visible as such, the first 
routinely not.” (38: 8). 
Collins adds another distinction that we find useful for our analysis—between passive 
and active trust. In his work on gravitation wave science and scientists Collins argues 
that trust is often passive: scientists unconsciously trust the results of earlier experiments 
performed by others, as well as the materials, machines and computers in their experiments. 
Only when there are reasons for distrust, trust becomes active. Jill Fisher (20) has analyzed 
the role of trust in clinical trials, especially focusing on the pharmaceutical industry’s mistrust 
of the clinicians and human subjects in drug-testing trials. Starting point of her analysis is 
the observation that pharmaceutical industry typically does not trust researchers and trial 
subjects to execute the trials in such a way that the industry’s economic interests are served. 
Researchers are expected “to follow study protocols, not to have scientific insights or ethical 
misgivings about the studies (…) collect data honestly and thoroughly.” (20: 406-407) And 
trial subjects are expected to be compliant, even if they do not directly benefit and even if 
they experience adverse effects. So here is a case where there were previous instances of 
the passive trust being violated, probably at a personal level and at isolated instances; this 
then resulted in active trust requirements being formulated, also at an institutional level; but 
then, Fisher argues, the general climate of distrust was too strong and recourse to control 
was necessary, which took shape in strict monitoring schemes. Even though the type of trials 
discussed by Fisher is very different from the CHMIs, her example of closely relating (mis)
trust and control is illuminating. She distinguishes personal and institutional trust, to which 
we want to add a third type.
For our understanding of the functioning of the CHMIs, we will distinguish three types, 
or rather locations, of trust—trust between persons, trust in machines and materials, and trust 
in institutions—mirroring the control of people, of machines, and of institutions that we 
introduced previously. We thus follow a similar course as Sally Wyatt (28) and colleagues 
who analyzed the development of trust relationships in people, data and machines at different 
moments and in different ways in the case of online genetic research. 
First, interpersonal trust between actors can be based on perceived intentions or on 
perceived abilities (41), as clearly exemplified in the triangle of clinical investigator–PI–
clinical supervisor. The PI has the final and overall responsibility, but has delegated for 
example clinical responsibility to the clinical supervisor who is an experienced infectious 
disease specialist. All daily activities are carried out by the clinical investigator, who is thus 
supervised by both the PI and the clinical supervisor (on clinical decisions specifically). 
Both the PI and the clinical supervisor need to trust the clinical investigator’s abilities. Both 
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supervisors also need to trust the clinical investigator’s intentions and integrity: will she 
perform all activities as required and not modify data or conceal adverse events to produce 
better results? The clinical investigator, on the other hand, also needs to trust the intentions 
and capacities of both supervisors, in order for the supervision to be successful. Similar trust 
relations, based on perceived or assumed abilities and intentions, exist between the PI and 
the clinical supervisor. 
Second, researchers also need to trust the machines and instruments they use. If things 
go smoothly, this trust becomes taken for granted and thus implicit, or with Collins’ term 
passive. But often enough there are hiccups—the machine for parasite detection is not giving 
the expected signal, or there is increased and unexplainable mosquito mortality—an example 
we will describe below. In such cases trust has to be restored actively to be able to continue. 
Thirdly, researchers need to trust the relevant institutions and vice versa. As the PI in 
an asthma study where a healthy volunteer died after administration of a drug to investigate 
pathophysiology of asthma said: “responsibility for protection of patients in research 
activities is collective and systemic in nature” (36: 718). The PI did not intend “to deny or 
diminish his own role in ensuring the safety of research subjects” and he expressed “deep 
concern and sorrow regarding the death.” But he underlined that clinical trial participants 
trust the various institutions that are involved in designing, approving and conducting the 
clinical trials.5 Both interpersonal trust and institutional trust in the regulatory authorities and 
the research institution where the study takes place have indeed been shown to be a reason 
for patients to participate and cooperate with clinical research (42, 43).
Controlled Human Malaria Infection trials (CHMIs)
In 1917, Julius Wagner-Jauregg was the first to perform deliberate infections with malaria 
parasites, as treatment for neurosyphilis patients. These patients benefitted from the fever 
that was induced by the malaria parasites. The number of parasites in the blood could be 
controlled by targeted administration of antimalarial drugs. Wagner-Jauregg received the 
Nobel Prize for his discovery, but malaria-treatment became obsolete when antibiotics were 
discovered. In the 1960s, experimental malaria infections were used to test antimalarial drugs 
in healthy prison inmates in the US. The development of protocols for in vitro culture of 
malaria parasites in 1976 allowed for more routine execution of human malaria infections. 
Between 1985 and 2012, a total of more than 1400 subjects were experimentally infected 
with malaria (44, 45)
Initially, these deliberate infections were known as EHMIs: Experimental Human 
5 See also the letter by Daniel A. Kracov, Counsel to Alkis Togias, M.D., to Martin H. Cohen, 
Food and Drug Administration, 16 July 2001. http://www.hopkinsmedicine.org/press/2001/july/
togiasletter.htm; last retrieved on 19 June 2014.
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Malaria Infections. During a meeting in Amsterdam in June 2011, sponsored by the European 
Malaria Vaccine Development Association, clinical malaria researchers from the Netherlands, 
USA, UK, Germany, Switzerland and Tanzania collectively decided that a new term with a 
more positive connotation was desirable. Someone proposed the word ‘controlled’, arguing 
that the deliberate human malaria infections were executed under controlled circumstances 
and with standardized protocols. The proposal was immediately embraced6. From that day 
onwards, Experimental Human Malaria Infections were called Controlled Human Malaria 
Infections (CHMI), without any change in the actual procedures or protocols at that point in 
time.7
Table 1 ‘Relevant Social Groups’ in CHMI trials 
Sponsor1 Person or entity who initiates the clinical trial. 
Principal investigator Is responsible and accountable for conducting the clinical trial, for the 
treatment and evaluation of the participants and for the integrity of the 
research data and results.
Clinical investigators Medical doctors who conduct the clinical trial in practice.
Lab technicians Perform several tasks during CHMI: serology tests, blood safety 
measurements, reading thick smears, performing PCR analysis, etc.
Nurses Assist clinical investigators. 
Volunteers Clinical trial participants (also called ‘subjects’)
Funders Provide funding2.
Institutional review board Institution responsible for conducting the medical ethics review.
Biological evaluators Researchers who are responsible for the measurement of biological 
outcomes, such as parasitemia or immunological readouts.
Clinical supervisors3 Medical doctors (infectious diseases specialists) responsible for safety, 
clinical follow-up and treatment of the volunteers.
Safety monitor Independent physician based in study site. Volunteers advocate and 
sounding board for investigators regarding safety of the volunteers.
Data Safety Monitoring 
Board (DSMB)
A group of independent experts who monitor participant safety and 
outcomes while a clinical trial is going on.
6 Source: notes from EMVDA workshop Optimization and Standardization of Human Experimental 
Malaria Infections. Amsterdam, 22 and 23 June 2011; made by first author. 
7 Until 2012, CHMI-trials were performed in only six clinical centers worldwide. However, since 
cryopreserved parasites ‘in a bottle’ have become available, many more centers worldwide can now 
perform CHMIs. 
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What makes these CHMI trials work? We shall try to answer this question by analyzing 
CHMIs as socio-technical machineries. CHMIs are complex systems of people, instruments, 
animals, institutions and protocols, which produce scientific knowledge. In our analysis of 
the machinery of CHMIs we will implicitly follow the heuristics of the “social construction 
of technology” (46, 47). We will meet many social groups that can be found in any scientific 
research laboratory, though some may be specific for clinical trials (see table 1). We trace 
the chronology of the trial, and by focusing on the various relevant social groups we shall 
describe the role of trust and control in conducting the CHMIs.
Medical ethics assessment
In the Netherlands, there are 24 accredited Institutional Review Boards (IRBs) and a Central 
Committee on Research involving Human Subjects (CCMO), which can perform the medical 
ethics assessment of clinical trials.8 The majority of studies is reviewed by IRBs, but certain 
types of complex research are by law required to be reviewed by the CCMO.9 The law does 
not require CHMI trials to be reviewed by the CCMO, but after the occurrence of a cardiac 
Serious Adverse Event (SAE)10, the local IRB requested that CHMI studies be reviewed by 
the CCMO.
The CCMO reviews whether the CHMI trial protocols are in accordance with the 
specifications laid down in the Dutch law. The CCMO will assess the ethical question of 
a proper balance between risk and benefit, i.e. the burden to the subjects and the scientific 
value of the research. CCMO’s main focus is the safety of the research subjects. It is 
therefore required that the investigators describe the procedures aimed at ensuring the safety 
8 For more on the CCMO, see http://www.ccmo.nl/en/reviewing-committee-mrec-or-ccmo. (last 
retrieved on March 29, 2015)
9 Ibidem
10 Definition of SAE (source: CCMO-website): “an undesired medical event which occurred to a 
research subject that does not necessarily have a causal link to the treatment and:
- is fatal, and/or;
- is life-threatening for the research subject, and/or;
- makes hospital admission or an extension of the admission necessary, and/or
- causes persistent or significant invalidity or work disability, and/or
- manifests itself in a congenital abnormality or malformation”
The cardiac event in this case was defined as an SAE because the subject was admitted to the 
hospital. She experienced chest pain after she had been treated for the induced malaria infection. 
The details of this SAE have been described in a case report (48). From the abstract of this article: 
“She recovered quickly and her follow-up was uneventful. Whether the event was related to the 
study procedures such as the preceding vaccinations, malaria infection or antimalarial drugs remains 
elusive. However, the relation in time with the experimental malaria infection and apparent absence 
of an underlying condition makes the infection the most probable trigger. This in striking contrast, 
however, with the millions of malaria cases each year and the fact that such complication has never 
been reported in the literature. The rare occurrence of cardiac events with any of the preceding study 
procedures may even support a coincidental finding.”
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of the volunteers as comprehensively as possible. These procedures include, for example, 
determining the sensitivity of the parasite for antimalarial drugs, regular assessment of 
routine laboratory values during follow-up, but also a specific safety protocol in case of 
cardiac complications. 
For the medical ethics evaluation it is important for the researchers to invest in 
and maintain open communication with the secretariat of the CCMO. It will help, when 
timelines are tight, that some ‘thinking along’ is offered by the CCMO’s secretariat. The 
CCMO Secretary may sometimes call to inform the investigators that the CCMO may raise 
additional questions in the up-coming committee meeting. If these issues can quickly be 
addressed before the CCMO meets, and then presented by the Secretary, an additional round 
of questions is avoided. Once all questions are answered to the satisfaction of the CCMO, 
the trial is approved. In our conclusion, we will critically reflect on this good relationship 
between researchers and CCMO.
After approval by the CCMO, the study centers where the study is carried out perform 
another check of the study: permission from the board of directors is required for execution 
in their center. At the Radboudumc, this check includes the volunteer information, the data 
management plan, a monitoring plan, a risk assessment and a check whether the involved 
researchers have followed the obligatory GCP course. After approval by the study center, 
official procedures can commence. 
Trial preparation
Already before CCMO approval is obtained, preparation of the trial has to start. The days 
for screening, for infection and for follow-up visits are planned. Based on this planning, the 
mosquito- and parasite cultures are prepared. 
The Radboudumc insectary produces approximately 15,000 mosquitoes per week. 
Mosquito eggs are distributed in plastic containers filled with water, in a climate-controlled 
room (Photograph 1). The eggs develop into larvae, then pupae and mosquitoes in 
approximately 2 weeks. Before the pupae develop into mosquitoes, a net is placed over the 
containers to prevent the mosquitoes from escaping. The mosquitoes are then collected and 
kept in a cage until they are infected with parasites. Parasites are cultured in glass flasks 
(Photograph 2). Twice a day, the medium with waste materials is removed, and fresh culture 
medium is added. In order to infect mosquitoes, they need to take a blood meal containing 
parasites via a “membrane feeder” (Photographs 3 and 4). 
The trial schedule, once fixed, creates a long chain of interconnected and interdependent 
actions. Enough infected mosquitoes must be available on the infection day. The infected 
mosquitoes have to be 14-21 days old, since younger mosquitoes are not infectious, and older 
mosquitoes are less eager to bite and the risk of mosquito-mortality increases. Complicated 
planning is required to have sufficient batches of high quality mosquitoes and parasites on 
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the planned dates. 
During a clinical trial in 2011, the malaria unit technicians noticed increased mosquito 
mortality. The reasons for this were not clear: protocols were followed strictly and had not 
been changed recently.11 In order to secure a sufficient number of infected mosquitoes, extra 
batches were bred and infected. Furthermore, the technicians tried to trace the cause of the 
mortality. They checked with the blood bank whether the blood-withdrawing methods or 
the collection tubes had changed, but this was not the case. They also considered whether 
chemicals, used in the building activities on the roof of the central animal facility where the 
malaria unit is located, might have caused the problem. Another option was that the tap water, 
which is used to breed to mosquitoes, was contaminated or that there was a problem with the 
ventilation of the climate rooms. But these options were ruled out when mortality was shown 
to have increased in both the old and new units in separate buildings. In the end, the cause of the 
increased mortality was never discovered, and the technicians found a way to circumvent the 
problem by using very young mosquitoes. The incident made the technicians and the scientists 
aware that, in our words and using Collins’ distinction, they had been passively trusting the 
heparin tubes, the ventilation system and the tap water for many years. After developing the 
new method to work around 
this problem, an active trust 
was built up in the mosquito 
breeding facilities.
Recruitment and screening 
of volunteers
After CCMO approval, the 
clinical investigators start 
recruiting and screening 
volunteers. These clinical 
trial participants are called 
‘volunteers’, because they 
make the choice to participate 
and have the right to terminate 
their participation at any 
point in time. But the fact 
that they receive financial 
11 As the head of the mosquito unit reported: “More than 25-50% of the mosquitoes die within 48 
hours, and I don’t have a good feeling with the remaining mosquitoes. The infectious mosquitoes 
that are needed for the first immunization of the EHMI9 study are now under pressure.” (e-mail from 
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reimbursement for their participation may diminish their autonomy in making the decision.12 
Calling them volunteers strengthens the notion that subjects are in control of their own 
involvement. It also suggests that society can trust that they independently and deliberately 
decide to participate in clinical research. Both in the communication to volunteers and in 
scientific publications, the terms ‘volunteer’ and ‘subject’ are used alternatingly; we will do 
that here as well. 
The recruitment process consists of four steps. 1) Distribution of advertisements on 
flyers and posters; 2) Comprehensive information package; 3) An information meeting; 4) The 
medical screening. Taken together, for a study with 30 subjects, approximately 240 have to 
show interest during the first phase of the recruitment trajectory. In the screening, volunteers 
are selected by applying in- and exclusion criteria, listed in the protocol as approved by the 
CCMO. In summary, participants are healthy, 18-35 years old, male or female. In practice 
the mean age has been 21.5 years, with a range of 18-32. The male-to-female ratio is on 
average 1:2. Most importantly, participants have to be very healthy to participate in the trial. 
Laboratory results outside the normal range, a deviant electrocardiogram, family history of 
cardiac disease, drug- or excessive alcohol use are all reasons for exclusion of a subject. They 
also have to be ‘malaria-naïve’: i.e. never had malaria. This is assessed by taking a detailed 
travel-history and by testing for antibodies against the malaria parasite. It is essential that the 
volunteers are malaria-naïve, since pre-existing immunity against the malaria parasite would 
interfere with the effect of the controlled infection and thus the result of the trial. During 
the trial, the subjects are not allowed to leave the country; The Netherlands becomes the 
12 For participating in a single CHMI with approximately 25 follow-up visits the volunteers receive 
1000 euros.
Photograph 2 Parasite culture.
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investigator’s laboratory.13 
This selection process results in a group of 
subjects that is distinctly different in comparison 
to most of the subjects that have been studied 
in STS research of clinical trials. There is one 
similarity with phase-I drug trials: that the subjects 
are healthy volunteers and cannot expect personal 
health benefit. But on all other accounts the CHMI 
selection process produces a quite different group 
of subjects. Unlike the ‘professional guinea 
pigs’ that Roberto Abadie (17) describes, CHMI 
volunteers can only participate once (because of 
the requirement of being malaria-naïve) and thus 
cannot be financially dependent on CHMIs for 
their livelihood. There is no ‘informal economy’ 
with volunteers living off CHMIs, as studied 
by Jill Fisher (8). CHMI volunteers do receive 
financial compensation, but this is a one-time 
addition to their regular budget, rather than a 
form of income.14 Since the recruitment efforts 
are targeted to university students, because of positive experience with their flexibility, 
motivation and reliability, the large majority of volunteers turn out to be students. However, 
unlike in the early history of medical student volunteers (15), the CHMI students typically 
do not have a student-teacher relationship with the researcher, nor are awarded study credits. 
This different profile of the CHMI volunteers has implications for the balance between trust 
and control, as we will discuss below.
Trust is of central importance in any medical relationship between doctor and patient 
(49), but to trust a doctor who is performing a clinical trial is a different matter than to trust 
your own physician—if only because other interests are at stake than only your own health. 
Within clinical research a further differentiation is useful. While treatment-trials offer a 
potential benefit to the participants—or at least to their fellow sufferers with the same disease 
in the future—this is not the case in trials with healthy volunteers, such as phase-I trials 
13 The infected volunteers will not be a source of secondary infections because of very early 
treatment when the transmission stages have not been formed yet.
14 In one instance, the parents of a student did not like him participating in the CHMI and offered 
him the same amount of money if he would withdraw. He did not do so. Then, later during the trial, 
his father once visited one of the monitoring sessions in the hospital and intensively interacted with 
the researchers, nurses and volunteers. He left with “now I understand why you do it”, and was 
reconciled with his son’s participation.




and CHMIs: there is no intended health benefit for them. In CHMIs, the trust relationship 
between volunteers and researchers can thus not be the same as in treatment trials or in 
common patient-doctor relations. Why do the volunteers trust the investigators; why would 
they trust someone who infects them with malaria? The investigators need to establish and to 
maintain such trust by the volunteers (see also Burgess (50)).
The investigators generate trust amongst the volunteers by informing them 
comprehensively, by explicating their good intentions, their expertise and abilities, and also 
how they are checked and controlled by the independent physician and the ethical review. For 
example, they explain the scientific background, the research questions, the study design, and 
the expected burden and possible risks. Pictures of the parasite culture, the mosquito breeding 
and the antimalarial drugs are shown during the information evening. They tell about the 
extensive experience, the team of “world-class technicians” behind the scenes and the good 
results that have been obtained in similar studies by the Radboudumc. The investigators 
emphasize that they will be always reachable and that the health and safety of the subjects 
is their primary concern. They further explain how the supporting technologies (such as the 
mosquito breeding and the microscopic parasite identification) help to control the parasites 
and thus the malaria infection in the volunteers. In other words, the researchers specifically 
explicate the various control-mechanisms—of persons, institutions and machines—that 
function in a CHMI, and thus seek to generate trust. Moreover, the investigators aim to 
remain very transparent during the trial about what is going on. Every once in a while the 
researchers and nurses discuss the greater goal of the project, and share the excitement about 
the possible results of the trial. In sum, the volunteers are more treated as partners in the 
research than as object of research.15 Some of the volunteering medical students indicate that 
15 See also the discussion about promoting research participation by recognizing a broader 
motivation in participants by Williams et al. (13, 51, 52)
Photograph 4 
Feeding of mosquitoes 
on midi-feeder.
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one reason to participate is to better understand the inner workings of a clinical trial. 
This hotel-housing of CHMI volunteers resembles the in-house confinement used in 
many drug trials (8, 17, 18, 20), but is distinctly different. In the CHMI case the aim is not 
to control the subjects’ behavior in detail, as described by Fisher (18) in her risk analysis 
of phase I trials. Rather, the purpose is to have the volunteers in a known location at close 
distance to the hospital. While staying in the hotel, the volunteers are free to do what they 
want—from going to their lectures to using the gym. They do receive instructions like ‘only 
one glass of alcohol per day’ and ‘sleep well’, but this is more done after fully informing 
them about the details of the trial and then giving them control over their own day-to-day 
affairs—it thus is more a matter of trusting them than controlling them.
And volunteers have, of course, other kinds of control too: they legally have the right to 
withdraw their informed consent at any time and for any reason. After a volunteer is infected 
this right remains the same, but they are then obliged to take antimalarial treatment to cure 
the infection before they can actually withdraw.16 
A different story evolves if the volunteers cuts communication and disappears. Such 
exertion of control by a volunteer happened in a CHMI trial in 2010 in Oxford when a 
volunteer, who had been included and infected, did not turn up for the first follow-up visit, 
and was only found after an extended search in the Netherlands.17 
The trial
One day before the infection, all subjects are checked again for eligibility and then officially 
‘included’ in the trial. One or more alternate volunteers who passed screening are available 
as substitutes for volunteers who withdraw or fall ill just before the start of the study. Once 
the trial starts, events of trust and control can be seen everywhere. We will describe the main 
course of the trial without each time explicitly labeling such control and trust occurrences, 
until in the next section we concentrate on the process of data gathering and monitoring.
On infection day all volunteers come to the central animal facility of the Radboud 
University. Infection day starts early because the mosquitoes are more eager to bite in the 
morning. While in the field mosquitoes bite in the evening, in the lab their day-night scheme 
is reversed for the convenience of the technicians. Mosquitoes are also starved overnight to 
further increase their eagerness to bite. The infection procedure takes place in a designated 
room in the insectary with a double-door barrier along with a blower system to prevent 
flight across entryways. For each volunteer a small cage, containing five mosquitoes, has 
been prepared. This cage is placed between the forearms of the volunteer (Photograph 5), a 
towel is placed over the cage (because mosquitoes bite better in the dark), and mosquitoes 
are allowed to bite for ten minutes. Afterwards, the volunteers return to a waiting room. 
16 If volunteers withdraw after being infected, they receive the same malaria treatment and have to 
fulfill the same post-treatment safety checks as volunteers who complete trial participation.
17 See http://www.bbc.co.uk/news/uk-england-11572862 (last retrieved on March 29, 2015)
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Technicians dissect all mosquitoes to check whether they have (1) fed on the volunteer and 
(2) were infected with malaria-parasites. If the answer to both questions is affirmative, the 
subject has received an infectious bite. Otherwise, the volunteer has to undergo an additional 
round, until exactly five infectious mosquitoes have bitten. 
After the infection a 5-day period of relative rest follows, because the parasites replicate 
in the human liver cells during this time, and symptoms don’t occur. From day 5 onwards, the 
subjects have to visit the trial center 1-3 times per day. At each visit, the subjects are asked 
questions about their complaints and symptoms, they show the diary they are keeping, and 
blood samples are drawn. Several blood parameters are tested. Most importantly, immediately 
after each visit all blood samples are checked for parasites with a standardized test.
When parasites are detected in the blood of a subject, this person is immediately called 
back to the trial center for treatment. The subject takes the first treatment dose at the trial 
center and goes home. Usually, most symptoms of the malaria infection occur on the next 
day. Common complaints are headache, fatigue, muscle pain, and fever. Nausea, abdominal 
pain, joint pain and vomiting might also occur, but are more rare. Complaints typically don’t 
last for more than two or three days. The second and third doses of medication are handed 
over to the volunteer during the subsequent morning visits for the volunteer to take at home, 
24 and 48 hours after the first dose. There are two more follow-up visits in the following 
three weeks.
At each visit, the clinical investigators record adverse events (AEs) that are reported 
by the subjects. All AEs are first recorded in the paper Case Report Form, and subsequently 
transferred to the electronic clinical data management system (CDMS). All AEs are described 
in safety reports regularly during the trial. 
The blood samples are prepared into so-called ‘thick smears’ according to an SOP. 
Photograph 5 
Exposure of human 
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Briefly, glass slides are used, with three wells with a standardized diameter (Photograph 
6). On each well, a fixed amount of blood is pipetted to create a standardized thickness and 
surface area. The slides are then stained with Giemsa staining solution and assessed under 
a standard light microscope. The number of High Power fields to be screened is calculated 
using the diameter of the ocular lens, resulting in the reading of a fixed volume of blood. 
All parasites seen need to be confirmed by a second microscopist. Thick smears are the 
worldwide gold standard for malaria diagnosis. 
In addition to the thick smears for parasite detection, several safety parameters are 
tested during the follow-up visits, such 
as routine hematology and biochemistry 
values. Since the above described cardiac 
event occurred in an experimental vaccine-
trial, several cardiovascular markers are 
now measured too (48). 
CHMIs have been performed in a 
handful of different trial centers around the 
world. There were differences in outcome 
that led to a discussion about methodologies 
in the different sites. The time-to-thick-
smear-positivity, for example, was a few days longer in Oxford than in Radboudumc. First 
it was thought that this was because of superior microscopic diagnostics in Radboudumc. 
Therefore, the SOP was further optimized and adjusted to the kind of microscope used, to 
make sure that all centers investigated exactly the same amount of blood. But even after 
the implementation, time-to-diagnosis by microscopy remained longer in Oxford. Therefore, 
samples from subjects in both centers were directly compared by Polymerase Chain Reaction 
(PCR), a more sensitive detection method. The conclusion of this comparison was that 
development of the parasites in Oxford was actually slower. When a trial in Radboudumc 
was done with the same parasite-strain from Oxford (3D7, a clone from the strain used in 
Nijmegen, NF54), time to diagnosis was longer in Radboudumc too, showing that the parasite 
was the critical variable. This is an example in which extra control (in the form of a SOP) 
allowed for the creation of new trust (amongst two research centers about the quality of their 
microscopy). We will return to this below.
Data monitoring
Reviewing the ways in which trust and control figure in carrying out CHMI’s, we mostly 
followed a chronological order through the trial process. We will now discuss in some 
detail the process of clinical trial monitoring to investigate the various control measures 
that are built into the trial process and their relation to questions of trust. Implementation 
Photograph 6 Thick blood smear.
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of monitoring is a crucial part of ’Good Clinical Practice (GCP)’, which is a prerequisite 
for trials with medicinal products and increasingly recommended for other trials as well. 
Monitoring entails a number of activities, which are meant to verify that:
a) The rights and wellbeing of human subjects are protected. 
b) The reported trial data are accurate, complete, and verifiable from source documents. 
c) The conduct of the trial is in compliance with the currently approved protocol/
amendment(s), with GCP, and with the applicable regulatory requirement(s). (53: 31)
The term ‘monitoring’ is generally used to describe on-site monitoring, where 
an independent monitor visits the trial site to check whether the research is carried out 
appropriately, and assesses some documents such as the curricula vitae and training records 
of the staff, and relevant SOPs. A monitor typically is a consultant from an independent 
CRO with a biomedical background, who is hired to perform the data monitoring. Data 
monitoring has been obligatory for trials that investigate a medicinal product for a while, 
but the Netherlands Federation of University Medical Centres (NFU) recently issued a 
report in which data monitoring is recommended to be obligatory for all clinical trials (54). 
Radboudumc, where the CHMIs are carried out, has already implemented this guideline. 
An important part of monitoring is source data verification. In the situation where data 
are initially collected in paper source documents and then transferred to a clinical data 
management system (CDMS), the monitor will check whether the data in the CDMS are the 
same as those in the source documents. 
In the NFU guideline, the amount of source data verification that is required depends 
on the estimated risk of the trial; when subjects in a trial are exposed to low risk, only 10% 
of patients case report files (CRFs) have to be checked, while for a high risk trial, all data 
have to be verified. Thus, according to the NFU, higher risk asks for more control. One of the 
most important source documents in CHMI trials is the paper CRF, in which the investigator 
makes notes during each follow up visit; e.g. symptoms and complaints, blood pressure and 
temperature. Other source documents are the diaries kept by volunteers, and forms with 
mosquito data from the infection day. From these source documents the investigators enter 
data on primary and secondary outcomes into the CDMS. From this system, data will later 
be extracted for analysis. 
However, the transfer of data from source documents to the data management system is 
only one link in the chain that generates results (see Figure 2). Before data are noted in a source 
document, they have to be collected. In the case of symptoms, this means questioning the 
volunteer; in the case of blood pressure and temperature, it means measuring these variables. 
But the data monitor is not standing next to the investigator while these measurements are 
performed, and thus cannot check whether the right questions are asked to the subject, or if 
the value is measured correctly and recorded properly in the source document. In order to 
make sure that measurements are performed correctly, protocols and SOPs are generated. 
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All people involved in the clinical trial are obliged to study the appropriate SOPs, to make 
sure they will perform their tasks accordingly. However, protocols are no guarantee for the 
proper execution of a task (55-57). Also recording of AEs, however much protocolled or 
standardized, remains in part a skilled, professional (others might call it: subjective) exercise.
After a trial has been completed, and all data have been checked by the monitor and 
found to be in agreement with the source documents, the data management system is locked: 
data can no longer be added, changed or removed. The final data are thus controlled. However, 
what happens after the data management system is locked? The data are exported and analyzed 
in programs such as Excel, Graphpad Prism or SPSS, leaving plenty of opportunities to affect 
the interpretation and presentation of the data. As any experienced researcher will recognize, 
the same set of data could result in quite different (though it is assumed: not contradictory) 
results and conclusions when analyzed by different people. To increase control over this part 
of the process, more and more journals are requiring the registration of the clinical trial in 
a publicly accessible database before inclusion of the first subject (58). Thus journals and 
readers can check whether the research questions, outcomes and methods of analysis are in 
agreement with the original plan. Furthermore, journals are increasingly formulating policies 
about making raw data files available, so that other researchers can repeat the analysis 
independently (59).18 
18 For a concrete example, see PLOS: www.plos.org/plos-data-policy-faq/ (last retrieved om April 
7, 2015)
Figure 2 The process of data-generation and different locations of control.
54
Chapter 2
The last step in the generation of scientific knowledge by clinical trials is the transfer 
of the results of data analysis into scientific papers. Here, peer-review is the institutionalized 
control of the quality of scientific data. 
The example of data management in CHMIs shows that control is exerted in many 
locations. Within the trial research community there is a strong focus on data transfer into 
the CDMS as location where control should be executed. The degree of control here seems 
to be nearly complete: the transfer of every single digit from the source document to the 
CDMS is checked and approved. But there are many other locations of control—with various 
degrees of strictness. The publicly available trial registration is such a location; comparing 
the original protocol in this database with the published article provides a measure of control 
that is certainly less strict than the data monitor’s checking of the CDMS, but more than peer-
review typically exerted in the pre-repository era. We also identified the consulting-room as 
a possible location for control: is the clinical investigator making proper use of the blood 
pressure meter? The degree of control seems much lower here, though SOPs are increasingly 
applied in order to increase control, as we will further discuss below. 
In one CHMI trial, the non-Dutch sponsor requested a new regime for controlling the 
CRF-CDMS transfer: the paper case report files needed to be written in English “to match the 
CDMS”. The sponsor intended to increase the control, since a non-Dutch speaking monitor 
would then be able to check exactly whether the paper file matched the CDMS. The outcome, 
however, is probably less rather than more control. Under this new regime something is 
left out of the CRF and therefore impossible to be checked: the translation step that the 
clinical investigator makes while talking to the volunteer in Dutch and making her notes 
in English. Where in the old regime a Dutch-and-English speaking monitor could check 
both this translation step and the transfer of data into the CDMS, the translation step is not 
accounted for in the new regime. So, in this case an intervention to increase the degree of 
control actually resulted in less control.
So, the data monitoring process involves a variety of control measures, some exerted 
by persons (e.g. the data monitor), some by institutional means (e.g. journals requiring the 
deposition of data in a publicly accessible repository), and others by machines (e.g. a blood 
pressure meter). They have complex relations to trust. In some cases they are installed to 
compensate for lack of trust and are meant to create more trust (e.g. the CRF in English rather 
than Dutch language), some are only possible because supported by underlying trust (e.g. 
peer review of the final reporting). It is these intricate relations between trust and control that 
we now turn to.
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Tandems of trust & control make the socio-technical trial 
machinery work
In this section we will argue that an important key to understanding CHMIs, clinical 
trials, and indeed scientific experiments in general, is the interplay of control and trust. 
Such a combined conceptualization of trust and control is not entirely new. Researchers in 
organizational studies have explored the “trust-control nexus” to map “the similarities and 
differences between trust-based and control-based modes of control” and asked whether 
“these modes of governance go hand in hand” and “does control chase out trust or does 
trust diminish the need for control?” (60: 260). We will now ask similar questions about 
the production of scientific knowledge and about the various relationships in carrying out 
CHMIs and other clinical trials. We will especially elaborate the distinction between trust in 
and control of persons, machines, and institutions.
Often, trust and control are considered in contrasting ways: trust tends to involve 
personal relationships, generally asks for some symmetry in them, and is commonly 
associated with subjectivity; control involves rules and protocols, often is hierarchical, 
and is associated with objectivity and standardization. Ted Porter thus proposes trust in 
quantification as an alternative to personal trust between scientists, and argues that standards 
became increasingly required by regulatory authorities in the 20th century as a response to 
distrust in these scientists’ expertise (35). More specifically about medical research, another 
historian, Harry Marks (61), noted that increasing distrust in medical practice in combination 
with a growing emphasis on efficiency led to increased standardization and regulation in 
clinical practice and medical research. 
We want to argue, however, that trust and control are not just alternatives, which 
substitute for each other when one does not suffice, but that they actually work in conjunction 
to make clinical trials and, more generally, scientific research work. We follow Guido 
Möllering’s (62: 284) plea for “a duality perspective, which entails that trust and control 
each assume the existence of the other, refer to each other and create each other, but remain 
irreducible to each other.” This will take our discussion of trust and control beyond the 
discussions in the clinical trial literature where this relationship is primarily considered in the 
context of industry-researcher and researcher-subject interactions. 
When the CCMO trusts the sponsor, when the subjects trust the investigators, when the 
investigators trust the technicians—in all cases such trust is not merely based on personal 
relationships, on the trusted persons’ good character or the color of their eyes. Such trust 
rests on the assumption that there are institutions and social structures in place that regulate 
the behavior of the other actors who are to be trusted. These social structures comprise 
the institute where the study takes place, the scientific infrastructure, the larger scientific 
community and society as a whole. Actors assuming the presence of these structures creates 
order and thereby control (62). Trust benefits from knowing that there is some measure of 
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control. Trust works in tandem with control—in this case trust in people with control by 
institutions.
Control, similarly, cannot exist without trust. Even when institutions, social structures 
and control measures are in place, actors still need to trust each other to comply with the rules 
since they cannot possibly monitor all other persons’ behavior. The CCMO, for example, 
ultimately trusts the sponsor’s abilities and intentions, because any contract or protocol 
leaves room for interpretation, and not every improper use can possibly be fully controlled. 
And data monitoring as a form of control builds on trusting that the researcher properly notes 
the data into the original paper file, whether in English or in Dutch.
Another example of such a tandem of trust & control could be seen at work in the 
previously described riddle of the difference in time-to-thick-smear-positivity between 
Oxford and Nijmegen. A new SOP to control the microscopy practices in the Radboudumc 
and Oxford labs worked in tandem with confirmed trust in the constancy of the parasite strain 
and other natural variables. So, in this case control of people combined with trust in the 
(institutional) world.
We want to highlight two aspects of tandems of trust & control. The first is that tandems 
of trust & control are sites where trust and control coproduce each other; the second is that 
they link the personal, the technical and the institutional domains. Trust and control thus 
do not only occur together and presuppose each other—they also produce each other (62). 
However, the relationship between the two elements in these tandems of trust & control is 
not unidirectional or unequivocal. Often they enhance each other (more control through the 
microscopy SOP yielded more trust by the Oxford and Nijmegen researchers in their basic 
materials and work processes), but sometimes one can partially substitute the other (more 
trust in measuring equipment might lead to less need for monitoring control of the data). 
Hence our use of the rather ambiguous term “tandem”: trust and control coproduce each 
other, but they can—within that tandem—also partly replace each other. Trust and control are 
bound together as the two riders on a tandem bicycle, including their ambivalent relationship: 
the idea is that both riders peddle and that their combined power moves the bike forward 
extra swiftly, but it is also possible that one freewheels a little (or even applies the brakes…) 
so that the other needs to push extra hard.
The investigators, for example, build and maintain trust by volunteers in the clinical 
trial’s socio-technical machinery by explicating the control measures: the frequent follow-
up visits, the testing of the drug-sensitivity of the parasite and the ethical review by an 
independent committee. The control measures produce the trust that volunteers have in 
the CHMI. Similarly, the sponsor builds and maintains trust by the CCMO, by the clinical 
supervisor and by the larger scientific community by implementing a variety of controls: the 
installation of a DSMB (though legally not required), an audit by an independent external 
party, and registration of the trial in a publicly accessible database. 
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Control thus creates trust, but this is not a simple positive association where more 
control always results in more trust, and thus in an unequivocally positive result. At a meso 
level, Collins (23) showed that when lack of trust between scientists would result in more and 
more control, an experimenter’s regress would follow and bring the production of scientific 
knowledge to a standstill. This also applies to the micro level of the scientific experiment. 
Machines and instruments are validated, checked and calibrated regularly, but at some point 
one needs to trust the validation and calibration methods for it not to result in an endless 
exercise of tests of tests. Similarly, CHMI staff members have to read and understand SOPs 
and work instructions, and sign a training record form indicating that they did so. This formal 
documentation is important for the records, but is only meaningful because of an appropriate 
balance between trust and control: rather than making them sign the form every month, the 
staff members are trusted to keep their knowledge up-to-date. So, control can produce trust, 
but more control does not always produce more trust.
Trust also produces control. The first mechanism by which this happens was already 
identified by Georg Simmel (63: 348): “the trust we receive contains an almost compulsory 
power, and to betray it requires thoroughly positive meanness”. Here Simmel examined 
interpersonal trust and stressed its moral dimension: “In the confidence of one man in another 
lies as high a moral value as in the fact that the trusted person shows himself worthy of it” 
(ibidem). Bestowing interpersonal trust on another person has a disciplining effect on that 
person, and thus results in exerting some degree of control. In the CHMIs, the interpersonal 
trust between the volunteers and the investigators thus enables methodological control: it 
helps to maintain the strict conditions that are required for a proper trial. The researchers 
bestow trust upon the subjects, for example by including them as much as possible in the 
process of the trial. Then typically the subjects will come to the check-ups on time, not drink 
more than one glass of alcohol, and generally follow the instructions. 
The second aspect of tandems of trust & control that we want to highlight is that 
they typically link the domains of persons, machines and institutions. Volunteers typically 
trust the socio-technical machinery of the trial, including the scientific instrumentation, the 
institutional infrastructure of CCMO + principal investigator + hospital institution, and the 
individual researchers they are interacting with. It is partly on the basis of this trust that 
they are willing to let themselves be controlled. The cases of the weight-lifting volunteer 
and of the Oxford-Nijmegen discrepancies in time-to-thick-smear-positivity both could 
be better understood by including the role of machines (e.g. microscopes and biochemical 
lab equipment). Another example, about interaction between the sponsor and the CCMO, 
illustrates how interpersonal trust can produce institutional control. In the Netherlands, the 
sponsor is free to choose any IRB for ethical evaluation and approval of the clinical trial. 
The CHMI sponsor submits studies for assessment to the CCMO, even though this national 
committee could be considered ‘more heavy’ and possibly ‘more strict’ than the average 
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local IRB. The CHMI sponsor trusts the CCMO. Based on many years of experience, he 
knows the members to be scientifically capable, to assess the protocol critically but fairly, to 
ask pertinent questions and to make reasonable demands. Vice versa he will readily provide 
them with all documentation, answer all questions that arise, and candidly discuss difficulties 
in the trial design. Interpersonal trust between sponsor and CCMO staff thus supports and 
perhaps to some degree even substitutes institutional control of the trial by the CCMO. This 
is, however, not without risk as Adam Hedgecoe (19) describes. We will discuss this issue at 
a more general level in the final section.
Implications for trial design and science studies
We have argued that both control and trust are crucial for the socio-technical machinery of 
clinical trials to function—not just as alternatives, but in tandem coproducing each other. 
This, then, sets two further agendas—first, a design-experimentation agenda for clinical 
trials; and, second, a research agenda for the sociology of scientific knowledge. 
If control and trust work in conjunction to make the socio-technical machinery of 
the clinical trial work, can researchers then also strategically shape them, to improve the 
functioning of a CHMI? Can clinical researchers decide where and how to locate control, 
which institutions and people to trust, and where to apply one to enable the other? An example 
from our fieldwork suggests that this is the case. After an SAE in 201319 the researchers 
decided to change the CHMI protocol and increase control by adjusting the treatment criteria. 
Rather than treating subjects at the time that parasites are detected by thick smear, the 
investigators decided to replace thick smear analysis by PCR as primary treatment criterion 
since the latter is a more sensitive method and thus leading to earlier treatment. The increased 
control of this adjusted treatment paradigm will lead to lower parasitemia and is expected 
to result in fewer complaints and possible complications. This helped to restore trust by the 
CCMO in the CHMI protocol. The CCMO approved the next trial. In this tandem of trust & 
control, a change in the control machinery led to an increase in institutional trust.
So, the shift from thick smear to PCR meant more control and resulted in more trust; 
but it came at a cost. The PCR-instigated treatment has a scientific disadvantage, because 
information about the development and kinetics of parasitemia is obtained over a shorter 
and thus less informative period since volunteers are treated earlier. So the design decision 
to change the protocol entailed a trade-off: less scientific output against higher safety. This 
is one example in which a conscious and strategic change in the tandem of trust & control 
(though these words were not used at the time) had direct effects on the production of 
scientific knowledge. 
19 Acute myocarditis occurred in a volunteer participating in a CHMI trial. This SAE is described 
in detail by Van Meer et al. (64). 
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Trying to control everything, as the clinical trial textbook suggests, does not work: 
protocols and standards cannot cover everything. In designing experiments and trials, as well 
as in running them, researchers must decide how to balance control and trust. One could, as 
it were, perform a ‘sensitivity analysis’20 to assess where and how trust and control could 
be best applied: one could do thought experiments to see how the machinery might work 
differently when designed with differently attuned tandems of trust & control. Some critical 
reflection on the trend of increased control, which we mentioned before (see figure 1), might 
thus lead to rebalancing the tandem of trust & control and consciously investing more in 
trust relations. Investing in the trust relation between, for example, the ethical committee and 
researchers by creating semi-public scientific meetings between committee members and 
researchers—rather than restricting the interactions to documents, forms and check-boxes—
could be one way of countering the trend of over-regulation and production of an illusion of 
security through control.
The multi-domain aspect of tandems of trust & control is particularly useful. Hedgecoe 
(19) describes a severe drug trial disaster at London’s Northwick Park Hospital in 2006, in 
which six volunteers fell unexpectedly and seriously ill. They were sent to an intensive care 
unit and eventually all survived, but at least one of them never completely recovered. The 
ensuing press coverage made this trial “world famous”. An Expert Scientific Group, which 
investigated the event, concluded that the trial, “however unfortunate for the individuals 
effected, did what it was designed to do”—reveal the toxicity of a drug. In contrast, many 
public press media “insisted that given the severity of what went wrong, someone must be 
at fault“ (19: 60). Hedgecoe’s analysis is that both the expert group and the newspapers 
are wrong and that something happened that is similar to Snook’s (65) “practical drift”. In 
his analysis of the shooting down of two US helicopters over Iraq by ‘friendly fire’, Snook 
shows how in an incremental process the day-to-day practice gradually drifted away from 
the written guidelines.21 Hedgecoe concludes that something similar happened in the trial in 
Northwick Park Hospital. His central observation is that good personal relations between 
the research ethics committee and the researchers “can, on occasion, serve as the basis of 
pathological decision making.” (19: 63). 
Hedgecoe’s observation can be read as a critical warning about the good personal 
relationships we described as existing between the CCMO and CHMI researchers. It is 
exactly a similarly good relationship between ethical reviewers and researchers that in the 
Northwick Park Hospital trial caused the “organizational deviance [to be] normalized within 
and by the culture shared between the part of the company running the research and the 
Research Ethics Committee which approved the trial.” (19: 74). We now want to suggest that 
20 We thank Koen Dechering, CEO of the Radboudumc spin-off TropIQ, for this formulation.
21 Snook’s concept of practical drift has been taken up more widely in STS studies of risk and 
vulnerability (66, 67). Diana Vaughan’s (68) study of the Challenger disaster makes a similar 
argument about “normalization of deviance.”
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this drift and organizational deviance could happen because the tandem of trust & control 
in the Northwick Park case became too mono-dimensionally personal. Maintaining, and if 
necessary increasing, the multi-domain aspect of tandems of trust & control—incorporating 
technological and institutional means of trust and control in addition to personal trust and 
control—will make such drift processes less likely to happen. The requirement that trials in 
Nijmegen—in addition to the CCMO approval—seek permission by the Radboudumc Board 
of Directors, as we mentioned at the end of the section on medical ethics assessment, is an 
extra institutional control that helps to guard against possible ‘drifting’ unchecked by the 
good personal trust relationship between the CCMO secretary and the researcher.
The second implication of our argument can be translated into a research agenda for the 
social studies of science and technology. The construction of scientific knowledge can, we 
want to suggest, be understood in terms of tandems of trust & control: by tracing how specific 
combinations of trust and control shape scientific knowledge during its construction. We will, 
as a first illustration, discuss two examples.
Wyatt et al. (69) analyze how the use of self-reported data in scientific research 
affects several methodological and epistemological questions, such as informed consent by 
subjects, ownership of research data, representativeness of samples, validity of data, and 
generalizability of findings. One of their cases is 23andMe, a large and well-known company 
offering genetic testing online. The tests are not just offered to their web-site visitors, but 
the accumulated self-reported data from these consumers is used by 23andMe for scientific 
research. Quoting a report in WIRED Magazine, Wyatt and colleagues suggest that this online 
use of self-reported data bypasses “centuries of epistemology in favor of a more Googley 
kind of science” (69: 137, 70). 
It is crucial for 23andMe to build up a trust relationship with its consumers. After 
persuading them to “part with their money and saliva”, the company needs to exert control 
over these customers/subjects to transform them “into research participants, willing to share 
information about themselves, not just once, but regularly and often.” (69: 145). Because of 
the exclusively online relationship with these customers/subjects/participants, such control 
can only be exerted through trust. In this tandem of trust & control, several institutional 
and technological means can be identified. First, 23andMe obtained ethical approval from 
an (albeit commercial) IRB and presents this proudly on its website to generate trust—not 
only by its customers, but also by the scientific community. Second, Wyatt and co-authors 
demonstrate how 23andMe tries to build this trust through a variety of ‘material, literary and 
social technologies’ (71), such as rhetorical techniques on the website and in surveys, the 
(claimed) use of encryption and firewall technologies to guarantee privacy, and of course its 
genetic tests. By use of this tandem of trust & control, 23andMe seeks to circumvent problems 
of self-reported data such as quality of data, verifiability of data, and representativeness of 
sample, and thus to produce credible scientific knowledge.
61
CHMIs: tandems of trust and control construct scientific knowledge
We have shown how tandems of trust & control allow the complex clinical trials 
with malaria-infected human volunteers to produce scientific knowledge. This insight from 
studying CHMIs can, we have argued, also be extrapolated to other scientific experiments. 
Vice versa, our science-studies analysis of CHMIs can inform and inspire changes and 
improvements in the design and execution of clinical trials by strategically modifying 
tandems of trust & control.
List of abbreviations
3D7 Clone of NF54 Plasmodium falciparum strain
AE Adverse Event
CCMO Central Committee on Research Involving Human Subjects
CDMS Clinical Data Management System
CEO Chief executive officer
CHMI Controlled Human Malaria Infection
CRF Case Report Form
CRO Contract Research Organization
DSMB Data and Safety Monitoring Board
GCP Good Clinical Practice
HIV Human Immunodeficiency Virus
IRB Institutional Review Board
LDH Lactate Dehydrogenase
NF54 Nijmegen falciparum 54
NFU Netherlands Federation of University Medical Centres
NWO  Netherlands Organization for Scientific Research
PCR Polymerase chain reaction
SAE Serious Adverse Event
SCORE Systematic COronary Risk Evaluation
SCOT Social Construction of Technology
SOP Standard Operating Procedure
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Supplementary table 1 Standard Operating Procedures (SOP’s) in the Parasite Lab, Radboud 
university medical center, October 2014
Number SOP Title
RMW401 Preparation of Plasmodium falciparum culture medium
RMW403 Preparing human serum for culturing and transmission of Plasmodium falciparum 
RMW406 Giemsa staining of blood films
RMW407 Gametocyte production
RMW413 Preparation of blood with Plasmodium falciparum gametocytes for the prefeed
RMW414
Preparation of blood with Plasmodium falciparum gametocytes for sporozoite 
production
RMW415 Preparing erytrocytes for culturing and transmission of Plasmodium falciparum
RMW416 Preparation of sodium bicarbonate solution
RMW417 Preparation of Giemsa stock, phosphate buffer and Giemsa working solutions
RMW422 Cryopreservation of Plasmodium falciparum parasites
RMW423 Retrieval of Plasmodium falciparum parasites
RMW424 Checking maturity of gametocytes
RMW426 Collecting culture material for MSP/Mycoplasma PCR
RMW427 Sterility test of the medium RPMI1640
RMW428 Cleaning and decontamination of culture flasks
RNW013 Mycoplasma detection in Plasmodium falciparum cultures by PCR
RNW014 Genotyping Plasmodium falciparum strains by PCR
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Although significant progress has been made in clinical development, a protective malaria 
vaccine remains elusive. Here we review some of the immune subversive mechanisms 
used by the Plasmodium malaria parasite and propose a potentially effective strategy to 
achieve complete protection that may serve as a blue print for clinical usage. The premise 
is to modulate the immune response with drugs that neutralize suppressive functions and 
potentiate protective responses. Chloroquine may be a first attractive candidate facilitating 
protective cellular immune responses by improving cross-presentation and reducing 
suppressive regulatory T cell responses.
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Introduction
Both natural and experimental exposure to malaria parasites can lead to development of 
protective immunity, providing a strong foothold for the development of a vaccine (1-5). The 
development of a malaria vaccine has been a continuous effort over the past half century (6). 
Several strategies are being followed, aiming at the sporozoite, liver, blood and/or sexual 
transmission stages (Figure 1). The main efforts have been concentrated on development 
of a sporozoite / liver-stage vaccine against P. falciparum, on the basis of the observation 
that potent protection could be achieved by inoculation with irradiated non-replicating but 
metabolically active sporozoites (4). 
Figure 1 Plasmodium lifecycle. P. 
falciparum malaria is caused by a 
protozoan parasite that has a complex 
multi-stage lifecycle involving 
both intracellular and extracellular 
stages in human host and mosquito 
vector. Malaria infection starts by 
the bite of an infected Anopheles 
mosquito that inoculates sporozoite 
forms. Via the bloodstream they 
reach the liver and invade, mature 
and multiply in hepatocytes. Once 
released by infected hepatocytes 
into the bloodstream as pathogenic 
asexual forms they start to multiply 
in invaded red blood cells. A small 
fraction of blood stage parasites are 
committed to become sexual forms 
and mature into gametocytes that 
are responsible for transmission to 
mosquitoes. Mature gametocytes 
are ingested by blood-feeding 
mosquitoes and differentiate after a number of transitions into sporozoites and migrate to 
the salivary gland. At each mosquito bloodmeal these motile parasites are injected into the 
human host resulting in the spread of the parasite and associated disease in the population. 
Unlike sporozoites and gametocytes, which are clinically silent, only asexual stages of the 
life cycle are responsible for clinical symptoms, complications and the possibility of death. 
Figure is reproduced with permission from Richie TL and Saul A: Progress and challenges 
for malaria vaccines. Nature 2002, 415(6872): 694–701 (Nature Publishing Group).
The field of malaria vaccinology has followed the traditional vaccine approach: expose the 
host to a malaria antigen or antigens and, in the case of subunit vaccines, maximally stimulate 
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the immune response using adjuvants, immune-stimulatory compounds or self-adjuvanting 
delivery systems such as viral vectors or virus-like particles. No vaccine based on this paradigm 
has worked well, however, for inducing high grade protection against malaria in humans, and 
the majority of candidates have failed. Different formulations of a number of antigens have 
been tested in Phase 1 trials and only about a dozen candidates have been evaluated in Phase 2 
clinical field trials (WHO. Date Accessed 19th April 2010. Malaria Vaccine Rainbow Tables; 
URL: http://www.who.int/vaccine_research/links/Rainbow/en/index.html). The best vaccine 
to date, RTS,S, does not provide long term protection against infection but delays patency 
and reduces clinical severity. After several field trials demonstrating roughly 50% protection 
as measured by delays in the time to acquiring parasitemia or clinical malaria, RTS,S is 
now undergoing testing in a Phase 3 multicenter trial in Africa (7, 8). Although a milestone 
in itself and potentially a welcome tool in the combat against malaria, it is clear that better 
vaccine efficacies will be required in particular for the purpose of malaria elimination (9). 
One rational approach would be to counteract the immune-modulating effects of the parasite 
that result in slow or partial induction of protection and effective memory responses. Co-
administration of drugs with immune-modulating properties may be a strategy to meet this 
objective. 
Natural acquisition and evasion of malaria immunity 
Malaria parasites generate strong immune responses, and a degree of protective immunity 
can be acquired through natural exposure, although the mechanisms of protection are poorly 
understood (1, 2). The development of this immunity is marked initially by the ability to 
control the clinical symptoms associated with parasitemia, allowing the individual to tolerate 
significant parasite densities without overt disease. The type of clinical immunity, typically 
developing in children, is followed by resistance to parasitemia, such that older children and 
adults no longer experience high densities of asexual forms in the blood. However, sterile 
immunity is never observed in naturally exposed populations; adults living in endemic areas 
often harbor parasites albeit at low densities, and will promptly re-acquire infections if cured 
through the administration of antimalarial drugs.
Where and how invading Plasmodia are recognized and processed by the immune 
system is not well understood, but probably involves dendritic cells [DCs] with extracellular 
and intracellular pattern recognition receptors [PRRs]. PRR signal transduction determines 
the nature of the DC response, and is modulated by the PRRs involved, antigen dose, 
duration of exposure and microenvironment. Both TLR-dependent [TLR2, TLR4 and TLR9] 
as well TLR-independent [NALP3 inflammasome] pathways are involved in Plasmodium 
recognition but major differences between human and murine immune systems hamper 
conclusive interpretation (10-13). Activation of DCs preferentially leads to their maturation 
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followed by induction of T effector cells or it may lead to tolerogenic responses by induction 
of regulatory T cells [Tregs]. The ratio of effector and regulatory responses may influence 
the risk of productive malaria infection and clinical disease (14). Protection is accomplished 
by stage-specific host effector responses and seems to require both cellular and humoral 
components. While specific antibodies are primarily important against sporozoites and blood 
stages, distinct cellular responses are required for protection against liver-stage parasites (2). 
There is substantial evidence that cytotoxic lymphocytes recognize intra-hepatic parasites and 
that interferon-γ [IFN-γ] plays an essential role in protection. However, cellular mechanisms 
are also induced by infected red blood cells [iRBCs] and may control blood stages (3, 15). 
Thus, malaria manifests itself initially as an acute infectious disease in susceptible 
persons but evolves into a chronic infection with acquisition of partial immunity. The human 
immune system gradually controls acute clinical disease, but Plasmodia are adapted to 
prevent complete elimination, establishing a lowgrade, chronic infection in the majority of 
hosts. This clinical immunity is difficult to acquire and wanes once exposure is withheld. 
Thus frequent parasite exposure is required to ensure continuity of protection. The efficiency 
of mounting a protective response is challenged by the morphologically and antigenically 
distinct lifecycle stages, the existence of genetic and antigenic diversity as well as the 
parasite’s ability to modulate immune responses to its own survival benefit (1, 16). 
Malaria parasites can manipulate recognition by DCs and can compromise the induction 
of effective immune responses by stimulating Tregs or by other immunosuppressive or 
immunodiversionary tactics (14, 16, 17). However, the picture in human and animal studies 
is inconsistent and the outcome depends on the DC subset as well as the model of parasites 
and animals studied. While DC maturation may be inhibited or stimulated, the capacity to 
activate human T cells is generally impaired. Results depend on the subset of DCs studied 
and the ratio of iRBC to DCs; low ratios are stimulatory while high ratios inhibit or result in 
apoptosis (16, 17). Reduced DC function may also be the result of immune inhibition across 
parasite lifecycle stages as shown in a murine model where asexual stages in the circulation 
inhibit the generation of effective CD8+ T cell responses targeting liver stages (18). The DCs 
exhibit poor maturation and a shifted cytokine profile from primary IL-12 to IL-10 production 
upon blood stage exposure. In the P. berghei model, reduced CD8+ T cell priming is caused 
by impairment of the cross-presentation by DCs normally essential for antigen presentation 
by the exogenous route (19). Also in humans, inhibition of pre-erythrocytic T cell responses 
by blood stages is suggested by in vitro studies comparing lymphocytes from Duffy antigen-
positive individuals [exposed to P. vivax blood stages] and Duffy-negative individuals [no 
exposure to blood stages] (20). These data fit the epidemiological observation that naturally 
acquired immunity fails to prevent re-infection even in areas with high infection rates. CD8+ 
responses are relatively low in individuals from such areas and these effector mechanisms 
appear incapable of eliminating parasites from the population (21, 22). Thus, DCs that are 
74
Chapter 3
influenced by blood stages might affect clearance of liver stages upon re-infection. 
CD4+CD25+Foxp3+ Tregs are crucial for maintenance of self-tolerance and control of 
damaging pro-inflammatory responses induced by pathogens including malaria parasites. 
Expansion of Treg-populations induced by Plasmodia is generally seen in both humans and 
animal models but the functional consequences remain equivocal (14, 16). Outcomes of 
functional studies show large variation and, similar to studies of DCs, relate to the model 
and circumstances chosen. Human Treg activation, however, generally points towards lower 
pro-inflammatory responses and facilitation of blood stage infection (14). The balance 
between Th1 effector cell and Treg responses may determine the clinical presentation. Strong 
inflammatory responses may overwhelm suppressive Tregs and leave effector T cells unabated 
with possibly severe clinical symptomatology in an effort to control parasitemia. On the 
contrary strong Tregs responses dampen inflammation and symptoms but permit parasitemia 
and suppress the magnitude of T memory responses possibly owing to competition for IL-2 
(14).
Better than nature
Chronic exposure to malaria blood stage parasites may help to explain the slow generation of 
an effective immune response under natural conditions. Support for this concept comes from 
rodent studies, where sterile protection against malaria can be achieved by the inoculation 
of intact sporozoites while treating the animals concomitantly with chloroquine, a drug that 
kills parasites in the asexual blood stage but not in the pre-erythrocytic liver stage (23). 
A proof-of-concept clinical study with a similar protocol in volunteers who had not been 
previously exposed to malaria likewise showed sterile protection against an experimental P. 
falciparum malaria infection (5). This approach exposed volunteers’ immune systems to the 
full course of intra-hepatic development combined with a very brief blood stage parasitemia 
abrogated by chloroquine. The high degree of protection achieved by a relatively miniscule 
dose, that is a total of 45 infectious mosquito bites over a period of 3 months, is remarkable. 
Such inoculation rates may approach the levels in areas of periodical intense transmission 
in Africa, but sterile protection is not seen under natural conditions. A possible explanation 
for this difference is the very brief and extremely low parasite density achieved in the blood 
owing to the killing effect of chloroquine. Parasitemia in nonimmune Africans will, at the 
minimum, increase to the threshold of clinical symptoms that is at least 1000-fold higher 
compromising any protection that may result from exposure to sporozoites and liver-stage 
parasites.
Previously it has been shown that radiation-attenuated sporozoites induce >90% 
protection in humans (4). Irradiation of infectious mosquitoes disrupts the gene expression 
of sporozoites, which remain capable of hepatocyte invasion but are no longer capable of 
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complete liver-stage maturation or progression to the pathogenic blood stage. However, this 
generally requires 1000 bites by irradiated mosquitoes during five or more immunization 
sessions which is a strikingly 20-fold lower potency than the 45 bites in the human model 
using chloroquine. Similar results are found in mouse studies (23).
Many hypotheses could be generated why intact sporozoites provide substantially better 
protection than radiation-attenuated sporozoites. These include [i] improved homing to the 
liver or other sites such as lymph nodes where antigen presentation occurs, [ii] larger antigen 
yield per sporozoite due to unrestricted asexual reproduction in the liver, [iii] expression of 
late liver-stage /early blood stage antigens, which are not expressed by irradiated sporozoites. 
Although these hypotheses are plausible and should be tested, they beg the question why 
natural exposure to a few mosquito bites does not provide equivalent protection to the 
experimental model under chloroquine. What other mechanisms might be operative?
Low parasitemia may induce protective effector mechanisms as shown by Pombo et 
al. where repeated intravenous injections of low numbers of parasites followed by a curative 
treatment before patency resulted in protection against a subsequent blood stage challenge 
administered without curative drugs (3). More recently, it was shown in a murine model that 
subpatent blood stage infection with genetically attenuated blood stage parasites likewise 
provides complete protection apparently through both humoral and cellular immune responses 
(24). By contrast, high parasitemia as observed in the field may inhibit the development 
of protective immunity and may relate to inhibition of cross-presentation required for the 
induction of cytotoxic T cells (18-20). 
A cost-effective vaccine requires efficient induction of protective immunity over a short 
period of time and should therefore perform better than nature.
A fresh perspective for failing vaccines 
Malaria vaccine development faces a variety of scientific challenges and some of these 
are addressed by ongoing subunit vaccine initiatives (8, 25, 26). The most advanced 
among several recombinant protein-adjuvant combinations is RTS,S, a virus-like particle 
displaying recombinant circumsporozoite protein [CSP] on its surface, expressed together 
with recombinant hepatitis B surface antigen. The vaccine is formulated with the proprietary 
adjuvant ASO2A later replaced by its liposomal form ASO1B. Several clinical trials have 
been conducted in endemic populations including young children age 1–4 years with follow-
up up to 45 months. Both anti-CSP antibodies and CD4+ T cell responses show correlation 
with the observed partial protection. It has proven difficult, however, to achieve significant 
improvements through combination with other antigens (27).
More recently, vaccine platforms designed to induce cytotoxic T lymphocyte responses 
targeting hepatic stage parasites through gene-based approaches have achieved partial 
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protection in human volunteers challenged by infected mosquito bites. For example, in a 
heterologous vaccination strategy, approximately 25% protection was observed both after 
priming volunteers with a chimpanzee-derived adenovirus vector encoding the TRAP antigen 
then boosting with a modified vaccinia virus Ankara [MVA] vector also encoding TRAP 
(AVS Hill, oral presentation, 5th MIM Pan-African Malaria Conference, Nairobi, Kenya; 
November 2009), and after priming with naked DNA and boosting with a human-derived 
adenovirus vector [serotype 5] with both platforms encoding CSP and AMA1 (I Chuang et 
al. poster presentation, given at Malaria: New Approaches to Understanding Host-Parasite 
Interactions, Keystone Symposia on Molecular and Cellular Biology, Copper Mountain, 
Colorado; April 2010). Whether the modest protection achieved by viral vectors can be 
improved by the addition of antigens is not yet known. 
One approach to enhance the protection afforded by subunit vaccines is to combine 
recombinant protein in adjuvant with viral vectors. The former induces primarily antibodies 
and helper T cell responses, while the latter induce strong cell mediated immunity including 
cytotoxic CD8+ T cells. Combined into heterologous regimens, these two approaches might 
powerfully activate both the humoral and cellular arms of the immune system, thereby 
enabling the destruction of multiple parasite stages (28). However, all subunit vaccines 
must overcome the challenge of antigenic heterogeneity and the difficulty of protecting a 
genetically heterogeneous population.
Intact parasites attenuated by irradiation (4), genetic modification (29) or by co- 
administration of antimalarial drugs (3, 5, 23), show a superior degree of protection to subunit 
vaccines in animal studies and in controlled experimental human infections. Presenting 
potentially hundreds of antigens to the immune system, these approaches are designed to 
provide ‘something for everyone’ thereby circumventing the limitations of genetic restriction 
by broadening the antigenic repertoire. A radiation-attenuated sporozoite vaccine is currently 
undergoing clinical testing, while a genetically attenuated sporozoite vaccine will soon 
follow into the clinic. Although it is too early to judge the success of these approaches, some 
may be confronted with the generation of immune suppressive mechanisms normally used 
by wild type parasites thereby limiting their ability to protect. A major challenge may be to 
redress such malaria-associated suppressive mechanisms.
Co-administration of chloroquine may enhance protection induced by sporozoite 
inoculation owing to lowering of parasitemia and/or its immune-modulating effects. Short-
course treatment of mice with chloroquine improves the priming of naïve CD8+ T cell 
responses against soluble antigens in vivo (30). Cross-presentation of soluble viral antigens 
to specific CD8+ T cell clones in vitro is improved when DCs are pulsed with the antigen in 
the presence of chloroquine. Furthermore, if hepatitis B virus vaccine [HBV] responders are 
further boosted together with a single dose of chloroquine a substantial increase of HBV-
specific CD8+ T cells is observed (31). Presentation of soluble viral antigens to specific CD8+ 
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T cell clones by DCs is greatly improved in the presence of chloroquine, which prevents 
endosomal acidification, and seems to promote the transfer of endocytosed material into 
the cytosol. The net effect will depend on the routing and processing conditions such as 
acidification of the endosomal compartment (32).
There may be more drug choices to explore for co-administration during vaccinaton. 
Chemotherapeutic drugs have shown potential benefits for the immune response against 
tumors (33, 34). It has for instance been shown that low dose cyclophosphamide selectively 
depletes Tregs in both animal models and cancer patients with resulting enhancement of T 
cell functions. The potential benefits and safety risks of low dose cytostatic drugs in healthy 
volunteers should be carefully considered. The combined data show that orchestration of 
the antigen presenting pathways by drug modulation might tailor the immune response to a 
desired profile. The functionality of the increased numbers of Tregs observed in human and 
animal malaria is not clear but there is an inverse correlation during acute disease between 
Tregs and malaria-specific memory responses (35). Antigen presentation by immature or 
partially mature DCs conditions the emergence of Tregs. To activate Tregs, TLR9 signaling 
Figure 2 Model for modulation of cellular responses by chloroquine during malaria. Blood 
stage parasites inhibit the development of liver-stage immunity via antigen presenting 
cells and hemozoin. This results in upregulation of Tregs and therefore less effective 
establishment of CD8+ T cell responses. Chloroquine prevents the development of blood 
stage parasitemia, thereby diminishing the immune-evasing action of these parasites. 
Furthermore, it inhibits Treg induction and improves cross-presentation, therefore leading 
to a more effective CD8+ T cell response. CTL = cytotoxic T lymphocyte.
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in dendritic cells is required and mediated by hemozoin, a digestion product of hemoglobin 
produced by Plasmodium that is involved in TLR9 activation (11). Since chloroquine 
abrogates hemozoin-mediated cytokine production, this drug might inhibit this evading 
mechanism leading to a more effective establishment of immunological memory (36) (Figure 
2). 
Does combining a parenterally administered vaccine with orally administered 
chloroquine or other immunomodulatory drug hold any practical application as a novel 
vaccination strategy? Given the long half-life of chloroquine, a single administration might 
maintain effective plasma levels throughout the induction phase of an immune response, 
making it possible to administer single doses of co-drug and vaccine as the immunization 
procedure, although the effectiveness of this reduced-dose approach would need to be tested. 
In the RUNMC study, the vaccine component consisted of intact P. falciparum sporozoites, 
presenting a potentially insurmountable safety concern (5). However, both radiation-
attenuated and genetically attenuated sporozoite approaches should demonstrate very low 
levels of breakthrough blood stage infection, if they occur at all, and thus could serve as ideal 
partners for an immunomodulatory co-drug. A first step would be to test these combinations 
in order to determine the minimal protective dose of both vaccine and co-drug, as well as the 
fewest number of immunizations needed to achieve high grade protection. If chloroquine or 
another antimalarial were chosen, this approach could provide an added level of safety since 
it would treat any emergent blood stage infections even if the sporozoite vaccine were only 
partially attenuated. As long as the vaccine strain was completely sensitive to the co-drug, 
both immune modulation and protection against breakthrough blood stage infections could 
be achieved at the same time. Practical application will depend on the selected drug, drug 
half-life and vaccination regime. 
Conclusion 
In malaria where immune diversionary mechanisms are a primary immune-evasion strategy, 
co-administration of immune-modulating drugs along with the vaccine may be required 
in order to achieve high grade protection. The hypothesis of vaccination with drug co-
administration assumes that the vaccine component mimics the natural pathogen in terms of 
subverting the host immune responses. This is a reasonable assumption in the case of whole 
organism vaccines such as attenuated sporozoites. This approach might be less applicable to 
a subunit vaccine based on discrete single antigens, although even in this instance there may 
be immunodominant immune responses [repeat motifs, for example, that if suppressed would 
allow more protective, subdominant responses to emerge]. The current armamentarium of 
immunomodulatory agents used to affect the immune system including cytostatic drugs 
could have potential as co-agents and be screened for activity. Clearly dose and duration of 
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treatment will be important, not too high and not too low, to strike the balance to interfere 
with the pathogen’s adaptation strategy without preventing the host immune system from 
responding adequately and safely.
Chloroquine may be the first opportunity to test and this could be done by comparing 
the administration of chloroquine with that of less immune-modulating antimalarials, or by 
giving chloroquine with irradiated or genetically attenuated sporozoites to see if the potency 
of the vaccine is increased. Despite more than 30 years of chloroquine resistance in Africa, 
this antimalarial drug is still widely available and used for presumed treatment. Although 
responsible for increasing numbers of treatment failures, one may hypothesize that the 
immune-modulating effects of chloroquine may still have some contribution to development 
of clinical protection.
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Sporozoite immunization of animals and humans under a chemo-prophylactic cover of 
chloroquine (CPS-CQ) efficiently induces sterile protection against malaria. In humans, 
CPS-CQ is strikingly more efficient than immunization with radiation attenuated sporozoites 
(RAS), and we hypothesize that this might be partially due to CQ. CQ, an established anti-
malarial drug, is also well known for its immune modulating properties including improvement 
of cross-presentation. We therefore aimed to investigate whether co-administration of CQ 
during sporozoite immunization improves cellular responses and protective efficacy in 
Plasmodium berghei models. 
Methods
We performed a number of experiments in selected complimentary P. berghei murine models 
in Balb/cByJ and C57BL/6j mice. First, we studied the effect of CQ administration on the 
induction of protection and immune responses by RAS immunization. Next, we investigated 
the effect of CQ on the induction of circumsporozoite (CS) protein-specific CD8+ T cells 
by immunization with P. berghei parasites expressing a mutant CS protein. Finally, we 
performed a direct comparison of CPS-CQ to CPS with mefloquine (MQ) an antimalarial 
with little known immune modulating effects. 
Results
When CQ was co-administered during immunization with graded numbers of RAS, we 
observed no increase in frequencies of total memory CD8+ T cells or CS protein-specific 
CD8+ T cells. Also parasite-specific cytokine production and protection remained unaltered. 
Replacement of CQ by MQ for CPS immunization resulted in significantly reduced 
percentages of IFNγ producing memory T cells in the liver (p=0.01), but similar protection. 
Conclusions
Our data do not provide evidence for a direct beneficial effect of CQ on the induction 
of sporozoite-induced immune responses and protection in P. berghei malaria models. 
Alternatively, the higher efficiency of CPS compared to RAS might be explained by an 
indirect effect of CQ through limiting blood-stage exposure after immunization or to 
increased antigen exposure and therefore improved breadth of the immune response.
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Background
Whole sporozoite immunization approaches such as chloroquine chemoprophylaxis and 
sporozoites (CPS-CQ) and radiation-attenuated sporozoites (RAS) efficiently induce 
protection in murine malaria models (1-3). In humans CPS-CQ is about 20 times more 
efficient than RAS, requiring bites from a total of 45 versus 1000 mosquitoes, respectively 
(4-6). Moreover, long-lasting immune responses after CPS-CQ immunization in studies with 
mice (7) and healthy human volunteers (8) go together with protracted protection. Several 
murine studies have demonstrated the essential role of CD8+ T cells in sporozoite-induced pre-
erythrocytic immunity (2, 9-14). Generation of these CD8+ T cells against pre-erythrocytic 
antigens requires cross-priming by dendritic cells (15). 
CQ has since its discovery in 1934 been used widely and successfully as antimalarial, 
until resistance developed (16), and has more recently been explored for treating cancer and 
viral infections (17, 18). Interestingly, CQ was also shown to enhance cross-presentation of 
soluble antigens and non-replicating influenza virus in vitro (19, 20). Moreover, in vivo cross-
priming of naïve CD8+ T cells with soluble ovalbumin was more effective in CQ–treated 
compared to untreated mice (21), and CQ improved the induction of influenza-specific 
cytolytic T cells in mice (20). In humans, co-administration of CQ with a hepatitis B vaccine 
booster significantly increased the number of virus-specific IFNγ-producing CD8+ T cells 
(19).
We hypothesized that CQ, which affects endosomal acidification and the degradation 
and transport of antigens to the cytosol (22, 23), could favor cross-presentation of pre-
erythrocytic Plasmodium antigens and thereby contributed to the efficient induction of 
immune responses and protection by CPS-CQ immunization. We first studied the effect 
of CQ on immunization by RAS, an established immunization model relying on CD8+ T 
cell responses, thus potentially benefiting from improved cross-presentation. CD8+ T cells 
recognizing the immunodominant circumsporozoite (CS) protein can mediate protective 
immunity (24), so we next investigated the effect of CQ on the induction of CS-specific CD8+ 
T cells by immunization with P. berghei parasites that express a mutant CS protein containing 
the model SIINFEKL H-2Kb epitope. Finally, we performed a direct comparison of CPS-CQ 
to CPS with mefloquine (MQ) an antimalarial with little known immune modulating effects 
(25-27), not including improvement of cross-presentation. Akin to CQ, MQ induces arrest of 
early blood-stage parasites without an effect on pre-erythrocytic parasite stages, allowing full 
liver-stage development and brief exposure to early blood stages. By performing experiments 
in these selected complimentary P. berghei murine models we aimed to explore the effect of 





Balb/cByJ and C57BL/6j mice (6 to 8 weeks old) were purchased from Elevage-Janvier (Le 
Genest Saint Isle, France). These mouse strains were selected based on extensive experience 
with these strains for malaria immunization studies (28). We used P. berghei (ANKA) wild 
type parasites and P. berghei CS5M parasites in which the endogenous CS gene had been 
replaced with a modified circumsporozoite gene expressing the H-2Kb restricted SIINFEKL 
(15). Sporozoites  were obtained by dissection of the salivary glands of infected female 
Anopheles stephensi mosquitoes 21-29 days after a blood meal on infected mice. All animal 
studies and procedures performed in the Netherlands were approved by the Ethical Committee 
on Animal Research of the Radboud University Nijmegen (RU-DEC 2009-179, 2009-225, 
2010-115, 2010-135). Mice were housed at the Central Animal Facility in Nijmegen and 
received a standard diet and water ad libitum. All animal procedures in the United States of 
America were approved by the Institutional Animal Care and Use Committee of the Johns 
Hopkins University (Protocol Number MO10H167) and followed the National Institutes of 
Health guidelines for animal housing and care. 
Immunization schedules, sporozoite challenge and assessment of protection
Mice were immunized with one (Balb/cByJ; . S1A) or two to three (C57BL/6j; Figure S1B) 
intravenous (iv) injections of P. berghei RAS (16krad, Gammacel 1000 137Cs) at weekly 
intervals or with one intradermal injection of P. berghei CS5M RAS (Figure S1C). Dose 
de-escalation of RAS immunization was performed in order to obtain a suboptimal RAS 
dose to detect possible beneficial effects of CQ (Figure S1A and S1B). In RAS experiments, 
RAS-CQ groups received either CQ prophylaxis (chloroquine diphosphate, Sigma-Aldrich) 
for 10 days (Balb/cByJ –1040µg base/day oral) or 17 days (C57BL/6j –800µg base/day 
intraperitoneal). Efficacy of these prophylactic regimens was established in pilot studies, 
and they were chosen because of their closest resemblance to the human CPS-protocol. 
Alternatively, mice were given two subcutaneous injections of 500µg CQ base, 2h before 
and 6h after each immunization, because this particular regimen was previously shown to 
improve cross-presentation (Figure S1B)(20, 21).
Furthermore, mice under CQ or MQ prophylaxis were immunized three times at weekly 
intervals by intravenous administration of 20,000 wild-type PbSPZ (CPS immunization; 
Figure S1D). For CPS immunization, CQ (diluted in PBS) and MQ (diluted in DMSO/water 
for injection) were given orally for 24 consecutive days at dosage 1040µg base/day (CQ) or 
350µg base/day (mefloquine hydrochloride, Sigma-Aldrich) starting from the first day of 
PbSPZ administration. 
Challenge infections were performed by intravenous injection of 10,000 or 50,000 
sporozoites around four or eleven weeks after the end of CQ/MQ prophylaxis. Giemsa-
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stained blood smears were screened for parasitized red blood cells every other day from days 
3-14 and finally on day 21 after challenge. Protection was defined as the absence of blood-
stage parasites until day 21 post-challenge (Figure S1A, S1B and S1C). 
Ex vivo memory phenotyping and in vitro IFNγ responses against sporozoites and 
blood-stage parasites 
Mice were euthanized by isoflurane inhalation after intravenous injection of 50 units heparin. 
Spleen and liver were collected after perfusion of the liver with 10ml PBS. Cell suspensions of 
liver and spleen were made by passage of the organs through a 70-µm nylon cell strainer (BD 
Labware). Liver cells were re-suspended in 35% Percoll (GE Healthcare) and centrifuged at 
800g for 20min. Liver and spleen erythrocytes were lysed using 5 min incubation on ice in 
a lysing solution of ammonium chloride. After erythrocyte lysis, hepatic mononuclear cells 
(HMC) and splenocytes were re-suspended in RPMI 1640 medium. 
Five-color staining of HMC and splenocytes was performed using monoclonal 
antibodies purchased from Biolegend: Pacific blue-conjugated anti CD3 (17A2), Peridinin 
Chlorophyll Protein (PerCP)-conjugated anti CD4 (RM4.5), Alexa fluor 700-conjugated anti 
CD8a (53-6.7), fluorescein isothiocyanate (FITC)–conjugated anti-CD44, allophycocyanin 
(APC)– or phycoerythrin-Cy7 (PE-Cy7)-conjugated anti-CD62L (MEL-14). Briefly, 106 
cells were re-suspended in cold assay buffer (PBS supplemented with 0.5% bovine serum 
albumin (Sigma-Aldrich)) and incubated for 30min at 4°C with the monoclonal antibodies. 
Cells were fixed with Fix & Perm medium A (Invitrogen) and collected in an assay buffer 
for measurement. 
For the detection of parasite-specific cytokine production, HMC and splenocytes (5x105 
cells/well) were co-cultured in complete RPMI 1640 culture medium (29) in the presence 
of P. berghei cryopreserved sporozoites (PbSPZ - 5x104/ml) or infected red blood cells 
(PbiRBC - 5x106/ml). Exposure to salivary gland preparations from uninfected mosquitoes 
and uninfected red blood cells (uRBC - 5x106/ml) were used as respective  negative controls. 
Cells were stimulated at 37°C/5%CO2 for 24 hours and Brefeldin A (Sigma-Aldrich) was 
added during the last four hours (10µg/ml final concentration). As positive control, PMA 
(100ng/ml) and Ionomycin (1.25µg/ml) (Sigma-Aldrich) were added simultaneously along 
with Brefeldin A. Cells were harvested after 24-hours in vitro stimulation and stained with 
monoclonal antibodies against CD3, CD4, CD8a and CD44 as indicated above. Fixed 
and permeabilized cells were stained with PE-conjugated anti-IL-2 (JES6-5H4) and APC-
conjugated anti-IFNγ (XMG1.2) in Fix & Perm medium B (Invitrogen) at 4°C for 30min. 
Flow cytometry was performed on a 9-color Cyan ADP (Beckman Coulter) and data analysis 




Quantification of SIINFEKL specific CD8+ T cells
Prior to intradermal immunization with 20.000 P. berghei CS5M RAS, C57BL/6j mice 
received 2*103 CD45.1+OT-1 cells and the RAS-CQ group received a 10-days CQ treatment 
(1040µg base/day – oral). Expansion of CD45.1+CD8+ SIINFEKL cells in liver and spleen 
was assessed by flow cytometry ten days after immunization as described previously (15) 
(Figure S1C).
Data analysis and statistics
Difference in protection between two groups was tested with a Fisher’s exact test. Overall 
comparisons between immunized and naïve groups were performed using the Kruskal-
Wallis test. Direct comparisons between two groups (RAS versus RAS-CQ or CPS-CQ 
versus CPS-MQ) were performed by Mann-Whitney U test. For the analysis of cytokine 
production, background responses to salivary glands and uRBC were subtracted from PbSPZ 
and PbiRBC responses, respectively, for each individual mouse. All statistical analyses were 
performed using PRISM software version 5.0 (Graphpad, San Diego, CA). A p-value of 
≤0.05 was considered statistically significant.
Results
Effects of chloroquine on RAS immunization
First, we investigated whether administration of a prophylactic regimen of CQ improved 
CD8+ memory T cell responses induced by RAS immunization in C57BL/6j mice. Ex vivo 
Figure 1 Frequencies of CD8+ Tem cells following RAS immunization of C57BL/6j 
mice under CQ cover. Percentages of CD8+ T cells with effector memory phenotype 
(CD44+CD62L- Tem) were measured one day before challenge by direct ex vivo staining 
in the liver and spleen of RAS immunized mice (filled squares), RAS immunized and CQ 
treated mice (open squares), naïve mice (filled circles) and naïve-CQ mice (open circles). 
Horizontal lines represent group medians. NS=not significant.
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analysis showed that percentages of CD8+ T cells with an effector memory phenotype 
(CD44+CD62L-; Tem) in the liver were 4-5 fold higher a day before challenge (C-1) in 
immunized compared to naïve mice (p=0.011). However, the percentage of CD8+ Tem cells 
was similar in RAS versus RAS-CQ mice (Figure 1A). Similar patterns were observed in the 
spleen with 3-fold increased Tem levels at C-1 (p=0.007, Figure 1B). 
In vitro re-exposure of immune cells to PbSPZ showed high levels of IFNγ producing memory 
T cells in both liver and spleen of RAS-immunized mice (p=0.003 and 0.027, respectively), 
which were not increased by additional CQ administration (Figure 2A). Similar observations 
were made for hepatic and splenic pluripotent memory T cells producing both IFNγ and IL-2, 
with a major contribution of CD8+ cells in the liver (Figure 2B). In summary, additional CQ 
Figure 2 Sporozoite specific cytokine responses following RAS immunization under CQ 
cover. Percentages of IFNγ (A) and IFNγ and IL-2 (B) producing memory T cells were 
measured in RAS (n=5) RAS-CQ (n=4), naïve control (n=5) and CQ-control (n=4) mice, a 
day before challenge by intracellular staining after in vitro re-exposure of liver and spleen 
cells to P. berghei sporozoites (PbSPZ). Responses of CD4+ T cells (open area), CD8+ 
T cells (grey area) and CD4-CD8- T cells (dotted area) relative to total memory T cell 
responses are presented. Background responses to salivary glands were subtracted from 
PbSPZ responses for each individual mouse. Error bars represent standard error of the 
mean. NS= not significant.
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administration affected neither frequency of RAS-induced CD8+ Tem cells, nor sporozoite-
specific cytokine production by T cells.
Next, we investigated the effect of CQ on CD8+ T cell responses against a SIINFEKL 
H-2Kb restricted epitope integrated in the circumsporozoite (CS) protein; an established 
target protein of protective immunity in mice and humans (24, 30). In line with the results 
above, mice immunized with RAS whilst under CQ cover showed similar percentages of 
hepatic and splenic CS-specific CD8+ T cells compared to untreated mice (Figure 3).
To evaluate a potential effect of CQ on RAS protective efficacy, groups of Balb/cByJ 
and C57BL/6j mice were immunized with graded numbers of RAS, then challenged and 
monitored for parasitemia. In both mice strains, reduction of immunization dose resulted in 
a stepwise decrease in protection that was not influenced by either a prophylactic regimen 
of daily CQ, or two low doses of CQ at 2h before and 6h after each immunization (Table 1). 
We also did not observe a difference in pre-patent period between RAS and RAS-CQ groups 
(data not shown). The CQ administered during immunization had no effect on the challenge 
infection, since all control mice that received CQ-prophylaxis showed the same pre-patent 
period as untreated naïve mice. 
Comparing chloroquine to mefloquine prophylaxis for CPS immunization 
Next, we studied immune responses and protection after CPS-CQ and CPS-MQ immunization. 
CD8+ Tem levels (Figure 4), IFNγ production upon in vitro restimulation with PbSPZ or 
PbiRBC and pluripotent T cells producing both IFNγ and IL-2 (Figure 5) were significantly 
increased in immunized compared to control mice. 
Figure 3 Frequencies SIINFEKL specific CD8+ T cells following RAS immunization 
under CQ cover. Prior to RAS intradermal immunization with (RAS-CQ) or without 
chloroquine (RAS), mice received injection of SIINFEKL-specific CD8+ T cells. Ten days 
after a single immunization, expansion of CD45.1+CD8+ SIINFEKL-specific cells was 
determined in the liver and spleen of both immunized groups.
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Table 1 Effect of chloroquine on RAS protective efficacy





(n) Chloroquine - Chloroquine +
#
RAS Balb/cByJ 1 1 14/16 (88) 13/16 (81)
0.5 1 4/10 (40) 4/10 (40)
0.3 1 5/10 (50) 2/10 (20)
C57BL/6j 10 3 5/5 (100) 4/5 (80)
4 3 4/5 (80) 4/5 (80)
1 3 0/5 (0) 1/5 (20)
4 2 15/23 (65) 14/23 (61) ##
None Balb/cByJ N/A N/A 1/6 (16) 0/6 (0)
C57BL/6j N/A N/A 0/10 (0) 0/15 (0)
#Mice received chloroquine prophylaxis for 10 or 17 days, with the exception of the experiment 
indicated with ##, where mice received two injections of CQ, 2h before and 6h after each 
immunization.
Although not significant, there was a trend for higher CD8+ Tem levels in CPS-CQ compared 
to CPS-MQ in both liver and spleen (p=0.08 and 0.16, respectively; Figure 4). T cells isolated 
from the liver of CPS-CQ mice showed higher IFNγ responses after in vitro re-exposure to 
Figure 4 Frequencies of CD8+ Tem cells following sporozoite immunization under CQ or 
MQ cover. Percentages of CD8+ T cells with effector memory phenotype (CD44+CD62L- 
Tem) were measured by direct ex vivo staining a day before challenge (C-1) in the liver 
and spleen of C57BL/6j mice immunized with sporozoites under CQ cover (filled triangle) 
or MQ cover (filled diamonds), naïve-CQ mice (open triangles), naïve-MQ mice (open 




 Figure 5 Sporozoite specific cytokine responses following sporozoite immunization 
under CQ or MQ cover. Percentages of IFNγ producing memory T cells were measured in 
CPS-CQ (n=10), CPS-MQ (n-9), naïve-CQ (n=10), naïve-MQ (n=10) and no-drug naïve 
controls (n=10) a day before challenge by intracellular staining after re-exposure of (A) 
liver and (B) spleen cells to P. berghei sporozoites (PbSPZ) or infected red blood cells 
(PbiRBC). Responses of CD4+ T cells (open area), CD8+ T cells (grey area) and CD4-
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PbiRBC (p=0.01) and a trend for higher IFNγ responses to PbSPZ re-exposure (p=0.09; 
Figure 5A). In the spleen, a similar trend of higher IFNγ responses in the CPS-CQ group 
was observed upon re-exposure to PbSPZ but not PbiRBC (Figure 5B). Following in vitro 
re-exposure to PbiRBC but not PbSPZ, the percentage of hepatic pluripotent memory T cells 
producing both IFNγ and IL-2 was significantly higher in the CPS-CQ group compared to 
the CPS-MQ group (p=0.02, Figure 5C). Thus, CPS-CQ resulted in somewhat higher specific 
cytokine responses compared to CPS-MQ.
Finally, mice were challenged by intravenous administration of 10,000 sporozoites five 
or ten weeks after the second booster (day 50 or 100) or with 50,000 sporozoites at day 50. 
At day 50, 100% of CPS-CQ (13/13) and CPS-MQ (21/21) immunized mice were protected 
against challenge with low (10K) or high (50K) sporozoite dose. All control mice including 
CQ (10/10) and MQ (10/10) prophylaxis groups developed blood-stage parasitemia. 
Postponement of challenge to day 100 resulted in 90% protection (9/10) in both the CPS-CQ 
and CPS-MQ group (Table 2). 
Altogether, there was no difference in protection after CPS immunization with either 
CPS-CQ or CPS-MQ, although we observed increased cellular responses after whole 
sporozoite immunization under CQ cover.
Table 2 Protection by sporozoite immunization under CQ or MQ cover#
Day 50 Day 100
(x103 PbSPZ challenge) (x103 PbSPZ challenge)
10 50 10
CPS-CQ 3/3 (100) 10/10 (100) 9/10 (90)
CPS-MQ 11/11 (100) 10/10 (100) 9/10 (90)
Naïve-CQ 0/5 (0) 0/5 (0) -
Naïve-MQ 0/5 (0) 0/5 (0) -
Naïve 0/5 (0) 0/5 (0) 0/5 (0)
#No. protected / No. challenged (% protection)
CD8- T cells (dotted area) relative to total memory CD3+ T cell responses are presented. 
(C) Hepatic IFNγ and IL-2 responses of memory T cells after re-exposure to PbSPZ and 
PbiRBC are presented similarly. Background responses to salivary glands and uninfected 
red blood cells were subtracted from PbSPZ and PbiRBC responses respectively for each 




Addition of CQ to a P. berghei RAS immunization protocol improves neither protection nor 
parasite-specific CD8+ T cells responses. Only slightly reduced T cell responses and similar 
protective efficacy are found when CPS-CQ is compared to CPS-MQ. We did not study the 
effect of CQ on cross-presentation in vitro, nor did we perform detailed mechanistic antigen 
presentation studies (31). Alternatively, we decided to investigate more functional readouts 
such as parasite-specific CD8+ T cell responses and protection from challenge infection to 
assess potential immune enhancing effects of CQ. These combined P. berghei data do not 
provide evidence for significant improvement of whole sporozoite immunization in the 
presence of CQ and therefore indicate that CQ is not responsible for the strikingly higher 
efficiency of CPS-CQ compared to RAS in humans.
Improved cross-presentation resulting in increased IFNγ production by CD8+ T cells 
has been shown in in vitro studies where dendritic cells were pulsed with soluble viral antigen 
in the presence of CQ (19). In mice, CQ was shown to enhance cross-presentation of soluble 
OVA to OT-I cells both in vitro and in vivo and to improve specific CD8+ T cell responses after 
alum-OVA immunization (21). An effect of CQ on OVA cross-presentation was observed upon 
administration of 20µg but not 200µg protein (21), suggesting that immunomodulatory effects 
of CQ are only beneficial under suboptimal immunization conditions. In our experiments, 
RAS immunization both with and without CQ induces strong cellular responses with similar 
contribution of CD8+ T cells, which translates to equal protection levels. Even after down-
titration of RAS immunization dose, which is associated with decreasing protection, clear 
improvement by CQ remains undetected.
In humans, a single administration of CQ during Hepatitis B booster vaccination 
significantly improved CD8+ T cell response (19). But despite several reports of enhanced 
immune responses by CQ in mice and men (19, 21, 23, 32), only one study has reported 
improved protection; mice immunized with a heat-inactivated influenza virus showed 
improved survival rates after challenge infection (20). The significance of improved immune 
responses for protection thus remains to be further explored.
One cannot assume that improvement of cross-presentation by CQ is applicable to 
any soluble protein or peptide, or antigens presented in the form of a whole sporozoite. 
Improvement of cross-presentation of SIINFEKL peptide (OVA
257-264
) and inactivated 
influenza virus by CQ in mice have been demonstrated (20, 21). In our study however, 
CQ administration during sporozoite immunization with SIINFEKL expressing P. berghei 
sporozoites showed no increase of SIINFEKL-specific CD8+ T cells, suggesting that 
presentation pathways and effects of CQ might differ between pathogens or antigens.
CPS-CQ immunization of C57BL/6j mice requires relatively high and lengthy drug 
prophylaxis to prevent development of P. berghei infection (K. Nganou-Makamdop, 
unpublished data). As a result, CPS-CQ mice cumulatively receive much more CQ than the 
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two doses of 800µg chloroquine diphosphate salt that were previously shown to improve 
cross-presentation (21). We therefore assessed in a separate experiment the effect of this low 
CQ-dose regimen on RAS immunization but did not find higher protection levels compared 
to RAS alone, indicating that the choice of CQ dose was not crucial.
Immune modulating effects of MQ have been reported but do not include cross-
presentation (25-27, 33). We cannot formally exclude that MQ in CPS immunization regimes 
may have similar properties as CQ. Both CQ and MQ are lysosomotropic agents that limit 
endosomal acidification (22), which for CQ is known to result in inhibition of lysosomal 
enzymes that require an acidic pH to function and the fusion of endosomes with lysosomes 
(34). As such CQ, but not MQ, has been widely used to study the role of endosomal 
acidification in cellular processes (35). CQ has also been studied extensively for its inhibitory 
effect on autophagy (17), but a recent publication suggests that MQ has similar effects on 
autophagy (36). Because both endosomal acidification and autophagy might influence antigen 
presentation, the effect of MQ on these processes may result in immune modulating effects 
just as is the case for CQ.
In the absence of evidence for a direct immune-modulating effect of CQ during whole 
sporozoite immunization, we cannot rule out that both CQ and MQ might instead contribute 
to the efficient induction of protection in an indirect way. A review of rodent sporozoite 
immunization studies demonstrates the importance of optimal exposure to the entire repertoire 
of liver stage antigens as occurs during CPS-CQ and CPS-MQ, with reduced protective 
efficacy if liver stage development is halted by drugs or in the case of RAS or genetically 
attenuated parasites (37). Furthermore, some reports show a negative effect of blood-stage 
parasites on induced pre-erythrocytic CD8+ T cell responses by interfering with dendritic cell 
function (1, 38). By limiting exposure to blood stages during CPS immunization, CQ and 
MQ might thus have an indirect positive effect on pre-erythrocytic immunity.
Conclusions
We did not find evidence of improved immune responses or protective efficacy by CQ in 
the P. berghei model. Instead, the higher efficiency of CPS compared to RAS in humans 
might be explained by an indirect effect of CQ through limiting blood-stage exposure after 
immunization or to an improved breadth of the immune response as a result of increased 
antigen exposure. In the absence of a clear immune enhancing effect of CQ here, future work 
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Supplementary Figure 1 (next page): Study designs. The effect of chloroquine (CQ) on 
immune responses and protection by whole sporozoite immunization was tested in a number 
of P. berghei models. Balb/cByJ (A) and C57BL/6j mice (B) received intravenous (iv) 
immunizations with radiation attenuated sporozoites (RAS; immunization dose in grey), 
with or without additional administration of CQ (grey bars). All mice were challenged by 
iv injection of 10x103 wild type (WT) P. berghei sporozoites (spz), and followed up with 
blood smears for the detection of parasites. (C) C57BL/6j mice were immunized with P. 
berghei CS5M RAS after receiving CD45.1+OT-1 cells, with or without CQ prophylaxis 
(grey bar). Expansion of CD45.1+CD8+ SIINFEKL cells in liver and spleen was assessed 
by flow cytometry 10 days after immunization. (D) C57BL/6j mice were immunized by 
iv administration of WT P. berghei spz while receiving either CQ or mefloquine (MQ) 
prophylaxis, then challenged after 50 days with either 10x103 or 50x103  WT berghei spz 
or after 100 days with 10x103 WT berghei spz, and followed up with blood smears for the 
detection of parasites
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Chapter 5 
Enhancement of naturally acquired 
immunity against malaria by drug use
Else M. Bijker and Robert W. Sauerwein




Combination of chemoprophylaxis with chloroquine and so-called ‘controlled human malaria 
infections’ has been shown to induce sustained and fully protective immunity against malaria 
in experimental settings. This opens possibilities of translating this approach into an effective 
and applicable strategy for the field. We review the different ways in which antimalarial drugs 
have been used for prevention of malaria in endemic settings and discuss the possibilities and 
challenges of applying a strategy of drug use and naturally acquired infection in the field.
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Introduction
Malaria remains one of the most important infectious diseases worldwide, causing almost 
655,000 deaths per year, of which the majority are children under five years of age. Intense 
malaria control interventions during the past decade have successfully established a reduction 
of more than 50% in either confirmed cases of malaria or malaria admissions and deaths 
in eleven countries of the WHO African region (1). However, increases in the number of 
malaria cases in 2009 in Rwanda, Sao Tome and Principe and Zambia, which previously 
reported reductions illustrate the fragility of the current successes. This underlines the need 
for additional and innovative strategies. 
Availability of an effective vaccine would greatly contribute to malaria control and 
elimination. It is well known that clinical immunity is acquired in endemic areas after a 
number of years and a sufficient number of naturally acquired infections (2). The search 
for malaria-vaccines against Plasmodium falciparum has been pursued for decades, with 
the main focus on the development of subunit-vaccines, but with limited success. Twenty 
candidate vaccines are currently under clinical investigation but only one product, RTS,S, 
has progressed into a phase 3 field trial having recently shown encouraging indications of 
protection in an interim evaluation (3, 4). 
One of the shortcomings of subunit-vaccines is the inability to appropriately address the 
significant antigenic diversity of target epitopes and the often-observed poor immunogenicity 
of the soluble parasite derived proteins used. Against that background a whole-parasite 
approach may perform better. Indeed, immunization with sporozoite forms has consistently 
been shown to induce >90% protection in rodents and humans in experimental set-ups (5, 6). 
Transmission intensity varies greatly in sub-Saharan Africa where individuals can be 
subjected to up to 10 infectious bites per night at certain periods of the year. Here we explore 
the idea that using medicines together with naturally acquired infection could result in the 
induction of protective immunity. We will review the different ways in which antimalarial 
drugs have been used for prevention of malaria in endemic areas and we will reflect on 
the possibilities and challenges of applying a strategy of drug use together with naturally 
acquired infection in the field (see Table for an overview of the interventions discussed in 
this review). 
Drug applications for prevention of malaria in endemic areas
Millions of travellers visit malaria-endemic areas for short periods of time while using 
chemoprophylaxis for prevention of malaria. Such practice has never been considered as a 
realistic strategy for endemic populations. Reasons include lack of sustainability, problems 
with acceptance by the community, risk of emerging drug resistance and concerns about 
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impairment of the development of natural immunity (7).
Nevertheless, the potential effects of drug administration on development of clinical 
protection in natural settings have been explored in a number of studies. Different recipes 
of chemoprevention have been applied, including mass drug administration in the general 
population and application of drugs in specific risk groups including children, infants and 
pregnant women (7). 
Intervention Definition
Chemoprophylaxis Administration of a drug in such a way that its blood concentration 
is maintained above the minimum inhibitory level
Mass Drug Administration 
(MDA)
Administration of a full therapeutic course of an anti-malarial drug 
to a whole population at risk
Intermittent Preventive 
Treatment (IPT)
Administration of anti-malarial treatment to a population at risk 
at specified time points, regardless of whether or not they are 
infected
Controlled Human Malaria 
Infections (CHMI) under 
chemoprophylaxis
Exposure of healthy malaria-naïve volunteers to Plasmodium 
infected mosquito-bites, whilst taking prophylactic drugs
Immunization by drug use and 
natural infection
Exposure to parasites under drug-cover in malaria-endemic areas
Table Overview of interventions 
Mass drug administration (MDA) involves the prescription of antimalarial drugs to 
whole populations without screening for the presence of parasitemia. This can be done either 
directly, when a curative dose of the antimalarial drug is given to an entire population; or 
indirectly, when the antimalarial is added to food, usually to salt. 
Several studies have been conducted since the late 1950’s, which show that MDA does 
substantially reduce the incidence of clinical malaria and parasite prevalence but that the 
impact of MDAs was transitory (8). Evaluation and interpretation of the true effects are 
likely compromised by missing a substantial proportion of P. falciparum infections due to 
the limited sensitivity of microscopic parasite detection (9). Submicroscopic parasitemia and 
frequent asymptomatic parasite carriage widely exist in endemic areas, particularly in those 
with very low endemicity. However, it is currently unknown what the effects on the immune 
responses are and how these individuals manage to control malaria. 
Chemoprophylaxis is the administration of a drug in such a way that its blood 
concentration is maintained above the minimum inhibitory level. Travellers who visit 
malaria-endemic areas use chemoprophylaxis to prevent malaria, and in endemic areas it has 
been applied for specific risk groups, such as children. In children, it can effectively reduce 
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overall mortality and clinical malaria attacks; it also improves mean hemoglobin levels, 
reduces severe anaemia and improves school attendance (10). 
To further increase adherence and sustainability and reduce the risk of inducing drug-
resistance, a more targeted approach has been developed. Intermittent preventive treatment 
(IPT) is the administration of a full course antimalarial treatment at specified time points 
without parasite screening. This IPT restricts the use of antimalarials to specific risk groups at 
specified time points. The idea is that parasite exposure will be less to undesired subtherapeutic 
drug-concentrations while concomitantly allowing a more effective generation of natural 
immunity in the intermittent periods between two doses of IPT (11, 12). When administered 
in the existing health system during routine visits, for example during pregnancy or at infant-
vaccinations, costs can be reduced and sustainability increased (7).
IPT was initially investigated in the context of pregnant women (IPTp), and subsequently 
extended to infants and children (IPTi, IPTc). IPTp with sulfadoxine–pyrimethamine (SP), 
administered two or three times during the second and third trimesters, effectively reduces 
disease burden and adverse outcomes of malaria in pregnancy by substantially reducing 
placental malaria [relative risk (RR) 0.48; 95% confidence interval (CI) 0.35-0.68], low 
birth weight (RR, 0.71; 95% CI, 0.55-0.92) and anaemia (13). Moreover, IPTp is readily 
implementable and cost effective (14, 15). The WHO therefore recommends IPTp with SP 
for areas with high or moderate transmission, and many countries have substantially scaled 
up delivery of IPTp, although coverage is still inadequate (16). IPTi has been shown to be 
safe in infants, with a protective efficacy of ~30% against clinical malaria and 21% against 
the risk of anaemia from the first dose until 12 months of age (17). Unfortunately, levels of 
SP resistance are on the rise in many areas, requiring adaptation of SP regimes. This further 
underlines the need for new drugs or drug combinations and for innovative interventions. 
Immune responses in the context of reduced parasite exposure
More than fifteen years ago it was suggested that interventions that reduce malaria transmission 
and thus the level of exposure may interfere with the acquisition of natural immunity (2, 18). 
This hypothesis, however, is difficult to address in the absence of an established immune 
correlate of clinical protection against malaria. More than two decades ago, a number of 
studies made attempts to investigate the effects of chemoprophylactic measures on humoral 
and/or cellular immune responses. The effect of insecticide-treated bed net use on antimalarial 
immunity has been investigated separately, showing inconclusive results that we will not 
explore further here (19-21).
While the majority of studies on humoral responses show a decrease in antibodies to 
malaria antigens after chemoprophylaxis (22-28), this may simply represent less parasite 
exposure rather than an actual loss of protective immunity. Similar results were obtained in a 
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number of IPT studies; IgG levels against crude P. falciparum lysate were significantly lower 
in Ghanian children after a single dose of SP compared to a placebo, without any evidence 
of rebound malaria (29). In Senegal, a slightly decreased antibody response was measured 
in children receiving IPTc, when compared to non-treated controls (30). In contrast, a study 
in Mozambique showed no significant difference in antibody responses between children 
receiving IPTi with SP and placebo-treated controls. Interestingly, one exception was 
observed here in that IgG and IgG1 responses to P. falciparum apical membrane antigen 
(AMA)-1 and/or merozoite surface protein (MSP)-1
19
 at ages 5, 9, and 24 months were 
actually significantly increased in the SP group (31). Therefore, these authors concluded that 
IPTi reduces the incidence of illness while allowing the development of naturally acquired 
antibody responses.
Relatively few studies have been conducted on cellular immune responses after 
chemoprophylaxis. These point towards higher lymphoproliferative responses and interferon 
(IFN)-γ production in the presence of a lower overall exposure to parasites (27, 32). 
Clinical rebound after chemoprophylactic interventions
One could argue that incidences of malaria morbidity and mortality are actually more relevant 
than immune responses after drug-based preventive measures. Prophylaxis with various 
drugs has been tested for children in many studies in Africa, Asia, Central America and the 
Pacific. Assessments showed that rebound malaria generally occurred from three months to 
one year after discontinuation of chemoprophylaxis, which was given for a period of three 
months to five years in infants aged less than one year up to children aged five to ten years. 
Different end points were used to assess rebound malaria (10). 
Of twelve studies investigating rebound-malaria after termination of chemoprophylaxis, 
nine did not show increased clinical malaria or parasitemia (10). For example, data from 
the famous Garki project in Nigeria, where pyrimethamine prophylaxis was combined with 
insecticide spraying, show large reductions in infant and child mortality rates during the 
intervention without increased morbidity or mortality afterwards (33). Similar results were 
obtained in another Nigerian study that investigated the effects of chloroquine-prophylaxis 
in children (26). Furthermore, when dapsone-pyrimethamine was administered to Gambian 
children for two years between their 3rd and 5th birthdays, there was no increase in clinical 
malaria after cessation of the prophylaxis (28). The same lack of rebound-malaria was shown 
in a study using pyrimethamine or chlorproguanil in 2–9-year-old children in Liberia (34). 
Finally, a non-immune adult population in Irian Jaya (West Papua), Indonesia, having used 
chloroquine for a year, initially showed an increased incidence of P. falciparum parasitemia 
in the post-chloroquine group but did not show any significant difference in time to first 
parasitemia and clinical malaria incidence in the complete 28-week follow-up period (35).
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Few studies have shown a significant increase in clinical malaria (36, 37). Taken weekly, 
dapsone-pyrimethamine effectively reduced the risk of clinical malaria and severe anaemia 
when given to Tanzanian infants between 2 and 12 months of age. Once stopped, however, 
the group of treated children showed a significantly higher incidence rate of clinical malaria 
compared to the placebo group (38). Gambian children receiving dapsone-pyrimethamine 
between the ages of six months and five years during the transmission season developed an 
increased risk of clinical malaria in the year after stopping chemoprophylaxis. There was, 
however, a beneficial effect of a 15% increase in survival rates during the overall surveillance 
period up until the age of seven years (39). 
The perceived fear of a clinical rebound effect was one of the arguments for limiting 
the presumptive drug use to high risk groups and/or to specified time points. Drug levels that 
fall below inhibitory concentrations in-between IPT gifts would allow for limited parasite 
exposure and may, therefore, lead to building of immunity. Indeed, the first IPTi study actually 
showed a reduction in malaria incidence for a much longer period than could have been 
expected as a direct effect of the drug, suggesting that the desired enhanced acquisition of 
immunity did occur (11). Unfortunately, this effect has not been reproduced in later studies. 
In some occasions, even a small increase in malaria incidence was observed after cessation 
of the intervention (40, 41) but, as was the case for chemoprophylaxis, most studies did not 
show a change in malaria incidence after the end of the intervention (17, 29, 42-44).
There are large methodological differences between these studies, including age group, 
drug choice, dosage, frequency and duration of administration, malaria endemicity and 
clinical evaluation. Variation in these parameters prevents the possibility to draw unequivocal 
conclusions regarding the effects of drug use on the acquisition of natural immunity. The 
combined data, however, suggest that there is insufficient empirical evidence to support the 
earlier concept that chemoprophylaxis or IPT, when given in field conditions, substantially 
impairs the development of clinical immunity. Occasional breakthrough infections seem to 
be equally effective or even better at inducing protective immunity compared to uncontrolled 
parasite exposure. Since antibody responses are consistently reported to be lower following 
chemoprophylactic interventions, cellular immune responses may be responsible for this 
clinical immunity. 
Protection by controlled human malaria infections under 
chemoprophylaxis
In contrast to data from a variety of field studies, there is strong experimental evidence that 
a combination of chemoprophylaxis and so-called ‘controlled human malaria infection’ 
(CHMI) (45) can induce fully protective immune responses. Efficient induction of sterile 
protection against malaria can be achieved in rodents by inoculation of intact sporozoites 
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under chemoprophylaxis (46, 47). In an analogous proof-of-concept CHMI study, malaria-
naïve adult volunteers received 12–15 P. falciparum-infected mosquito bites once a month 
for three months under chloroquine prophylaxis. In a subsequent challenge infection with five 
infected mosquitoes at three months post-immunization and discontinuation of chloroquine, 
immunized volunteers were completely protected. When re-challenged after >2 years, the 
majority of these volunteers was still fully protected against a CHMI. Long-lasting cellular 
immune responses, more specifically multifunctional effector memory T-cells that produce 
both IFN-γ and interleukin-2 upon ex vivo stimulation, are associated with protection (48-50).
The difference in the efficiency of inducing full protection is striking when compared 
to the situation in endemic countries where it may take years to acquire clinical protection. 
So what is the critical difference between CHMI and chemoprophylactic interventions 
in the field? Several differences may contribute to, or account for, these results: i) In the 
experimental studies, challenge infection was performed by a homologous strain, while the 
genetic diversity of Plasmodium in the field is immense. Therefore, observed protection 
may be strain-`specific; however, we do not favour this explanation, since protection from 
a heterologous challenge has been shown after immunization with irradiated sporozoites by 
mosquito bites (6); ii) Asexual parasites have been shown to suppress immune responses 
in rodent studies (51); therefore, the presence of (submicroscopic) parasitemia might be 
accountable for a compromised induction of protective immune responses in field studies; 
iii) When hepatitis B virus (HBV) vaccine responders are boosted with hepatitis B envelope 
protein vaccine with or without a single dose of chloroquine, a substantial increase in HBV-
specific CD8+ T-cells is observed in the individuals receiving chloroquine (52). Some have 
argued that exposure to Plasmodium-infected mosquito bites induces malaria-specific 
regulatory T-cells in the skin and, therefore, parasite-specific immunotolerance, which blocks 
vaccine efficacy. Chloroquine may inhibit this induction of regulatory T-cells and, therefore, 
enhance the acquisition of immunity (53). As such, the known immune-modulating effects 
of the drug chloroquine may be, at least partially, responsible for the efficient induction of 
immunity in the CHMI model (54). A clinical trial where immunization with CHMI under 
chloroquine is compared to another antimalarial drug that does not have these immune-
modulating effects, for example mefloquine, will provide clarification on this hypothesis 
(54).
Innovative application of drug use in the field 
Now that the potential for induction of complete and sterile protection has been demonstrated 
under conditions of CHMI, one may consider the translation of this to a practical application 
under field conditions. Evidence for a proof-of-concept may be obtained from a study in an 
area with a short but intensive transmission season that approaches similar inoculation rates 
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as CHMI (46). This will allow for high exposure to pre-erythrocytic antigens while blood-
stage infections are controlled. If transmission is low or virtually absent between the malaria 
seasons, one can evaluate the possibility of induced protective efficacy in the next season. 
For safety reasons, alternatives to chloroquine monotherapy have to be used because 
of the widespread chloroquine-resistance. Recently, immunization with sporozoites of the 
rodent malaria Plasmodium berghei in combination with azithromycin, pyrimethamine or 
primaquine, resulted in a high protective efficacy. Interestingly, when animals received 
azithromycin prophylaxis during sporozoite exposure, lower liver loads and superior 
protection were observed (5). The combination of azithromycin and chloroquine has 
demonstrated synergistic effect against parasite growth in vitro (55) and has shown 
substantially improved clinical and parasitological outcomes compared to azithromycin or 
chloroquine monotherapy in vivo (56). In treatment trials with azithromycin–chloroquine 
in Africa, this drug combination showed non-inferiority compared to mefloquine (57). Both 
drugs have been safely administered in all trimesters of pregnancy. Since the antimalarial 
activity of chloroquine is pleiotropic, drug resistance may be due to different mechanisms, 
each amenable to reversal by drug combination (58). This opens up exciting possibilities of 
combining azithromycin and chloroquine as an effective drug combination for immunization 
by drug use and naturally acquired infections. In this way, even in areas with chloroquine 
resistance, the antimalarial effects of both drugs and the possibly beneficial immune-
modulating effects of chloroquine could be combined. Another interesting candidate might be 
dihydroartemisinin–piperaquine, which is an effective first-line treatment for P. falciparum 
malaria in both adults and children (59, 60).
In conclusion, this concept of drug use and naturally acquired infections may be used in 
the road map towards innovative use of antimalarial drugs for the control or even elimination 
of malaria. Once field trials are as effective as the promising data from CHMI studies, the 
concept can hopefully be translated to an effective and applicable strategy for endemic 
populations.
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Volunteers immunized under chloroquine chemoprophylaxis with Plasmodium falciparum 
sporozoites (CPS) develop complete, long-lasting protection against homologous sporozoite 
challenge. Chloroquine affects neither sporozoites nor liver-stages, but kills only asexual 
forms in erythrocytes once released from the liver into the circulation. Consequently, CPS-
immunization exposes the host to antigens from both preerythrocytic and blood stages, and 
induced immunity might target either of these stages. We therefore explored the life cycle 
stage specificity of CPS-induced protection. 
Twenty-five malaria-naïve volunteers were enrolled in a clinical trial, fifteen of whom 
received CPS-immunization. Five immunized subjects and five controls received a sporozoite 
challenge by mosquito bites, whereas nine immunized and five control subjects received 
an i.v. challenge with P. falciparum-infected erythrocytes. The latter approach completely 
bypasses preerythrocytic stages, enabling a direct comparison of protection against either 
life cycle stage. 
CPS-immunized subjects (13 of 14) developed anti-circumsporozoite antibodies, 
whereas only one volunteer generated minimal titers against typical blood-stage antigens. 
IgG from CPS-immunized volunteers did not inhibit asexual blood-stage growth in vitro. All 
CPS-immunized subjects (5 of 5) were protected against sporozoite challenge. In contrast, 
nine of nine CPS-immunized subjects developed parasitemia after blood-stage challenge, 
with identical prepatent periods and blood-stage multiplication rates compared with controls. 
Intravenously challenged CPS-immunized subjects showed earlier fever and increased 
plasma concentrations of inflammatory markers D-dimer, IFN-γ, and monokine induced by 
IFN-γ than i.v. challenged controls. 
The complete lack of protection against blood-stage challenge indicates that CPS-
induced protection is mediated by immunity against preerythrocytic stages. However, 
evidence is presented for immune recognition of P. falciparum-infected erythrocytes, 
suggesting memory responses unable to generate functional immunity.
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Introduction
Malaria remains one of the most common and severe infectious diseases, with an estimated 216 
million cases and 655,000 deaths annually (1). The malaria parasite Plasmodium falciparum 
is responsible for most of these cases, particularly in sub-Saharan Africa. P. falciparum 
sporozoites are transmitted to humans by the bites of infected Anopheles mosquitoes. 
Sporozoites migrate from the skin to the liver, where they invade hepatocytes, develop and 
multiply. Approximately six days after invasion, hepatocytes rupture and merozoites are 
released into the bloodstream where they multiply in 48-hour cycles of erythrocyte invasion, 
replication, erythrocyte rupture, and release of infectious merozoites. These asexual blood-
stage parasites cause the clinical symptoms of malaria. To fight malaria, an effective vaccine 
is urgently needed. Development of vaccines generally has been stage-oriented, specifically 
targeting preerythrocytic or asexual blood stages of the parasite (2). 
In the controlled human malaria infection model, we previously showed that 
immunization of healthy malaria-naïve volunteers while they are taking chloroquine 
prophylaxis with P. falciparum sporozoites via infected mosquito bites [chemoprophylaxis 
and sporozoites (CPS)-immunization], induces long-lasting sterile protection against a 
homologous challenge infection (3, 4). The unprecedented efficacy of the CPS-immunization 
model is represented by the low dose sufficient to induce protection, i.e., three times 12–15 
infected mosquito bites, compared with 1,000 bites required in the irradiated sporozoite 
approach (5).
Chloroquine kills only developing blood stages of P. falciparum, without affecting 
sporozoites or liver stages (6). This results in transient low-level blood-stage parasitemia 
during CPS-immunization (3). Consequently, the host’s immune system will be exposed 
to a relatively broad repertoire of antigens, including sporozoite, liver-stage, and early 
blood-stage antigens. Humoral and cellular immune responses are induced against both 
sporozoites and blood stages (3, 7). In addition, many antigens are shared between these 
stages (8), leaving open the possibility that the observed protection may be mediated by 
immune responses against either of these parasite life cycle stages or a combination thereof 
(9). The absence of parasitemia after challenge infection and the predominant induction of 
preerythrocytic antibodies suggest that preerythrocytic immunity primarily is responsible 
for protection, although a possible requirement for immune responses against asexual stages 
cannot be ruled out (3). Indeed, previously it was shown that exposure to very low densities 
of blood stages may induce protection in the controlled human malaria infection model (10). 
In this study, protected subjects displayed strong parasite-specific T-cell proliferation and 
IFN-γ production (10). Moreover, CPS-immunized volunteers also exhibited strong IFN-γ 
responses upon in vitro restimulation with infected erythrocytes (7).
To explore the possible role of immunity against pre-erythrocytic- and/or blood-stage 
in protection, CPS-immunized volunteers were subjected to either a P. falciparum sporozoite 
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or asexual blood-stage challenge. Because the latter approach completely bypasses the liver 
stages, any protection seen would indicate that blood-stage immunity may contribute to CPS-
induced protection. 
Results
Twenty-five out of 42 screened subjects (median age 21 years; range 19–32) were included in 
the study (Figure S1). Fifteen volunteers were immunized according to the CPS protocol as 
described previously (3). Briefly, while taking chloroquine prophylaxis, volunteers (groups 
1 and 2) were exposed to bites of 15 P. falciparum-infected mosquitoes (8 mosquitoes with 
the NF54 strain and 7 mosquitoes with the 3D7 clone) at monthly intervals for a period of 
three months. Control volunteers (groups 3 and 4) received chloroquine prophylaxis only. 
One subject in group 1 withdrew consent after the third immunization for reasons unrelated 
to the trial. 
After the first immunization, 14 of 15 subjects (groups 1 and 2) developed transient low 
blood-stage parasitemia, as retrospectively detected by quantitative real time PCR (qPCR). 
The geometric mean of peak parasitemia was 1,378 parasites/mL [95% confidence interval 
(CI) 456-4,165 parasites/mL; Figure 1]. Thick smears remained negative except in two 
subjects (one each in groups 1 and 2), who developed a positive thick smear on day 7. Their 
peak parasitemia was 14,454 and 6,761 P. falciparum/mL. Both the severity and frequency 
Figure 1 Blood-stage parasitemia during CPS-immunization. Blood-stage parasitemia was 
measured from day 6 until day 10 after the first (I), second (II) and third (III) immunization 
by qPCR. Each line represents an individual subject (n=15); values shown as 10 on the 
logarithmic scale were negative.
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of adverse events (AEs) were similar to those in the other subjects, and chloroquine plasma 
concentrations were within the prophylactic range (53 and 56 µg/L). These two subjects were 
treated promptly with atovaquone/proguanil and continued study participation according to 
protocol. All subjects in groups 1 and 2 reported solicited AEs (mean duration, 1.0 ± 0.11 days) 
after the first immunization. The most common AEs were headache (13/15 subjects), and 
fever and nausea (both in 8/15 subjects). Four subjects experienced a grade 3 AE (headache 
n=2, malaise n=2; mean duration 1.8 ± 0.6 days), which all occurred between days 7 and 10 
after the first immunization and were considered probably related to the immunization. 
After the second immunization, four subjects developed parasitemia by qPCR 
(geometric mean peak parasitemia, 351 parasites/mL; 95% CI 43-2,857; Figure 1), whereas 
thick smears remained negative. Two subjects experienced mild or moderate AEs. After the 
third immunization, only one subject showed blood-stage parasitemia (178 parasites/mL; 
Figure 1) and three subjects experienced mild AEs. No serious AEs occurred during the trial.
Antibody levels against the circumsporozoite protein (CSP), apical membrane antigen 
1 (AMA-1) and glutamate-rich protein (GLURP) were measured before CPS-immunization 
and before challenge. CPS-immunized subjects (13/14) showed induction of anti-CSP 
antibodies (at least a twofold increase in antibody titer), whereas only a single subject (group 
1) showed a minimal increase in AMA-1 and GLURP antibody titers (Table 1). IgG was 
isolated from plasma of all immunized subjects at baseline and before challenge-infection. In 
vitro blood-stage growth inhibition assay (GIA) did not show an inhibitory effect of purified 
IgG on blood-stage parasite growth in any of the subjects (Table 1).
Table 1 Antibody titers and in vitro growth inhibition# 
I-7 C-1 Δ [(C-1)-( I-7)] p-value
Antibody 
titer (AU)
CSP 0.91 (0; 2.15) 24.3 (15.2; 48.5) 24.3 (10.8; 47.3) 0.006
AMA-1 0.12 (0.08; 0.17) 0.11 (0.09; 0.17) 0.00 (-0.03; 0.01) 0.35
GLURP 1.23 (1.01; 2.39) 1.06 (0.90; 3.39) -0.13 (-0.35; 0.14) 0.46
Growth inhibition (%) -3.3 (-7.1;-1.1) -8.6 (-10.0; -5.46) -4.4 (-6.0; 1.8) 0.03
#Antibody titers against CSP, AMA-1 and GLURP, and in vitro growth inhibitory activity of isolated 
IgG in all CPS-immunized subjects, before immunization (I-7) and on the day before challenge (C-1). 
Data are expressed as median (25;75 percentile). Differences between time points were tested using a 
paired t-test. 
The minimum therapeutic plasma chloroquine concentration is 30 μg/L (11) and 
its reported half-life varies from 5 to 58 days (11, 12). To ensure sufficient clearance of 
chloroquine in view of the very low blood-stage challenge dose, the challenge infection was 
conducted 17 weeks after the last chloroquine dose, corresponding to 21 weeks after the 
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last immunization. Group 1 (n=9) and group 3 (n=5) received a blood-stage challenge by 
i.v. administration of 3D7 asexual parasites. Group 2 (n=5) and 4 (n=5) were subjected to a 
sporozoite challenge using five mosquitoes infected with 3D7 sporozoites (13). There was no 
difference in parasitemia between CPS-immunized group 1 and control group 3; both groups 
became thick smear positive with a median prepatent period of 8.0 days (range 7.0–8.3 days 
and 8.0–8.3 days, respectively; p=0.83). Likewise, the prepatent period by qPCR was similar 
in both groups (median 5.0 days; range 3.0–5.3 days and 2.0–6.3 days, respectively; p=0.41; 
Table 2). Furthermore, there was no statistically significant difference in multiplication rates 
of blood-stage parasites between the CPS-immunized subjects and naïve controls [median 8 
(range 6–18) and 14 (range 7–24), respectively; p=0.19; Table 2 and Figure 2]. 
In group 2, challenged with sporozoites, four of five CPS-immunized subjects 
remained negative throughout the follow-up period by both thick smear and qPCR. One CPS-
immunized subject, however, showed a positive qPCR at day 21 post challenge (457 parasites/
mL; determined retrospectively). Controls in group 4 all became thick smear positive with 
a median prepatent period of 12.3 days (range 9.3–12.3; multiplication rate 10, range 5–23). 
Figure 2 Parasitemia after challenge as assessed by qPCR. Geometric mean parasite 
density ±95% CI, from day of inoculation until the day of treatment after blood-stage 
challenge [black line, group 1, CPS-immunized (n=9); dashed dark grey line, group 3, 
controls (n=5))] or sporozoite challenge [light gray line, group 2, CPS-immunized (n=5); 
dashed light gray line, group 4, controls (n=5)]. Values shown as 10 on the logarithmic 
scale were negative.
121
Pre-erythrocytic immunity mediates protection after CPS-immunization
Parasitemia in group 4 (sporozoite-challenged controls) developed approximately four days 
later compared with group 3 (blood stage-challenged controls; day 5 vs. 9 by qPCR, p=0.01, 
and day 8 vs. 12.3 by thick smear, p=0.01; Table 2). The range in prepatent periods was 
significantly smaller in group 3 (8.0–8.3 days) than in group 4 (9.3–12.3 days). The parasite 
multiplication rate in the blood of control subjects was similar in those receiving either a 
blood-stage or sporozoite challenge (14 (7–24) vs. 10 (5–23) respectively; p 0.57). 







median (range) Blood-stage parasite 
multiplication rate 
median (range)Thick smear PCR
CPS
Sporozoite 5/5 (100) N/A N/A* N/A
Blood-stage 0/9 (0) 8.0 (7.0-8.3) 5.0 (3.0-5.3) 8 (6-18)
Control
Sporozoite 0/5 (0) 12.3 (9.3-12.3) 9.0 (7.0-10.0) 10 (5-23)
Blood-stage 0/5 (0) 8.0 (8.0-8.3) 5.0 (2.0-6.3) 14 (7-24)
*One subject became PCR positive on day 21 after challenge.
All 19 unprotected volunteers reported solicited AEs considered possibly or probably 
related to the challenge (mean number of AEs per subject, 6.4; mean duration: 1.4 ± 0.1 
days), including headache, fever and nausea as the most common symptoms (Table S1). 
The peak of AEs occurred later in subjects who received a sporozoite challenge, concordant 
with the later onset of parasitemia, but there was no difference in accumulative duration 
of AEs compared with blood stage-challenged controls (Figure 3 A1 and A2 p=0.24). In 
contrast, protected subjects showed significantly fewer AEs: three of five experienced mild or 
moderate AEs (mean number/subject, 1.4; mean duration: 0.3 ± 0.1 days; p=0.002 compared 
with unprotected subjects; Figure 3A2). 
Lymphocyte counts decreased after challenge in all unprotected subjects (Figure 4A), as 
did platelet counts (Figure 4B), with the exception of one volunteer. Platelet counts declined 
below the lower limit of normal (150 x 109/L) in 9 of 19 unprotected subjects (mean lowest 
value 132 ± 10 x 109/L). D-dimer concentrations were elevated in all thick smear-positive 
subjects (n=19; mean peak concentration 3,908 ± 650 ng/mL; Figure 4C). All abnormal 
laboratory values normalized without complications; bleeding or thrombotic complications 
were not detected in any of the subjects. 
There was a remarkable difference in occurrence of fever and AEs between blood 
stage-challenged groups 1 and 3, although curves of developing parasitemia were identical 
(Figures 2 and 3). CPS-immunized subjects in group 1 developed fever at a significantly 
earlier time point than controls in group 3 (mean first day of temperature ≥37.5 °C, day 7.25 
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vs. day 8.5; p=0.002; Figure 3B1), concordant with an earlier mean decline in lymphocytes 
(Figure 4A; p < 0.01) and increase in D-dimer concentrations (mean first day of D-dimer 
>1,000 ng/mL: day 8.0 vs. day 9.0; p=0.05; Figure 4C).
We next investigated plasma concentrations of IFN-γ, a key mediator of cellular 
immunity in malaria (14), and monokine induced by IFN-γ (MIG), a downstream mediator 
in the IFN-γ pathway (15). Figure 4 D and E shows distinct increases of both IFN-γ and MIG 
plasma concentrations upon blood-stage challenge at 2-3 days earlier in group 1 compared 
with group 3 (p < 0.001). 
 
Figure 3 AEs and temperature after challenge. AEs and body temperature were recorded 
daily after challenge. Blood-stage challenge (A1) and sporozoite challenge (A2): mean 
number of possibly or probably related solicited AEs per subject. Blood-stage challenge 
(B1) and sporozoite challenge (B2): temperature (mean +SEM). Black line, group 1 (CPS-
immunized, blood-stage challenge; n=9); dashed dark gray line, group 3 (controls, blood-
stage challenge; n=5); light gray line, group 2 (CPS-immunized, sporozoite challenge; 
n=5); dashed light gray line, group 4 (controls, sporozoite challenge; n=5). 
123
Pre-erythrocytic immunity mediates protection after CPS-immunization
Figure 4 Hematological and inflammatory markers after challenge. (A) Peripheral 
lymphocyte counts (x109/L); (B) Platelet counts (difference from value at inclusion, 
x10^9/L); (C) D-dimer (ng/mL); (D) IFN-γ (pg/mL); (E) MIG (pg/mL). Black line, group 
1 (CPS-immunized, blood-stage challenge; n=9); dashed dark gray line, group 3 (controls, 
blood-stage challenge; n=5); light gray line, group 2 (CPS-immunized, sporozoite 
challenge; n=5); dashed light gray line, group 4 (controls, sporozoite challenge; n=5). Data 




This study shows that sporozoite immunization by P. falciparum-infected mosquito bites of 
human subjects while taking chloroquine chemoprophylaxis (CPS-immunization) does not 
protect against an i.v. administered blood-stage challenge infection. The presence of transient 
low-level parasitemia during CPS-immunization is sufficient to induce immune recognition 
of asexual forms, as indicated by an earlier increase of IFN-γ and MIG after blood-stage 
challenge. However, these responses apparently are insufficient to confer any functional 
blood-stage immunity. In contrast, complete protection is obtained against a sporozoite 
challenge by mosquito bites as described before (3, 4).
The previously observed absence of detectable parasitemia in CPS-immunized subjects 
after mosquito challenge suggested predominance of preerythrocytic immunity, but asexual 
stage immunity might have contributed to protection (3). In the present study, however, 
the complete lack of any sign of clinical and/or parasitological protection against even an 
unphysiologically low blood-stage infection [<2,000 ring forms, i.e. 20 fold lower than an 
estimated average of 40,000 merozoites released from a single infected hepatocyte (16)], 
suggests the complete absence of any functional blood-stage immunity. This is supported 
by the lack of antibodies against blood-stage antigens after CPS-immunization in all but one 
volunteer, and the absence of in vitro growth-inhibitory activity of IgG isolated from CPS-
immunized subjects. The single volunteer who developed detectable, although very low, 
AMA-1 and GLURP antibody levels was the only subject who experienced qPCR-detectable 
blood-stage parasitemia after all three immunizations. One immunized subject developed 
parasitemia on day 21 after sporozoite challenge, as retrospectively detected by qPCR. 
The blood-stage parasite multiplication rate after controlled human malaria infection in 
malaria-naïve subjects is 10.9 on average, but may be as low as 2 (17). With a multiplication 
rate of 2, a load of 457 parasites/mL on day 21 would be the result of an estimated 9,000 
merozoites released from the liver (i.e., one infected hepatocyte). Given the total lack of in 
vivo protection from blood-stage challenge and in vitro growth-inhibitory activity of IgG in 
all immunized subjects, the delayed prepatency in this volunteer most likely was caused by 
either a profound reduction in liver-stage burden or a prolonged liver stage and therefore 
delayed release of merozoites into the blood.
Although clinical immunity and control of blood-stage parasitemia are acquired with 
repeated parasite exposure in endemic populations, the occurrence of sterile protection 
mediated by sporozoite/liver stages alone has not been confirmed (18). Hence, this study is 
a unique and unambiguous demonstration of induction of sterile preerythrocytic immunity 
generated against nonattenuated wild-type P. falciparum sporozoites. Sterile protection 
induced by immunization with irradiated sporozoites that arrest early after liver cell invasion 
also most likely is based on preerythrocytic immunity (5). In this situation, asexual forms 
never occur, and the apparent lack of blood-stage immunity was shown in the 1970s in a 
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single irradiated sporozoite-immunized volunteer challenged with blood-stage parasites (19). 
Blood stage-challenged subjects in our study showed neither a delay in the prepatent 
period nor a reduction in asexual multiplication rate compared with naïve controls. This is 
remarkable because several studies have shown that protective immunity to P. falciparum 
blood stages can be induced readily after very few infections (10, 20): i) Adult patients 
treated with prolonged P. falciparum infections for neurosyphilis in the 1920s and 1930s 
showed clear evidence of clinical and parasitological immunity during a second asexual 
blood-stage infection by a decrease in frequency of fever and parasitemia (20), ii) Repeated 
administration of ±30 P. falciparum-infected erythrocytes followed by early treatment with 
atovaquone/proguanil induced protection against blood-stage challenge (10) in three of four 
subjects, although a potential effect of residual atovaquone blood levels could not be ruled 
out (21). A plausible explanation for the absence of blood-stage protection might be the 
short duration and low grade of parasitemia as a result of the use of chloroquine and hence 
insufficient exposure to blood-stage antigens. Induction of protective immunity against blood 
stages requires several cycles of parasite replication and sufficient duration of parasitemia 
(20, 22). Even in the trial by Pombo et al (10), in which subjects were immunized with 
unphysiologically low numbers of blood-stage parasites, treatment was initiated only after 8 
or 14 days, allowing at least four replication cycles and therefore sufficiently long exposure 
to blood-stage antigens. This stands in contrast to the CPS-immunization protocol, in which 
prophylactic levels of chloroquine constantly are present, preventing a full blood-stage 
replication cycle of parasites to occur. Thus, although the occurrence of low parasitemia 
during CPS-immunization might benefit the induction of preerythrocytic immunity as a 
result of the expression of cross-stage antigens, it clearly is insufficient to induce a functional 
protective immune response against blood stages. 
Notwithstanding the absence of protection against blood-stage challenge, we do find 
evidence for immune recognition of blood stages. Previously, we showed that P. falciparum-
infected erythrocytes elicit release of IFN-γ, mainly from innate cells including natural killer 
and γδT cells (7, 23, 24). This innate response may be enhanced through and supplemented 
by adaptive memory T cells producing cytokines (25). In addition, effector memory T cells 
produce IL-2 and IFN-γ upon in vitro restimulation with P. falciparum-infected erythrocytes 
(7). In the present study, CPS-immunized subjects, while unprotected against a blood-stage 
challenge, showed an earlier in vivo peak of plasma IFN-γ in the course of blood-stage 
infection than naïve controls, despite identical kinetics of developing parasitemia. Early 
recognition of blood stages by memory cells in these immunized subjects apparently led to an 
accelerated and enhanced production of IFN-γ and further downstream mediators, including 
the chemokine MIG (15). MIG may have contributed to the observed earlier lymphocyte 
recruitment out of the peripheral circulation. The clinical and laboratory signs/symptoms 
in the unprotected CPS-immunized and blood stage-challenged volunteers (group 1) most 
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likely represent a shift of inflammatory responses common to malaria (26) to earlier time 
points compared with the challenged controls. Thus, immune recognition represented by 
these markers took place at an earlier time point in CPS-immunized individuals compared 
with naïve volunteers, suggesting the presence of memory responses to asexual blood stages 
despite the absence of protection. 
Mechanisms and target antigens for protective immunity induced by CPS-immunization 
remain to be unraveled. Although mainly antibodies are important in controlling blood-stage 
parasitemia (27), rodent and primate studies indicate that CD8+ T-cell responses against 
parasite liver stages are critically involved in preerythrocytic immunity (28-30). Therefore, 
detailed analysis of T-cell responses will be the subject of future studies. 
Furthermore, this efficient immunization model will enable studies of antigen specificity 
of cellular and humoral immune responses for identification of potential new antigens or 
combinations thereof for subunit vaccine candidates. Malaria vaccine development to date 
has been stage oriented, aimed at targeting either the preerythrocytic or asexual blood stage of 
the parasite. Vaccines against asexual blood-stage antigens likely will not prevent infection, 
but instead may reduce parasite densities and provide protection against clinical disease. 
Preerythrocytic immunization strategies such as CPS-immunization, however, induce sterile 
protection, thereby preventing blood-stage infection (31). 
In conclusion, sporozoite immunization by the CPS protocol may induce sterile 
protection entirely mediated by immune responses against the preerythrocytic stages of 
P. falciparum. These findings support a continued focus on vaccine development toward 
preerythrocytic stages, particularly whole-sporozoite approaches. 
Materials and Methods
Study Design 
We conducted this single-center, open-label study at the Radboud University Nijmegen 
Medical Centre (Nijmegen, The Netherlands) from April 2011 until March 2012 following 
approval by the Central Committee for Research Involving Human Subjects of The 
Netherlands (CCMO NL34273.091.10). The study team complied with the Declaration of 
Helsinki and Good Clinical Practice including monitoring of data. The trial is registered at 
ClinicalTrials.gov (NCT01236612). Written informed consent of all volunteers was obtained 
before screening.
Twenty-five healthy subjects (age 18–35 years) without a history of malaria or residence 
in a malaria-endemic area in the 6 months before study entry were included (SI Materials 
and Methods, Screening of Study Subjects) and randomly assigned to four groups (groups 
1, 2, 3 and 4; Figure S1). Fifteen subjects received chemoprophylaxis and sporozoites (CPS) 
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immunization (groups 1 and 2) as described in detail in SI Materials and Methods. Ten 
controls (groups 3 and 4) received only chloroquine chemoprophylaxis. 
Seventeen weeks after discontinuation of chloroquine prophylaxis, corresponding to 21 
weeks after the last immunization, all subjects received a challenge infection. Group 1 (n=9; 
one lost to follow-up) and control group 3 (n=5) were challenged by i.v. administration of 
1,962 viable 3D7 P. falciparum-infected erythrocytes (blood-stage challenge), which were 
derived from a stock produced at the Queensland Institute of Medical Research as described 
previously (32) and used in numerous studies (10, 32-36). Group 2 (n=5) and group 4 
(n=5) were exposed to the bites of five 3D7 P. falciparum-infected Anopheles stephensi 
mosquitoes (sporozoite challenge). Subjects and investigators were aware of the study group, 
whereas primary outcome assessors were kept blinded to the allocation. All volunteers were 
treated with a curative regimen of antimalarial drugs at time of thick smear positivity, or 
presumptively on day 21 after challenge if thick smears remained negative. 
Study Outcomes
The primary study outcome was time to parasitemia after challenge, as assessed by 
microscopy (SI Materials and Methods). The prepatent period was defined as the period 
between challenge and the first positive thick smear. Volunteers were defined as protected 
from challenge if they remained thick smear negative until day 21. Additionally, parasitemia 
was measured retrospectively by real-time quantitative PCR (qPCR) (37). Blood-stage 
parasite multiplication rate was calculated as described previously (17). Assessment of in 
vitro growth inhibition and measurements of antibodies, hematological parameters, MIG and 
IFN-γ are described in detail in SI Materials and Methods.
 
Statistical Methods
Statistical analysis was performed using GraphPad Prism 5. The difference in adverse 
events (AEs) among groups was calculated by unpaired Student t test on the accumulative 
duration of AEs. Differences among groups on the first day of fever (≥37.5°C), first day of 
D-dimer increase above two times the upper limit of normal (≥1,000 ng/mL), and first day of 
detectable IFN-γ and MIG were tested by unpaired Student t test. Differences among groups 
in prepatent periods by thick smear and qPCR and blood-stage parasite multiplication rates 
were tested by the Mann–Whitney test. Differences in antibody-levels and in vitro growth 
inhibition between time points were tested by paired t test.
Analysis of lymphocyte kinetics after challenge was performed with SPSS version 
18 and based on data obtained at days 5, 6, and 7 (pretreatment). Two regression-type 
models were fitted to the data. The dependent variable was lymphocyte number, and 
independent variables were time, treatment, the interaction between time and treatment, and 
the baseline observation of the dependent variable. The longitudinal character of the data 
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was accommodated using general least-squares estimation; a heterogeneous, unstructured 
covariance matrix was assumed.
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Supplementary information Materials and Methods
Screening of study subjects   
Forty-two subjects without a history of malaria or residence in a malaria-endemic area in 
the 6 months prior to study entry were screened for eligibility based on medical and family 
history, physical examination and general haematological and biochemical tests. Serologic 
analyses for HIV, hepatitis B, hepatitis C and P. falciparum were negative in all subjects. 
Urine toxicology screening was negative and none of the volunteers was pregnant or lactating. 
All subjects had an estimated 10-year risk of developing a cardiac event smaller than 5% as 
estimated by the systematic coronary evaluation system (38). 
Preparation of P. falciparum-infected mosquitoes for CPS-immunization 
A. stephensi mosquitoes were reared at our insectary and infected by allowing them to feed 
on cultured gametocytes of P. falciparum parasites according to standard procedures as 
described previously (39). We intended to immunize the subjects with 3D7 parasites only, 
since this P. falciparum strain was to be used for the challenge infections. Initial stocks of 
3D7 parasites for immunization and challenge were kindly provided by Adrian Hill, Oxford. 
However, due to difficulties in culturing 3D7 parasites during the immunization period, we 
immunized each volunteer with seven 3D7-infected plus eight NF54-infected mosquito 
bites per immunization instead. The 3D7-strain is a clone of NF54 and both are sensitive to 
chloroquine. The percentage infected mosquitoes of the batches used for immunization 1, 2 
and 3 was 75, 85 and 90 for 3D7 and 95, 90 and 100 for NF54 respectively. Mosquitoes were 
infected with an average of 5.042 and 109.000 sporozoites for 3D7 and NF54 respectively.
Chemoprophylaxis and sporozoites (CPS) immunization procedure
Chloroquine was administered to all subjects according to a standard prophylactic regimen 
for a period of 14 weeks (98 days) as described previously by Roestenberg et al (3). While 
receiving chloroquine, Groups 1+2 (15 subjects) were immunized three times at monthly 
intervals, starting eight days after the first chloroquine dose. Immunization was performed by 
exposure to the bites of exactly 15 P. falciparum-infected mosquitoes for 15 minutes, twice 
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briefly interrupted. Following each feeding session, the salivary glands of all blood-engorged 
mosquitoes were dissected to confirm the presence of sporozoites. All ten control subjects 
(Groups 3+4) received chloroquine prophylaxis only, but no mosquito bites. 
On days 6 to 10 after each immunization we checked all 15 immunized subjects once 
daily at our outpatient clinical research department. Blood was drawn for thick blood smears, 
standard haematological markers and retrospective assessment of blood-stage parasitemia 
by quantitative real-time real-time quantitative PCR (qPCR) using P. falciparum standard 
curves prepared by DNA extraction from titrated samples of ring-infected cells (qPCR, (37)). 
All signs and symptoms were recorded by the attending physician as mild (grade 1, easily 
tolerated), moderate (grade 2, interferes with normal activity), or severe (grade 3, prevents 
normal activity), or in case of fever grade 1 (>37·5–38·0°C), grade 2 (>38·0–39·0°C), or 
grade 3 (>39·0°C). For safety reasons related to a previously reported cardiac event (40), we 
measured cardiovascular markers throughout the trial (highly sensitive troponin, platelets, 
d-dimer, and lactate dehydrogenase). Whenever abnormal, blood samples were checked for 
the presence of fragmentocytes and von Willebrand-cleaving protease activity, according to 
previous protocols (4).
Challenge infections
Seventeen weeks after discontinuation of chloroquine prophylaxis, corresponding to 21 
weeks after the last immunization, all subjects received a challenge infection. Group 1 (N=9, 
one lost to follow-up) and control Group 3 (N=5) subjects were challenged by intravenous 
administration of 3D7 P. falciparum-infected erythrocytes (blood-stage challenge), while 
Group 2 (N=5) and Group 4 (N=5) were exposed to the bites of five 3D7 P. falciparum-
infected Anopheles stephensi mosquitoes (sporozoite challenge).
Subjects were checked daily on an outpatient basis for symptoms and signs of malaria, 
thick blood smears, hematologic tests and cardiovascular markers. Subjects who received a 
blood-stage challenge were checked from the first day after challenge onwards, sporozoite-
challenged subjects from day 5 onwards. All signs and symptoms (solicited and unsolicited) 
were recorded as described for the CPS-immunization. At time of thick smear positivity, each 
subject was treated with a curative regimen of 1000 mg atovaquone and 400 mg proguanil 
once daily for three days according to Dutch national guidelines. Subjects who remained 
thick smear negative until day 21 after challenge were presumptively treated with the same 
curative regimen. Complete cure was confirmed by two consecutive parasite-negative blood 
smears after treatment. 
Blood-stage inoculum
Inocula for blood-stage challenge were derived from a stock of 3D7 P. falciparum-infected 
erythrocytes (blood group O, rhesus negative) produced at the Queensland Institute of Medical 
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Research as described previously (32). The donor was seronegative or PCR negative, or both, 
for a panel of parenterally transmissible viruses at the time of donation and one year later, but 
was IgG positive for EBV and CMV (32). The blood-stage inoculum was cryopreserved in 
Glycerolyte 57 and stored in liquid nitrogen under temperature-monitored conditions. 
To prepare the inocula for intravenous administration, an aliquot of the seed stock was 
thawed and washed under sterile conditions as described previously (33) using solutions 
licensed for clinical use and sterile, single-use consumables. Bacterial culture plates of the 
hood and both aerobic and anaerobic blood culture of the inoculum did not show any bacterial 
growth. The inoculum was prepared by diluting to the appropriate dose and dispensed 
aseptically into 5mL syringes for administration. Based on microscopic estimates of the 
donor’s parasite density prior to freezing of blood samples, each inoculum contained 4,289 
infected erythrocytes. The inocula were kept on ice during preparation. Alternating between 
CPS-immunized and control subjects, all volunteers were inoculated intravenously between 
103 and 111 minutes after thawing. The number of viable parasites in the inoculum was 
verified in retrospect by limiting dilution culture and qPCR detection as previously described 
(33, 37) and the inoculum was calculated to contain 1.962/4,289 (46%) viable/total parasites 
per subject. This recovery of viable parasites was in the range of what has been reported for 
the inoculum elsewhere (10, 33, 36).
Sporozoite challenge
A. stephensi mosquitoes fed on cultured gametocytes of P. falciparum strain 3D7 were 100% 
infected with an average of 100.000 sporozoites per mosquito. A total of 10 volunteers 
from Group 2 (N=5) and Group 4 (N=5) were exposed to bites of five infected A. stephensi 
mosquitoes for ten minutes as described previously (3). One feeding session was sufficient 
for 5 volunteers, while a second session was required in the remaining 5 volunteers in order 
to obtain an infectious challenge by exactly five infected mosquitoes in all 10 subjects. 
Study outcomes
The primary study outcome was time to parasitemia after challenge, as assessed by 
microscopy. Sampling started on a daily basis for Group 1+3 (blood-stage challenge) on 
days 1-4 and continued for all groups post-challenge twice daily on days 5 and 6, thrice 
daily on days 7-11, again twice daily on days 12-15, and finally once daily on days 16-
21. Thick blood smears were made from 15μL of EDTA-anti-coagulated blood, spread over 
the standardised surface of one well of a three-well glass slide according to harmonized 
standard protocol for Controlled Human Malaria Infections (Laurens MB, Roestenberg M, 
and Moorthy VS; manuscript in preparation). After drying, wells were stained with Giemsa 
for 30 minutes. Slides were read at 1000-times magnification by assessing 200 high-power 
fields, equal to about 0.5μL of blood. The smear was deemed positive if two unambiguously 
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identifiable parasites were found. Lymphocyte and platelet counts were determined in EDTA 
anti-coagulated blood with the Sysmex XE-5000. D-dimer concentrations were assessed in 
citrate plasma by STA-R (Roche, Almere, The Netherlands).
Immunological measurements
Concentrations of malaria antigen-specific antibodies were determined in serially diluted 
citrate plasma by standardized enzyme-linked immunosorbent assay in NUNC™ Maxisorp 
plates (Thermo Scientific) coated with 1 µg/ml full-length CSP, AMA-1 (FVO-allele, (41) 
or GLURP (42) diluted in PBS. ELISAs were developed using biotinylated polyclonal goat 
anti-human IgG (1/2500), streptavidin-conjugated horseradish peroxidase (1/2000) and 
Tetramethylbenzidine (all Mabtech). Spectrophotometrical absorbance was measured at 450 
nm. Levels of antibody reactivity were analyzed in relation to a pool of sera from adults 
living in a highly endemic area in Tanzania (3), which was defined to contain 100 arbitrary 
units (AU) of IgG directed against an antigen. Antibody responses were considered positive 
when they were increased at least two-fold after immunization, compared to baseline.
Antibodies for growth inhibition assay (GIA) were isolated from citrate plasma 
that was collected the day before the start of chloroquine prophylaxis and the day before 
challenge infection. IgG was purified using protein G columns (HiTrapTM Protein G HP, 
GE Healthcare). Eluted samples were exchanged into RPMI 1640 on a Vivaspin 20, 30kDa 
molecular mass cutoff ultra-filtration unit (Sartorius Stedim, Germany), concentrated 
to 20mg/ml, filter-sterilised and stored at -20°C until used. IgG protein concentrations 
were measured using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, 
Wilmington, DE, USA). The GIA was performed as previously described (41). Briefly, the 
effect of IgG on in vitro parasite growth was evaluated at an IgG concentration of 10 mg/
mL. Samples were run in triplicate using alanine-synchronized cultures of P. falciparum 
3D7 schizonts at an initial parasitaemia of 0.7%. After 40 to 42 hours, parasite growth was 
assessed by measuring parasite lactate dehydrogenase levels in culture supernatants with the 
lactate diaphorase APAD substrate system. EDTA (4 mM) was included in every test plate as 
positive control. Induction of growth inhibitory activity by CPS-immunization was assessed 
by subtracting for each volunteer the pre-immunization percentage of growth inhibition from 
the post-immunization value.
Monokine-induced-by-gamma (MIG, CXCL9) and interferon-γ (IFNγ) concentrations 
in frozen and stored EDTA anti-coagulated plasma samples were determined retrospectively. 
MIG was measured using a DuoSet® ELISA (R&D systems) and IFNγ was measured using 
a Ready-SET-Go!® ELISA (eBioscience) according to the manufacturer’s recommendations.
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42 Assessed for eligibility
16 Ineligible:
- 1 repetitive fainting during blood drawing
- 4 family history of cardiovascular event <50 
year 
- 3 BMI <18 or >30
- 1 history of drug use
- 6 laboratory abnormalities
- 1 unable to attend all study visits
1 Eligible but not included
25 Included and randomized
1 Lost to follow-up
15 Chloroquine Prophylaxis and  
Sporozoites Immunization
Group 1
9 Blood-stage challenge 
(4 female)
Median age 21 years (19-32)
Group 2
5 Sporozoite challenge 
(3 female)
Median age 22 years (19-30)
Group 3
5 Blood-stage challenge 
(4 female)
Median age 22 years(19-26)
10 Control
Group 4
5 Sporozoite challenge 
(3 female)
Median age 21 years (19-23)
24 Completed follow-up and included in analysis
Figure S1 Study flow diagram with relevant baseline data. Fifteen subjects were CPS-
immunized by the bites of three times fifteen P. falciparum-infected mosquitoes whilst 
taking chloroquine prophylaxis (Group 1 and 2). Ten control subjects received chloroquine 
prophylaxis, but no infected mosquito-bites (Group 3 and 4). One subject withdrew 
informed consent after the immunization for reasons unrelated to the trial. Seventeen 
weeks after discontinuation of chloroquine prophylaxis nine immunized (Group 1) and 
five control volunteers (Group 3) received a blood-stage challenge, while five immunized 































































Abdominal pain 3 1.5 ± 0.4 2 0.6 ± 0.3 0 N/A 1 0.0 
Arthralgia 1 1.6 0 N/A 0 N/A 0 N/A
Chills 2 0.8 ± 0.0 0 N/A 0 N/A 1 0.0
Fatigue 3 2.2 ± 4.3 2 2.8 ± 0.3 0 N/A 2 1.9 ± 2.5
Fever 8 1.4 ± 0.6 5 1.6 ± 1.0 1 0.3 4 0.8 ± 0.3
Headache 8 1.6 ± 0.9 5 1.4 ± 1.2 2 1.4 ± 2.2 5 1.4 ± 1.1
Malaise 3 2.3 ± 1.4 0 N/A 0 N/A 2 1.5 ± 0.7
Myalgia 6 1.6 ± 0.9 3 2.9 ± 2.7 0 N/A 1 1.5 
Nausea 8 0.9 ± 0.6 4 1.8 ± 1.5 2 0.4 ± 0.6 4 1.1 ± 1.5
Vomiting 4 0.9 ± 0.8 1 1.4 0 N/A 1 0.0 
Any 9 1.6 ± 1.5 5 1.7 ± 0.8 3 0.8 ± 1.4 5 1.0 ± 0.8
Grade 3                
Abdominal pain 1 1.8 0 N/A 0 N/A 0 N/A
Arthralgia 0 N/A 0 N/A 0 N/A 0 N/A
Chills 0 N/A 0 N/A 0 N/A 0 N/A
Fatigue 0 N/A 1 3.0 0 N/A 1 3.7 
Fever 4 1.3 ± 0.7 0 N/A 0 N/A 2 0.9 ± 0.4
Headache 1 1.0 2 1.2 ± 1.0 0 N/A 1 1.8 
Malaise 3 2.3 ± 1.7 0 N/A 0 N/A 1 2.0 
Myalgia 0 N/A 0 N/A 0 N/A 0 N/A
Nausea 6 0.9 ± 0.5 1 0.8 0 N/A 1 0.0 
Vomiting 4 0.9 ± 0.8 1 1.4 0 N/A 1 0.0 
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Immunization of healthy volunteers under chloroquine chemoprophylaxis by bites from 
Plasmodium falciparum (Pf)-infected mosquitoes (CPS immunization) induces sterile 
protection against malaria. CPS-induced protection is mediated by immunity against pre-
erythrocytic stages, presumably at least partially by cytotoxic cellular responses. We therefore 
aimed to investigate the association of CPS-induced cytotoxic T cell markers with protection. 
Methods 
In a double-blind randomized controlled trial (NCT01218893), we performed dose titration 
of CPS immunization followed by homologous challenge infection in 29 subjects. Immune 
responses were assessed by in vitro restimulation of PBMCs and flow cytometry.
Results
Dose-dependent complete protection was obtained in 4/5 volunteers after immunization 
with bites from a total of 45, in 8/9 volunteers with 30, and in 5/10 volunteers with 15 
Pf-infected mosquitoes respectively (OR=5.0; 95% CI 1.5-17). Proportions of CD4 T cells 
expressing the degranulation marker CD107a and CD8 cells producing granzyme B after Pf-
restimulation were significantly higher in completely protected subjects (OR=8.4; 95% CI 
1.5-123; p=0.011 and OR=11; 95% CI 1.9-212; p=0.004 respectively).
Conclusions 
These data underline the efficiency of CPS immunization to induce sterile protection, and 
support a possible role for cytotoxic CD4 and CD8 T cell responses in pre-erythrocytic 
immunity. 
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Introduction
Malaria remains a major public health problem, with an estimated incidence of 207 
million clinical cases leading to approximately 627,000 deaths every year (1). Plasmodium 
falciparum (Pf) is the most severe and lethal of five species that can cause malaria in humans. 
Availability of an effective vaccine will be critical to fight this disease, but currently there is 
no licensed vaccine available, despite decades of research. Most efforts have focused on the 
development of subunit vaccines, unfortunately showing only limited protective efficacy (2, 
3). Immunization strategies based on whole parasites, however, have repeatedly induced high 
levels of protection in experimental settings (4-7). Previously we showed that immunization 
of healthy, malaria-naive subjects, while taking chloroquine chemoprophylaxis, with live 
sporozoites delivered by 36-45 mosquito bites (ChemoProphylaxis and Sporozoites (CPS) 
immunization) induces robust, long-lasting sterile protection against Pf malaria (8, 9). CPS 
immunization is about 20 times more efficient than the only alternative approach for complete 
sterile protection against malaria in humans i.e. immunization with radiation-attenuated Pf 
sporozoites (RAS), requiring bites from >1000 infected and irradiated mosquitoes (4), or 
intravenous administration of 675,000 sporozoites (10).
CPS-induced protective immunity targets the earliest stages of the parasite lifecycle, i.e. 
sporozoites and/or liver stages, rather than the subsequently developing asexual blood stages 
(11). The immune pathways responsible for this pre-erythrocytic protection, however, remain 
unknown. In murine malaria models, cytotoxic killing of Plasmodium-infected hepatocytes 
appears to play a role in protection, but the exact contribution and mechanism of cytotoxicity 
remain elusive (12, 13). Also in humans, a role for both cytotoxic CD4 T cells and CD8 T 
cells has been suggested, but evidence is scarce and largely circumstantial (reviewed by 
Tsuji et al. (14)). We conducted a double-blind randomized controlled CPS immunization 
dose titration and challenge study. Subjects, while taking chloroquine prophylaxis, were 
immunized by bites from a total of 45 (3x15), 30 (3x10) or 15 (3x5) infected mosquitoes 
followed by a challenge infection, resulting in dose-dependent protection. Next, we explored 
markers of cytotoxic T cell responses induced by CPS immunization and identified two 
cytotoxic markers associated with protection.
Materials and Methods
Human ethics statement
All subjects provided written informed consent before screening. The study was approved 
by the Central Committee for Research Involving Human Subjects of The Netherlands 
(NL33904.091.10) and complied with the Declaration of Helsinki and Good Clinical Practice 
including monitoring of data. ClinicalTrials.gov Identifier: NCT01218893.
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Clinical trial design and procedures
A single centre, double-blind study was conducted at the Leiden University Medical Center 
from April 2011 until April 2012. Healthy subjects between 18 and 35 years of age with no 
history of malaria were screened as described previously (11). Thirty subjects were randomly 
divided into four groups using a computer-generated random-number table. Subjects, 
investigators and primary outcome assessors were blinded to the allocation. All subjects 
received CPS immunization as described previously (8, 11), but the number of NF54 Pf 
infected versus uninfected mosquitoes varied per group: five subjects received three times 
bites from 15 infected mosquitoes (Group 1), ten subjects received three times bites from 
10 infected and 5 uninfected mosquitoes (Group 2), ten subjects received three times bites 
from 5 infected and 10 uninfected mosquitoes (Group 3) and five control subjects received 
three times bites from 15 uninfected mosquitoes (Group 4). Nineteen weeks after the last 
immunization (fifteen weeks after the last chloroquine dose), all subjects were challenged 
by the bites of five mosquitoes infected with the homologous NF54 Pf strain, according to 
previous protocols (8, 15). The primary outcome was prepatent period, defined as the time 
between challenge and first positive thick blood smear. Thick blood smears were prepared 
and read as described previously (11). For more details about the immunization and challenge 
procedures and follow-up, see supplementary information.
Immunological methods
Peripheral blood mononuclear cells (PBMCs) were collected on the following time points: 
before initiation of chloroquine prophylaxis (baseline; B), 27 days after each immunization; 
I1, I2 and I3 (I1 and I2 are one day before the second and third immunization respectively), 
the day before and twenty weeks after the challenge infection (C-1 and C+140). For the 
assessment of Pf specific immune responses, PBMCs were restimulated in vitro with Pf 
infected red blood cells (PfRBC) as described before (16). Expression of the degranulation 
marker CD107a, the cytotoxic molecule granzyme B and the cytokine IFNγ by CD4, CD8 
and γδ T cells was assessed by flow cytometry. For a detailed description, see supplementary 
information.
Statistical analysis
The dose-dependent induction of protection was tested by logistic regression using SPSS 20. 
Comparison of CD107a expression and granzyme B and IFNγ production by T cell subsets 
between immunized unprotected and protected volunteers after CPS immunization was done 
per selected cellular response by means of Firth’s penalized logistic regression (17, 18), 
resulting in p-values, odds ratios (OR) related to a change of one interquartile range, and 95% 
profile likelihood Confidence Intervals (95% CI) for the OR, using R software version 3.0.1 
(19), with R packages logistf version 1.21 (20), rms version 4.1-3 (21) and penalized version 
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0.9-42 (22, 23). The ability of (a combination of) markers to discriminate between protected 
and unprotected volunteers was assessed with the Area under the Receiver Operator Curve 
(ROC), based on leave-one-out cross-validation (LOOCV), using the R-software and pROC 
package version 1.7.1 (24). For further details, see supplementary information. 
Results
CPS immunization
Thirty volunteers were included (median age 21 years, range 19–31), out of sixty-three subjects 
screened for eligibility (Figure S1). Volunteers were randomly assigned to four groups and 
received CPS immunization by bites from 3x15 (Group 1, n=5), 3x10 (Group 2, n=10) or 3x5 
(Group 3, n=10) mosquitoes infected with strain NF54 sporozoites. Control subjects (Group 
4, n=5) received chloroquine prophylaxis and bites from 3x15 uninfected mosquitoes. After 
each consecutive immunization the number of subjects with parasitemia, as retrospectively 
detected by qPCR, steadily decreased in Group 1 and 2. In Group 3, however, five volunteers 
still showed parasitemia after the second and third immunization (Figure 1). Remarkably, in 
four immunized subjects, parasitemia was never detectable by qPCR at any time point (three 
subjects in Group 2, one in Group 3). One subject from Group 2 withdrew consent after the 
first immunization for reasons unrelated to the trial, and was excluded from the analysis.
Challenge infection
Nineteen weeks after the last immunization, volunteers were challenged by standard exposure 
to bites from five homologous strain NF54-infected mosquitoes (5). 
Table 1 Protection against challenge infection after CPS immunization. 





Day of positivity after challenge 
(TS+ subjects)c
Numbera Percentageb Thick smear qPCR
Group 1 (3x15) 4/5 80 (36.0 – 98.0) 12.0 9.5
Group 2 (3x10) 8/9 89 (54.3 – >99.9) 12.0 8.5
Group 3 (3x5) 5/10 50 (23.7 – 76.3) 11.0 (9.0-15.0) 9.0 (6.5-13.0)
Group 4 (Control) 0/5 0 (0.0 – 48.9) 9.5 (9.0-13.5) 6.5 (6.5-10.5)
a Presented as protected/total number of subjects
b Presented as % protected (95% CI by modified Wald Method)
c Presented as median (min-max).
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Protection by CPS immunization was dose-dependently induced in four out of five subjects 
in Group 1, eight out of nine subjects in Group 2 and five out of ten subjects in Group 3, while 
Figure 1 Parasitemia after the 
first, second and third CPS 
immunization. Parasitemia was 
determined once daily by qPCR 
from day 6 until day 10 after 
each immunization. Each line 
represents an individual subject. 
Panels show data for volunteers 
from (A) Group 1 (3x15), (B) 
Group 2 (3x10), (C) Group 3 
(3x5) and (D) Group 4 (controls). 
Values shown as 10 on the log-
scale were negative (i.e. half the 
detection limit of the qPCR: 20 
parasites/ml). The number of 
subjects with a positive qPCR/
total number of volunteers after 
each immunization are shown 
below the graphs.
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all control subjects became thick smear positive (OR=5.0; 95% CI 1.5-17; p=0.01). 
The median prepatent period was 2.5 days longer in CPS-immunized unprotected 
subjects compared to controls, both by thick smear and qPCR. Although not statistically 
significant (p=0.22 and 0.31 respectively), this delay is suggestive for the presence of partial 
protection at least in some of the unprotected CPS-immunized subjects (Figure 2 and Table 
1). In retrospect, all six volunteers with detectable parasitemia by qPCR after the third 
immunization were not completely protected from challenge infection, while 17 out of 18 
subjects with a negative qPCR after the third immunization were fully protected. 
Platelets decreased below reference value (150x109/L) in eight out of twelve thick 
smear positive (TS+; i.e. both controls and CPS-unprotected) subjects at any point after 
challenge (median for all TS+: 134x109/L, range 79 - 213x109/L). D-dimer was elevated in 
all TS+ subjects after challenge (median peak concentration 2431 ng/mL, range 1014-5000 
Figure 2 Parasitemia after challenge infection. Parasitemia was assessed retrospectively 
by real-time quantitative PCR (qPCR) from day 5 after challenge onwards, up until day 
21, at two time points per day for TS+ volunteers, and one time point per day for protected 
volunteers. Each line represents an individual subject. Grey dotted lines show CPS-
immunized volunteers from group 1 (3x15; n=5), grey dashed lines subjects from group 2 
(3x10; n=9), grey solid lines subjects from group 3 (3x5; n=10) and black lines represent 
malaria-naive control subjects (n=5). Values shown as 10 on the log-scale were negative. 
The two TS+ subjects from Group 1 and 2 became qPCR positive on day 8.5 and 9.5 
respectively, both became thick smear positive on day 12.0.
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ng/ml). Parameters normalized in all subjects after treatment without complications. All TS+ 
subjects experienced solicited adverse events (AEs) during challenge infection consistent 
with uncomplicated malaria (median number of AEs per subject 9.5 (range 4-14), median 
duration of each AE 1.1 days (range 0.0-12.3)). As expected, protected subjects presented 
with less AEs: 15 out of 17 subjects experienced solicited AEs possibly or probably related to 
the challenge (median number of AEs per subject: 2 (range 0-15), median duration 0.7 days 
(range 0.00-15.9)). One subject from Group 2 was preliminarily treated with atovaquone/
proguanil at day 10.5 after challenge because of unrelated exertional rhabdomyolysis after 
extensive sports activity (weightlifting) followed by sauna visits. No other severe adverse 
events (SAE) occurred. One volunteer from Group 1 was treated for reasons unrelated to the 
trial at day 19. Both these volunteers remained parasite negative by qPCR analysis after the 
third immunization and at any time point after challenge and were considered protected in 
further analysis. 
Analysis of cytotoxic T cell markers after in vitro Pf-stimulation 
Next, we tested a panel of representative cytotoxic T cell markers including surface 
expression of degranulation marker CD107a, and granzyme B and IFNγ production in CD4, 
CD8 and γδ-T cells after in vitro restimulation with Pf-infected red blood cells (PfRBC) 
in all immunized subjects (Table 2). CPS-immunization induced a significant increase in 
both the percentage and iMFI of CD107a positive CD4 and γδ-T cells, already after the 
first immunization up until challenge. Similarly CD8 T cells expressed a significantly higher 
CD107a iMFI after the second immunization. The proportion of granzyme B positive cells 
did not change after immunization, but granzyme B iMFI was significantly increased in both 
CD8 and γδ-T cells, returning to baseline at C-1. Production of IFNγ was induced in all T cell 
subsets, but most pronouncedly in CD4 and γδ-T cells. There were only weak correlations 
between cellular responses on C-1 and total blood-stage parasite exposure, as calculated by 
the sum of parasites/ml after all three immunizations (data not shown, Spearman’s rho for 
all <0.5). None of the responses in the control group changed significantly from baseline at 
any point of time (Table 2), suggesting that chloroquine alone did not affect P. falciparum 
specific T cell responses.
We next assessed the association of these markers with protection after challenge 
(Figure 3). Indeed, complete protection associated with the proportion of CD107a positive 
CD4 T cells (OR=8.4; 95% CI 1.5-123; p=0.011, Figure 3A), the iMFI of CD107a on CD4 
T cells (OR=11; 95% CI 1.6-188; p=0.011, data not shown) and granzyme B by CD8 T 
cells (OR=11; 95% CI 1.9-212; p=0.004, Figure 3E) at C-1. A subgroup analysis of data 
from Group 3 only confirmed these findings: the proportion of both CD107a positive CD4 
T cells and granzyme B positive CD8 T cells were the only markers higher in protected 
subjects (OR=4.2; 95% CI 0.9-140; p=0.081 and OR=27; 95% CI 1.5-27687; p= 0.019 
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respectively). While expression of CD107 on CD4 T cells and granzyme B in CD8 T cells 
predicted protection with an Area Under the ROC Curve (AUC) of 0.73 (95% CI 0.48-0.98) 
and 0.81 (95% CI 0.63-0.99) respectively, combining both markers resulted in only a slight 
improvement of the AUC (0.82, 95% CI 0.61-1). 
Figure 3 Cytotoxic immune responses upon in vitro PfRBC stimulation at one day before 
challenge infection (C-1). Each symbol represents a single protected (black symbols) 
or CPS-immunized unprotected (grey symbols) individual from group 1 (dots), group 2 
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Pf-specific IFNγ production by CD4, CD8 or γδ-T cells could not distinguish protected 
volunteers (Figure 3G, 3H and 3I). Also pluripotent (IFNγ+IL-2+) effector memory T cell 
(CD4+ CD62L- CD45RO+) responses, previously shown to be significantly increased by 
CPS immunization (8), were again induced (p=0.013), but did not differentiate between 
protected and unprotected volunteers (OR=1.6; 95% CI 0.5-4.9; p=0.41; data not shown). 
CD107a expressing CD4 T cells presented as the clearest marker associated with 
protection, consistently higher in fully protected subjects from I1 onwards (Figure 4A), and 
independent of immunization dose (Figure 4B). A significant correlation was found between 
CD107a expression by CD4 T cells after one immunization and prepatent period after 
challenge-infection in all TS+ (Spearman’s rho=0.69; p=0.013, Figure 4C). The proportion 
CD107a+ CD4 T cells in the control subject who developed parasitemia significantly later 
than the other controls (i.e. day 13.5 versus day 9-10.5), was at baseline on average 2.8 fold 
higher than in the other subjects. Possibly, the inherently higher response in this volunteer 
contributed to delayed pre-patency after challenge.
CD107a+ CD4 T cells expressed proportionally more granzyme B (7.4% versus 0.39% 
on C-1; p<0.0008) in protected subjects, indicative for their cytotoxic phenotype, and IFNγ 
(13.3% versus 0.39% on C-1; p<0.0001) than CD4 T cells negative for CD107a (Figure 4D 
and Figure 4E). CD8 T cells, traditionally considered the cytotoxic subclass of T cells, indeed 
contained a larger proportion of CD107a positive cells at baseline than CD4 T cells when 
unstimulated (uRBC); 0.39% versus 0.19% respectively; p<0.0001 (all volunteers). However, 
the proportion of Pf-specific degranulation of CD8 T cells was not notably increased by CPS 
immunization (p=0.44), in contrast to CD4 T cells (p<0.0001, Figure S2A&B). 
Both CD107a expression by CD4 T cells and granzyme B production by CD8 T cells 
remained significantly elevated up to twenty weeks after the challenge-infection (C+140) 
(p<0.05 and p<0.01; Figure 5A and 5B), demonstrating longevity of the CPS-induced T cell 
response.
(triangles) or group 3 (squares). Horizontal bars and whiskers represent means and SEMs. 
Panels show CD107a+ CD4 (A), CD8 (B) and γδ (C) T cells, granzyme B expression on 
CD4 (D), CD8 (E) and γδ (F) T cells and IFNγ+ CD4 (G), CD8 (H) and γδ (I) T cells. 
Values are corrected for uRBC background and for baseline-response before immunization. 
Background responses to uRBC stimulation were 0.19±0.01, 0.41±0.02 and 0.61±0.05 for 
CD107a, 1.65±0.50, 15.34±1.46 and 64.56±1.74 for granzyme B and 0.09±0.00, 0.07±0.00 
and 0.14±0.01 for IFNγ, on CD4, CD8 and γδT cells respectively (mean ±SEM, calculated 
for all volunteers on both baseline and C-1). High uRBC granzyme B responses in CD8 
and γδ T cells indicate that a significant percentage of these cells contains granzyme B 
even in a resting situation. uRBC responses did not change significantly from baseline 
for any of the readouts. The differences between responses of protected and unprotected 
volunteers in the graphs without a p-value are non-significant. The differences between 
protected and unprotected volunteers are calculated using logistic regression.
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Figure 4 Cytotoxic profile of CPS-induced CD4 T cells. (A+B) Induction of Pf-specific 
CD107a positive CD4 T cells was determined (A) in protected and unprotected CPS-
immunized subjects over the course of immunization and (B) in protected subjects separated 
for each immunization dose. Horizontal bars and whiskers represent mean responses 
and SEM. (C) The relationship between Pf-specific CD107a CD4 T cells on I1 and the 
prepatent period after challenge for all TS+ volunteers (CPS-immunized and controls). 
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Discussion
We show that CPS immunization reproducibly and dose-dependently induces protection 
against a homologous challenge infection. With exposure to a total number of Pf infected 
mosquito bites as low as 30, CPS immunization still induces 89% protection in healthy 
volunteers. We furthermore demonstrate that markers of cytotoxic T cell responses are 
associated with protection against malaria after whole sporozoite immunization. 
This study provides further support for the remarkable potency of the CPS-protocol 
Within protected CPS-immunized subjects, (D) granzyme B and (E) IFNγ production by 
CD107a+ (black dots) and CD107a- (grey dots) CD4 T cells was analyzed at baseline 
(B on x-axis) and after CPS immunization (C-1) in all protected subjects. Horizontal 
bars show the mean response. All data were corrected for uRBC background for every 
volunteer at each time point. Abbreviations on the x-axis: B= baseline; I= 27 days after 
indicated immunization; C-1=one day before challenge. *=p<0.05 **p<0.01 ***p<0.001
Figure 5 Longevity of cellular immune responses after CPS immunization. Pf-specific 
cellular immune responses (corrected for uRBC background) were assessed in protected 
(black dots) and unprotected (grey squares) CPS-immunized volunteers before CPS 
immunization (B), and before (C-1) and 20 weeks after challenge infection (C+140). Data 
are shown as mean ±SEM for (A) CD107a expression on CD4 T cells and (B) granzyme 
B production by CD8 T cells. Tests are performed separately for protected and immunized 
unprotected volunteers, by the repeated measures ANOVA (including all time points 
before and after immunizations) and the Dunnett’s Multiple comparison post test, using 
B as control column. Only the test results of C+140 compared to baseline for protected 




to induce complete protection by using even lower numbers of Pf-infected mosquitoes 
than before (8). The observed dose-dependent protection is in line with results from RAS 
immunization trials with sporozoites administered either intravenously by needle and syringe 
(10) or by bites from irradiated infected mosquitoes (4). Although the delay of patency 
in unprotected CPS-immunized subjects was not statistically significant, the patterns of 
parasitemia indicate partial protection in some subjects. The unexpectedly delayed control 
subject hampered statistical significance but could be considered an outlier, possibly because 
of the inherently high baseline immune response. The establishment of a sub-optimal CPS 
immunization regimen inducing protection in 50% of the immunized volunteers with 3x5 
mosquito bites will facilitate further studies of protective immune mechanisms against Pf 
malaria.
Our data provide evidence for a role of cytotoxic T cell responses in pre-erythrocytic 
immunity in humans. Due to obvious practical limitations, we only assessed immune cells 
in the peripheral blood, which may not necessarily reflect responses in the liver but rather 
represent a surrogate. The results of this exploratory analysis will have to be confirmed in 
future trials, and the functional relevance remains to be investigated.
‘Classical’ cytotoxic CD8 T cells can be activated by malaria antigen on infected 
hepatocytes via major histocompatibility complex (MHC) class I (25) and are associated 
with protection in a number of (animal) models (13, 14, 26). CD8 T cells are involved in 
protection in the murine CPS and RAS models (27-29), but their precise effector mechanisms 
remain subject of debate. They might either require direct contact with infected hepatocytes 
(13), or in fact be independent of granzyme B and/or other cytotoxic molecules, suggestive 
for a more indirect cytokine mediated effect by CD8 T cells (12) or other hepatic immune 
cells (30). In addition, a functional role for cytotoxic CD4 T cells is also conceivable as these 
cells can use cytolytic pathways such as granulysin, perforin and granzymes and FAS-L, 
as shown mostly in viral infections (31, 32). The protective role of CD4 T cells in murine 
malaria has been suggested, using in vitro experiments (33), and in vivo depletion (12) or 
passive transfer (34). Furthermore, functional cytotoxic CD4 T cells, derived from RAS- or 
synthetic peptide immunized volunteers, are able to lyse autologous B cells pulsed with a 
peptide from the circumsporozoite protein (35-37). We used surface expression of CD107a 
(LAMP-1), a marker for cytotoxic degranulation, to phenotypically identify cytotoxic CD4 
T cells (31). In order to directly kill a Pf- infected hepatocyte, parasite antigens should be 
presented in the context of MHC class II (MHCII) to the cytotoxic CD4 T cells. Although 
hepatocytes do not express MHCII in non-inflammatory circumstances, the presence of 
MHCII on human hepatocytes has been shown in a small number of patients with chronic 
hepatitis (38) and immune mediated liver disorders (39, 40). Functionally, over-expression of 
MHCII on hepatocytes in a transgenic mice model showed their capacity for co-stimulation, 
antigen-presentation and CD4 T cell activation (41). Only indirect evidence suggests that 
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MHCII expression on mice hepatocytes may play a role in murine malaria (33, 42), and the 
presence of MHCII on hepatocytes in human malaria has never been studied. Here, we show 
for the first time that degranulating CD4 T cells are associated with protection in human 
malaria and already significantly induced after one immunization. 
The observed lack of boosting by the second and third immunization may reflect a 
saturated response of antigen specific memory cells. This raises the possibility that fewer 
immunizations may be sufficient to induce protection, supported by the increased proportion 
of volunteers without parasitemia after the second and third immunization in Group 1 and 2. 
Moreover, the observed longevity of the immune response is in line with long-term protection 
after CPS immunization in a previous study (9).
The TH1 cytokine IFNγ has been repeatedly shown to be an important effector molecule 
in protection against the malaria parasite (43), and the clear induction of TH1 responses in 
our study corroborates earlier findings in both animals and humans after whole sporozoite 
immunization (8, 10, 12, 26, 27). We previously showed that a broad range of both innate and 
adaptive cellular subsets contribute to CPS-induced Pf-specific IFNγ production (16), which 
is sustained at least up to 2.5 years after immunization (9). IFNγ production alone, however, 
does not correlate with protection in neither RAS (10) nor our CPS model. Also production 
of both IFNγ and IL-2 by effector memory CD4 T cells, and IFNγ production by γδ-T cells, 
although clearly increased in immunized volunteers (8, 16), did not differentiate between 
protected and unprotected volunteers. 
During CPS immunization, four protected subjects did not show parasitemia by qPCR 
at any measured time point, not even after the first immunization. A possible explanation is 
that the number of merozoites released from the liver is too low for qPCR detection. A strong 
primary innate immune response may be responsible for clearing sporozoites and/or killing 
infected hepatocytes upon first encounter. Previous studies in mice indeed showed that 
inflammatory cytokines IL-1 and IL-6 block pre-erythrocytic development in mice (16, 44). 
Alternatively, chloroquine may have contributed to the decreased, i.e. undetectable number 
of parasites released from the liver either by direct killing, or indirectly by stimulating the 
immune system.
Antigen recognition and immune cell activation are essential for an effective response. 
To investigate pre-erythrocytic cellular immune responses, stimulation with cultured Pf 
liver stages would be preferred, but this is currently impossible. We therefore used asexual 
blood stage parasites for our experiments and although responses to purely pre-erythrocytic 
antigens may be missed, the majority of potential memory responses are likely detected upon 
PfRBC stimulation, given the large overlap between liver and blood stage antigens (45). 
Future antigen screening by stimulation with a comprehensive library of pre-erythrocytic and 
cross-stage proteins or peptides, and subsequent functional studies focussing on cytotoxic T 
cells will further identify and delineate the specificity of protective responses (33, 46). 
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In conclusion, we identified two in vitro cellular cytotoxic immune markers that are 
associated with protection against malaria in a controlled clinical setting. Furthermore, this 
study confirms the robustness of CPS immunization as a highly efficient and reproducible 
immunization strategy for complete homologous protection. Further exploration of immune 
responses induced by CPS immunization will make important contributions to pre-
erythrocytic malaria vaccine development and clinical testing.
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CPS immunization and challenge
All subjects received a standard prophylactic regimen of chloroquine consisting of a loading 
dose of 300 mg on each of the first two days and then 300 mg once a week for a total 
duration of 14 weeks. During this period, all subjects were exposed three times to the 
bites of Anopheles stephensi mosquitoes at monthly intervals starting eight days after the 
first chloroquine dose as described previously (11). All volunteers were exposed to bites 
from exactly 15 mosquitoes at each session, but the number of NF54 Pf infected versus 
uninfected mosquitoes varied per group: five subjects received three times bites from 15 
infected mosquitoes (Group 1), ten subjects received three times bites from 10 infected and 5 
uninfected mosquitoes (Group 2), ten subjects received three times bites from 5 infected and 
10 uninfected mosquitoes (Group 3) and five control subjects received three times bites from 
15 uninfected mosquitoes (Group 4). From day 6 to 10 after each immunization, subjects 
were checked daily on an outpatient basis and blood was drawn for peripheral blood smears, 
standard haematological measurements and cardiovascular safety markers and stored for 
retrospective analysis of parasitemia by quantitative real-time PCR (qPCR) (47).
After the challenge-infection, volunteers were checked twice daily on an outpatient 
basis from day 5-21 for (un)solicited symptoms and signs. As soon as parasites were 
detected by thick smear, subjects were treated with a standard curative regimen of 1000 mg 
atovaquone and 400 mg proguanil once daily for three days, according to Dutch national 
guidelines. If subjects remained thick smear negative, they were presumptively treated with 
the same curative regimen on day 21 after challenge infection. Chloroquine levels one day 
before challenge were measured in EDTA-plasma by liquid chromatography and were below 
detection limit (5 µg/L) in all volunteers one day before challenge (48).
Retrospectively, parasitemia was quantified on day six until day ten after each 
immunization and from day five until day 21 after challenge by qPCR using Pf standard 
curves prepared by DNA extraction from titrated samples of ring-infected cells (47). Adverse 
events (AEs) were recorded as described previously (11). 
Platelet counts were determined in EDTA-anticoagulated blood with the Sysmex XE-
2100 (Sysmex Europe GmbH, Norderstedt, Germany). D-dimer concentrations were assessed 
in citrate plasma by STA-R Evolution (Roche Diagnostics, Almere, The Netherlands).
PBMC isolation and cryopreservation
Venous whole blood was collected into citrated vacutainer cell preparation tubes (CPT; 
Becton and Dickinson) and stored at room temperature for a maximum of 4 hours; PBMCs 
were isolated by centrifugation and washed four times in ice-cold phosphate-buffered saline 
(PBS). Cells were counted and cryopreserved at a concentration of 107 cells/ml in ice-cold 
foetal-calf serum (Gibco) containing 10% dimethylsulfoxide (Merck, Germany) using Mr. 
159
Cytotoxic markers associate with protection after CPS-immunization
Frosty freezing containers (Nalgene). Samples were stored in vapour-phase nitrogen. 
In vitro Pf- infected erythrocyte re-stimulation assay
PBMC were thawed, washed twice in Dutch-modified RPMI 1640 (Gibco/ Invitrogen) and 
counted in 1% trypan blue containing 5% zap-oglobin II Lytic Reagent (Beckman Coulter) 
using a Neubauer improved bright line counting chamber (Marienfield, Germany); median 
cell recovery was 80%. PBMCs were in vitro re-stimulated with cryopreserved NF54 Pf-
infected erythrocytes (PfRBC) as described previously (16). Cells were re-suspended in 
complete culture medium (Dutch-modified RPMI 1640 containing 2 mM glutamine, 1mM 
pyruvate, 0.05 mM gentamycine and 10% human A+ serum, (Sanquin, Nijmegen) at a 
final concentration of 2.5x106/ml. PBMC were transferred into polystyrene 96- well round-
bottom plates and stimulated in duplicate wells with either 5x106/ml (final concentration) 
cryopreserved PfRBC or uRBC (uninfected erythrocytes) in a total volume of 110 µl/well for 
24 hours at 37°C/ 5%CO
2
. For the last four hours, 10 µg/ml Brefeldin A (Sigma-Aldrich) and 
2µM monensin (eBioscience) were added, based on pilot experiments. In positive control 
wells, PMA (50 ng/ml, Sigma-Aldrich) and ionomycin (1 mg/ml, Sigma-Aldrich) were 
added the last four hours. After a total of 24 hours, cells were harvested and stained.
Flow cytometry analysis
PBMCs were co-incubated during the 24 hour-stimulation with CD107a Pacific Blue 
(Biolegend, clone H4A3). All cells were transferred to a polystyrene V-bottom plate and 
washed twice with 200µl PBS. Next, cells were stained with Live/Dead fixable dead cell 
stain dye aqua (Invitrogen) in 50 µl PBS for 30 minutes at 4°C. After washing with PBS 
containing 0.5% bovine serum albumin (BSA, Sigma-Aldrich) cells were stained with 
antibodies against the surface markers CD3 PerCP (Biolegend, clone UCHT1), CD4 ECD 
(Beckman-Coulter, clone SFCI12T4D11) CD8 APC-H7 (BD Biosciences, clone SK1), γδ-T 
cell receptor PE (Beckman-Coulter, clone IMMU510) and CD56 APC (eBioscience, clone 
MEM188) in 50 µl PBS containing 0.5% BSA for 30 minutes at 4°C. Cells were washed 
again and fixed in Foxp3 fixation/permeabilization buffer (eBioscience). Following a wash 
step with Foxp3 permeabilization buffer (eBioscience), cells were stained in permeabilization 
buffer containing granzyme B FITC (Biolegend, clone GB11) and IFNγ PeCy7 (Biolegend, 
clone 4S.B3). Cells were washed again in permeabilization buffer and kept cold and dark 
in fixation buffer (1% paraformaldehyde in PBS) until measured by flow cytometry on the 
same day. For every individual volunteer, all time points were thawed, stimulated and stained 
within the same experimental round. In a separate experiment, cells from the time points B 
and C-1 were in vitro re-exposed to Pf infected erythrocytes and stained for viability, γδ-T 
cell receptor PE, CD56 PE, CD3 PerCP, CD45RO ECD (Beckman-Coulter, clone mIgG2a), 
CD62L PeCy7 (Biolegend, clone DREG-56) CD4 Pacific Blue (eBioscience, clone OKT-4) 
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CD8 AF700 (Biolegend, clone HIT8A), IFNγ FITC and IL-2 APC (eBioscience, clone MQ1-
17H12) using the same protocol as described for the other staining panel. 
Samples were acquired using a 9-color Cyan ADP (Beckman Coulter), each round 
using single stained cells for compensation. Per sample, a median of 93.8x103 (range 
12.5x103 - 221x103) singlet living lymphocytes were acquired. Data analysis was performed 
using FlowJo software (version 9.6; Tree Star). A representative example showing the 
gating strategy is shown in  S3. The definition of cell positivity (for cytokines and cytotoxic 
molecules) was performed automatically, based on the MFI of unresponding PBMCs for 
each sample separately. Responses to uRBC were subtracted from the response to PfRBC for 
every volunteer on every time point.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 5 unless mentioned otherwise. 
Differences between immunized unprotected and control volunteers in prepatent periods by 
thick smear and qPCR were tested by Mann-Whitney U test. Induction of cytotoxic immune 
responses on the time points I1, I2, I3 and C-1 were tested by the repeated measures ANOVA 
and the Dunnett’s Multiple comparison post test, with baseline as control column. Induction 
of immune responses on 140 days after challenge (C+140) was tested separately for protected 
and immunized unprotected volunteers, by the repeated measures ANOVA (including all 
previous time points mentioned above) and the Dunnett’s Multiple comparison post test, 
with baseline as control column. The correlation of CD107a expression by CD4 T cells 
with the prepatent period, and the correlation of cellular immune responses with cumulative 
parasitemia during CPS immunization were assessed by non-parametric Spearman 
correlation. The proportion of CD107a+ CD4 vs CD8 T cells and the production of granzyme 
B and IFNγ on CD107a+ vs CD107a- CD4 T cells were tested by the paired Student’s t-test. 
For the correlation of CD107a CD4 T cells with prepatent period after challenge, immune 
re-call responses to PfRBC (corrected for uRBC stimulation background) were tested on the 
different time points, while for all other tests we assessed the change from baseline (B).
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Assessed for eligibility (n=63) Ineligible (n=28):
- history of psychiatric disease (n=5)
- laboratory abnormalities at screening (n=4)
- BMI > 30 kg/m2 (n=4)
- not able to attend all study visits (n=3)
- history of living in malaria endemic area (n=3)
- family history of cardiac disease (n=2)
- abnormal ECG at screening (n=2)
- history of drug use (n=2)
- hypertension (n=1)
- history of palpitations (n=1)
- difficulties with blood withdrawal (n=1)







Mean age 20, SD 0.9
Challenged, completed follow-up 
and included in analysis (n=29)
Group 2
CPS immunization 3x10 
(n=10, 7 female)
Mean age 22, SD 3.7
Group 3
CPS immunization 3x5 
(n=10, 5 female)
Mean age 21, SD 2.2
Group 4
No CPS immunization 
(n=5, 5 female)
Mean age 21, SD 1.5
Figure S1 Study flow diagram. Twenty-five subjects were randomly assigned to receive 
different doses of CPS immunization in a double-blind fashion; five control subjects 
received bites from uninfected mosquitoes. One subject withdrew informed consent 
after the first immunization for reasons unrelated to the trial. Twenty-nine subjects 
received a challenge infection by the bites of five infected mosquitoes fifteen weeks after 
discontinuation of chloroquine chemoprophylaxis.
Figure S2 Induction of cytotoxic CD4 and CD8 T cell responses by CPS immunization. 
CD107a expression was assessed on (A) CD4 T cells and (B) CD8 T cells after stimulation 
with PfRBC (black dots) and uRBC (grey dots) before, during and after CPS immunization 




Figure S3 Flow cytometry gating strategy. (A) Representative flow cytometry plots for a 
uRBC stimulated sample from one volunteer at baseline (before immunization). Singlet 
viable CD3+ PBMC were subdivided into (i) γδT cells, (ii) CD8 T cells and (iii) CD4 T 
cells; No additional dump channel for CD14, CD19 and CD20 was used. (B) Gating of 
CD107a, granzyme B and IFNγ positive cells for uRBC, PfRBC and PMA/ionomycin re-
stimulated cells at baseline. For uRBC and PfRBC stimulation CD4 T cells are shown, for 
PMA/ionomycin total viable PBMCs. Within each sample, gating of marker positive cells 
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Immunization of malaria-naïve volunteers under chemoprophylaxis with Plasmodium 
falciparum sporozoites (CPS) efficiently and reproducibly induces sterile protection and thus 
constitutes an excellent model to study protective immune responses against malaria. Here 
we performed the first longitudinal assessment of lymphocyte activation and differentiation 
kinetics during sporozoite immunization in 15 volunteers by ex vivo lymphocyte flow cytometry 
analysis. Both CD4 and CD8 T cells as well as γδT cells, NK cells and CD3+CD56+ cells 
showed increased activation and proliferation following immunization. Transient induction 
of the transcription factor T-bet and the cytotoxic molecule granzyme B indicated a role 
of Th1 responses and cytotoxic T cells in CPS-induced immunity. The absolute number of 
γδT cells as well as the proportion of granzyme B-containing γδT cells showed a significant 
and sustained increase. Regulatory T cell (Treg) proliferation was significantly higher after 
the second immunization in subjects subsequently not protected against challenge infection. 
These findings indicate an important role for γδT cells, Th1 and cytotoxic responses in whole 
sporozoite immunization with a possibly suppressive role of Tregs. 
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Introduction
Sterile protection of healthy volunteers against Plasmodium falciparum can be efficiently 
and reproducibly induced by exposing them to sporozoites while they are taking antimalarial 
chemoprophylaxis (1-3). This chemoprophylaxis and sporozoites (CPS) immunization 
protocol provides a unique opportunity to investigate protective immune responses against 
malaria (3, 4). Cellular memory responses induced by a number of sporozoite immunization 
approaches including both CPS as well as radiation attenuated sporozoites (RAS), have 
been investigated by in vitro re-stimulation of cells collected post-immunization (1, 4, 5). 
These studies have provided insight into the composition of P. falciparum specific memory 
responses, indicating an important role of Th1 and cytotoxic responses (1, 4, 5).
Th1 cytokines such as IFN-γ are crucial mediators of protection against malaria (6). In 
humans, both CPS and RAS immunization induce IFN-γ production by innate and adaptive 
lymphocytes (4, 5). Additionally, cytotoxic markers, i.e. degranulation of CD4 T cells and 
granzyme B expression by CD8 T cells, were shown to associate with protection from 
challenge infection after CPS immunization (3). Pre-clinical data indicate that in addition to 
CD4 and CD8 T cells, also γδT cells and NK cells can play a role (7-14). 
Here we investigated the early kinetics and composition of ex vivo immune cell responses 
in the days after sporozoite exposure, when memory responses are initiated and orchestrated 
by the interplay between stimulating and suppressive signals. As activation markers we used 
CD38 and HLA-DR, which were shown to accurately identify virus-specific effector CD8 
T cells after yellow fever vaccination, allowing for the quantification of the magnitude of 
the induced response (15). For the assessment of Th1 lineage commitment (16) we used the 
transcription factor T-bet, which also controls the generation of cytotoxic CD8 T cells (17). 
As possible suppressive markers, we focused on programmed cell death-1 (PD-1), which 
is associated with T cell exhaustion (18) and shown to significantly reduce Plasmodium–
specific CD8 T cell responses in a rodent model (19) and on regulatory T cells (Tregs) (20).
Materials and Methods
Study subjects and CPS immunization 
Nineteen healthy, malaria naïve adult Dutch volunteers (age 18-25 years, median 21) were 
included in a randomized double-blind controlled CPS immunization trial as described 
elsewhere (21). In short, five subjects received chloroquine prophylaxis and three times 
bites from 8 NF54 P. falciparum infected mosquitoes (CPS-CQ) at monthly intervals; ten 
subjects received mefloquine prophylaxis and bites from the same number of mosquitoes 
(CPS-MQ). Four control subjects received mefloquine prophylaxis and bites from uninfected 
mosquitoes. There was no significant difference in protection against homologous challenge 
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infection or recall responses after CPS-CQ or CPS-MQ: 3/5 and 7/10 subjects were protected 
respectively (21). Therefore, all CPS immunized subjects were pooled for immunological 
analysis in the current study. 
Cell isolation, cryopreservation and staining
Peripheral blood mononuclear cells (PBMCs) were collected and cryopreserved one day 
before the first immunization (I1-1), 7 and 10 days after the first immunization (I1+7 and 
I1+10, respectively), one day before the second immunization (I2-1, 27 days after the first 
immunization), 7 and 10 days after the second immunization (I2+7 and I2+10, respectively) 
and one day before the third immunization (I3-1, 27 days after the second immunization). 
PBMCs were isolated, cryopreserved and stored as described previously (3). Immediately 
prior to use cells were thawed, washed twice in Dutch-modified RPMI 1640 (Gibco/
Invitrogen) and counted in 0.1% trypan blue (to assess viability) containing 5% zap-oglobin 
II Lytic Reagent (Beckman Coulter) using a Neubauer improved bright line counting chamber 
(Marienfield, Germany). Median recovery of cells directly after thawing was 82%, with a 
viability of  >95%. 
Sequential samples from each volunteer were stained simultaneously to avoid influence 
of day-to-day variation. Fluorochrome-labeled antibodies that were used for flow cytometry 
are listed in Table S1. From each sample, 106 cells per panel were transferred to a 96 well 
V-bottom plate, washed twice with 200 μl phosphate buffered saline (PBS) and incubated with 
viability stain for 30 minutes on ice. Next, cells were washed twice with staining buffer (PBS 
containing 0.5% bovine serum albumin (Sigma)), stained with 50 μl antibody mix diluted in 
staining buffer for 30 minutes at room temperature, and again washed with staining buffer. 
For panel II, this was followed by a second staining step with streptavidin. Subsequently, 
cells were resuspended in 50 μl FoxP3 fixation/permeabilization buffer (eBioscience) and 
kept on ice for 30 minutes, after which they were washed with FoxP3 Permeabilization buffer 
(eBioscience). Next, cells were incubated with 50 μl antibody mix for intracellular staining 
in permeabilization buffer at room temperature for 30 min, followed by another wash with 
permeabilization buffer. Cells were then resuspended in 200 μl PBS/1% paraformaldehyde 
and kept at 4°C until acquisition on a Cyan ADP 9-colour flow cytometer (Dako/Beckman 
Coulter). A viability stain was included in all flow cytometry panels. A median of 217,000 
(range 15,443-590,000) singlet living PBMCs were acquired per sample. Flow cytometry 
data were analyzed using FlowJo v9.7 software; a representative gating strategy for each 
panel is shown in Figure S1. Lymphocyte counts were determined in EDTA-anti-coagulated 
blood with the Sysmex XE-2100 (Sysmex Europe GmbH, Norderstedt, Germany). Absolute 
cell numbers of different lymphocyte subsets were calculated using these lymphocyte counts 
and percentages (within the Boolean lymphocyte gate, figure S1 [panel II]), obtained by 
flow cytometry. In this gating strategy we took care to exclude monocytes, based on their 
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differential SSC. As an additional measure to minimize inclusion of monocytes into this 
gate, we plotted SSC against either CD3 or CD56 staining, to enable inclusion of lymphocyte 
blasts, which would otherwise overlap with monocytes if simple FSC/SSC gating had been 
applied. Integrated median fluorescence intensity (iMFI) of Ki67 in CD4+CD45RO+FoxP3+ 
regulatory T cells (Tregs) was calculated as the percentage of Ki67+ cells multiplied with the 
MFI of Ki67 in these cells.
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 6. Data from sequential 
samples were tested by repeated measures one-way ANOVA with Dunnett’s post-hoc test, 
comparing all time points to baseline data (I1-1). Relationships between parasitemia and 
cellular responses were analyzed by Pearson correlation, as were relationships between ex 
vivo responses and re-call responses published previously (21). Two-Way ANOVA with 
Bonferroni post-test was used to assess whether responses differed between protected and 
unprotected subjects. Since we aimed to assess the effect of sporozoite immunization on 
cellular responses rather than the effect of different drugs, we did not compare responses 
between the CPS-CQ and CPS-MQ groups. A p-value of <0.05 was considered statistically 
significant. 
Results
Changes in lymphocyte numbers after sporozoite immunization 
The number of αβT, NK and CD3+CD56+ cells significantly decreased after the first 
sporozoite immunization, suggesting redistribution to possible effector sites including liver 
and/or spleen (Figure 1A, B, D, and E). While these subsets normalized four weeks after 
exposure, the number of γδT cells remained significantly increased (mean ± SEM 0.07x109/L 
± 0.01x109/L, 0.12x109/L ± 0.01x109/L and 0.14x109/L ± 0.02x109/L at I1-1, I2-1 and I3-1, 
respectively; Figure 1C). In controls, cell numbers did not change significantly at any time 
point (data not shown).
Activation and proliferation of lymphocytes directly following sporozoite 
immunization
Both CD4 and CD8 T cells in peripheral blood showed significantly increased proliferation 
by intracellular Ki67 staining (p<0.001 for both CD4 and CD8; Figure 2A and 2B) and 
activation by increased co-expression of CD38 and HLA-DR (p<0.001 for both CD4 and 
CD8; Figure 2C and 2D) on day 10 after the first sporozoite immunization. Activation strongly 
correlated with proliferation for both CD4 and CD8 T cells at I1+10 (r=0.91 p<0.0001 and 
r=0.88 p<0.0001, respectively). After the second immunization, CD8 T cell proliferation and 
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Figure 1 Changes in cell subsets induced by CPS immunization. αβT cells (A), CD8 T 
cells (B), γδT cells (C), CD3+CD56+ cells (D) and NK cells (E) were assessed one day 
before the first, second and third immunization (I1-1, I2-1 and I3-1, respectively) and 
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activation did not significantly increase, while CD4 T cells responses were comparable to the 
first immunization (Figure 2A-D). 
Similarly, γδT, NK and CD3+CD56+ cells showed a significant increase in proliferation, 
but only after the first immunization (all p<0.001; Figure 3A, 3B and 3C). Expression of CD25 
did not change on γδT cells over the course of CPS immunization (Figure 3D). Activation of 
NK and CD3+CD56+ cells, however, was increased after the first immunization. After the 
second immunization activation of NK cells was again induced, but reduced in CD3+CD56+ 
cells compared to baseline (Figure 3E and 2F).
In control subjects, we also observed increased proliferation and activation of CD4 
and CD8 T cells over the course of immunization by uninfected mosquitoes. The magnitude 
of these responses, however, was much smaller and analysis of statistical significance was 
hampered by the small sample size (Figure 2 E-H).
Activation and proliferation of lymphocyte subsets correlate with parasite exposure 
during immunization rather than protection
Parasite density correlated with proliferation of almost all lymphocyte subsets at I1+10 
(CD4 r=0.64 p=0.011, CD8 r=0.56 p=0.03, γδ T r=0.57 p=0.03, CD3+CD56+ cells r=0.56 
p=0.03, NK cells: ns). Activation of both CD4 and CD8 T cells (r=0.79 p=0.0005, and 
r=0.81 p=0.0003, respectively) but not of the other T cell or lymphocyte subsets correlated 
with parasitemia. Notably, immunized subjects without parasitemia also showed increased 
responses, mainly CD4 T cell proliferation (Figure 2A-D). Neither proliferation nor activation 
of any lymphocyte subset during immunization was associated with subsequent protection 
from challenge infection (not shown). 
Induction of regulatory markers during CPS immunization 
Proliferation of CD4+CD45RO+FoxP3+ regulatory T cells (Tregs) significantly increased 
directly following both the first and second immunization and returned to baseline levels 
after a month (Figure 4A). In contrast to other lymphocyte subsets, proliferation of Tregs 
was already significantly increased 7 days after immunization, the first day of detectable 
parasitemia. Neither Treg proliferation nor the number of circulating Tregs correlated 
with parasitemia (data not shown). There was also no relationship between ex vivo Treg 
proliferation during immunization and induced memory responses, i.e. de-granulation or 
7 and 10 days after the first and second immunization (I1+7, I1+10, I2+7 and I2+10, 
respectively). Data are represented as individual values for CPS immunization subjects 
(n=15) and lines indicate mean±SEM. Data were tested by repeated measures one-way 
ANOVA with Dunnett’s post-hoc test, comparing all time points to baseline data (I1-
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IFNγ production by CD4 T cells in response to in vitro re-stimulation twenty weeks after the 
last immunization ((21), data not shown). The degree of Treg proliferation as quantified by 
integrated MFI of Ki67, however, was significantly higher at I2+10 in subjects not protected 
against challenge infection (p<0.0001; Figure S2). Expression of programmed cell death-1 
(PD-1) was transiently increased on both CD4 and CD8 T cells, but returned to baseline 
levels at I3-1 (Figure 4B and 4C). Expression of PD-1 was not different in unprotected 
subjects compared to protected subjects at any time point (not shown).
Phenotypic analysis of CD4 and CD8 T cells shows Th1 and cytotoxic commitment 
In both CD4 and CD8 T cells, T-bet expression was transiently increased in proliferating cells 
10 days after the first immunization, indicating Th1 and cytotoxic commitment, respectively 
(Figure 5A and 5B, Figure S3). Furthermore, expression of the cytotoxic molecule granzyme 
B was increased significantly in the activated CD8 T cells after the first immunization 
(Figure 5C). γδT cells also gained a more cytotoxic phenotype during CPS immunization: 
the proportion of these cells containing granzyme B increased significantly and remained 
elevated over the course of CPS immunization (Figure 5D). 
Figure 2 Proliferation and activation of CD4 and CD8 T cells following CPS immunization 
or uninfected mosquito bites. Proliferation of CD4 (A, E) and CD8 (B, F) T cells was 
measured by Ki67 expression and activation of CD4 T cells (C, G) and CD8 T cells (D, 
H) was measured by co-expression of HLA-DR and CD38 one day before the first, second 
and third immunization (I1-1, I2-1 and I3-1, respectively) and 7 and 10 days after the first 
and second immunization (I1+7, I1+10, I2+7 and I2+10, respectively) in CPS-immunized 
subjects (A-D, n=15) or control subjects who received bites from 8 uninfected mosquitoes 
at each immunization (E-H, n=4). Data are represented as individual values; data from 
subjects who experienced parasitemia after immunization are indicated as red circles, 
subjects who remained PCR negative as grey circles; lines indicate mean ± SEM. The 
inserts in graphs E-H show the same data for control volunteers on a different axis to 
show the changes over time. Data were tested by repeated measures one-way ANOVA 
with Dunnett’s post-hoc test, comparing all time points to baseline data (I1-1). Significant 
differences are indicated with **=p<0.01, ***=p<0.001. Note different scales of y-axes in 
CD4 versus CD8 graphs.
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Figure 3 Proliferation and activation of γδT cells, NK cells and CD3+CD56+ cells. 
Proliferation of γδT cells (A), CD3+CD56+ cells (B) and NK cells (C) was measured by 
Ki67 expression and activation of γδT cells (D), CD3+CD56+ cells (E) and NK cells (F) was 
measured by expression of CD25 one day before the first, second and third immunization 
(I1-1, I2-1 and I3-1 respectively) and 7 and 10 days after the first and second immunization 
(I1+7, I1+10, I2+7 and I2+10 respectively). Data are represented as individual values 
for CPS immunization subjects (n=15); data from subjects who experienced parasitemia 
after immunization are indicated as red circles, subjects who remained PCR negative as 
grey circles; lines indicate mean ± SEM. Data were tested by repeated measures one-way 
ANOVA with Dunnett’s post-hoc test, comparing all time points to baseline data (I1-1). 
Significant differences are indicated with *=p<0.05, **=p<0.01, ***=p<0.001. 
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Figure 4 Induction of Tregs 
and the PD-1 during CPS 
immunization. Proliferation 
of CD45RO+FoxP3+ 
Tregs (A) and PD-1 
expression by CD4 (B) 
and CD8 (C) T cells was 
assessed one day before 
the first, second and third 
immunization (I1-1, I2-1 
and I3-1 respectively) and 
7 and 10 days after the first 
and second immunization 
(I1+7, I1+10, I2+7 and 
I2+10 respectively). 
Data are represented as 
individual values for CPS 
immunization subjects 
(n=15) and lines indicate 
mean±SEM. Data were 
tested by repeated measures 
one-way ANOVA with 
Dunnett’s post-hoc test, 
comparing all time points 
to baseline data (I1-1). 
Significant differences are 




Figure 5 Induction of T cells with a cytotoxic phenotype directly following CPS 
immunization. T-bet expression of proliferating CD4 T cells (A) and proliferating CD8 
T cells (B), and percentage of granzyme B positive activated CD8 T cells (C) and γδT 
cells (D) were assessed one day before the first, second and third immunization (I1-1, I2-1 
and I3-1, respectively) and 7 and 10 days after the first and second immunization (I1+7, 
I1+10, I2+7 and I2+10, respectively). Data are represented as individual values for CPS 
immunized subjects (n=15) and lines indicate mean±SEM. Data were tested by repeated 
measures one-way ANOVA with Dunnett’s post-hoc test, comparing all time points to 
baseline data (I1-1). Significant differences are indicated with *=p<0.05, **=p<0.01, 
***=p<0.001. 
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Discussion
Our data show that both T cells and other lymphocytes are readily activated shortly after 
the first sporozoite immunization, with increased T-bet expression in CD4 and CD8 T cells 
indicative for differentiation towards a Th1 and cytotoxic phenotype. This is in line with 
previous findings suggesting a contribution of these cells to CPS-induced protection (3, 4) 
and their induction in other sporozoite-immunization regimens (5, 22). These responses 
were most prominent at 10 days post CPS, in particular after the first immunization, and 
returned to baseline four weeks later. Since parasitemia occurred 7 or 8 days after exposure to 
mosquito bites, these responses could be a result of exposure to pre-erythrocytic stages and/
or blood-stages. Indeed, T cells from RAS and CPS immunized subjects recognize both pre-
erythrocytic and blood-stage antigens in vitro (4, 23). Since activation, particularly of CD4 
T cells, also occurs in a number of subjects without parasitemia, pre-erythrocytic exposure 
alone may be apparently sufficient; however, an effect of very low parasitemia at sub-qPCR 
densities cannot be formally excluded. Proliferative responses of CD8 T cells and innate 
cells were lower after the second immunization, probably related to the reduced development 
of late liver stage parasites and hence parasitemia after subsequent immunizations as a 
consequence of developing pre-erythrocytic immunity (2, 21). 
Target antigens of protective immunity after sporozoite immunization have thus far not 
been identified. It is therefore not yet feasible to assess whether the observed lymphocyte 
activation is P. falciparum-specific, or the result of an aspecific bystander effect. After 
smallpox or yellow fever vaccination at least, only a minimal bystander CD8 T cell response 
has been shown to occur, but the lack of a human challenge model for these infections 
hampers assessment of the functional significance of these findings (15). Here we established 
that after CPS immunization neither proliferation nor activation of CD4 or CD8 T cells 
predicts protection. Studies are ongoing to identify target antigens of CPS-induced protection 
(Clinicaltrials.gov NCT02080026), which would allow tetramer analysis of T cells in order 
to shed light on the composition and heterogeneity of the induced responses and possible 
correlation of individual antigen-specific responses with protection. 
As known markers of immune-regulation in malaria, we measured Treg proliferation 
and PD-1 expression during immunization. Tregs are known to suppress Th1 responses in 
mice (24-26). Also in humans, Tregs are induced during blood-stage infection following 
controlled malaria infection, in association with decreased antigen-specific immune responses 
and pro-inflammatory cytokine production (27). Moreover, FOXP3 mRNA levels during 
acute disease in Gambian children were inversely correlated with cultured IFNγ responses to 
P. falciparum schizont extract 28 days later (28). We did not find an association between Treg 
proliferation and Th1 memory responses, but proliferation of Tregs was significantly higher 
after the second immunization in subjects subsequently not protected against challenge. 
Although the sample size for this comparison is low, this finding might support the notion 
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that Tregs have a negative role in the induction of protection by CPS. In fact, the Treg subset 
was the first measured cell population that significantly proliferated already 7 days after 
exposure. 
PD-1 is up-regulated on CD4 and CD8 T cells upon activation, and indeed increased 
expression of PD-1 on both CD4 and CD8 T cells concurred with emergence of parasitemia 
during immunization. PD-1 inhibits cytokine production and cytotoxic functions of T cells 
(29); in Malian children infected with malaria PD-1 expression on CD4 T cells was associated 
with T cell dysfunction, and in mice blockade of the PD-1 ligand PD-L1 restored CD4 T 
cell function (30). However, data on the role of PD-1 are not unambiguous. For example, 
analysis of PBMCs from healthy humans showed that most CD8 T cells expressing PD-1 are 
effector memory cells, rather than exhausted cells (31). Our data show that up-regulation of 
PD-1 expression is not associated with lack of protection, suggesting that immune responses 
are not compromised via this inhibitory pathway during CPS immunization. Instead, it may 
rather represent a physiological regulatory mechanism or indicate activation of these cells 
(32).
The absolute number of circulating γδT cells doubled over the course of two CPS 
immunizations, in line with previous findings in both CPS and RAS studies (4, 5). In addition, 
we observed a substantial specific IFNγ production (4) as well as sustained increase in 
granzyme B content of γδT cells, which supports their potential cytotoxic role in protection. 
A protective role for γδT cells has been shown in rodents after RAS immunization (12). 
Whether the expansion of the γδT cell population is an antigen-specific or bystander effect 
remains to be investigated.
We did observe a positive but non-significant response of CD4 T cell activation 
after bites from uninfected mosquitoes. Although clearly inconclusive, a mosquito-saliva 
component might contribute to the efficiency of CPS immunization. In rodent studies, bites 
from uninfected Anopheles mosquitoes resulted in lower liver-stage infection after challenge, 
concurrent with the induction of a Th1 immune response (33).
CPS-induced protection is mediated by immune responses directed against pre-
erythrocytic stages (2) and skin, liver and blood have unique characteristics including distinct 
immune cell compositions that could be important in the interaction with Plasmodium (34). A 
major shortcoming for human CD8 T cell studies is the fact that peripheral blood is generally 
the only accessible lymphocyte source, which is obviously not the compartment of major 
CD8 activity. Alternatively, non-human primate studies can be used to shed light on the role 
of tissue-resident memory CD8 T cells (35).  Indeed, the frequency of P. falciparum specific 
IFNγ producing T cells was shown to be significantly higher in the liver than in peripheral 
blood of RAS-immunized rhesus macaques (36) and depletion of CD8 T cells abrogates RAS 
induced immunity (11). Another limitation of our study is that the majority of panels used to 
assess CD8 T cells did not include markers for the γδ T cell receptor or the semi-invariant 
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T-cell receptor Vα7.2-Jα33/12/20. Only a minor fraction of CD8 T cells in our volunteers 
expressed the γδ T cell receptor, and proliferation kinetics of γδ negative CD8 T cells were 
comparable to those of total CD8 T cells (data not shown). Nevertheless, we can thus not 
exclude that γδTCR+CD8+ T cells and mucosal-associated invariant T (MAIT) (37) cells 
possibly included in the CD8 T cell gate might show slightly different patterns in  activation, 
PD-1 and T-bet expression from classic αβ CD8 T cells.
Taken together, we find that different lymphocyte subsets have distinct activation 
kinetics during whole sporozoite immunization, that T cell activation also occurs in the 
absence of blood stage parasitemia and that Treg proliferation negatively associates with 
protection. Moreover, we show that T cell proliferation goes hand in hand with differentiation 
towards the Th1 and cytotoxic lineages and a particular increase in the cytotoxic potential 
of γδT cells in a majority of subjects. Once target antigens are identified, future studies 
using the relatively simple and highly efficient CPS immunization model can be designed to 
disentangle the regulatory and effector functions of different antigen-specific T cell subsets 
and their role in protection. 
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Figure S2 Proliferation of regulatory T cells. The degree of CD4+CD45RO+FoxP3+ Treg 
proliferation was assessed as Ki67 integrated MFI. Differences between protected (filled 
circles) and unprotected (open circles) subjects were assessed by two-way ANOVA with 
Bonferroni post-hoc test for multiple comparison correction.
Figure S3 T-bet expression in CD4 T cells. Representative flow cytometry plots for two 




Table S1 Antibodies used for flow cytometry
Target Fluorochrome Clone Supplier
All panels
Fixable viability Aqua - eBioscience
Panel I
HLA-DR PE L243 BioLegend
CD4 PerCP RPA-T4 BioLegend
CD3 ECD UCHT1 Beckman Coulter
CD38 PeCy7 HIT2 BioLegend
CD8 APC-H7 SK1 BD Biosciences
Granzyme B Fitc GB11 BioLegend
Ki67 AF647 B56 BD Biosciences
Panel II
γδTCR PE IMMU510 Beckman Coulter
CD25 ECD B1.49.9 Beckman Coulter
CD3 PerCP UCHT1 BioLegend
CD8 APC-H7 SK1 BD Biosciences
CD56 biotin HCD56 BioLegend
Streptavidin eF450 - eBioscience
Granzyme B Fitc GB11 BioLegend
Ki67 AF647 B56 BD Biosciences
Panel III
CD3 PerCp UCHT1 BioLegend
CD45RO ECD UCHL1 Beckman Coulter
CD4 APC-H7 RPA-T4 BD Biosciences
Ki67 Fitc B56 BD Biosciences
FoxP3 eF450 PCH101 eBioscience
Panel IV
CD3 Fitc OKT3 BioLegend
CD4 PerCP RPA-T4 BioLegend
PD-1 PeCy7 EH12.2H7 BioLegend
CD8 APC-H7 SK1 BD Biosciences
Ki67 AF647 B56 BD Biosciences
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In the controlled human malaria infection (CHMI) model, complete protection in >90% 
of volunteers against homologous Plasmodium falciparum infection has so far only been 
achieved after immunization with whole parasites. The most efficient regimen is sporozoite 
immunization of healthy volunteers under chloroquine prophylaxis (CPS immunization), 
requiring bites from only 30-45 mosquitoes infected with P. falciparum-sporozoites. Given 
the large diversity of P. falciparum parasites, it is essential to assess protection against 
heterologous parasite strains.
Methods 
In an open-label follow-up study, 16 volunteers previously CPS-immunized and challenged 
with P. falciparum NF54 (West-Africa) in a dose de-escalation and challenge trial, were 
re-challenged with clone NF135.C10 (Cambodia) at 14 months after the last immunization 
(NCT01660854). 
Results
Two out of thirteen NF54 protected volunteers previously fully protected against NF54 were 
also fully protected against NF135.C10, while 11/13 showed a delayed patency [median 
prepatent period of 10.5 days (range 9.0-15.5) versus 8.5 days in 5 malaria-naïve controls 
(p=0.0005)]. Analysis of patency by qPCR indicated an estimated 91 to >99% reduction 
of liver parasite load in 7/11 partially protected subjects. Three volunteers previously not 
protected against NF54, were also not protected against NF135.C10. 
Conclusion
This study shows that CPS immunization can induce heterologous protection for a period of 
more than one year, which is a further impetus for clinical development of whole parasite 
vaccines.
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Introduction
Malaria remains a tremendous public health problem affecting approximately 40% of the 
world’s population. The global incidence of malaria is estimated to be around 198 million 
clinical cases resulting in 584.000 deaths (1) most of which are caused by Plasmodium 
falciparum. Since current interventions fail to reduce malaria incidence sufficiently, a vaccine 
is needed to combat this disease. 
Sterile protection against P. falciparum malaria can efficiently and reproducibly be 
achieved in the Controlled Human Malaria Infection (CHMI) setting by repeated inoculation 
of live sporozoites by bites of laboratory-reared Anopheles mosquitoes to healthy malaria-
naïve volunteers under chemoprophylaxis: ChemoProphylaxis and Sporozoites (CPS) 
immunization (2, 3). CPS-induced protection is dose-dependent (3) and was shown in a 
subset of volunteers to last for more than two years (4). Furthermore, bites from only 30-45 P. 
falciparum-infected mosquitoes are sufficient to induce sterile protection in >90% of subjects, 
while immunization with radiation-attenuated sporozoites (RAS) requires a minimum of 
1,000 P. falciparum-infected mosquitoes, or intravenous injection of 675,000 cryopreserved 
sporozoites (5, 6). So far, CPS immunizations and challenges have been performed with the 
homologous NF54 strain only, while in malaria-endemic areas there is a large genetic and 
antigenic diversity of P. falciparum strains. This diversity is considered an important reason 
why naturally acquired immunity is obtained slowly, only after several years of repeated 
exposure (7). Previously, heterologous protection has been reported in 4/6 RAS-immunized 
volunteers (5). 
Next to the widely used P. falciparum strain NF54 and its clone 3D7, NF135.C10 
originating from Cambodia has become available for CHMI (8). In this study, volunteers who 
had previously participated in a NF54 dose de-escalation CPS immunization and challenge 
trial (9) were re-challenged with NF135.C10 after more than one year. 
Materials and Methods 
Study design
A single center open label clinical trial was conducted at the Leiden University Medical 
Center (LUMC) from July 2012 until February 2013. The study was approved by the Central 
Committee for Research Involving Human Subjects of The Netherlands (NL39414.000.12) 
and complied with the Declaration of Helsinki and Good Clinical Practice including 
monitoring of data. ClinicalTrials.gov Identifier: NCT01660854. 
Study participants
Eighteen volunteers from a NF54 CPS dose-de-escalating study (ClinicalTrials.gov 
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Identifier: NCT01218893; (9) and 8 newly recruited malaria-naïve subjects aged 18-35 years 
were all screened in July 2012 for eligibility based on medical and family history, physical 
examination and standard hematological and biochemical measurements (Figure 1). 
 
Seventeen NF54 CPS-immunized volunteers and five controls were included. One 




Challenged, completed follow-up 





Screened for heterologous 
re-challenge (n=18)






3x15 bites (n=3; 2P/1NP)
3x10 bites (n=8; 7P U/1NP)





Figure 1 Study flow diagram. The previous NF54 CPS immunization study is shown in 
grey. P=NF54 protected, NP=NF54 unprotected. U=Volunteer presumptively treated on 
day 10.5 after NF54 challenge and considered NF54 protected
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treated with atovaquone/proguanil two days after challenge. Two of the remaining included 
volunteers had previously received the highest dose of NF54 CPS (3x15 bites), 8 a medium 
dose (3x10 bites) and 6 the lowest dose (3x5 bites). Thirteen were NF54 protected, of which 
one volunteer was presumptively treated because of a non-malaria related SAE on day 10,5 
after NF54 challenge, but considered NF54 protected (9). 
None of the female volunteers were pregnant or lactating. Serology for HIV, hepatitis 
B and hepatitis C was negative in all volunteers. Plasma samples tested by Enzyme-Linked 
ImmunoSorbent Assay (ELISA) against crude NF54 asexual blood stages were negative in 
all control volunteers. None of the volunteers had travelled to a malaria-endemic area within 
6 months prior to the start of the study. All volunteers provided written informed consent 
before screening. 
Study procedures
All volunteers were challenged simultaneously by exposure to five bites of Anopheles 
stephensi mosquitoes infected with the NF135.C10 P. falciparum clone (8) in August 2012. 
This heterologous challenge was performed 14 months after the last NF54 CPS immunization 
and 9.5 months after NF54 challenge. Volunteers were followed-up on an outpatient basis 
once daily on days 5-6 after challenge, twice daily between days 7-15 and once daily between 
days 16-21. During each visit, blood was drawn for parasite detection by thick smear. 
Volunteers were treated with 1000 mg atovaquone and 400 mg proguanil once daily for three 
days according to Dutch national malaria guidelines as soon as parasites were detected by 
thick smear, or on day 21 after challenge if they had remained thick smear negative. The last 
visit for volunteers was conducted in February 2013.
Safety parameters were determined daily: platelet counts were determined in EDTA 
blood with the Sysmex XE-2100 (Sysmex Europe GmbH. Norderstedt. Germany). D-dimer 
concentrations were assessed in citrate plasma by STA-R Evolution (Roche Diagnostics, 
Almere, The Netherlands; upper limit of detection 5000 ng/ml), Highly sensitive (Hs) 
Troponine T and Lactate Dehydrogenase (LDH) were determined in serum by Modular E170 
(Roche Diagnostics, Almere, The Netherlands).
Endpoints
The primary endpoint was time to parasitemia after challenge infection as assessed by thick 
smear. Blood was screened by microscopy for parasites as described before, and the thick 
smear was considered positive if two unambiguous parasites were detected in 0.5µL of blood, 
confirmed by a second independent reader. Volunteers were considered protected when thick 
smears remained negative up until 21 days after challenge. 
Secondary endpoints were the kinetics of parasitemia and frequency of signs and 
symptoms. Parasitemia was retrospectively quantified by qPCR on samples collected up 
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to twice daily from day 5 until day 21 after challenge as described previously (10) with 
some modifications. Briefly, 5µL Zap-oglobin II Lytic Reagent (Beckman Coulter) was 
added to 0.5ml of EDTA blood, after which the samples were mixed and stored at -80°C. 
After thawing, samples were spiked with the extraction control Phocine Herpes Virus 
(PhHV) and DNA was extracted with a MagnaPure LC isolation station. Isolated DNA 
was resuspended in 50µl H
2
O and 5µl was used as template. For the detection of P. 
falciparum, the primers as described earlier (10) and the TaqMan MGB FAM-labelled probe 
5’-AACAATTGGAGGGCAAG-3’ were used. For quantification of PhHV the primers 
5’-GGGCGAATCACAGATTGAATC-3’, 5’-GCGGTTCCAAACGTACCAA-3’ and the 
probe Cy5-5’-TTTTTATGTGTCCGCCACCATCTGGATC-3’ were used.
Adverse events (AEs) reported by volunteers or observed by the investigator were 
recorded according to the following scale: mild (grade 1; easily tolerated), moderate (grade 
2; interferes with normal activity) or severe (grade 3; prevents normal activity). Fever was 
recorded as grade 1 (37.5-38.0°C), grade 2 (38.0-39.0°C) or grade 3 (>39.0°C). 
Statistical analysis
All possibly and probably (both solicited and unsolicited) related AEs were tabulated, 
grouped and analyzed by calculating the average number of mild, moderate or severe AEs 
per volunteer in each group. Statistical analyses were performed using GraphPad Prism 6.02. 
Differences in prepatent period and parasitemia at time of treatment between two groups 
(NF54 protected and controls) were tested by Mann Whitney test, and between the three dose 
groups by Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test. A p value of 
<0.05 was considered statistically significant.
Results  
Heterologous protection induced by CPS immunization
Sterile heterologous protection against NF135.C10 was complete in 15% (2/13) of NF54 
protected volunteers (Figure 2A). Patency was significantly delayed in the other 11 volunteers, 
indicative of partial protection [median prepatent period determined by thick smear was 10.5 
days (range 9.0-15.5) versus 8.5 days (range 8.5-8.5) in controls; p=0.0005 (Table 1, Figure 
2B)]. Seven out of 11 partially protected subjects showed a delay in patency by qPCR of at 
least 48 hours, and thus more than one P. falciparum multiplication cycle. 
The 3 volunteers previously not protected against NF54 were neither protected 
against NF135.C10 (Table 1, Figure 1). The prepatent period by thick smear did not differ 
significantly between NF54 CPS immunization dose groups (Figure 2C/2D). Parasitemia at 
time of treatment was higher in controls compared to CPS-immunized (p=0.047; Figure 3).
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Figure 2 Protection and prepatent period after heterologous NF135.C10 challenge. Left 
panels: Kaplan-Meier curves showing percentage of thick smear negative volunteers after 
NF135.C10 challenge according to previous NF54 protection status (A) and NF54 CPS 
immunization dose for NF54-protected subjects (C). Right panels: The corresponding 
distribution of prepatent period of thick smear positive volunteers is shown in dot 
plots according to NF54 protection status (B) and NF54 CPS immunization dose (D). 
Lines represent medians. U=Volunteer presumptively treated after NF54 challenge and 




All volunteers reported possibly or probably related AEs after challenge. Partially protected 
volunteers and controls showed a peak of AEs on the first day after start of treatment (Figure 
4). Fourteen volunteers experienced related grade 3 AEs, which were more frequently reported 
in partially protected than in control volunteers (8/10 versus 2/5 respectively). There were no 
serious AEs. In partially protected volunteers, delayed patency concurred with earlier onset 
of AEs relative to the time of parasite-detection by thick smear. While control volunteers did 
not experience any AEs up until one day before parasite-detection by thick smear, partially 
protected volunteers experienced AEs as early as three days before thick smear positivity. 
Figure 3 Parasitemia before and after treatment. Parasitemia measured by qPCR up until 
initiation of treatment (A and C) and from treatment onwards (B and D) in previously 
NF54 protected volunteers (A and B) and controls (C and D). Each line represents an 
individual subject with the same colour before and after treatment. Values shown as 25 Pf/
ml were negative (i.e. half the detection limit of the qPCR: 50 parasites/ml). 
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Table 1 Protection against NF135.C10 challenge after NF54 CPS immunization
NF135.C10 NF135.C10 
Protected (n) TS+ (n) Prepatent period a 
Previously NF54 protected
3x15 1 1 12.5
3x10 1 6 10.5 (10.5-15.0)
3x5 0 4 12.0 (9.0-15.5)
all 2 11 10.5 (9.0-15.5)***
NF54 unprotected
3x15 0 0
3x10 0 1 8.5
3x5 0 2 8.8 (7.0-10.5)
all 0 3 8.5 (7.0-10.5)
Malaria-naive controls 0 5 8.5 (8.5-8.5)
Sixteen previously CPS-immunized and challenged with P. falciparum NF54 volunteers in 
a CPS dose de-escalation and challenge trial were re-challenged with clone NF135.C10. 
a in days, median (range). TS: Thick smear
***: p=0.0005 compared to controls
All controls and one partially protected volunteer showed persisting fever (maximum 
39.0 °C) and/or mild to moderate complaints in the evening of day 3 after start of treatment. 
Resolution of the AEs took longer (up to 7 days) in controls compared to partially protected 
volunteers, and to historical controls (11). Additional thick smears performed in these 
volunteers on day 4, 5 and 6 after start of treatment were negative. All volunteers recovered 
fully without requiring additional antimalarial treatment. 
 
Safety parameters
Hs troponin T concentrations remained within normal range (<0.03 μg/L) in all volunteers. 
LDH was elevated in ten volunteers after initiation of treatment (median maximum value 
242 U/L, range 182-718 U/L) and returned within normal range (0-248 U/L) during follow-
up. D-dimer levels were elevated in all volunteers (median maximum value 1748 ng/ml, 
range 524 – <5000 ng/ml) and returned within normal range (0-220 ng/ml) during follow-
up. The number of platelets decreased below lower reference value (150x109/L) in 13 
volunteers (median lowest value 127x109/L, range 51-275x109/L) without apparent clinical 
manifestations of bleeding or thrombotic complications. Safety parameters returned within 




Our principle finding is that protection against a heterologous challenge infection with 
NF135.C10 is present in NF54 CPS-immunized and protected volunteers challenged more 
than one year before. Heterologous protection against NF135.C10 was complete in 15% 
(2/13) of volunteers while there was a delayed patency of more than 48 hours in 54% (7/13) 
of subjects. Taking into account a mean multiplication factor of 11.1 (11) and the presumed 
absence of functional blood stage immunity at this low parasitemia (3), this delay indicates 
that liver parasite load was reduced by approximately 91%. In three out of these seven 
volunteers a delay of more than two or three cycles was observed, indicating an estimated 
reduction of >99%. Three volunteers with no protection in the earlier homologous NF54 
challenge study were also fully susceptible to NF135.C10. 
Previous CPS studies showed that protection is mediated by immunity against pre-
erythrocytic stages rather than asexual blood stages (3). NF135.C10 originates from Cambodia, 
while NF54, isolated near Schiphol Amsterdam airport, likely originates from West Africa 
Figure 4 Adverse events before and after initiation of treatment. Average number of 
possibly and probably related (both solicited and unsolicited) AEs per previously NF54 
protected or control volunteer in relation to the time of positive thick smear (day of 
treatment). Time points are plotted towards day of treatment, depicted as ‘T’, from 3 days 
before until 7 days after start of treatment. 
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(8). Both isolates show distinct differences in genes encoding three well-established antigens 
(MSP-1, MSP-2 and GLURP) as well as in the rif repetitive elements (8). The target antigens 
of CPS-mediated protection remain to be elucidated in further studies including possible 
differences in antigen-specific responses to NF54 and NF135.C10. 
Heterologous protection was incomplete in the majority of NF135.C10 re-challenged 
volunteers demonstrated by a delayed patency compared to controls. Apart from the genetic/
antigenic variation between NF135.C10 and NF54, and thus insufficient breadth of the 
induced immune response, this incomplete heterologous protection may relate to a number 
of alternative explanations: i) Waning immunity: the heterologous challenge was performed 
at 14 months, rather than the usual 2 to 5 months post CPS immunization; ii) Suboptimal 
sporozoite immunization dose received by the majority (14/16) of volunteers, indicating an 
antigen threshold for complete protection (9). The minimally required immunization dose 
may increase for longevity of homologous protection and may be even higher for (long-
lasting) heterologous protection. This trial was not powered to detect any dose-response 
relationships, but the two fully protected volunteers had indeed been immunized with the 
medium and high dose; iii) A possible difference between NF54 and NF135C.10 in sporozoite 
infectivity for liver cell invasion and/or maturation. This is supported by the higher first peak 
of NF135.C10 parasitemia compared to historical NF54 controls (2871 Pf/ml versus 456 Pf/
ml respectively (11). 
In partially protected volunteers, delayed patency concurred with earlier onset of AEs 
in relation to parasite-detection by thick smear. This might be due to the longer time frame 
before parasitemia reaches the thick smear detection limit. Alternatively, early immune 
recognition of blood stage parasites by the host may result in an increased inflammatory 
response and subsequent increase in AEs. A comparable effect was observed in a previous 
trial, where CPS-immunized subjects who received a blood-stage challenge developed 
inflammatory markers and fever earlier than naïve controls (3).
Compared to partially protected volunteers, control volunteers showed prolonged AEs 
after treatment. This continuation of AEs until day 7 after treatment has not been observed 
in previous CHMI trials with either strain NF54 or NF135.C10, neither in the CPS studies 
nor in RAS studies (5). Whether this represents an incidental finding or strain-specific 
characteristics needs to be investigated in future trials.
In conclusion, NF54 CPS immunization induces heterologous protection against the 
geographically and genetically distinct P. falciparum NF135.C10 clone.  Increasing the 
immunization dose, altering the immunizing strain, or even immunization with a combination 
of strains may further improve protection. These results and further optimization of CPS 
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Immunization of healthy volunteers with chloroquine ChemoProphylaxis and Sporozoites 
(CPS-CQ) efficiently and reproducibly induces dose-dependent and long-lasting protection 
against homologous Plasmodium falciparum challenge. Here, we studied whether 
chloroquine can be replaced by mefloquine, which is the only other licensed anti-malarial 
chemoprophylactic drug that does not affect pre-erythrocytic stages, exposure to which is 
considered essential for induction of protection by CPS immunization. In a double blind 
randomized controlled clinical trial, volunteers under either chloroquine prophylaxis (CPS-
CQ, n = 5) or mefloquine prophylaxis (CPS-MQ, n = 10) received three sub-optimal CPS 
immunizations by bites from eight P. falciparum infected mosquitoes each, at monthly 
intervals. Four control volunteers received mefloquine prophylaxis and bites from uninfected 
mosquitoes. CPS-MQ immunization is safe and equally potent compared to CPS-CQ 
inducing protection in 7/10 (70%) versus 3/5 (60%) volunteers, respectively. Furthermore, 
specific antibody levels and cellular immune memory responses were comparable between 
both groups. We therefore conclude that mefloquine and chloroquine are equally effective in 
CPS-induced immune responses and protection.
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Introduction
Malaria remains one of the most important infectious diseases worldwide and still causes 
approximately 207 million cases and 627,000 deaths every year (1). Anti-disease immunity 
against malaria is not easily induced: in endemic areas this takes many years of repeated 
exposure to develop (2), and sterile protection against infection does not seem to be induced 
at all (3). Also candidate vaccines have shown only limited protective efficacy so far (4, 5). 
Novel vaccines and drugs can be tested for efficacy at an early stage of clinical development 
in Controlled Human Malaria Infection (CHMI) studies, exposing a small number of 
healthy volunteers to Plasmodium falciparum by bites from infected Anopheles mosquitoes. 
Immunization of healthy volunteers under chloroquine ChemoProphylaxis with Sporozoites 
(CPS-CQ immunization) efficiently, reproducibly and dose-dependently induces protection 
against homologous CHMI (6, 7), shown in a subset of volunteers to last for more than 2 
years (8). CPS-CQ immunization requires exposure to bites from only a total of 30-45 P. 
falciparum infected mosquitoes to induce 89–95% protection (6, 7, 9). In contrast, protection 
by immunization with radiation-attenuated sporozoites (RAS) requires a minimum of 1000 
infected mosquito bites (10), or intravenous injection of five times 135,000 cryopreserved 
sporozoites (11). 
The unprecedented efficiency of the CPS immunization regime may relate to its design: 
in contrast to RAS, CPS immunization allows full liver stage development and exposure to 
early blood-stages. Moreover, chloroquine is known for its immunomodulatory capacities 
(12-14) that may play a role in induction of protection, which is mediated by pre-erythrocytic 
immunity (9) including antibodies directed against sporozoites (15-17), and likely T cells 
targeting liver-stages (7). Next to chloroquine, mefloquine (MQ) is the only licensed drug for 
chemoprophylaxis that does not affect pre-erythrocytic stage development (18). We therefore 
aimed to assess whether chloroquine could be replaced by mefloquine for CPS immunization. 
In a double blind randomized controlled clinical trial we assessed safety, immunogenicity 
and protection against challenge for CPS-MQ compared to CPS-CQ. 
Methods
Study subjects   
Healthy subjects between 18 and 35 years old with no history of malaria were screened 
for eligibility based on medical and family history, physical examination and standard 
hematological and biochemical measurements. Urine toxicology screening was negative in 
all included subjects; none of the subjects were pregnant or lactating. Serological analysis 
for HIV, hepatitis B, hepatitis C and P. falciparum asexual blood-stages was negative in 
all subjects. All subjects had an estimated 10-year risk smaller than 5% of developing a 
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cardiac event as estimated by the Systematic Coronary Evaluation System adjusted for the 
Dutch population (19). None of the subjects had travelled to a malaria-endemic area during 
or within 6 months prior to the start of the study. All subjects provided written informed 
consent before screening. The Central Committee for Research Involving Human Subjects 
of The Netherlands approved the study (NL 37563.058.11). Investigators complied with the 
Declaration of Helsinki and Good Clinical Practice including monitoring of data. This trial is 
registered at ClinicalTrials.gov, identifier NCT01422954. 
Study design and procedures
This single center, double blind randomized controlled trial was conducted at Leiden 
University Medical Center (Leiden, the Netherlands) from April 2012 until April 2013 
Assessed for eligibility (n=36) Excluded (n=13):- Psychiatric history subject or family member 
(n=5)
- BMI <20 kg/m2 (n=2)
- Informed consent withdrawn (n=2)
- Travel to malaria-endemic country (n=2) 
- Hypertension (n=1)
- Laboratory abnormalities (n=1)







Median age 20 (19-22)
Challenged, completed follow-up 








Median age 21 (20-22)
Figure 1 Study flow diagram. Thirty-six subjects were screened for eligibility, of whom 
twenty were included in the trial and randomized over three groups. One control subject was 
excluded after initiation of chemoprophylaxis but before the first immunization because 
of an unexpected visit to a malaria-endemic area during the study period. In a double-
blind fashion, fifteen subjects received either CPS-CQ or CPS-MQ immunization and four 
control subjects received bites from uninfected mosquitoes and mefloquine prophylaxis. 
Subjects received a challenge infection by bites of five infected mosquitoes sixteen weeks 
after discontinuation of prophylaxis.
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(Figure 1). Twenty subjects were randomly divided into three groups by an independent 
investigator using a computer-generated random-number table. Subjects, investigators and 
primary outcome assessors were blinded to the allocation. Subjects in the CPS-CQ group (n 
= 5) received a standard prophylactic regimen of chloroquine consisting of a loading dose 
of 300 mg on the first and fourth day and subsequently 300 mg once a week for 12 weeks. 
Subjects in the CPS-MQ group (n = 10) and the control group (n = 5) received mefloquine 
prophylaxis starting with a loading split dose regimen to limit potential side-effects: 125 mg 
twice per week for a duration of 3 weeks and subsequently 250 mg once a week for 12 weeks. 
Chloroquine and mefloquine were administered as capsules, indistinguishable from each 
other. During this period all subjects were exposed to the bites of 8 Anopheles mosquitoes 
three times at monthly intervals, starting 22 days after start of mefloquine prophylaxis and 8 
days after start of chloroquine prophylaxis. 
Volunteers in the CPS-CQ and CPS-MQ groups received bites from mosquitoes 
infected with the P. falciparum NF54 strain, control subjects received bites from uninfected 
mosquitoes. The immunization dose was based on our previous dose-de-escalation trial (7) 
and aimed to establish partial protection in the CPS-CQ group in order to enable detection of 
either improved or reduced protection in the CPS-MQ group. Sample sizes were calculated 
based on the expected difference of 4 days in prepatent period between the CPS-CQ and 
CPS-MQ groups, a standard deviation of 1.6 and 2.3 days respectively, an α of 5% and a 
power of 0.90. This calculation resulted in a CPS-CQ group of 4 and a CPS-MQ group of 8 
subjects. To account for possible dropouts based on (perceived) side effects we included one 
and two extra volunteers in the CPS-CQ and CPS-MQ groups respectively. The control group 
was included as infectivity control for the challenge infection.
On days 6 to 10 after each immunization by mosquito exposure, all subjects were 
followed on an outpatient basis and peripheral blood was drawn for blood smears, standard 
hematological measurements, cardiovascular markers and retrospective qPCR. 
Twenty weeks after the last immunization, sixteen weeks after discontinuation of 
prophylaxis, all subjects were challenged by the bites of five mosquitoes infected with the 
homologous NF54 P. falciparum strain, according to previous protocols (20). After this 
challenge-infection, all subjects were checked twice daily on an outpatient basis from day 
5 up until day 15 and once daily from day 16 up until day 21 for symptoms and signs of 
malaria. Thick blood smears for parasite detection were made during each of these visits 
after challenge, hematological and cardiovascular markers were assessed daily. As soon 
as parasites were detected by thick smear, subjects were treated with a standard curative 
regimen of 1000 mg atovaquone and 400 mg proguanil once daily for three days according 
to Dutch national malaria treatment guidelines. If subjects remained thick smear negative, 
they were presumptively treated with the same curative regimen on day 21 after challenge 
infection. All subjects were followed closely for 3 days after initiation of treatment and 
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complete cure was confirmed by two negative blood smears after the last treatment dose. 
Chloroquine and mefloquine levels were measured retrospectively in citrate-plasma from 
the day before challenge by liquid chromatography (detection limit for both chloroquine and 
mefloquine: 5 μg/L) (21).
Anopheles stephensi mosquitoes for immunizations and challenge-infection were 
reared according to standard procedures at the insectary of the Radboud university medical 
center. Infected mosquitoes were obtained by feeding on NF54 gametocytes, a chloroquine- 
and mefloquine-sensitive P. falciparum strain, as described previously (22). After exposure 
of volunteers, all blood-engorged mosquitoes were dissected to confirm the presence of 
sporozoites. If necessary, feeding sessions were repeated until the predefined number of 
infected or uninfected mosquitoes had fed. 
Endpoints
The primary endpoint was prepatent period, defined as the time between challenge and first 
positive thick blood smear. Secondary endpoints were parasitemia and kinetics of parasitemia 
as measured by qPCR, adverse events and immune responses.
Detection of parasites by thick smear
Blood was sampled twice daily from day 5 until day 15 and once daily from day 16 up until 
day 21 after challenge and thick smears were prepared and read as described previously (9). 
In short, approximately 0.5 µl of blood were assessed by microscopy and the smear was 
considered positive if two unambiguous parasites were seen.
Quantification of parasitemia by qPCR
Retrospectively, parasitemia was quantified by real-time quantitative PCR (qPCR) on 
samples from day 6 until day 10 after each immunization and from day 5 until day 21 after 
challenge as described previously (23), with some modifications. Briefly, 5 µl Zap-Oglobin 
II Lytic Reagent (Beckman Coulter) was added to 0.5 ml of EDTA blood, after which the 
samples were mixed and stored at –80°C. After thawing, samples were spiked with the 
extraction control Phocine Herpes Virus (PhHV) and DNA was extracted with a MagnaPure 
LC isolation instrument. Isolated DNA was resuspended in 50 µl H
2
O, and 5 µl was used 
as template. For the detection of P. falciparum, the primers as described earlier (23) and the 
TaqMan MGB probe AAC AAT TGG AGG GCA AG-FAM were used. For quantification of 
PhHV the primers GGGCGAATCACAGATTGAATC, GCGGTTCCAAACGTACCAA and 
the probe Cy5-TTTTTATGTGTCCGCCACCATCTGGATC were used. The sensitivity of 
qPCR was 35 parasites/ml of whole blood.
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Adverse events and safety lab
Adverse events (AEs) were recorded as following: mild events (easily tolerated), moderate 
events (interfering with normal activity), or severe events (preventing normal activity). 
Fever was recorded as grade 1 (>37×5°C–38×0°C), grade 2 (>38×0°C–39×0°C) or grade 
3 (>39×0°C). Platelet and lymphocyte counts were determined in EDTA-anti-coagulated 
blood with the Sysmex XE-2100 (Sysmex Europe GmbH, Norderstedt, Germany). D-dimer 
concentrations were assessed in citrate plasma by STA-R Evolution (Roche Diagnostics, 
Almere, The Netherlands). 
Immunological analyses
In order to assess cellular immune memory responses, peripheral blood mononuclear cell 
(PBMC) re-stimulation assays were performed as described previously (7). PBMCs were 
collected, frozen in fetal calf serum containing 10% dimethylsulfoxide, and stored in vapor 
phase nitrogen before initiation of prophylaxis (baseline; B) and one day before the challenge 
infection (C-1). 
After thawing, PBMCs were re-exposed in vitro to P. falciparum-infected red blood 
cells (PfRBC) and incubated for 24 hours at 37°C in the presence of a fluorochrome-labeled 
antibody against CD107a. Uninfected red blood cells (uRBCs) were used as a negative 
control. During the last 4 hours of incubation, 10 µg/ml Brefeldin A and 2 µM Monensin 
were added, allowing cytokines to accumulate within the cells. As a positive control, 50 ng/
ml PMA and 1 mg/ml ionomycin were added for the last four hours of incubation. After 
24h stimulation, cells were further stained with a viability marker and fluorochrome-labeled 
antibodies against CD3, CD4, CD8, CD56, γδ-T cell receptor, IFNγ and granzyme B (Table 
S1 (7)). For each volunteer, cells from all time points were tested in a single experiment: 
thawed and stimulated on the same day and stained the following day. Samples were acquired 
on a 9-color Cyan ADP (Beckman Coulter) and data analysis was performed using FlowJo 
software (version 9.6.4; Tree Star). A representative example showing the full gating strategy 
is shown in Figure S1. Gating of cytokine-positive cells was performed in a standardized 
way by multiplying a fixed factor with the 75 percentile of the geometric Mean Fluorescent 
Intensity (MFI) of cytokine negative PBMCs for each volunteer, time point and stimulus. 
Responses to uRBC were subtracted from the response to PfRBC for each volunteer on every 
time point.
Plasma for the assessment of malaria-specific antibodies was collected and stored at 
baseline (B), 27 days after the first immunization (I1; one day before the second immunization), 
27 days after the second immunization (I2; one day before the third immunization), and 
one day before the challenge infection (C-1). Antibody titers were assessed as described 
previously (17). In summary, serially diluted citrate plasma was used to perform standardized 
enzyme-linked immunosorbent assay (ELISA) in NUNC™ Maxisorp plates (Thermo 
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Scientific) coated with 1 µg/ml circumsporozoite protein (CSP), liver-stage antigen-1 (LSA-
1) or merozoite surface protein-1 (MSP-1) antigen, diluted in PBS. Bound IgG was detected 
using horseradish peroxidase (HRP) conjugated anti-human IgG) (Thermo Scientific, 
1/60000) and Tetramethylbenzidine (all Mabtech). Spectrophotometrical absorbance was 
measured at 450 nm. OD values were converted into AUs by four-parameter logistic curve fit 
using Auditable Data Analysis and Management System for ELISA (ADAMSEL-v1.1, http://
www.malariaresearch.eu/content/software; accessed 27 October 2014). Levels of antibodies 
were calculated in relation to a pool of 100 sera from adults living in a highly endemic area 
in Tanzania (HIT serum (24)), which was defined to contain 100 arbitrary units (AU) of IgG 
directed against each antigen. 
Statistical analyses
The proportion of protected subjects in the CPS-CQ versus CPS-MQ group was tested with 
the Fisher’s exact test using Graphpad Quickcalcs online and the 95% confidence interval 
(CI) of protection for each group was calculated by modified Wald Method (25). Further 
statistical analyses were performed with GraphPad Prism 5. Differences in prepatent period 
and time from qPCR positivity until thick smear positivity were tested by Mann Whitney 
test. Antibody levels are shown as individual titers with medians and differences between 
time points were analyzed by Friedman test with Dunn’s multiple comparison post-hoc 
test. Induction of cellular immune responses was tested for CPS-CQ and CPS-MQ groups 
separately by Wilcoxon matched-pairs signed rank test (B versus C-1). A p-value of 
<0.05 was considered statistically significant. Analyses of parasitemia were performed on 
log transformed data, the geometric mean peak parasitemia after each immunization was 
calculated using the maximum parasitemia for each subject.
Results
Safety of CPS-CQ and CPS-MQ immunization
Twenty out of 36 screened subjects (median age 21 years; range 18–25) were included in 
the study (Figure 1). One control subject was excluded between start of prophylaxis and the 
first immunization because of an unexpected intermittent visit to a malaria-endemic area. 
Thick blood smears performed from day 6 up until day 10 after each immunization remained 
negative in all volunteers. As determined retrospectively by qPCR, 2/5 subjects in the CPS-
CQ group and 7/10 subjects in the CPS-MQ group  showed sub-microscopic parasitemia 
after the first immunization (geometric mean peak parasitemia for positive subjects: 948 
parasites/ml [range 228–3938] and 256 parasites/ml [range 48–1559] respectively, Figure 2). 
After the second immunization, four CPS-MQ subjects showed sub-microscopic parasitemia 
(geometric mean peak parasitemia for positive subjects 104 parasites/ml [range 48–223]), 
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Figure 2 Parasitemia during CPS immunization. Parasitemia was determined 
retrospectively, once daily from day 6 until day 10 after each immunization, by real-time 
quantitative PCR (qPCR). Each line represents an individual subject from the CPS-MQ 
(dashed blue lines) or CPS-CQ group (red lines). The number of subjects with a positive 
qPCR/total number of volunteers in the CPS-MQ (blue) and CPS-CQ (red) groups after 
each immunization are shown above the graph. Values shown as 17.5 on the log-scale were 
negative (i.e. half the detection limit of the qPCR: 35 parasites/ml). 
Figure 3 Adverse events 
during CPS immunization. 
Percentage of volunteers 
in each group experiencing 
possibly or probably 
related AE after the first 
(I), second (II) and third 
(III) immunization. AEs 
were evaluated at each visit 
and graded for severity as 
described in the methods 
paragraph: mild (light grey), 
moderate (dark grey) and 
severe (black). Only the 
highest intensity per subject 




while none of the CPS-CQ subjects showed parasitemia. After the third immunization, only 
one CPS-MQ subject showed parasitemia by qPCR (peak parasitemia 1059 Pf/ml). 
After the first immunization, all subjects (5/5) in the CPS-CQ group and almost all 
CPS-MQ subjects (8/9) experienced possibly or probably related AEs. One subject in each 
group had a grade 3 AE (headache and vomiting, respectively). Two control volunteers 
reported mild AEs (Figure 3 and Table S2). After the second immunization, two CPS-CQ 
volunteers and six volunteers in the CPS-MQ group had mild AEs. Two control subjects 
experienced moderate and severe headache, respectively. After the third immunization, one 
volunteer in the CPS-CQ group and four CPS-MQ volunteers had AEs; one control subject 
experienced mild AEs (Figure 3 and Table S2). One CPS-CQ subject reported moderate 
sleeping problems while taking chloroquine prophylaxis. One control subject had moderate 
problems with initiation of sleep and another control subject experienced vivid dreams under 
mefloquine prophylaxis. Other than mild to moderate dizziness and sleep related AEs, which 
all resolved after chemoprophylaxis was stopped, no neuropsychiatric AEs occurred. No 
serious adverse events occurred. 
During immunization, one subject each in the CPS-CQ, CPS-MQ and control 
groups showed platelet counts below the lower limit of normal (150x109/L); lowest values 
105x109/L, 116x109/L and 131x109/L, respectively. Three, five and two subjects from the 
Figure 4 Parasitemia after challenge infection. Parasitemia was assessed retrospectively by 
real-time quantitative PCR (qPCR) twice daily from day 5 until day 15 and once daily up 
until day 21 after challenge. Each line represents an individual subject. Red lines represent 
CPS-CQ immunized volunteers (n = 5), dashed blue lines CPS-MQ immunized subjects 
(n = 10) and dotted grey lines malaria-naive control subjects (n = 4). Values shown as 17.5 
on the log-scale were negative (i.e. half the detection limit of the qPCR: 35 parasites/ml).
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CPS-CQ, CPS-MQ and control groups respectively, showed leukocyte counts below the 
lower limit of normal (4x109/L); mean lowest value during immunization period: 3.8x109/L 
[SD 1.2], 4.0x109/L [SD 1.1] and 4.2x109/L [SD 0.7] respectively. No subject developed 
leukocyte counts lower than 2.0x109/L. One volunteer in each group showed leukocyte 
counts above the upper limit of normal (10x109/L; highest values 10.8x109/L, 13.8x109/L 
and 10.1x109/L respectively). After the first immunization, 3/5 CPS-CQ subjects, 7/10 in 
the CPS-MQ group and none in the control group developed elevated d-dimer levels (>500 
ng/ml). After the second immunization, six CPS-MQ subjects but none in the CPS-CQ or 
control groups showed elevated d-dimer levels. After the third immunization, three CPS-MQ 
subjects showed elevated d-dimer levels, while none of the subjects in the other groups did. 
Protection against challenge infection
In the CPS-CQ group 3/5 subjects and in the CPS-MQ group 7/10 volunteers were protected 
against challenge infection (Fisher’s exact test p = 1.0). All control subjects became thick 
smear positive (median day 8.5, range 7–12, p = 0.03 versus CPS-immunized subjects; Table 
1). None of the protected subjects showed parasitemia by qPCR at any time point during 
follow-up (Figure 4). The median prepatent period was not significantly different between 
the CPS-CQ and CPS-MQ groups, neither when protected subjects were arbitrarily set at a 
prepatent period of 21 days (p = 1.00), nor when comparing unprotected subjects only (p = 
0.1). The median chloroquine plasma concentration on the day before challenge infection 
was 9 µg/L (range 7–10) in the CPS-CQ group, and the median mefloquine concentration 
was 24 µg/L (range 5–116) in the mefloquine groups. 
Table 1 Protection against challenge infection after CPS-CQ and CPS-MQ immunization.
Group
Unprotected volunteers
Protection Day of positivity after challengec
























a Presented as protected/total number of subjects
b Presented as % protected (95% CI by modified Wald Method)
c Presented as median (range) days.
d,e p-value calculated by Fisher’s exact test comparing dCPS-MQ versus CPS-CQ or econtrol 
versus all CPS-immunized subjects
f,g p-value calculated by Mann Whitney test comparing fCPS-MQ versus CPS-CQ or gcontrol 
versus all CPS-immunized subjects (both excluding protected subjects)
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Immunogenicity of CPS-CQ and CPS-MQ
Antibodies against the pre-erythrocytic antigens CSP and LSA-1 and the cross-stage antigen 
MSP-1 were assessed by ELISA. Antibodies against CSP were induced in both CPS-CQ 
and CPS-MQ immunized volunteers (p<0.05 and p<0.01 respectively, on C-1; Figure 5A 
and 5B), but not significantly higher in protected compared to unprotected subjects (p = 
0.88 and p = 0.48 respectively). Antibodies against LSA-1 were only significantly induced 
in CPS-MQ immunized volunteers on I2 (p<0.001; Figure 5C and 5D), although not higher 
in protected subjects (p = 0.39). Anti-MSP-1 antibodies by CPS immunization were not 
statistically significant increased in either group (Figure 5E and 5F).
IFNγ production by both adaptive and innate cell subsets in response to in vitro P. 
falciparum re-stimulation was induced by both CPS-CQ and CPS-MQ (Figure S2), without 
a clear quantitative or qualitative difference between the study groups. Next, CD107a 
expression by CD4 T cells and granzyme B production by CD8 T cells, both associated with 
protection in a previous CPS-CQ trial (7), were assessed by flow cytometry. Four out of 5 
CPS-CQ and 8/10 CPS-MQ immunized subjects showed induction of CD107a expression by 
CD4 T cells upon in vitro re-stimulation after immunization (Figure 6A and 6B). Although 
volunteer numbers were too low to reach statistical significance, the magnitude of this 
response appeared to be associated with protection for CPS-CQ (Figure 6A), while for CPS-
MQ it was not (Figure 6B). Granzyme B production by CD8 T cells was not significantly 
induced in either CPS-CQ or CPS-MQ group, nor was it associated with protection (Figure 
6C and 6D).
After challenge, MSP-1 specific antibodies were boosted in all unprotected volunteers 
(fold change median 20.4 (range 7.1–33.6), 76.0 (5.7–06.3) and 7.7 (2.9–15.3) for CPS-
CQ, CPS-MQ and control groups respectively). None of the protected subjects showed an 
increase in MSP-1 antibody levels on C+35 compared to C-1 (median fold change 1.0 (range 
1.0–1.3) and 1.0 (0.6–2.4) for CPS-CQ and CPS-MQ groups, respectively). 
Discussion
Immunization of healthy volunteers with P. falciparum sporozoites while taking mefloquine 
prophylaxis is safe, induces both humoral and cellular immune responses and protects against 
homologous malaria challenge. 
Although most volunteers experienced AEs after the first immunization, their frequency 
declined after subsequent immunizations in line with a reducing number of volunteers 
developing parasitemia. The majority of AEs was mild, with only 10–20% of subjects 
experiencing a grade 3 AEs after each immunization. In general, the reported neurologic 
and psychiatric side effects of mefloquine are a major concern limiting its acceptability and 
clinical application. In this study, mild to moderate dizziness and sleep-related complaints 
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Figure 5 Antibody responses induced by CPS-CQ and CPS-MQ immunization. Antibodies 
against CSP (A and B; in AU), LSA-1 (C and D), and MSP-1 (E and F) were analyzed at 
baseline (B), 28 days after the first (I1) and second (I2) immunization and one day before 
challenge (C-1; 20 weeks after the last immunization) for all CPS-CQ (A, C and E, n = 5) 
and CPS-MQ (B, D and F, n = 10) immunized volunteers. Data are shown as individual 
titers with medians. Open squares indicate protected subjects, filled circles indicate 
unprotected subjects. Differences between the time points were analyzed by Friedman test 
with Dunn’s multiple comparison post-hoc test. Significant differences are indicated by 
asterices with * (p<0.05), ** (p<0.01), *** (p<0.001).
214
Chapter 10
occurred in a small number of subjects in both chloroquine and mefloquine groups. Although 
this study was not powered to detect differences in AEs, frequency of neuropsychiatric AEs 
did not appear to differ between both drugs. This is in line with most reports in literature 
comparing AEs of mefloquine or chloroquine (with or without proguanil) for chemo-
prophylactic use (26-29) although one study found more neuropsychiatric AEs in subjects 
taking mefloquine by retrospective questionnaire (30). Taking the small sample size into 
consideration, both CPS-CQ and CPS-MQ immunization regimens appear to be reasonably 
well tolerated and safe. In 2013, however, after completion of this study, the U.S. Food and 
Drug Administration (FDA) issued a boxed warning for mefloquine, stating that neurologic 
Figure 6 Cellular immune responses: CD107a expression by CD4 T cells and granzyme B 
production by CD8 T cells. CD107a expression by CD4 T cells after PfRBC re-stimulation, 
corrected for uRBC background in CPS-CQ (A) and CPS-MQ (B) groups; granzyme B 
production by CD8 T cells after PfRBC re-stimulation, corrected for uRBC background 
in CPS-CQ (C) and CPS-MQ (D) groups. Symbols and lines represent individual subjects 
before immunization (B) and one day before challenge (C-1). Open squares indicate 
protected subjects, filled circles indicate unprotected subjects. Differences between B and 
C-1 for all subjects were tested by Wilcoxon matched-pairs signed rank test.
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side effects might be permanent. This might lead to adjustment of prophylaxis guidelines 
and limitation of mefloquine use where alternatives are available, as for now it remains a 
recommended antimalarial prophylactic for several target groups (31). 
In previous studies we showed that 19/20 subjects (95%) were protected after bites 
from 45 infected mosquitoes, 8/9 (89%) after bites from 30 and 5/10 (50%) after bites from 
15 infected mosquitoes during chloroquine prophylaxis (6, 7, 9). The 60–70% protection 
observed in the current CPS-CQ and CPQ-MQ groups, immunized with bites from 24 
mosquitoes, demonstrates the reproducibility of CPS immunization and indicates a linear 
relationship between immunization dose and protection. This confirms the consistency 
of the CPS approach and is remarkable, given the assumed variation in the number of 
sporozoites injected by mosquitoes (32). This study further establishes CPS immunization 
as a worthwhile immunization protocol to relatively easily induce protection and create 
differentially protected cohorts to study target antigens and correlates of protection, both of 
which would be highly valuable tools in the search for P. falciparum vaccines and biomarkers 
of protection (33). 
Although the study was not powered to detect these differences, there are hints 
suggestive of more efficient induction of protection by CPS-CQ compared to CPS-MQ: i) 
the two unprotected CPS-CQ volunteers showed a longer prepatent period than the CPS-MQ 
subjects (14 versus 12 days, Mann-Whitney test p = 0.13); ii) induction of immunity required 
less immunizations in the CPS-CQ group i.e. none of these subjects showed blood-stage 
parasites after the second immunization while subjects in the CPS-MQ group still developed 
parasitemia after the second and third immunization. If there is a difference between CPS-CQ 
and CPS-MQ in protective efficacy, it is small, but possibly detectable in larger cohorts or 
when the immunization dose is further reduced.
Induction of anti-circumsporozoite antibodies by CPS-CQ is consistent with previous 
work, but neither anti-LSA-1, nor MSP-1 antibodies were induced by CPS-CQ in the current 
study (17). Antibodies against the latter antigens are dose-dependently induced (17), and 
the current immunization regime using bites from 3×8 P. falciparum-infected mosquitoes 
might have been insufficient (7). The induction of cellular P. falciparum-specific memory 
responses, as reflected by IFNγ production, is in line with previous CPS-CQ studies, even 
though limited sample size hampered statistical significance for some cell types. Interestingly, 
CD107a expression by CD4 T cells upon in vitro re-stimulation, associated with protection 
in a previous CPS-CQ study (7), appeared again to be associated with protection in the CPS-
CQ group, but not the CPS-MQ group. Granzyme B production by CD8 T cells upon in vitro 
re-stimulation did not appear to be a reproducible marker of protection in this second CPS 
study (7). Whether this might be related to immunization dose remains to be investigated in 
future CPS trials.
The striking efficiency of CPS immunization might at least be partly due to the 
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established immune modulating properties of the 4-amino-quinoline chloroquine (12), 
possibly reflected by the more efficient induction of degranulating CD4 T cells. Chloroquine 
has been shown to increase cross-presentation in hepatitis B vaccination and influenza (13, 
14), and thus may enhance cellular immune responses considered essential for protection 
against liver-stages (12). For mefloquine, a 4-methanolquinoline, this immune-modulating 
property has, to our knowledge, not been reported. A possible strategy to assess whether 
chloroquine and/or mefloquine indeed have immune enhancing effects on whole sporozoite 
immunization would be to compare immunization with RAS in the presence or absence of 
these drugs.
Mefloquine or chloroquine plasma concentrations were still detectable in all volunteers 
one day before the challenge infection. Possible contributing effects of these remaining drug 
levels to the protective efficacy outcome were considered in several ways; i) The interval 
between first qPCR and thick smear positivity, as proxy for parasite multiplication, was 2.8 
in the CPS-CQ group, 2.0 in the CPS-MQ group and 2.5 in the control group. This interval 
is similar to previous CHMI studies with the NF54 P. falciparum strain in the absence of 
prophylactic drug levels (7, 34); ii) the two volunteers with the highest mefloquine levels (116 
and 77 µg/L) were control subjects who became thick smear positive with only a minimal 
delay in patency within the time-frame of historical controls (35); iii) plasma chloroquine 
and mefloquine levels at C-1 were in all volunteers well below the minimum therapeutic 
concentration (CQ: 30 µg/L (36)) or the concentration at which breakthrough infections are 
observed in non-immune people (MQ <406 – 603 µg/L (37)). iv) We cannot rule out that 
protected subjects experienced transient parasitemia after challenge, which was cleared in the 
first blood-stage cycle by remaining drug levels. But because parasitemia was not detected by 
qPCR in any of the protected subjects at any time point after challenge potential parasitemia 
must have been below the qPCR detection limit of 35 parasites/ml, indicating a  reduction of 
at least 92% in liver load, given a geometric mean height of the first peak or parasitemia in 
non-immune historical controls of 456 parasites/ml (35); v) None of the protected subjects 
showed a boost in anti-MSP-1 antibodies after challenge while all unprotected subjects did, 
suggesting that protected subjects did not experience blood-stage parasitemia after challenge. 
(9). From these combined data we believe that remaining drug concentrations are unlikely 
to have contributed to the observed protection, although this cannot be formally excluded.
A review of rodent studies using different attenuation methods for whole sporozoite 
immunization shows that increased development of the parasite in the liver, but absence 
of blood-stage parasitemia during immunization is associated with the highest protective 
efficacy (38). It would therefore be interesting to investigate CPS immunization with 
alternative antimalarials with varying targets in the parasite life cycle. CPS immunization 
with causal prophylactic drugs affecting liver-stages, e.g. primaquine, will likely results in 
a reduction of AEs because of reduced or absent blood-stage exposure. Whether antigen-
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exposure is sufficient to induce protection when the liver-stage is abrogated, remains to be 
answered.
In conclusion, we show that immunization of healthy volunteers under mefloquine 
prophylaxis with P. falciparum sporozoites is safe, immunogenic and protective. These 
findings could have important implications for malaria vaccine development and further 
development of CPS approaches.
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Table S1 Antibodies used for flow cytometry.
Target Fluorochrome Clone Supplier
Fixable viability Aqua N/A eBioscience
CD3 PerCP UCHT-1 Biolegend
CD4 ECD SFCI12T4D11 BeckmanCoulter
CD8 APC-H7 SK1 BD Biosciences
γδTcell receptor PE IMMU510 BeckmanCoulter
CD56 Biotin HCD56 Biolegend
Streptavidin eF660 N/A eBioscience
IFNγ PeCy7 4S.B3 Biolegend
CD107a Pacific Blue H4A3 Biolegend
Granzyme B FITC GB11 Biolegend
Table S2 Possibly and probably related adverse events during CPS immunization*# (next page).
*Number of volunteers (%); for each subject, only the highest intensity is listed.
#CQ, MQ: after start of respective chemoprophylaxis up until first immunization; I, II, III: 
after the first, second and third immunization respectively.
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CPS-CQ CPS-MQ Control
CQ I II III MQ I II III MQ I II III
Abdominal pain None 5 (100) 4 (80) 5 (100) 5 (100) 10 (100) 9 (90) 10 (100) 10 (100) 2 (50) 3 (75) 4 (100) 4 (100)
Mild 0 (0) 1 (20) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 1 (25) 1 (25) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Arthralgia None 5 (100) 5 (100) 5 (100) 5 (100) 10 (100) 10 (100) 10 (100) 10 (100) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Chest pain  None 5 (100) 5 (100) 5 (100) 5 (100) 10 (100) 10 (100) 10 (100) 10 (100) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Chills 
 
None 5 (100) 5 (100) 5 (100) 5 (100) 10 (100) 10 (100) 10 (100) 10 (100) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Diarrhea 
 
None 5 (100) 5 (100) 4 (80) 5 (100) 10 (100) 9 (90) 10 (100) 10 (100) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 1 (20) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Dizziness 
 
None 4 (80) 5 (100) 5 (100) 5 (100) 10 (100) 9 (90) 9 (90) 9 (90) 3 (75) 4 (100) 4 (100) 4 (100)
Mild 1 (20) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 1 (25) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue 
 
None 5 (100) 5 (100) 5 (100) 5 (100) 10 (100) 9 (90) 10 (100) 10 (100) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fever
 
None 5 (100) 4 (80) 5 (100) 5 (100) 10 (100) 7 (70) 10 (100) 8 (80) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (30) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 1 (20) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Headache 
 
None 3 (60) 0 (0) 4 (80) 4 (80) 7 (70) 4 (40) 5 (50) 7 (70) 4 (100) 4 (100) 3 (75) 3 (75)
Mild 2 (40) 3 (60) 1 (20) 0 (0) 3 (30) 4 (40) 4 (40) 3 (30) 0 (0) 0 (0) 0 (0) 1 (25)
Moderate 0 (0) 1 (20) 0 (0) 0 (0) 0 (0) 2 (20) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25) 0 (0)
Severe 0 (0) 1 (20) 0 (0) 1 (20) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Malaise
  
None 5 (100) 4 (80) 5 (100) 5 (100) 10 (100) 9 (90) 10 (100) 9 (90) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 1 (20) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Myalgia
  
None 5 (100) 4 (80) 5 (100) 5 (100) 10 (100) 10 (100) 9 (90) 9 (90) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 1 (20) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Nausea
 
None 4 (80) 4 (80) 5 (100) 5 (100) 10 (100) 7 (70) 10 (100) 10 (100) 2 (50) 4 (100) 4 (100) 4 (100)
Mild 1 (20) 1 (20) 0 (0) 0 (0) 0 (0) 2 (20) 0 (0) 0 (0) 1 (25) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 1 (25) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Vomiting
 
None 5 (100) 4 (80) 5 (100) 5 (100) 10 (100) 9 (90) 10 (100) 10 (100) 4 (100) 4 (100) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate 0 (0) 1 (20) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Vivid dreams or other 
sleeping problems 
None 4 (80) 5 (100) 5 (100) 5 (100) 10 (100) 10 (100) 10 (100) 10 (100) 2 (50) 3 (75) 4 (100) 4 (100)
Mild 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25) 1 (25) 0 (0) 0 (0)
Moderate 1 (20) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other None 4 (80) 4 (80) 5 (100) 5 (100) 10 (100) 4 (40) 8 (80) 8 (80) 3 (75) 4 (100) 4 (100) 3 (75)
Mild 1 (20) 1 (20) 0 (0) 0 (0) 0 (0) 4 (40) 2 (20) 2 (20) 0 (0) 0 (0) 0 (0) 1 (25)
Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (20) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25) 0 (0) 0 (0) 0 (0)
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Figure S1 Gating strategy (A) Representative flow cytometry plots for a uRBC stimulated 
sample from one volunteer at baseline (before immunization). Singlet viable PBMCs were 
subdivided into (i) CD56hi NK cells, (ii) CD56dim NK cells, (iii) NKT cells, (iv) γδT 
cells, (v) CD8 T cells, (vi) CD4 T cells.
(B) Gating of IFNγ, CD107a and granzyme B positive cells for uRBC, PfRBC and PMA/
ionomycin re-stimulated cells at baseline. For uRBC and PfRBC stimulation CD4 T 
cells are shown, for PMA/ionomycin total viable PBMCs. Within each sample, gating of 
cytokine-positive cells was performed in a standardized way by multiplying a fixed factor 
with the 75 percentile of the geometric Mean Fluorescent Intensity (MFI) of cytokine 
negative PBMCs
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Figure S2 Cellular immune responses: IFNγ production. IFNγ production by different 
cell subtypes in response to in vitro re-stimulation with PfRBC (corrected for uRBC 
background), before immunization (B) and one day before challenge (C-1). Differences 
between B and C-1 were tested by Wilcoxon matched-pairs signed rank test.
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Plasmodium falciparum sporozoites
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Controlled human malaria infection with sporozoites is a standardized and powerful tool for 
evaluation of malaria vaccine and drug efficacy but so far only applied by exposure to bites of 
Plasmodium falciparum (Pf)-infected mosquitoes. We assessed in an open label Phase 1 trial, 
infection after intradermal (ID) injection of respectively 2,500, 10,000, or 25,000 aseptic, 
purified, vialed, cryopreserved Pf sporozoites (PfSPZ) in 3 groups (n = 6/group) of healthy 
Dutch volunteers. Infection was safe and parasitemia developed in 15 of 18 volunteers 
(84%), 5 of 6 volunteers in each group. There were no differences between groups in time 
until parasitemia by microscopy or qPCR, parasite kinetics, clinical symptoms or laboratory 
values. This is the first successful infection by needle and syringe with PfSPZ manufactured 
in compliance with regulatory standards. After further optimization, the use of such PfSPZ 
may facilitate and accelerate clinical development of novel malaria drugs and vaccines.
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Introduction
Malaria caused by Plasmodium falciparum (Pf) causes approximately one million deaths and 
250 million clinical cases annually (1, 2). Implementation of insecticide impregnated bed nets, 
residual insecticide spraying, and combinations of antimalarial drugs, has reduced malaria-
associated morbidity and mortality in many areas (1). Questions related to sustainability of 
this effort, however, have led to a recent delineation of requirements for new tools (3, 4). A 
safe, long-acting anti-malarial drug and a highly effective malaria vaccine would be powerful 
tools for control and elimination of Pf malaria.
Progress has been facilitated by the capacity to infect volunteers under controlled 
conditions in order to test new vaccines and drugs. Infection of volunteers by exposure to 
laboratory-reared Anopheles spp. mosquitoes transmitting Pf sporozoites (SPZ) (5) was first 
introduced for treatment of neurosyphilis in the 1920s (6). The development of drugs such 
as chloroquine (7), primaquine (8). and atovaquone (9) were facilitated by these controlled 
human malaria infections (CHMIs). The ability to culture Pf gametocytes (10-12) enhanced 
the capacity to produce infected mosquitoes for CHMI studies. Although potentially serious, 
Pf malaria can be radically cured at the earliest stages of blood infection when risks are 
virtually absent. CHMIs are restricted to a few specialized centers that can produce PfSPZ-
infected mosquitoes, where more than 1,300 volunteers have been safely infected by the 
bites of PfSPZ-infected mosquitoes since 1986, primarily for clinical trials of drugs (9) and 
malaria vaccines (5, 13-21), but also for trials of diagnostic tests (22), and studying human 
immune responses to Pf (23). 
In addition to the use of CHMIs for testing vaccines and drugs, controlled infections 
can also be used to immunize against malaria. For example, immunization with radiation-
attenuated PfSPZ by bites of mosquitoes protects > 90% of volunteers according to the 
published literature (24-26), and recently 100% protection against CHMI was achieved 
by immunization of volunteers taking a prophylactic regimen of chloroquine, with PfSPZ 
administered by mosquito bites (27, 28). 
These highly protective immunization strategies could not be translated into an 
implementable vaccine, because they depended on inoculation of SPZ by mosquito bites. 
Inoculation of SPZ by injection would be a more feasible method and was performed through 
the early 1950s. The SPZ preparations used, however, were heavily contaminated with 
bacteria and mosquito material, and rates of infection with frozen and thawed SPZ were highly 
variable (29-33). A contemporary approach to production of SPZ for infection or vaccination 
requires generating aseptic SPZ-infected mosquitoes, purifying SPZ from mosquito tissues, 
vialing, preserving, and administering the SPZ by needle and syringe. Sanaria has met these 
requirements to produce infectious aseptic, purified, vialed, cryopreserved PfSPZ (PfSPZ 
Challenge), and produced and tested the world’s first vaccine composed of these sporozoites 
(34, 35). Here, we report infection of volunteers with PfSPZ Challenge administered 
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intradermally (ID) by needle and syringe. 
Materials and methods
Study population and study design
This open label, Phase 1 clinical trial was performed at Radboud University Nijmegen Medical 
Center, the Netherlands, from October 2010 to July 2011. Volunteers aged 18–35 years of age 
were screened for eligibility by medical history, physical examination, and laboratory tests 
of blood, serum, and urine, including standard hematological, biochemical, and pregnancy 
tests, and malaria, HIV, hepatitis B and hepatitis C serology. The main exclusion criteria were 
pregnancy, residence in a malaria-endemic area within the previous six months, positive Pf 
serology, symptoms, physical signs or laboratory test results suggestive of systemic disorders, 
and history of drug or alcohol abuse interfering with normal social function. All volunteers 
gave written informed consent. 
Eighteen healthy malaria-naïve volunteers were included in this trial. Groups of six 
volunteers were injected intradermally (ID) with 2,500, 10,000, or 25,000 PfSPZ Challenge. 
The sample size of six per group had a power of 75% to show a difference between 2 of 6 
volunteers infected in the 2,500 PfSPZ group and 6 of 6 volunteers infected in the 25,000 
PfSPZ group. Dose escalation was done at a minimum interval of 3.5 weeks. 
The trial was performed in accordance with Good Clinical Practice and an Investigational 
New Drug application filed with the U.S. Food and Drug Administration, and approved by 
the Central Committee for Research Involving Human Subjects of The Netherlands (CCMO 
NL31858.091.10). Clinicaltrials.gov identifier: NCT 01086917.
Study intervention (PfSPZ Challenge)
PfSPZ Challenge contains aseptic, purified, cryopreserved PfSPZ isolated from salivary glands 
of aseptically reared mosquitoes (34, 35). Anopheles stephensi mosquitoes were raised under 
aseptic conditions, then fed on cultured Stage V gametocytes of the NF54 strain of Pf (36). 
Approximately two weeks later, mosquito salivary glands containing PfSPZ were dissected, 
and PfSPZ were purified, formulated, vialed (15,000 PfSPZ per vial), and cryopreserved in 
liquid nitrogen vapor phase at –140°C to –196°C (35). PfSPZ Challenge released for clinical 
use met quality control specifications including sterility (USP 71 compendial assay), purity 
(Supplemental Figure 1), and potency (Table 1). 
Potency was assessed as previously described (34, 35) by quantification of late liver 
stage parasites expressing Pf merozoite surface protein 1 (PfMSP-1) (37) in cultured human 
hepatocytes (HC-04 cells) (38) six days after addition of PfSPZ (Table 1, Supplemental 
Figure 2). For this 6-day hepatocyte potency assay, 4.0 × 104 HC-04 (1F9) cells/well in 
triplicate were infected with 5.0 × 104 PfSPZ and incubated for 6 days with daily media 
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change. Late liver stage parasites expressing PfMSP-1 were counted by staining the slides 
with an anti-PfMSP-1 mAb and fluorescently labeled secondary antibody. As previously 
described (34, 35) the membrane integrity of PfSPZ was used to assess cell viability (Table 
1). For the sporozoite membrane integrity assay, propidium iodide and SYBR Green were 
added to 15,000 PfSPZ. PfSPZ were applied to a hemocytometer and incubated in a dark 
humidity chamber for 20 minutes, at which point the red PfSPZ (those with compromised 
membranes) and green PfSPZ (those with intact membranes) were counted under a fluorescent 
microscope. Those with intact membranes were considered viable, and viability is expressed 
as the percentage of total green PfSPZ over the total number of PfSPZ. Sporozoites were 
assessed before cryopreservation, for release of the lot, and to assess stability at defined time 
points after cryopreservation. 
Table 1 Results of potency and sporozoite membrane integrity assays on the lot of PfSPZ Challenge 
used in this clinical trial 
Time point
Potency





Fresh 27 ± 4.6 ND
Release 20 ± 1.7 83.3% ± 6.5%
6 Month 18 ± 2.1 86.6% ± 1.9%
9 Month 20 ± 2.1 83.7% ± 8.4%
12 Month 21 ± 1.5 84.8% ± 3.0%
18 Month 20 ± 0.6 83.7% ± 4.2%
24 Month 18 ± 1.0 86.0% ± 1.5%
Pre-1st clinical dose (26 Month) 17 ± 0.6 79.4% ± 6.5%
Post-last clinical dose (30 Month) 16 ± 2.6 87.4% ± 1.9%
Fresh PfSPZ used for the lot of PfSPZ Challenge used in this clinical trial produced 26% more PfMSP-
1-expressing parasites in this assay than did PfSPZ that had been cryopreserved for several days (Release); at 
30 months, several weeks after inoculation of the last volunteers the PfSPZ had a 40.7% reduction in potency 
by this assay as compared to fresh PfSPZ. There was no reduction in the results of the sporozoite membrane 
integrity of cryopreserved PfSPZ during 30 months of storage. 
The sporozoite membrane integrity assay was not done on fresh PfSPZ for this particular lot. In our most 
recent three production campaigns for PfSPZ Challenge, fresh viability was 97.8%, 99.0% and 98.2% while 
after cryopreservation viability was reduced to 90.9%, 91.5%, and 87.4% respectively, a mean reduction of 
8.5%. 
ND = not done.
The lot of PfSPZ Challenge used in this study had been cryopreserved in liquid nitrogen 
vapor phase for 27 (dose of 2,500 PfSPZ) to 30 months (dose of 25,000 PfSPZ) before 
administration. Immediately before use, a vial of PfSPZ Challenge was thawed and diluted 
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with phosphate buffered saline containing human serum albumin (HSA). Volunteers were 
injected within 30 minutes of thawing.
Controlled human malaria infection 
Three groups of six volunteers each were injected ID with PfSPZ Challenge over the deltoid 
muscle, one injection in each upper arm. Each injection of 50 µL contained half the total dose. 
After injection, volunteers were observed for at least 60 minutes. Inoculations of volunteers 
were spaced 60 minutes apart. In each dose group, two volunteers were inoculated three days 
before the remaining four volunteers. 
Volunteers made at least one daily outpatient clinical visit beginning five days after 
inoculation of PfSPZ Challenge. All symptoms and signs (solicited and unsolicited) were 
recorded and graded by the attending physician as follows: mild (easily tolerated), moderate 
(interferes with normal activity), or severe (prevents normal activity); fever was recorded as 
grade 1 (> 37.5°C–38.0°C), grade 2 (> 38.0°C–39.0°C) or grade 3 (> 39.0°C). Hematological 
and biochemical parameters were monitored daily. Because of a previous cardiac related 
serious adverse event (SAE) following CHMI with Pf infection (39), markers of cardiac 
damage and coagulation were assessed. Troponin, lactate dehydrogenase (LDH), platelets, 
and D-dimer were assessed daily during the period when blood stage parasitemia was 
expected, and for three days after initiating curative treatment with atovaquone/proguanil. 
If D-dimer or LDH were abnormal, blood samples were tested for fragmentocytes and von 
Willebrand cleaving protease activity, as markers for vascular endothelial cell activation 
(40). Final follow-up visits were on Days 35 and 140 after infection.
As soon as parasites were detected by microscopic examination of blood smears, 
volunteers were treated with atovaquone/proguanil (1,000/400 mg) administered orally once 
daily for three days. Complete cure was confirmed in all volunteers by two consecutive 
parasite-negative blood-slides after treatment, at least 4 days apart. Volunteers who did not 
develop parasitemia by Day 21 after challenge were presumptively treated with the same 
regimen. 
Outcomes
The primary outcome was occurrence of Pf parasitemia detected by microscopic examination 
of blood smears. Sampling was done twice daily on Days 5 and 6 post-inoculation, thrice 
daily on Days 7–11, twice daily on Days 12–15, once daily on Days 16–21, and for two days 
after initiation of treatment for positive smears. To make thick blood smears, 15 µL of EDTA-
anti-coagulated blood was spread on each well of a 3-well glass slide (CEL-LINE Diagnostic 
Microscope Slides, 30-12A-black-CE24; Braunschweig, Germany). After drying, wells were 
stained with Giemsa for 45 minutes, and examined at 1,000 × magnification to assess 0.5 µL 
of blood. The smear was scored as positive if two unambiguous parasites were found. Thus, 
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volunteers could be diagnosed with as few as 4 parasites/µL of blood. The pre-patent period 
was defined as the period between inoculation of PfSPZ Challenge and appearance of first 
positive blood smear. 
Retrospectively, parasitemias were determined by real-time quantitative polymerase 
chain reaction (qPCR), performed on all samples collected after challenge, as previously 
described (41). The sensitivity of qPCR was 20 parasites/mL of blood.
Statistical analysis
Data analysis was performed using SPSS software version 16.0. Q-PCR results were assessed 
by analysis of variance (ANOVA) on log-transformed data.
Results
Parasitemia after injection of PfSPZ Challenge
Thirty-six healthy, malaria-naïve volunteers were screened and eighteen were included. 
All volunteers completed follow-up (Supplemental Figure 3). After ID injection of PfSPZ 
Challenge, 15 of the 18 volunteers developed a positive blood smear for Pf, five of six 
volunteers from each group (Table 2). The slide-negative volunteers in each group were 
presumptively treated with atovaquone/proguanil at 21 days post-infection. 
Blood slides were first positive 11 to 14.3 days after administration of PfSPZ Challenge. 
The geometric mean (GM) pre-patent period was similar for all groups, i.e., 13.0, 12.7, and 
13.0 days for the groups receiving 2,500, 10,000, and 25,000 PfSPZ Challenge, respectively 
(ANOVA p = 0.92). The GM parasite densities by microscopy at the time of diagnosis were 
12.4, 11.2, and 23.4 parasites/µL blood (ANOVA p = 0.69 on log-transformed data) (Table 2).
Quantitative PCRs (qPCRs) were first positive 9.0 to 12.0 days after challenge (Table 2). 
Volunteers in the 2,500, 10,000, and 25,000 PfSPZ Challenge groups had similar GM times 
to first detection of parasites by qPCR of 10.6, 10.3, and 9.9 days (ANOVA p = 0.486) at a 
GM parasite density of 0.07, 0.2 and 0.2 parasites/µL blood (ANOVA p = 0.24), respectively. 
The GM parasite densities by PCR at the time of thick smear diagnosis were 35, 5, and 132 
parasites/µL (ANOVA p = 0.23). qPCR was negative throughout the 21-day follow-up for 
the three slide-negative volunteers. Parasite growth was cyclical, and was similar in all dose 
groups (Figure 1), and the parasite replication rate in the bloodstream was comparable to that 




Table 2 Parasitemia data by thick blood smear and quantitative polymerase chain reaction (qPCR) 
 Thick Smear qPCR
Parasite density by 
qPCR at time of 












at first day 
positive (Pf/µL)
Group 1 - 2,500 PfSPZ
696-18 12.3 4 9.6 0.08 5
711-08 14.0 16 12 0.16 71
795-06 N/A N/A N/A N/A N/A
935-01 14.0 124 10.6 0.03 89
937-20 12.3 6 10.6 0.12 43
940-14 12.3 6 10.3 0.06 35
Geom. mean 13.0 12 10.59 0.1 35
# of positives 5/6 5/6
Group 2 - 10,000 PfSPZ
119-03 12.6 24 9.6 0.68 6
603-11 13.0 8 11 0.17 2
736-04 11.0 6 9.6 0.04 3
783-25 13.3 6 10.6 0.03 15
788-21 14.0 26 11 1.12 6
925-26 N/A N/A N/A N/A N/A
Geom. mean 12.7 11 10.34 0.2 5
# of positives 5/6 5/6
Group 3 - 25,000 PfSPZ
647-30 14.0 512 9.3 0.32 759
720-13 12.3 6 10.3 0.32 162
789-15 N/A N/A N/A N/A N/A
806-09 12.3 8 9 0.25 48
909-29 14.3 48 11.3 0.13 102
926-24 12.3 6 10 0.19 68
Geom. mean 13.0 23 9.95 0.2 132
# of positives 5/6 5/6
N/A: not applicable; thick-smear negative volunteers were presumptively treated on day 21 after infection.
Safety
Local reactogenicity was not observed after ID administration of PfSPZ in any of the 
volunteers. All volunteers, including the three volunteers who did not develop parasitemia, 
reported solicited adverse events (AEs) considered possibly, probably, or definitely related to 
the trial procedures (clinical malaria) (Table 3). Headache was the most frequently reported 
AE, and occurred in all volunteers including the three who did not develop parasitemia. 
There were no significant differences among the groups in solicited AEs, which were most 
frequently reported between Days 12 and 18 post-injection. The percentage of volunteers 
with related grade 3 AEs was comparable to historical data from subjects subjected to CHMIs 
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by mosquito-bites (44% versus 49%, respectively) (42). The total number of solicited and 
unsolicited AEs reported over time is shown in Figure 2. There were few AEs before Day 7; 
PfSPZ Challenge inoculations were well tolerated.
Routine daily laboratory tests showed no clinically significant abnormalities before 
initiation of anti-malarial treatment. Three or four days after receiving the first dose of 
atovaquone/proguanil, four volunteers had thrombocyte levels in the range 78–95 × 109/L, 
which was below the lower limit of normal (120 × 109/L). Leukocyte counts decreased after 
initiation of treatment in all thick smear positive volunteers (minimum 2.89 × 109/L compared 
with 5.46 × 109/L at baseline). In thirteen volunteers, D-dimers were > 500 ng/mL, the upper 
limit of normal (ULN), at one or two days after initiation of anti-malarial treatment (range of 
Figure 1 Parasite density as measured by qPCR in the 2,500 (A), 10,000 (B), and 25,000 
(C) PfSPZ Challenge dose groups. Panels A, B, and C show geometric mean parasite 
density of positive volunteers per group with confidence intervals (N = 5 for all groups) 
from day of inoculation through last day of positivity after initiation of treatment. Panel 




peaks: 540–10,200 ng/mL). D-dimer increases most likely reflect non-specific inflammatory 
responses to parasite-derived material released after initiation of treatment. In all volunteers, 
D-dimer concentrations normalized without complications. One volunteer had abnormal 
liver function tests at Day 2 post atovaquone/proguanil initiation. Maximum values were 
526 units/L ASAT (ULN 40 units/L), 745 units/L ALAT (ULN 45 units/L), 777 units/L LDH 
(ULN 450 units/L), and 74 units/L γGT (ULN 50 units/L). Bilirubin and alkaline phosphatase 
were normal. Abnormal values had returned to baseline levels at Day 100 after infection. 
One SAE occurred in a volunteer who reported chest pain one day after the first dose 
of atovaquone/proguanil. Based on medical history, the chest pain was initially considered 
possibly consistent with angina pectoris. Pain resolved within one hour without treatment. 
The volunteer was admitted to the cardiac care unit for monitoring for 6.5 hours. The first 
electrocardiogram (ECG) had a negative T-wave in V2, which was absent at the time of 
study initiation. All subsequent ECGs, beginning 2.5 hours after the first ECG, were 
comparable to baseline, with a negative T in V1 only. Troponin T levels were normal at the 
time of chest pain, 6 and 17 hours later, daily for the next three days and at trial Days 28 
and 35. As per protocol, the trial was put on hold, and the event was reported to the Safety 
Monitoring Committee (SMC) and regulatory authorities. The SMC concurred with the 
principalinvestigator’s attribution of the chest pain as “possibly related” to participation in 
the trial. The SMC concluded that although the cause of chest pain was not clear, the clinical 
data suggested that the SAE was not a serious cardiac event, and recommended resumption 
of the trial within three days of the event. The regulatory authorities concurred.
Figure 2 Number of possibly, probably, or definitely related solicited and unsolicited 
adverse events reported over time in the 2,500 (black dashed), 10,000 (red dotted) and 
25,000 PfSPZ Challenge dose (green straight) groups. 
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Table 3 Numbers of volunteers reporting solicited adverse events possibly, probably, or definitely 
related to administration of PfSPZ Challenge, with mean duration of events.* 
Any adverse event
















Abdominal pain 1 2.9 1 0.04 2 0.3±0.1
Arthralgia 0 N/A 0 N/A 0 N/A
Chest pain 1 0.04 0 N/A 0 N/A
Chills 1 2.0 2 0.3±0.2 2 0.9±0.6
Diarrhea 0 N/A 0 N/A 1 0.8
Fatigue 5 2.9±3.3 3 2.5±1.7 5 3.0±3.9
Fever 3 1.6±1.5 2 1.8±0.6 4 0.8±0.4
Headache 6 1.1±1.1 6 1.5±1.6 6 1.4±2.6
Malaise 2 2.2±2.4 5 1.8±1.4 1 0.7
Myalgia 2 3.7±3.2 2 1.3±0.5 2 0.8±0.1
Nausea 3 1.7±1.3 5 0.9±0.9 3 1.0±0.9
Vomiting 0 N/A 2 0.01±0.0 0 N/A
Any 6 2.0±1.4 6 1.1±0.8 6 1.1±1.0
Grade 3 adverse event
Fatigue 0 N/A 0 N/A 1 2.2
Fever 0 N/A 1 1.2 0 N/A
Headache 2 3.0±0.4 0 N/A 0 N/A
Malaise 1 4.8 0 N/A 1 0.1
Vomiting 0 N/A 2 0.01±0.0 0 N/A
Any 2 3.9±0.2 3 0.6±0.0 2 1.2±0.0
*There were few AEs before day 7 (Figure 2). Thus, administration of PfSPZ Challenge was well-tolerated. 
The AEs were expected and attributed to malaria.
N/A: not applicable
Discussion
We report for the first time that healthy, malaria-naïve volunteers can be infected with P. 
falciparum malaria by injection of aseptic, purified, cryopreserved PfSPZ manufactured in 
compliance with regulatory standards. Five of six volunteers became infected when 2,500, 
10,000 or 25,000 PfSPZ were inoculated ID. The AEs were comparable with those in 
mosquito bite challenge trials (17, 19, 42, 43). Virtually all related AEs were attributed to 
malaria, not to the inoculations with PfSPZ Challenge.
The capacity to infect volunteers with PfSPZ Challenge is dependent on the efficiency 
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of administration and the infectiousness/fitness of the cryopreserved PfSPZ. It can be 
expressed by the success rate of infection in the exposed individuals and/or the pre-patent 
period, i.e., the time from inoculation until first detected parasitemia. Since 1986 CHMIs 
have been performed by exposing volunteers to bites of laboratory-reared mosquitoes 
infected by feeding on Pf gametocyte-infected erythrocytes grown in culture (12). Essentially 
all volunteers challenged by bites of five PfSPZ-infected mosquitoes develop Pf parasitemia 
(5, 12, 17, 19). When numbers are reduced to one or two mosquitoes, success rates drop to 
50% or less (43-45). The ID inoculation of the lowest dose of 2,500 cryopreserved PfSPZ 
Challenge, which resulted in infection of 5 of 6 volunteers in the current study, was thus at 
least as effective in achieving blood stage infection as the bites of 1–2 infected mosquitoes. 
In regard to the pre-patent period the results were not straightforward. The pre-patent 
period in the 2,500 PfSPZ group was longer than was observed after 1–2 bites of PfSPZ 
(NF54)-infected mosquitoes at RUNMC (43) but shorter than after 1–2 bites of PfSPZ 
(3D7)-infected mosquitoes at the Naval Medical Research Center (44). The longer pre-patent 
period in our study compared with the pre-patent period after exposure to NF54-infected 
mosquitoes may have been caused by fewer developing liver stage schizonts after inoculation 
than after exposure to the bites of 1–2 PfSPZ-infected mosquitoes. Alternatively, replication 
in the liver stage could have been of lower magnitude or slower with the aseptic, purified, 
cryopreserved PfSPZ as compared with the fresh PfSPZ delivered by mosquito bite. Finally, 
the findings may just reflect expected biologic variability, because the study with 1–2 3D7 
infected mosquitoes showed a longer pre-patent period than after PfSPZ Challenge (44). 
The asexual erythrocytic stage parasites in our study replicated ~11.5-fold every ~48 
hours. Thus, with a 10-fold increase in PfSPZ, the theoretical time until parasitemia by 
microscopic examination (pre-patent period) should have been 2 days less in the 25,000 
PfSPZ group as compared with the 2,500 PfSPZ group. However, this was not the case as 
pre-patent periods of 13.0 and 13.0 days by microscopy and 10.59 and 9.95 days by qPCR 
were obtained in the 2,500 PfSPZ and 25,000 PfSPZ groups respectively. Thus, increasing 
the dose of PfSPZ Challenge 10-fold from 2,500 PfSPZ to 25,000 PfSPZ administered ID did 
not increase the percentage of infected volunteers or reduce the pre-patent period. Apparently, 
increasing the dose administered in two 50 µL injections did not result in higher numbers 
of PfSPZ getting from the skin to the circulation, invading and maturing in hepatocytes, 
eventually resulting in merozoites that invaded and multiplied in erythrocytes. Understanding 
this lack of dose response will be important for optimization of administration of PfSPZ 
Challenge. A possible explanation for this lack of dose response may be trapping of PfSPZ 
at the inoculation site. The use of five mosquitoes that probe in multiple sites must result in 
distribution of PfSPZ in the dermis and subcutaneous tissue in at least five different sites, 
and probably considerably more. Therefore, increase in the number of inoculation sites and 
injection of much smaller volumes (< 0.5 µL) may result in better infections. Such strategies 
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may also be useful for improving the efficiency of administration of the irradiated PfSPZ in 
the PfSPZ Vaccine. Although not as profound, there was a lack of a linear dose response in 
the first trial of the PfSPZ Vaccine in which irradiated PfSPZ were administered in 120 uL 
ID or SC (35). 
To determine the minimal numbers of PfSPZ required to achieve 100% infection rates, 
and a pre-patent period similar to five PfSPZ-infected mosquitoes, it would be most useful 
to assess intravenous (IV) administration of PfSPZ Challenge. Data from studies in mice 
show that administration of purified cryopreserved Plasmodium yoelii (Py) SPZ required 
~23 times more PySPZ administered ID than IV to achieve 80% infection rates (ID80) (Table 
4). Similar differences in liver load in vivo between IV and ID routes of administration were 
demonstrated using luciferase-labeled, bioluminescent fresh Plasmodium berghei (Pb) SPZ 
(46). Thus, we will conduct studies to investigate the minimal IV-dose and to optimize 
non-IV administration by modifying the route of administration (e.g., ID, subcutaneous, 
intramuscular), inoculation volume, numbers of inoculations, and sites of injection.
Table 4 Infectivity in mice of purified, cryopreserved PySPZ administered IV or ID. 
Intravenous (IV) Intradermal (ID)
No. of PySPZ 
Injected
Number of mice Proportion 
infected
No. of PySPZ 
Injected
Number of mice Proportion 
infectedInfected Injected Infected Injected
33 2 5 40% 200 2 5 40%
100 1 5 20% 600 3 5 60%
300 5 5 100% 1800 3 5 60%
900 5 5 100% 5400 4 5 80%
80% infectious dose = 257 PySPZ
100% infectious dose = 528 PySPZ
80% infectious dose = 5871 PySPZ
100% infectious dose = N/A
 Purified, cryopreserved PySPZ were injected IV in the tail vein or ID at the base of the 
tail of 6-8 week old BALB/c. Infection was determined by examination of blood smears on 
days 7 and 14 after inoculation. The 80% and 100% infectious doses were calculated using 
CurveExpert ver. 1.4.
Next to route of administration, our manufacturing/cryopreservation process may also 
be responsible for reduced infectivity. In vitro assays of potency and viability estimate a 
maximum difference of 25–30% between fresh and cryopreserved PfSPZ Challenge (Table 
1). Rodent model in vivo data, however, suggest that a ~7-fold loss in infectivity caused by 
cryopreservation is more likely (Table 5). Therefore, we will continue to concentrate our 
efforts on improvement of infectivity of PfSPZ Challenge. Interestingly, once the merozoites 
are released from the liver into the bloodstream they are as fit as non-cryopreserved, mosquito-
administered parasites, as their replication rates are similar. 
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Table 5 Effect of cryopreservation on sporozoite membrane integrity and infectivity in mice 
inoculated intravenously with the same lot of P. yoelii sporozoites (PySPZ). Infectivity was the number 
of PySPZ required to infect 50% of BALB/c mice.
Date Status of PySPZ
Viability
(SMIA)
Number of PySPZ 
Inoculated (IV)
ID50 (Number of 
PySPZ)
Oct 2009 fresh 96.3% 24-12-6-3 8.9
Dec 2009 cryopreserved 72.7% 200-100-50-25 33.1
Dec 2009 cryopreserved 68.3% 200-100-50-25 62.1
Jan 2010 cryopreserved 67.7% 400-200-100-50-25 103.8
Feb 2010 cryopreserved 67.1% 400-200-100-50-25 55.2
Feb 2010 cryopreserved 71.6% 400-200-100-50-25 107
Feb 2010 cryopreserved 73.9% 400-200-100-50-25 34.5
Mean cryopreserved 70.2% 66.0
Difference between fresh and 
cryopreserved PySPZ
26.1% 7.4-fold
Successful development and application of PfSPZ Challenge will increase the 
global capacity to conduct CHMIs, including in Africa where a CHMI consortium has 
been established with representative institutes from seven countries. This expansion of 
clinical sites conducting CHMIs will facilitate the clinical development of malaria vaccine 
candidates and anti-malarial drugs (3, 47). Another advantage of CHMI by PfSPZ Challenge 
may be a better-defined number of injected PfSPZ compared with the numbers administered 
by mosquito bites. This may decrease the large inter-individual variation in the estimated 
number of infected hepatocytes (48). Furthermore, using needle administration of defined 
quantities of PfSPZ Challenge from the same lot, will allow for comparisons of parallel and 
sequential clinical trials at multiple sites, including malaria-endemic areas. Finally, needle 
and syringe administration of cryopreserved PfSPZ is critical for potential development of 
whole PfSPZ vaccines where parasite development is arrested by radiation, anti-malarial 
drugs or genetic modification. 
Freshly dissected, purified P. yoelii sporozoites (PySPZ) were assessed by the 
sporozoite membrane integrity assay (SMIA) as a measure of viability, and administered 
to BALB/c mice by intravenous (IV) injection. The remaining PySPZ from the same lot 
were cryopreserved, thawed at six different time points, assessed for viability by SMIA 
and administered IV to mice. To provide data for calculatiosn of the number of PySPZ that 
infected 50% of mice (ID
50
 calculated using an exponential association model y=a(1-e-bx)) 
(CurveExpert version 1×4) with fresh and cryopreserved PySPZ, groups of five mice each 
received PySPZ in de-escalating doses as indicated, and their infection status was determined 
by assessing Giemsa-stained blood smears 7-14 days after inoculation. The viability by SMIA 
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of purified, cryopreserved PySPZ was reduced 26.1% as compared to fresh, purified PySPZ. 
The cryopreserved PySPZ were 7.4-fold less infective than fresh PySPZ as it took 7.4 times 
more cryopreserved PySPZ to achieve 50% infection of mice. 
In summary, we show that aseptic, purified, vialed, cryopreserved PfSPZ (PfSPZ 
Challenge) are infectious to humans for at least 2.5 years after cryopreservation. These data 
provide the rationale and foundation for a clinical trials program aimed at establishing a dose 
and route of PfSPZ that consistently achieves 100% infection rates. This will allow for the 
global expansion of sites that can conduct CHMIs for assessment of malaria vaccines and 
new drugs, and the potential to develop whole parasite vaccines based on cryopreserved 
PfSPZ. 
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Supplemental Figures
Before Purification (14 × 106 PfSPZ/ml) After Purification (1.6 × 106 PfSPZ/ml)
Supplemental Figure 1 PfSPZ before and after purification. Photomicrograph (200 ×) 
of the PfSPZ in the lot of PfSPZ Challenge used in the clinical trial prior to and after 
purification. The purification process reduced the amount of salivary gland material in the 
PfSPZ samples by greater than 99.9%. 
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Supplemental Figure 2 Liver-stage Pf parasite expressing PfMSP-1 after six days in 
culture. PfSPZ from the lot of PfSPZ Challenge used in this clinical trial were used to infect 
a human hepatocyte line in vitro. Six days later the parasites were stained with an antibody 
to PfMSP-1. PfMSP-1 is the major protein on the surface of merozoites, and is required for 
merozoite invasion of erythrocytes. It is only expressed in mature liver stage parasites and 
blood stage parasites, and is required for the survival of blood stage parasites. Potency of 
lots of PfSPZ Challenge is assessed by expression of PfMSP-1 in vitro (see Table 1). Image 
captured with a Zeiss LSM510 META laser scanning confocal microscope.
 




Construction of personalized health 
curves in disease space for human 
malaria infections





Novel frameworks are needed to unravel complex host-pathogen interactions. A framework 
derived from population biology has previously been applied in fruit flies and mice to visualize 
infections in health-by-microbe disease space. By plotting the health of an individual against 
microbe load at several time points over the course of an infection, looping health curves 
were generated that traced the infection course through disease space. Such analyses have 
provided novel insights in tolerance and resistance to pathogens. 
Here, we investigated such an approach for the first time with longitudinal data from 
humans, acquired using the controlled human malaria infection (CHMI) model. Retrospective 
longitudinal data from 91 subjects participating in seven CHMI studies were used to generate 
health curves of individual subjects from before the start of a malaria infection up until 
complete cure and recovery. Visualization in disease space enabled us to distinguish different 
levels of tolerance against Plasmodium falciparum malaria. These data illustrate the potential 
of these personalized health curves for rational monitoring and treatment of infections such 
as malaria on an individual basis. 
249
Personalized health curves in human malaria
Introduction
Interactions between hosts and microbes exist in many different forms, with varying 
kinetics and outcomes that can be difficult to disentangle. A theoretical framework derived 
from population biology has been proposed to improve our understanding of host-microbe 
interactions on an individual level (1). In this framework, a disease space is created in 
which the health of an individual is plotted against microbe load at several time points over 
the course of an infection. This produces a looping health curve that traces the infection 
course through disease space, and visualizes the relationship between health and pathogen 
load across the infection (1). Describing infections using disease space may provide a new 
framework to study parts and characteristics of infections that are difficult to visualize or 
quantify otherwise, such as the recovery period (1).
Studies in fruit flies and mice have shown that these animals indeed trace looping 
paths through disease space and that these loops can reveal ‘safe’ and ‘dangerous’ areas, 
providing novel insights in resistance and tolerance to pathogens (B. Torres unpublished 
data). An important next step will be to show that infections in humans can also be described 
by personalized health curves in disease space. In order to create personalized health curves, 
it is very helpful if pathogen load can be quantified accurately and frequently over the course 
of the infection. Plasmodium falciparum infection will be a good candidate because of 
the availability of a sensitive quantitative real-time polymerase chain reaction (qPCR) for 
determination of parasite load in the circulation (2).
Analysis of cross-sectional data from children in a malaria-endemic area suggests 
that also humans trace curves through disease space, but limited information is available 
from the recovery period and longitudinal data are needed to confirm this finding (B. Torres 
unpublished data). Controlled human malaria infection (CHMI) trials offer the possibility to 
collect such longitudinal datasets to assess whether paths in disease space can be constructed 
for humans. In these CHMI studies, healthy adult volunteers are exposed to Plasmodium 
parasites by exposure to infected Anopheles mosquitoes, intravenous injection of asexual 
blood stage parasites or injection of cryopreserved sporozoites. Participants are immediately 
treated for safety reasons when parasites are detected in their blood (3). CHMI trials are 
typically used to study the protective effect of novel vaccines or drugs, but can also be 
exploited to study basic characteristics of parasite-host interaction and pathophysiology of 
early malaria infection. 
The aim of this study is to assess whether personalized health curves in disease space 
can be applied to study human P. falciparum infections, using retrospective longitudinal data 




We retrospectively analyzed data from a total of 91 subjects from seven CHMI studies (4-
10). Details of the studies are included in Table 1. All trials were approved by the Central 
Committee on Research involving Human Subjects (The Hague, The Netherlands), all 
subjects gave informed consent and investigators complied with the Declaration of Helsinki 
and Good Clinical Practice including monitoring of data. Subjects were infected with P. 
falciparum malaria by either mosquito bites, injection of cryopreserved sporozoites or 
intravenous administration of infected erythrocytes. All subjects were treated with a curative 
regimen of atovaquone/proguanil when parasites were detected by thick smear. Subjects who 
remained thick smear negative were not included in this study. Some of the included subjects 
(n=37) had received chemoprophylaxis and sporozoites (CPS) immunization (4-6, 8), and 
were thus not malaria-naïve at the time of CHMI, while the other subjects (n=54) were (Table 
1).









NCT00757887 (8) NF54 Mosquito bite Yes 2
NF54 Mosquito bite No 5
NCT01218893 (6) NF54 Mosquito bite Yes 7
NF54 Mosquito bite No 5
NCT01422954 (5) NF54 Mosquito bite Yes 5
NF54 Mosquito bite No 4
NCT01236612 (4) 3D7 Mosquito bite Yes 9
3D7 Blood stage No 5
3D7 Blood stage No 5
NCT01002833 (9) NF54 Mosquito bite No 7
NF135.C10 Mosquito bite No 3
NCT01660854 (10) NF135.C10 Mosquito bite Yes 14
NF135.C10 Mosquito bite No 5





Parasitemia and hematological parameters were assessed on samples collected one day 
before infection and from one day after infection onwards, up until 3 days after treatment and 
28 or 35 days after infection when fully recovered. Parasitemia was quantified by qPCR as 
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described previously (2, 4-10). Samples for parasitemia were obtained once, twice or thrice 
daily (for details see Table S1). Platelet and lymphocyte counts and D-dimer concentrations 
were measured once daily on all these days as described previously (2, 4-10). IFNγ plasma 
levels were measured daily in the 7 subjects from the EHMI8B study (8) and the 14 blood-
stage challenged subjects from the EHMI9 study (4) by ELISA. For time points where 
parasitemia was quantified but hematological parameters were not assessed (evening and 
night visits), these values were interpolated using LOWESS smoothing curve function in 
GraphPad Prism 6. Adverse events (AEs) were recorded during each follow-up visit as 
following: grade 1 (easily tolerated), grade 2 (interfering with normal activity), or grade 3 
(preventing normal activity). Fever was recorded as grade 1 (>37.5°C – 38.0°C), grade 2 
(>38.0°C – 39.0°C) or grade 3 (>39.0°C).
Individual health curves (Figures 1 and 4) were made using Tableau software (version 
8.2). Figure 2 and Figure 5 were generated by performing Topological Data Analysis on the 
combined data set of parasite load, platelet counts, lymphocyte counts, D-dimer and IFNγ 
levels from all 91 subjects with the Ayasdi Iris software platform (ayasdi.com). Nodes in 
the network represent clusters of samples and edges connect nodes that contain samples in 
common (11, 12).
Cumulative duration of AEs was calculated for each subject by adding up the duration of 
all AEs per individual. The association between parasite load at time of thick smear positivity 
and cumulative duration of AEs was tested by Pearson correlation in GraphPad Prism (version 
5). In order to quantify the tolerance status of each individual, the angle between parasitemia 
at time of treatment and the cumulative duration of AEs was calculated using the inverse 
tangent function in Microsoft Excel. Areas enclosed by the IFNγ by parasite load curves 
were calculated using the polygonloops function using Matlab (13). The difference between 
surface areas was tested by Mann-Whitney test in GraphPad Prism.
Results and discussion
Humans trace looping curves through disease space during malaria infection
We first used adverse events (AEs) as most direct and relevant measure of the subjects’ 
health, and plotted these against parasite load over the course of a CHMI for each individual 
volunteer. This created looping curves of which representative examples are shown in Figure 
1A. For most subjects parasitemia increased first and AEs occurred subsequently. When 
treatment was initiated, parasitemia reduced to zero and subjects recovered, thus closing 
the loop. The shape of these health curves was helpful to visualize differences between 
individuals, for example with regard to the recovery period: while for some subjects AEs 
decreased simultaneously with parasitemia, resulting in a collinear graph (e.g. subjects four 
and five), in others parasitemia declined first and AEs resolved subsequently (e.g. subjects 
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eleven and twelve). For all volunteers the curves ended where they started, without parasites 
in the blood and without symptoms or complaints, showing their resilience against this 
infection. Next to AEs, platelet numbers, lymphocyte counts and D-dimer concentrations 
created curves in disease space when plotted against parasite load over time (Figure 1B, C 
and D).
Figure 1 Loops in disease space from individual malaria infected human subjects. Loops 
were constructed in a disease space of parasitemia on the x-axis by (A) number of AEs, (B) 
platelets, (C) lymphocytes or (D) D-dimer on the y-axis. Each horizontal row of 4 graphs 
represents an individual i.v. blood-stage challenged subject (1-14) (4). Variables were 
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measured one day before challenge, and once to thrice daily from the day after challenge 
onwards. The line-color from light grey to black indicates increasing number of days after 
infection. 
An alternative topological data analysis method (ayasdi.com) allowed us to visualize 
the course of the infection by combining all available data including parasite levels, platelet 
counts, lymphocyte counts, D-dimer levels and IFNγ levels from all 91 subjects. This analysis 
resulted in a ring-shaped structure that clearly represented the course of infection: time points 
Figure 2 Topological data analysis of longitudinal data from controlled human malaria 
infections. Topological Data Analysis was performed on the combined data set of parasite 
load, platelet counts, lymphocyte counts, D-dimer and IFNγ levels from all 91 subjects with 
the Ayasdi Iris software platform (ayasdi.com). Nodes in the network represent clusters 
of samples and edges connect nodes that contain samples in common. Norm correlation 
was used as metric, and the lenses PCA coord 1 and PCA coord 2 were applied. Nodes 
are colored by the average value of their samples from dark blue (low) to red (high) for 
(A) parasite load, (B) platelet count, (C) lymphocyte count, (D) D-dimer levels, (E) IFNγ 
levels, and (F) adverse events.
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showing high parasite load, IFNγ levels and D-dimer concentrations and low platelet and 
lymphocyte counts clustered together (Figure 2A-E). This topological data analysis based 
on parasite load and laboratory values also accurately co-located AEs (Figure 2F). The 
combined data clearly show that malaria infections in humans can be described by health 
curves in disease space.
Varying levels of tolerance to P. falciparum malaria can be visualized using disease 
space
There are three different ways for an organism to defend itself against infections: i) resistance, 
defined as the ability to control pathogen load, ii) tolerance i.e. the ability to limit severity of 
disease at a given pathogen load or iii) avoidance. Often, the first two mechanisms go hand 
in hand, and the balance between them determines the clinical course and outcome of an 
infection (14, 15). Also in malaria the distinction between tolerance and resistance has been 
recognized for a long time (16).
The number and severity of AEs experienced by volunteers during CHMI trials showed 
a significant variation between participants (Table 2). Although a small part may be explained 
by differences in reporting and/or use of escape medication, we believe that these data likely 
reflect true differences in disease severity after CHMI. 
Table 2 Severity and duration of Adverse Events (AEs) after CHMI. 
Number of AEs per volunteer
Median (range)*
Cumulative duration of AEs per volunteer 
Median (range)*
Grade 1 3 (1-11) 4.2 (0.1-30.5)
Grade 2 1 (0-8) 1.9 (0-20.4)
Grade 3 1 (0-9) 1.2 (0-17.8)
All AEs 7 (1-13) 9.6 (0.8-31.1)
* days
Severity of clinical disease, expressed as cumulative duration of AEs, and parasite load 
at time of detection by thick smear were significantly correlated (Figure 3A; Pearson r=0.44, 
p<0.0001), indicating that clinical presentation depends on parasite density, which is in line 
with data from endemic areas (17). The spread of data points around the correlation line, 
however, illustrates that subjects with the same parasite density can have quite a different 
cumulative duration of AEs. This suggests the existence of different tolerance levels against 
P. falciparum in this malaria-naïve population. 
We next explored whether different levels of tolerance could be visualized using disease 
space. As shown in Figure 3B we defined subjects below the line as relatively tolerant and those 
above the line as relatively intolerant; subsequently the ‘tolerance-level’ of each volunteer 
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was quantified by calculating the angle between parasite load and cumulative duration of 
AEs. By plotting IFNγ plasma levels available from 21 volunteers against parasitemia, these 
different levels of tolerance could be distinguished in disease space (Figure 4). Within one 
trial (n=14 (4)), the surface area of these plots was significantly larger in intolerant compared 
to tolerant subjects (p=0.018). 
We finally created a second topological graph using ‘norm angle’ as an alternative data 
metric. This metric calculates the angle between data points, and is used to assess whether 
two data rows are collinear rather than the absolute magnitude of their distance (ayasdi.com; 
Figure 5A). Using platelet counts, lymphocyte counts, D-dimer levels, parasitemia and IFNγ 
levels, subjects with different levels of tolerance were differentially located in disease space. 
While tolerant subjects mainly stayed in the central area of the graph, intolerant subjects 
occupied the outer region (Figure 5B). 
 
Figure 3 Association between 
parasitemia and disease 
severity in CHMI. For all 91 
subjects, parasitemia at time of 
detection by thick smear (TS+) 
is plotted on the x-axis against 
the cumulative duration of AEs 
on the y-axis (A). The tolerance 
level of an individual (a) can 
be quantified by calculating 




Figure 4 Loops in disease space distinguish tolerance phenotypes. Loops were constructed 
in disease space of parasitemia on the x-axis and IFNγ-level on the y-axis for all 14 blood-
stage challenged subjects (4). These subjects were divided in 2 groups based on their 
tolerance level: (A) shows the 7 most tolerant subjects and (B) the 7 least tolerant subjects.
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Figure 5 Tolerance level of CHMI volunteers determines their location in disease space. 
Topological Data Analysis was performed on the combined data set of parasite load, 
platelet counts, lymphocyte counts, D-dimer and IFNγ levels from all 91 subjects with the 
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This study shows for the first time that human infections analyzed in disease space can 
provide important information by, for example, identifying and visualizing different levels 
of tolerance. For uncomplicated infections that respond sufficiently to antimalarial treatment, 
this analysis will not have clinical consequences. However, patients that are less tolerant 
or poorly responding to therapy, these curves may provide guidance for clinical care and 
treatment. For patients with severe malaria, or for example sepsis, where the balance between 
pro-inflammatory and anti-inflammatory cytokines is crucial for the outcome (18), the 
position and movement in disease space using biomarkers may direct personalized therapy 
(19). Since baseline samples will not be available from these patients, it will be impossible to 
construct a full health curve. Therefore, a next step will be to assess whether a limited number 
of longitudinal samples, constituting a vector in disease space, will be sufficient to provide 
useful information in such cases.
Future studies on malaria infections in endemic areas using disease space might elucidate 
patterns on tolerance and resistance after natural infection. In longitudinal cohort studies 
children can be treated with antimalarials before the start of the transmission season with 
intensive follow-up and regular blood-draws during the malaria season until development 
of parasitemia. Since only a proportion of these children will develop symptoms, analysis 
of immune markers and parasite kinetics might reveal pathways involved in tolerance and 
resistance in this partially immune population.
Conclusions
Data from this exploratory retrospective study show for the first time that disease space 
can be used to describe infections in humans. Personalized health curves have the potential 
to provide important information for clinical monitoring and treatment as well as insight 
in mechanisms and pathways involved in tolerance and resistance to malaria and other 
infectious diseases.
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Malaria continues to cause significant morbidity and mortality worldwide, and an effective 
vaccine will be crucial to fight this disease. However, rational design and development of 
such a vaccine has been hampered by our limited knowledge on what constitutes protective 
immune responses. This thesis aims to improve our understanding of protection and immune 
responses against malaria using the chemoprophylaxis and sporozoites (CPS) immunization 
model and Controlled Human Malaria Infections (CHMIs). 
Following the seminal proof-of-principle study (1), the CPS trials described in this 
thesis demonstrate a remarkable reproducibility in protective efficacy. CPS immunization 
of volunteers with bites from 3 times 12-15 mosquitoes infected with NF54 sporozoites 
consistently induces protection (19 of 20 subjects) against a standard NF54 challenge 
infection (95%; chapters 6 and 7). Reduction of the number of infected mosquitoes results in 
gradually decreased protection to 5/10 subjects (50%) after immunization by three times 5 
mosquitoes (Figure 1, chapters 7 and 10). These results reconfirm the impressive potency of 
CPS: the immunization dose is 20-30 times lower than for RAS requiring a minimum of 1000 
bites and known as the only other method to induce complete sterile protection in the CHMI 
model (2). Its efficacy, potency, reproducibility and dose-dependency make the CPS protocol 
a unique methodology for immunological and vaccination studies in healthy volunteers. 
The CPS immunization model can be exploited for two main purposes: the development 
of a whole parasite vaccine, and the investigation of protective immune responses. In this 
final chapter, I will discuss these two applications in the context of the existing body of 
knowledge, the novel insights gained from this thesis and recent developments. An important 
step towards application of a whole sporozoite vaccine will be to replace mosquito bites by 
injection of cryopreserved sporozoites (chapter 11) and I shall explore the implications and 
possibilities of this trajectory. A cornerstone in this thesis is the CHMI, and I will conclude 
this final chapter with some reflections on how our analysis of trust and control (chapter 2) 
may be used to improve the design and execution of clinical trials.
Figure 1 Protection after 3 CPS immunizations 




Whole sporozoite immunization: the road towards an applicable 
vaccine1
An ideal malaria vaccine is safe, practical, affordable, and induces a robust and long lasting 
protective immune response in all target populations including young children in Africa. The 
experience with RTS,S shows that it is possible to protect children in Africa against malaria 
by means of vaccination (3). This is encouraging, but the limited efficacy also demonstrates 
the need for a more effective “second-generation” vaccine. Immunization with whole 
sporozoites is highly efficacious when administered by mosquito bites or by intravenous 
administration (1, 4) (chapters 6, 7 and 10). The observed high protective efficacy strongly 
supports further exploration of their possible clinical development as a vaccine. 
Chemoprophylaxis and sporozoites
In the CPS immunization protocol as originally described by Roestenberg et al (1) and 
applied in this thesis, subjects are exposed to sporozoites by bites from infected Anopheles 
mosquitoes. This limits the use of this protocol to a few specialized centers with parasite-
culture facilities and well-equipped insectaries. Replacement of the mosquito bites by 
sporozoite injection with needle and syringe would greatly increase the possibilities for 
clinical application of CPS. 
In this thesis, we show for the first time that volunteers can be infected with P. 
falciparum malaria by intradermal injection of aseptic, purified, cryopreserved sporozoites, a 
product developed by Sanaria Inc (PfSPZ Challenge; chapter 11). This opens the possibility 
to immunize subjects using chloroquine prophylaxis by injection of sporozoites with needle 
and syringe. 
However, a first trial in which volunteers under chloroquine prophylaxis were immunized 
three or four times by intradermal administration of 75,000 cryopreserved sporozoites, 
showed no protection (5). CS-specific antibodies were induced with titers comparable to 
mosquito immunization, but LSA-1 antibodies and P. falciparum specific cellular memory 
responses were absent. Retrospective qPCR-analysis showed absence of parasitemia after 
all immunizations in all subjects, indicating that the parasite load achieved was much lower 
compared to immunization via mosquitoes, and apparently not sufficient to induce immunity. 
Protection after CPS immunization is dose-dependent (chapter 7), and this first PfSPZ-CVAC 
trial suggests that development of sufficient numbers of parasites developing in the liver may 
be more crucial than just exposure to high numbers of sporozoites. This hypothesis is in line 
1 Parts of this paragraph were previously published in 1) Bijker EM, Sauerwein RW. Malariavaccins: 
de huidige stand van zaken. [Malariavaccines: an update. In Dutch]. Tijdschrift voor Infectieziekten, 
2014 and 2) Bijker EM, Sauerwein RW. Plasmodium falciparum whole-parasite malaria vaccines. In: 
Malaria Vaccine Development: Over 40 Years of Trials and Tribulations. Corradin G, Engers H (Eds). 
Future Science Group, London, UK, 149–162
266
Chapter 13
with historical animal studies showing that immunization with heat-inactivated sporozoites 
did not induce protection (6, 7) and a more recent review describing the importance of liver-
stage development for protection in rodents (8). Therefore, it will be important to optimize 
the parasite liver load after administration of cryopreserved sporozoites.
After the first PfSPZ Challenge study at Radboudumc (chapter 11), a number of trials 
have been performed by Sanaria and collaborators to investigate alternative administration 
regimens, including an increased number of intradermal injections with fewer sporozoites per 
injection, intramuscular administration and intravenous injection. With the latter approach, 
100% infection can be induced with a prepatent period approximating CHMI by mosquito 
bites (9, 10). Apparently, efficient migration of the sporozoites from the skin to the liver 
was a crucial hurdle after intradermal injection and could be circumvented by intravenous 
administration. A logical next step would thus be to perform CPS immunization with 
intravenous injection of sporozoites. This trial has indeed been performed and the results are 
expected soon (Clinicaltrials.gov NCT02115516).
In chapter 3 we hypothesized that the striking efficiency of CPS compared to RAS 
might be partially due to immune modulatory effects of chloroquine. Chloroquine was 
shown to enhance cross-presentation in vitro and in rodents, resulting in improved cytolytic 
responses (11, 12). In humans, co-administration of chloroquine with a hepatitis B vaccine 
booster significantly increased the number of virus-specific IFNγ-producing CD8+ T cells 
(13). However, our results from rodent studies (chapter 5) and a clinical trial (chapter 10) do 
not support this concept so far: additional administration of chloroquine to mice that receive 
RAS immunization does not improve protection or immune responses, and replacement of 
chloroquine by mefloquine for CPS does not reduce immunogenicity or protective efficacy. 
Although we cannot formally rule out that chloroquine has a small direct immune-enhancing 
effect in CPS immunization, our work indicates that this effect is not substantive enough to 
warrant further investigation.
CPS with mefloquine is as immunogenic and protective as CPS with chloroquine 
(chapter 10). This observation that CPS immunization does not depend on chloroquine opens 
opportunities to investigate CPS with other drugs with killing effects at different points of the 
Plasmodium life cycle. A number of antimalarials have been shown to induce protection in 
rodent models. Primaquine and pyrimethamine affect parasites within the hepatocyte (14, 15) 
and azithromycin causes delayed death of intrahepatic parasites and release of noninfectious 
merozoites (16). The advantage of these drugs may be a potential reduction in adverse events 
as a result of the limited occurrence of blood-stage parasites. In contrast, chloroquine and 
mefloquine only affect blood-stage parasites, allowing the brief occurrence of parasitemia 
after immunization resulting in symptoms and complaints in the majority of subjects, 
including grade 3 adverse events (chapters 6, 7 and 10). Prevention of parasitemia will likely 
increase tolerability of the immunization regimen, but possibly at the expense of the efficacy 
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because of earlier arrest and thus diminished antigenic load and repertoire (8). Moreover, 
it remains to be investigated whether these drugs provide sufficient attenuation to prevent 
breakthrough infection, requiring additional administration of another compound such as 
chloroquine. These pros and cons of different attenuation methods comprise the classical 
balance between safety and immunogenicity of whole organism vaccination.
CPS immunization requires a much smaller number of mosquito bites to induce 
protection compared to RAS, but CPS vaccination by needle and syringe will require 
separate administration of chloroquine with the currently registered formulations, to 
prevent breakthrough infections. Realistically, clinical development of CPS as a vaccine for 
military personnel and selected traveler populations is worthwhile to explore. Large-scale 
implementation in malaria-endemic regions remains unlikely as long as a secure dosing 
schedule of CQ, currently requiring rigorous compliance from vaccinees, has not been 
established concomitant and limited to vaccination sessions.
Development and implementation of whole sporozoite vaccines
Sanaria Inc. has developed and tested the first GMP-produced whole sporozoite (RAS) vaccine: 
PfSPZ Vaccine. Sterile protection in 6/6 subjects has been obtained after intravenous, but not 
subcutaneous administration (4, 17). This vaccine has been taken forward for initial testing 
in Mali and Tanzania (Clinicaltrials.gov NCT01988636 and NCT02132299). Alternatively, 
genetically attenuated parasite (GAP) vaccines are still at early stages of clinical development, 
but may provide great potential. Compared to RAS, GAP vaccines provide the advantages 
of safer production and homogeneity of the product (18, 19). A number of crucial technical, 
economical and clinical hurdles need to be taken before application of whole sporozoite 
vaccines can be considered. For public health implementation, costs should be reasonable 
and the vaccine has to be suitable for administration to appropriate risk groups in malaria-
endemic areas.
Currently, Sanaria’s product PfSPZ Vaccine needs to be stored in liquid nitrogen vapor 
phase (LNVP) below -140°C and would have to be distributed through a LNVP cold chain, 
while the preferred storage condition as currently defined by the WHO is ambient, minimally 
2-8°C. If the vaccine remains dependent on this storage method, its implementation will 
require large investments in storage and transport facilities at different levels in endemic 
countries (20). While high protective efficacy would probably legitimize such an investment, 
optimization of cryopreservation to increase infectivity of sporozoites, even when stored at 
higher temperatures, should be a focus of investigation. 
Other points to be addressed include optimal vaccine dose, number of doses, interval 
between doses, site and route of administration. A new vaccine should ideally be administered 
along with the current vaccines in the Expanded Programme on Immunization (EPI) and 
therefore show no interference with other vaccines. The route of immunization should be 
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implementable on a large scale without the need for extensive healthcare workers’ training. 
Currently, PfSPZ Vaccine only confers protection when administered intravenously, a 
route that has not been used for the administration of preventive vaccines before. While 
the intravenous approach may be effective and feasible for adults, it entails an enormous 
challenge for implementation in children in Africa. Although a very high vaccine-efficacy 
might prompt the community to invest in this unprecedented administration route, further 
research will be required to investigate the technical, ethical and practical feasibility in 
young African children. Ideally, immunization dose and regimen of PfSPZ Vaccine will be 
optimized for more conventional routes of delivery or administration with novel devices such 
as microneedles.
Induction of sustained protection is the hallmark of an effective vaccine. Longevity 
of protection in the absence of parasite exposure, but also the potential boosting of immune 
responses by repeated exposure to sporozoites in the field should be assessed. If vaccine-
induced pre-erythrocytic immunity wanes, serious health consequences can be expected for 
individuals in endemic countries in the absence of clinical immunity (21). Furthermore, the 
possibility exists that antibodies in malaria-exposed individuals could capture the vaccine-
sporozoites and therefore interfere with induction of protective immunity. This question 
remains open since protective efficacy of whole sporozoite immunization approaches has 
only been investigated in malaria-naïve volunteers until now, but should be addressed in the 
near future. 
In summary, whole parasite immunization approaches hold great promise to play a role 
in the combat against malaria, once various technical, clinical and economic hurdles have 
been overcome. Furthermore, CPS has the potential to play a unique and pivotal role in the 
investigation of protective immune responses, which will inform vaccine development and 
could thereby have important implications.
CPS immunization as a model to investigate protective immune responses against 
P. falciparum malaria
One of the major findings from this thesis is that protective immunity induced by CPS 
immunization is directed against pre-erythrocytic stages (chapter 6). Although it is possible 
that a blood stage component would have contributed if we had not treated at time of thick 
smear positivity, it is clear that pre-erythrocytic immunity is the main component responsible 
for protection, legitimizing a focus of further research towards sporozoite- and liver-stages. 
Here, we will discuss our findings in relation to humoral, cellular and innate immunity in pre-
erythrocytic protection, and discuss four important lines of future research: target antigens of 
protective immunity, immune signatures of protection, comparing naturally acquired versus 
experimentally induced protection and heterologous protection.
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Humoral immunity in pre-erythrocytic protection
Antibodies can play a role in pre-erythrocytic protection through a number of possible 
mechanisms: i) Preventing sporozoites from exiting the proboscis at the biting site by forming 
immune complexes with soluble sporozoite proteins in the mosquito saliva: mosquitoes were 
shown to inject less sporozoites into RAS immunized mice or mice that were passively 
immunized with anti CS-protein monoclonal antibodies (22); ii) Inhibition of sporozoite 
motility. Sporozoites glide around and traverse the endothelium of the skin capillaries before 
entering the circulation (23); iii) Sporozoite clearance in circulation by opsonization; iv) 
Inhibition of hepatocyte traversal and/or invasion (24, 25); v) blockage of intrahepatic 
delevopment and/or elimination of liver stages, although the underlying mechanism of such 
an antibody-mediated effect remains unclear so far (26, 27). 
There is ample evidence from animal studies that humoral immunity contributes to pre-
erythrocytic protection. Naïve mice are protected against sporozoite challenge after passive 
transfer of serum or IgG from RAS-immunized mice (28-30). The circumsporozoite (CS) 
protein is a major target of these antibodies, and also monoclonal antibodies against the CS 
protein confer protection (31-35). Moreover, monkeys can be protected by a monoclonal 
antibody against the P. vivax CS protein repeat (36) or P. knowlesi sporozoites (37). 
In vivo studies of pre-erythrocytic immunity in humans are hampered by the 
inaccessibility of the liver. As a substitute, a number of in vitro tests is available to investigate 
the effect of antibodies on sporozoite gliding (38, 39), traversal (40, 41), hepatocyte invasion 
and intrahepatic development (42-44). More recently, humanized mouse models, i.e. mice 
with functional human hepatocytes, have been generated, allowing the assessment of in vivo 
development of P. falciparum liver stages (42-45). From these assays, there is clear evidence 
that specific antibodies from semi-immune individuals and RAS, GAP or RTS,S immunized 
subjects can inhibit hepatocyte invasion of P. falciparum and/or P. vivax (42, 43, 45-50).
Our studies clearly show that functional antibodies and memory B cell responses 
against pre-erythrocytic stages are also generated by CPS immunization (51, 52). However, 
in this setting the magnitude of responses against CS protein serves as a marker of parasites 
exposure, rather than protection from challenge infection (52). Although CPS-induced 
antibodies functionally inhibit hepatocyte traversal in vitro and reduce liver-stage infection 
in humanized mice (51), their exact specificities in relation to CPS-induced protection remain 
to be investigated.
Induction of T cell responses against pre-erythrocytic stages
T cell deficient mice cannot be protected by sporozoite immunization, which suggests that T 
cells play a critical role in protection (53). T-cell activation is initiated and orchestrated by 
dendritic cells (DCs) that process and present antigens from pre-erythrocytic Plasmodium 
stages (54, 55). As such DCs in skin draining lymph nodes can process antigens from 
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sporozoites (56) while liver DCs can present antigens from either live (57) or apoptotic (58) 
infected hepatocytes (59, 60). Alternatively, proteins egress from the cell and are taken up, 
processed and presented by antigen presenting cells such as Kupffer cells. In a subsequent 
infection, memory CD8 T cells can recognize antigens presented on the surface of infected 
hepatocytes and kill these cells. When sporozoites reach the liver, they traverse through 
several hepatocytes before they finally settle to multiply and mature (61). Rodent studies 
indicate that both traversed and infected hepatocytes present CS protein-derived peptides 
on their surface (62). CS protein and other parasite antigens are probably transported to the 
cytoplasm of the hepatocyte (63-65) after which they are processed and presented to T cells 
on the cell surface (62). 
Evidence for cellular immunity in pre-erythrocytic protection
Because of practical limitations in human studies, most of our knowledge on cellular 
immune responses against pre-erythrocytic stages is based on animal models. Protective 
immune mechanisms differ depending on for example the mouse strain and the Plasmodium 
species used (66), and we should emphasize the need to be careful in translating these 
findings to humans. However, evidence for an important role of both CD4 and CD8 T cells 
in pre-erythrocytic protection from animal models is substantial and consistent. CD8 T cell 
depletion of mice abrogates protection by GAP (67, 68), RAS (29, 30, 69-71) and CPS (72) 
immunization. And also in non-human primates CD8 depletion diminishes RAS-induced 
protection (73). CD4 T cell depletion reduces protection in some studies (30, 72), but not 
in others (29, 67, 69-71). In any case, CD4 T cells appear to provide important help during 
immunization for the induction of an appropriate CD8 response (74). In addition to these 
depletion studies, T cells from RAS-immunized animals were shown to have high cytolytic 
activity, to eliminate infected hepatocytes in vitro and to confer protection against sporozoite 
challenge upon passive transfer (29, 75-79). CD4 and CD8 T cells isolated form mice 
immunized with peptides from the P. yoelii CS protein inhibit liver-stage development in 
vitro (80), as do lymphocytes stimulated with CS peptides (81). The importance of antigen-
presentation in the context of MHC-I was further confirmed by studies showing that β2 
microglobulin knockout mice cannot be protected by RAS (82) or GAP (83) immunization. 
Together, these data provide strong evidence for the crucial role of CD8 T cells and the 
supportive role of CD4 T cells in pre-erythrocytic protection. 
Consistent with this evidence from animal studies, T cell responses are induced in 
humans by both sporozoite immunization and natural exposure (84-88), with specificities 
for pre-erythrocytic antigens such as CS protein (85, 86, 88, 89), Liver Stage Antigen-1 
(LSA-1) (90) and thrombospondin-related adhesion protein (TRAP) (91). Data from 
subunit vaccination studies indicate that T cells are important mediators of protection in 
humans. RTS,S for instance induces CS protein-specific CD4 T cells that produce IFN-γ 
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upon restimulation with peptides (49), with a higher frequency in protected compared to 
unprotected volunteers (49). Moreover, vaccination with the pre-erythrocytic multiple 
epitope –TRAP (ME-TRAP) using a chimpanzee adenovirus vector and a modified vaccinia 
virus Ankara booster induces specific IFN-γ producing CD8 T cells that correlate with sterile 
protection and prolonged prepatency (92).
The production of inflammatory cytokines such as IFNγ and TNFα (93, 94), is probably 
an important effector function of T cells against liver-stages (84, 85, 88), However, CD8-
mediated protection after sporozoite immunization can occur independent of IFNγ in rodents 
(68, 95, 96), and cytotoxic mechanisms such as granzyme B or perforin-mediated killing are 
likely to contribute. Indeed, this thesis shows that granzyme B expression by CD8 T cells 
and degranulation of CD4 T cells were associated with protection against challenge infection 
(chapter 7). This emphasizes that it is crucial to assess a variety of markers when reviewing 
T cell responses, including markers of cytotoxicity, rather than cytokine production alone 
(97). 
Innate immune responses in pre-erythrocytic protection
Vaccines are designed to induce adaptive memory responses, which have therefore rightly 
received the majority of attention. However, the innate immune system is crucial for the 
induction and orchestration of effective adaptive memory responses (98, 99), and there are 
even strong indications for a memory component in the innate immune compartment (100).
There is some evidence for a role of NK cells and γδ T cells in addition to CD8 and CD4 
T cells in pre-erythrocytic protection. NK cell depletion significantly reduced protection by 
RAS immunization in several mouse strains (66). One study demonstrated inhibition of liver-
stage development after sporozoite challenge by passive transfer of a γδ T cell clone isolated 
from an αβ deficient RAS immunized mouse (101). 
This thesis provides additional clues that innate immune responses might contribute to 
CPS-induced protection. The frequency of γδT cells for instance increases dramatically upon 
CPS immunization (chapter 8), and these cells contribute significantly to IFNγ production 
upon restimulation (chapter 7, (102)). The origin, target antigens and functional role of these 
γδT cells remain unclear and warrant further investigation (103). For example, sequencing of 
γδT cell receptors before and after CPS immunization could clarify whether the expansion is 
antigen specific, i.e. creating clonal lines, or an aspecific bystander effect ((104), M. Mamedov, 
M. Davis lab, Stanford University School of Medicine, USA; personal communication).
Furthermore, a total of 11 out of 54 volunteers in three CPS-immunization studies 
remained qPCR negative during immunization, all except one of whom were protected 
against challenge. Since all volunteers included in these trials are malaria-naïve and thus 
lack adaptive memory responses, the difference between these volunteers and others with 
confirmed parasitemia during immunization might be explained by differences in innate 
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responses, although we cannot exclude that sub-qPCR parasitemia occurred. From rodent 
models, there is evidence that IL-6 can significantly inhibit liver schizont development (105) 
and that Plasmodium triggers a functional type 1 IFN response that reduces liver parasite 
burden (106). Variation in these or other innate pathways could thus account for the difference 
seen in CPS-immunized subjects and deserves further study.
Target antigens of pre-erythrocytic immunity
Although their efficacy appears to be modest as best so far, subunit vaccines may have 
substantial manufacturing advantages over whole sporozoite vaccine approaches. However, 
clinical development of malaria subunit vaccines has proven to be slow and difficult, mainly 
suffering from insufficient efficacy. RTS,S is most advanced showing 30-50% efficacy in 
endemic areas with waning and eventually complete loss of protection after three years (3, 
107, 108). Clinical development might be accelerated by improved rational target antigen 
selection and vaccine design, and could greatly benefit from increased understanding of 
protective immunity. 
The CS protein, the malaria target in RTS,S, has been a major focus of vaccine 
development for a number of good reasons: it is an immunodominant antigen, present on 
the surface of both the sporozoite and the infected hepatocyte (109) and there is plenty of 
evidence for a role in protective immunity (110) as described above. But an immune response 
against the CS protein is not absolutely required for the induction of protective immunity, 
since CS transgenic mice tolerant for the CS T-cell epitope can still be protected by RAS 
immunization, although less efficient than wild type mice (111). This findings, in addition 
to the limited efficacy of RTS,S and other subunit vaccines compared to whole sporozoite 
immunization, indicate that immune responses directed against multiple antigens are required 
for full sterile protection. 
Identification of target antigens of protection will furthermore be important for 
a methodological reason. Assessment of cellular immune responses induced by CPS 
immunization have until now been investigated by in vitro restimulation with whole blood-
stage parasites (chapters 7 and 10). While we found markers associated with protection using 
this approach, in vitro stimulation with peptides derived from relevant target antigens or ex 
vivo staining with tetramers might reduce the ‘noise’ in the response and allow for a clearer 
distinction between protective and unprotective responses. Identification of novel target 
antigens will thus be important for both the development of an effective second generation 
subunit vaccine and the study of immune mechanisms of protection. 
Importantly, rather than being the result of a response against a single key antigen, sterile 
pre-erythrocytic immunity appears to be based on broad responses to numerous antigens 
(112, 113). The availability of the P. falciparum genome sequence (114) has facilitated the 
analysis of expression and transcription of the more than 5000 Plasmodium genes in its 
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different life cycle stages (115-117) and the identification of protein target antigens (112, 118, 
119). A number of studies indeed indicate the importance of novel pre-erythrocytic antigens 
in protective immunity induced by sporozoite immunization. Screening of PBMCs from 
RAS-immunized subjects revealed 16 P. falciparum protein antigens that had previously not 
been associated with protection, out of which 2 were preferentially recognized by protected 
volunteers, while the ‘traditional’ antigens CSP, SSP2, LSA1 and EXP2 were detected mainly 
in nonprotected volunteers (112). Moreover, screening of antibodies from RAS immunized 
donors revealed a number of novel pre-erythrocytic antigens (119). These data support a 
strategy for further research aimed at the identification of combinations of (novel) antigens 
against which protective immune responses are directed.
For the induction of sterile pre-erythrocytic immunity, expression of Plasmodium 
antigens by infected hepatocytes appears important. In rodent studies, protection after RAS 
or GAP immunization can be abrogated by primaquine treatment, indicating that liver-stage 
antigen persistence is required (120, 121). Moreover, lower sporozoite immunization doses 
are sufficient to protect mice in protocols with longer liver stage development (8), and the 
superiority of CPS compared to RAS in humans might also be partially attributed to the 
increased breadth of liver stage antigens expressed during immunization. Taken together, the 
infected hepatocyte seems to be an attractive vaccine target. However, studying Plasmodium 
gene expression in liver stages is problematic because of the low efficiency and reproducibility 
of hepatocyte invasion by sporozoites in vitro. One approach to overcome this problem might 
be to isolate liver stage schizonts from uninfected hepatocytes by microdissection; laser 
capture microdissection of 1500 P. yoelii schizonts was shown to be sufficient for generating 
a cDNA liary from 1 μg of total RNA (117). An alternative option might be the use of parasites 
transfected with green fluorescent protein (GFP) allowing for FACS sorting and subsequent 
analysis of infect hepatocytes. 
Of all in vitro hepatocyte models available, sporozoite invasion is most efficient in 
fresh primary hepatocytes, but their availability is limited and irregular. Investment in 
the generation of hepatocyte cell lines, optimization of hepatocyte-cryopreservation and 
development of novel platforms are therefore important. For example, a microscale human 
liver platform has been developed that is comprised of primary human hepatocytes and 
nonparenchymal cells in which full liver stage development of P. falciparum and P. vivax was 
established (122). Furthermore, application of hypoxic conditions might result in improved 
infections in hepatocyte cell lines (123), although superior results are still achieved with fresh 
hepatocytes.
Future work will exploit the reproducibility and efficiency of CPS immunization to 
identify novel target antigens of sterile pre-erythrocytic immunity for both cellular and 
humoral immunity (clinicaltrials.gov NCT02080026). Significant efforts have been made to 
identify target antigens in RAS immunization (112, 119, 124, 125), but the presence of late 
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liver stage development and early blood-stages in CPS probably allows for expression of a 
number of additional antigens that might be important for its unprecedented efficiency. For 
T cell targets, in vitro stimulation with synthetically produced, overlapping peptides might 
reveal novel targets. Alternatively, Plasmodium proteins can be expressed in Escherichia 
coli and then (cross-) presented by monocyte-derived DCs to which autologous T cells are 
added. Measurement of responses by these T cells, such as IFNγ production or degranulation, 
can be used in order to identify proteins that are recognized by CPS-immunized protected 
subjects (126). The advantage of this latter approach is that the processing of proteins is 
included in the assay, which might thus be a good representation of the in vivo processes. 
For the discovery of novel antibody targets, B cell receptor sequencing of plasmablasts after 
CPS immunization can be performed, in order to generate monoclonal antibodies that can be 
tested for specificity on protein microarrays (127) and for functional capacity in vitro or in 
humanized mice (128).
Immune signatures of protection
We identified degranulating, CD107a positive CD4 T cells and granzyme B producing CD8 
T cells to be associated with protection after CPS immunization (chapter 7). The role of Th1 
and cytotoxic T cells in CPS immunization was further supported by the increased expression 
of T-bet in both CD4 and CD8 T cells directly after immunization (chapter 8). While these 
observations aid to advance our understanding of protective immune responses, it remains a 
challenge to identify more accurate correlates of protection. Moreover, mechanistic studies 
will be required to reveal whether and how T cells actually contribute to protection.
Protective antimalarial immune responses are constituted of the two aspects that were 
discussed above: the human host, i.e. the quality and quantity of immune responses, and the 
Plasmodium parasite, i.e. the target antigens. It is unlikely that targeting a single antigen will 
result in a fully protective immune response (129). Similarly, it will probably be necessary 
to induce a multifaceted immune response including appropriate stimulation of the innate 
immune system and induction of both cellular and humoral memory responses. In order to 
fully understand protection, and to utilize this knowledge to design more effective vaccines, 
the next step will be to comprehensively analyze both target antigens and immune responses 
in conjunction, rather than separately, in order to identify immune signatures of protection. 
Although the full breadth and diversity of the protective immune responses could not 
yet be revealed by the techniques and assays available for use in this thesis, we indeed found 
an indication supporting the immune signature hypothesis. We performed a lasso analysis on 
a panel of diverse cellular immune readouts after CPS immunization, including Th1, Th2 and 
Th17 cytokines, chemokines and cytotoxic markers. By performing this lasso analysis, we 
searched for a combination of markers, rather than a single marker, that predicted protection 
optimally. A combination of 11 makers indeed resulted in an improved area under the receiver 
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operator characteristic (ROC) curve compared to CD107a expression by CD4 T cells alone 
(0.87; 95%CI 0.73-1.0 versus 0.73; 95%CI 0.48-0.98). This supports the hypothesis that it is 
important to assess immune responses in relation to each other, as a signature of protection, 
rather than each single marker separately. 
The next step will be to analyze target antigens of protective immunity, and combine 
these data with different approaches to assess the induced immune responses. Techniques 
for the identification of target antigens were discussed above. Assessment of immune 
responses could include gene-expression data ex vivo shortly after immunization or after 
in vitro restimulation of PBMCs using microarray or RNA sequencing (130), peripheral 
blood cytokine profiles and antigen specific memory responses. Humoral responses can be 
screened using protein microarray and confirmed by ELISA and functional assays. Cellular 
responses can be assessed ex vivo (chapter 8), or by flow cytometry or ELISpot after in 
vitro restimulation with whole parasites (chapters 7 and 10) or overlapping peptide pools. 
Flow cytometry technique used in this thesis allowed for the simultaneous assessment of 
9 markers. Currently, the number of markers that can be assessed by flow cytometry using 
fluorochromes has increased to 20, and integration of mass spectrometry using rare-earth-
metal isotopes overcomes the problem of spectral overlap of fluorescent dyes, extending 
the number of makers measured simultaneously to more than 35 (131). Once crucial target 
antigens are identified, this will also enable us to investigate the kinetics and characteristics 
of antigen-specific cells by tetramer-staining (132, 133) and perform functional cellular 
experiments, such as cytotoxic assays to assess lysis of peptide pulsed autologous target cells 
by T cells (78).
Combining data from such a comprehensive analysis of the induced immune responses 
on the one hand and target antigens on the other hand will create a multidimensional data set, 
which will be the next step towards identifying early predictive markers of vaccine efficacy 
and unraveling immune mechanisms of protection. The huge quantity of data generated 
will require intelligent bio-informatics approaches. The next biggest challenge will be to 
go from observational data to actual understanding; in order to make sense of the data, and 
assess the results for their clinical and immunological relevance, it will be necessary to 
build new collaborations between clinicians, immunologists, epidemiologists, statisticians 
and bio-informaticians working closely together in multidisciplinary teams (134). If such 
collaborations can be set up effectively, and novel bio-informatics approaches can be used 
in conjunction with classical immunology and vaccinology concepts and methods, important 
steps will be made to further advance our understanding of protective immunity against 




Naturally acquired immunity versus experimentally induced protection
An alternative strategy to advance our understanding of target antigens and protective 
immune responses will be to compare naturally acquired immunity to experimentally induced 
protection. Residents of malaria-endemic areas develop immunity against Plasmodium, 
but this takes many years of repeated exposure. In areas of high and stable transmission, 
morbidity and mortality occur mainly during early childhood, while most malaria infections 
during adulthood are asymptomatic (135). This huge infectious reservoir of asymptomatic 
infected individuals is an important hurdle in elimination efforts. Sterilizing immunity, as 
induced by experimental RAS and CPS immunization, does not appear to occur in the field 
(136). 
Comparative analysis of immune responses from CPS or RAS immunized subjects 
and clinically immune individuals from endemic areas might reveal important differences 
in antigen recognition and immune mechanisms of protection. Indeed, such an analysis of 
antibody response by protein microarray showed that antibodies from semi-immune and 
CPS immunized individuals recognized 202 and 192 antigens, respectively. While CPS 
immunized subjects recognized mainly pre-erythrocytic antigens, semi-immune individuals 
reacted mainly against blood stage proteins, and only 60 antigens were recognized by both 
groups (127).
This kind of information can be used to inform choices in vaccine design: should one 
aim for sterile pre-erythrocytic protection, as obtained in whole sporozoite immunization, 
with the risk of severe disease in the absence of a blood-stage component (chapter 6, (21))? 
Or should one focus on a vaccine directed against erythrocytic stages, in order to reduce 
clinical disease, although these vaccines have shown disappointing results until now? A 
logical step might be to focus on pre-erythrocytic stage vaccines in order to prevent infection, 
and thus transmission, as much as possible, but to invest in an erythrocytic component in 
parallel to prevent problematic reductions in blood-stage immunity (21). An interesting 
alternative in this context might be a vaccine aimed to reduce tolerance rather than resistance 
to the parasite. As proof-of-principle of such an approach, mice immunized with synthetic 
glycosylphosphatidylinositol (GPI), a Plasmodium toxin, were protected against severe 
malaria and fatality (137).
Heterologous protection
In chapter 9 we show that CPS immunization can induce protection against a heterologous 
P. falciparum strain. Although protection was partial in most subjects, this could possibly be 
explained by the suboptimal immunization dose, waning immunity and/or relatively high 
stringency of the NF135.C10 heterologous challenge. Substantial heterologous protection 
can hopefully be obtained in the near future by using an optimal immunization dose 
(clinicaltrials.gov NCT02098590). One way to further optimize the CPS protocol could be 
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to raise the immunization dose, since increasing antigen exposure might be required for the 
induction of protection in the following protection scenarios: homologous < long-lasting 
homologous < heterologous < long-lasting heterologous protection. Alternatively, using a 
mix of different P. falciparum strains for immunization could improve the breadth of the 
immune response and thereby heterologous protection.
Next to the importance of heterologous protection for the use of whole sporozoite 
immunization as an implementable vaccine, the lack of heterologous protection in the 
first study (chapter 9) can also be used to gain knowledge about protective target antigens. 
Once candidate antigens are identified in the context of homologous protection by CPS, 
these can be narrowed down by assessing recognition of their heterologous equivalents and 
association with protection against heterologous challenge in cell samples from this cohort. 
It will therefore be very important to annotate the sequences of the NF135.C10 and NF166.
C8 strains, and compare sequences of candidate target antigens.
Challenge in a vial
In chapter 11 we show that healthy adult volunteers can be infected with P. falciparum malaria 
by intradermal injection of aseptic, purified, cryopreserved sporozoites (PfSPZ Challenge). 
This will enable centers worldwide to perform CHMI, while previously such trials were 
limited to centers with specialized insectaries. One limitation of our study was the absence of 
a dose that resulted in parasitemia in all subjects. Moreover, the prepatent period was longer 
than typically obtained in CHMI by mosquito bites (9). Optimization of viability, dose and 
administration route were thus required in order to improve infectivity. Following our study, 
a number of clinical trials has been performed at other sites to optimize administration of 
PfSPZ Challenge for CHMI.
Rodent studies investigated the effect of administration route on the infectivity 
of sporozoites administered by needle and syringe. While intramuscular administration 
resulted in significantly higher liver load compared to intradermal or subcutaneous injection, 
intravenous administration was even more efficient (138). Consequently, intramuscular 
administration was assessed in humans with 50% (3/6) and 100% (6/6) infection after 
injection of 2,500 and 25,000 sporozoites, respectively. In this trial, 5/6 subjects became 
infected after intradermal injection of 2,500 sporozoites with a prepatent period of 13.2 days, 
as in our study (chapter 11), demonstrating the reproducibility of PfSPZ Challenge (139). 
The prepatent period, however, was still longer than after mosquito bites. Next, intravenous 
administration of PfSPZ was assessed, resulting in 100% infection and a shorter prepatent 
period of approximately 11 days by injection of 3,200 PfSPZ (10), resembling inoculation 
by mosquito bites.
However, one should be cautious in replacing the natural inoculation route of mosquito 
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bite by intravenous administration and thereby circumventing the skin. The skin is a crucial 
organ in the immune system, and Plasmodium sporozoites are thought to modulate systemic 
immune responses through mechanisms in the skin (140). Interestingly, rodent models showed 
that bites from uninfected Anopheles mosquitoes conferred protection against P. berghei 
challenge (141). Similarly, mice exposed to bites from uninfected sand flies are protected 
against Leishmania major challenge (142, 143). The work in this thesis also indicates an 
effect of mosquito bites, independent of the parasite: control subjects that were receiving 
bites from uninfected mosquitoes while taking chloroquine prophylaxis showed increased 
proliferation and activation of mainly CD4 T cells (chapter 8). 
Since intravenous and intramuscular administration of sporozoites bypass the skin and 
lack mosquito saliva-components, there is a risk of skewing study outcomes compared to 
the natural inoculation route. It will therefore be important to perform a direct comparison 
of both challenge methods, for example after CPS immunization, to assess the effect of 
circumventing the skin stage on immune responses and protection. Furthermore, the skin is 
an interesting organ to further explore, for example with a skin blister model. In this model, 
10-15 mm suction blisters are created using a vacuum pump, separating the epidermis from 
the dermis. Analysis of cells in the blister fluid can then be used to investigate cellular 
immune responses in the skin. This model has been used to study the effect of aging on 
recall responses (144), and could now be used to assess the effect of mosquito saliva and 
sporozoites on immune responses in the skin.
Another possibility that is created by the availability of PfSPZ Challenge, is to perform 
CHMI studies in malaria-endemic areas. A first study was conducted in Tanzania in which 
11 of 12 subjects who received 10,000 sporozoites intradermally developed parasitemia. The 
prepatent period was 15.4 days, compared to 12.6 in Dutch subjects (chapter 11). Whether 
this difference could be explained by acquired immunity or innate resistance affecting either 
pre-erythrocytic or blood-stages remained unclear (145), but this shows that PfSPZ Challenge 
might be useful to assess pre-existing immunity in endemic areas (Obiero et al. submitted).
Looking at CHMIs through different eyes: interdisciplinary 
collaboration between biomedical and social sciences to improve 
clinical trial practice
CHMIs are a cornerstone in the work described in this thesis. Every type of clinical trial 
is a complex ensemble of scientific knowledge and instrumentation, of methodology and 
theory, of protocols and creativity. A clinical trial, like any scientific experiment, can thus 
be seen as a complex machinery that produces scientific knowledge. It is worth analyzing 
such machinery to better understand its functioning and then using those insights to adapt 
and improve the design and execution of clinical trials. In chapter 2 we presented CHMIs 
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as a ‘strategic research site’ for such research into the production of clinical trial knowledge 
in general, and for the role of trust and control therein in particular, because deliberately 
infecting healthy volunteers with malaria seems to require extra levels of safety—and thus 
of trust and control.
The scientific field that investigates how scientific knowledge is constructed is called 
“Science, Technology and Society studies” or “Science & Technology Studies” (STS) (146, 
147). Much of this research uses qualitative methods, such as historical methods to investigate 
the origins of western scientific knowledge (148, 149), anthropological methods to study the 
practices in laboratories (150, 151), and sociological methods to investigate the development 
of scientific controversies (152, 153). In our study of the CHMI machinery, we used 
participant-observatory methods from the anthropology of science. Social-science research 
not only implies specific methodologies of data production and analysis, but also requires a 
different style of scholarly writing than is used in the natural sciences—the researcher-author 
needs to be more visible in the text (154, 155), resulting in the use of active rather than 
passive phrases and the use of ‘I’ rather than ‘we’.2 To signal this shift in style of research 
from natural science to anthropology of science, from discussing the results obtained with 
CHMIs to discussing the practice of doing CHMIs, the last part of this concluding chapter 
will be written in a social-science style that makes me more visible as author-researcher. 
Doing a PhD means being trained to focus and specialize. This happens by immersion 
of the PhD student in research on a specific topic, and by socialization into a limited scientific 
community. Historians, philosophers and sociologists of science have argued that this could 
not be otherwise: only through many years of socialization will researchers learn the required 
spectrum of knowledge, skills, methods, instrumentation and literature (151, 152, 157). 
Under normal circumstances, this process results in a PhD student getting more and more 
versed in the paradigm (Kuhn’s term) of that particular scientific specialty, during a process 
that is so gradual that many things are learnt without the student even noticing, and indeed 
forgetting what the world looked like before entering the field. Hence we call that knowledge 
‘tacit’, since it is not explicated, not spoken about, not written down. It often is only when 
one meets an ‘outsider’, who is surprised by what the ‘insider’ finds self-evident and normal, 
that the ‘insider’ also realizes how much has been learnt during the socialization process that 
the PhD training is. For example, I was confronted with surprise and incomprehension from 
outsiders—including other biomedical scientists—when I mentioned that I infected healthy 
volunteers with malaria in my research. That made me realize: it is indeed quite remarkable 
what we are doing, how is it possible, what makes the CHMI machinery work?
2 Sometimes natural scientists erroneously interpret this stylistic difference as an indication that 
social-science knowledge is less ‘scientific’ and ‘objective’ than natural-science knowledge. However, 
social-science research makes the same objectivity claim as natural-science research does: its findings 
will be replicated if another anthropologist would do the same research again (156)
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I realized that there was more to answering this question than the regular “well, we 
have figured out a way to do this”. I was still enough of an outsider to recognize some 
of the surprise about what is going on in a CHMI trial; but also enough of an insider to 
recognize that much of the answer is implicit in the clinical and laboratory practices, and 
nowhere spelled out explicitly—it is, indeed, ‘tacit knowledge’. Would it be possible to use 
my still ambiguous status of half-socialized in/outsider to reflect on these questions? Could 
I take a step back—or rather: step outside my socialization process—and reflect on my own 
research practices and explicate the various types of tacit knowledge, in order to learn about 
the broader issues of carrying out clinical trial research and the construction of scientific 
knowledge? 
And that is what I started out to do in the research that resulted in chapter 2 of this thesis. 
Scientific knowledge does not exist only in articles, books and protocols. Rather, knowledge 
is produced, carried and sustained by people. Chapter 2 of this thesis maps all who make 
the CHMI trials possible: the sponsors, PIs, clinical investigators, but also the nurses, the 
technicians, the thick smear readers and the experts in parasite culture and mosquito breeding. 
The complex sociotechnical machinery of the trial runs on their knowledge, expertise and 
engagement. To describe and analyze their work and tacit knowledge thus also testifies of 
the crucial role they play in carrying out CHMIs—a nice addition to thanking them in the 
acknowledgment section of this thesis. 
Understanding the role of the tacit knowledge that people use while doing research has 
been one result from STS research. Indeed this is so well established a finding, that it needs 
no further research or publications. Therefore, however insightful the explication of tacit 
knowledge was for myself as a medical PhD student, this research would not yield results 
that merit a publication in an STS journal. So, why do this STS research on CHMIs, present 
our findings at STS conferences, and submit it to an STS journal?
CHMI trials are, we have argued, a particularly strategic research site to study the 
role of trust and control in the construction of scientific knowledge. This is, as we have 
reviewed in chapter 2 of this thesis, a generally recognized but still under-researched insight 
in STS. For the sociotechnical machinery of the CHMI to work, we found that well-balanced 
combinations of control and trust need to be in place. In fact, we argue that it is tandems 
of trust and control that make the trials work. This analysis helps us to better understand 
why CHMI trials can be carried out successfully and how they produce valuable scientific 
knowledge. Moreover, we believe that our analysis can help to improve clinical trial research 
practices. 
Here, I would like to briefly reflect on two issues that arose from this chapter. First, I 
will make a plea for interdisciplinary collaboration, of which many chapters in this thesis are 
examples, albeit in very different forms. Next, I will discuss some ways in which the insights 




Science is becoming increasingly interdisciplinary and I strongly believe that this is vital 
for the development of innovative concepts and ideas. In interdisciplinary collaboration 
constructs, ideas, viewpoints and methodologies are shared across fields. In this way, 
medical doctors like me can learn about protective immune responses against malaria from 
immunologists (chapters 7 and 8), use methodologies developed by fruit fly biologists to 
study tolerance (chapter 12) and assess big data together with bioinformaticians (this chapter). 
With each partner bringing knowledge and experience from their own domain, insights can 
be mutually inspiring and further developed. Also the collaboration between myself as a 
medical researcher and my father as an STS scholar was fruitful for both sides. For me, it 
helped to look at my own research practice and find ways to improve this; for him, it was an 
opportunity to study in more detail the role that trust and control play in the construction of 
scientific knowledge: a question that has been on the STS agenda for a long time, but could 
now be studied in this ‘strategic research site’.
In the early years of STS, during the 1970’s and 1980’s, research was mainly about 
asking fundamental questions about the production of scientific knowledge and the role 
of knowledge in society. Questions about implications for practice, policy or politics were 
hardly raised. Although some argue that STS has “always been intervening in one way or 
another - by offering different perspectives, by taking part in discussions, or merely by being 
at the sites” (158), it is only since about a decade that frequent calls for a more engaged and 
interventionist STS can be heard (159, 160). In order to increase STS’ impact on the practices 
of the research it studies, new collaborative relationships between STS-scholars and scientists 
need to be built (161). Or in Zuiderent-Jerak’s words: it is needed to “experiment with the 
co-construction of (medical) work practices (…) and critical STS” (162). My collaboration 
as a medical researcher with an STS scholar, which led to the first chapter of this thesis, is an 
example of such an experiment. 
For a constructive discussion on interventionist STS, it is important to explicate “what 
STS researchers will bring to the table, how their contributions will enter joint processes of 
development, and what results will emerge” (158). In our case, we presented and discussed 
the STS work described in this thesis during a work-in-progress meeting of the Radboudumc 
malaria research group. We presented and used some concepts from STS — such as tacit 
knowledge, social construction and interpretative flexibility — to analyze the practices of 
our CHMI research. These concepts are not part of the standard training of medical PhD 
students, nor of lab technicians and nurses. While senior researchers in the group implicitly 
knew from their experience what these concepts tried to capture and describe, researchers at 
the beginning of their career found it illuminating and helpful to look into the STS mirror 
that we were holding up to them. It helped to critically review the research practices of the 
group. For example, it explicated why protocols are not sufficient to transfer knowledge 
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about how to execute a procedure. This is something that everyone knew from experience, 
but often it was thought to be a ‘failure’ to properly execute the protocol. With the help 
of STS concepts, it now could be understood as an effect of not enough socialization, not 
valuing tacit knowledge, and not recognizing interpretative flexibility. For me personally, the 
collaboration with a senior STS researcher made me aware of the huge disciplinary differences 
between medical sciences and humanities and social science — in problem definition, data 
analysis, explanatory strategies, writing, publication, and even footnoting. I do not think it 
has made me a lesser medical researcher, though there is some risk in tampering with one’s 
process of socialization. Looking at our CHMI practice from an STS perspective, for a while, 
has made me see some of its accomplishments and strengths in a clearer light — and this 
perhaps even made me a better medical researcher. 
What, then, has STS brought to the table? First, it is a set of concepts to better describe 
and understand our scientific practice. Using those concepts is like looking into a mirror: we 
see who we are and what we do, but in a slightly different guise. No mirror is neutral and 
innocent, nor is the STS mirror — it will highlight certain aspects of our scientific practice 
more than others (163). Second, STS will also offer an engagement with our research practice 
that possibly will lead to changes in that practice, perhaps some adaptations in protocols or 
changes in the set-up of CHMIs. The next section will discuss one possible example: how 
reconsidering the role of trust and control in clinical trials was helpful to improve our clinical 
trial practices.
Using the analysis of tandems of trust and control to improve research practices
A suggestion that was raised in the chapter but we did not further elaborate on, was to perform 
a ‘sensitivity analysis’ of trust and control in clinical trials — an idea that in fact came up 
during the meeting with the Radboudumc malaria group. Although we will not use traditional 
methodologies of performing such an analysis, we believe it could be useful to attempt this as 
a thought experiment to improve research practices: what are the optimal location and degree 
of both trust and control in a specific situation? What is the effect of increasing or reducing 
either of them? I will try this, using the example of an independent audit of the malaria unit 
that was performed in spring 2014. An audit typically is a systematic evaluation of processes 
and records involved in a production line, in this case of infectious mosquitoes for CHMI. 
During this audit, it became clear that it was indeed useful to be conscious of the location and 
degrees of control and trust. 
In any laboratory there is a lot of equipment, and it is important that this is controlled, 
i.e. calibrated and monitored. Let me take the example of freezers, in which samples and 
reagents are kept. In order to assure the quality of materials that are stored, it is important that 
freezer temperature is maintained within a pre-determined range around -80°C. One possible 
way to control the freezers is a monitoring system that can set off an alarm if the temperature 
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is out of range. This would allow the responsible person to take necessary action, for example 
move the content of the freezer to another freezer and call for technical assistance to repair 
the mal-functioning one. When we prepared for the audit of our malaria unit, not all freezers 
had such a monitoring system installed: we now had to choose whether to buy such a system, 
and decide on the degree of control we wanted to implement. 
However, it is nowhere prescribed how freezers for this particular use should be 
monitored, nor is it self-evident what the right degree of control would be. The strictest form 
of control would be to install a constant monitoring system on all freezers with automated 
alarm to be set off as soon as the temperature gets out of a narrow predetermined range. At the 
other extreme, an option would be to only measure the temperature manually, do that weekly, 
and do it only in the most crucial freezers. While in the second example the technology of 
the freezers is trusted almost completely, in the first example trust has been shifted to the 
monitoring system. The obvious disadvantage of the second, very permissive option is, that 
if the temperature of the freezer goes temporarily out of range (between two measurements), 
it might compromise the frozen materials without anyone being aware. The risk of the first, 
very strict option, however, is that one relies exclusively on the monitoring and alarm system, 
which itself is a technology with the potential to fail. Moreover, the setting of a narrow range 
might set the alarm off very frequently, annoying the personnel in charge, and eventually 
stopping them from adequately responding to the alarm. 
Therefore, it would probably be useful to consider other options somewhere midway 
in the control- and trust spectra. For example, one could decide to expand the temperature 
range beyond which the alarm would go off; one could choose not to monitor all freezers 
but only the ones that were crucial for the clinical trial processes; or one could consider 
installing a monitoring system without an alarm. In the latter option, the temperature course 
can be checked retrospectively by expert personnel, to assess whether the temperature has 
been out of range and whether materials may have been compromised. To make this choice 
of a midway option, it is crucial to what extent one relies on and trusts the expert judgment 
of the personnel that works with the freezer. They have to decide on the control measures, 
as they have the experience and (often tacit) knowledge to assess when the temperature of 
which fridge is crucial. It was interesting to see that the experienced auditor, in contrast to 
what some of us had expected, also recognized this. Instead of going to the extreme control 
side of the spectrum and obliging us to install continuous and strict monitoring on all fridges, 
the audit report took a midway position: “The necessity to implement a daily recording of the 
temperatures of the fridges should be assessed.” 
This example shows that it is useful to be conscious of and explicit about possible 
locations and degrees of control, where to invest in trust and the importance of trust for 
exercising control. More control is not always better, and trust in the technicians’ expertise 
is required to find an optimal solution. The alternative of insisting on control by outsiders 
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or technical monitoring systems may be more risky than trusting your own technicians. In 
other words, the outcome of this thought experiment in sensitivity analysis of the freezer 
monitoring, may be to invest in trust in the technicians’ expertise about control measurements, 
and thereby in fact using trust to make control work. 
Conclusions and future perspectives
The work in this thesis contributes to the unraveling of protective immune responses against 
malaria. We show that sterile protection can be established by pre-erythrocytic immune 
responses, and find indications that cytotoxic T cells are important herein. Moreover, we 
find that CPS immunization can be performed with different antimalarial drugs and that CPS 
can induce heterologous protection. These studies have established CPS as a pivotal model 
to delineate protective immune responses, and the possibility to replace mosquito bites with 
injection by needle and syringe for sporozoite inoculation opens avenues to further develop 
whole sporozoite vaccines. The findings from this thesis will be important to focus future 
research on the identification of pre-erythrocytic target antigens and immune signatures 
of protection, in which interdisciplinary collaboration-platforms will play a central role. 
Together, these research lines will be instrumental in the development of an effective vaccine, 
which will be a crucial tool to combat malaria.
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Malaria is an important infectious disease with more than 3 billion people at risk, resulting 
in more than  200 million clinical cases and almost 600,000 deaths annually. The disease 
is caused by Plasmodium parasites and transmitted by bites from Anopheline mosquitoes. 
Implementation of effective interventions such as insecticide-treated bed nets, indoor 
insecticide spraying and targeted diagnosis and treatment with artemisinin-based combination 
therapy has led to a significant decrease in the burden of malaria in the past decades. However, 
these interventions are threatened by emerging drug resistance of parasites and resistance 
of mosquitoes to insecticides. Therefore, novel strategies are needed to effectively control 
malaria. A potent vaccine would be a crucial component of such a strategy, and understanding 
protective immune responses will be of great help to design and develop such a vaccine.
In this thesis we use models in healthy volunteers to investigate protective immunity 
against P. falciparum malaria. In Controlled Human Malaria Infections (CHMIs), healthy 
subjects are infected with malaria, either through bites from mosquitoes infected with P. 
falciparum sporozoites, or by venous inoculation of blood-stage forms of the parasite. In the 
chemoprophylaxis and sporozoites (CPS) immunization model, volunteers are exposed to 
live sporozoites while receiving chloroquine prophylaxis. The CPS immunization regime has 
previously been shown to induce very high levels of protection against challenge infection 
in a controlled setting. We use these models to advance our understanding of anti-malarial 
immunity induced by whole sporozoite immunization and thereby aim to augment clinical 
development.
The thesis starts with an interdisciplinary study, using the heuristics from Science 
Technology and Society studies (STS), to investigate the social construction of scientific 
knowledge in CHMI trials (chapter 2). Specifically, we argue that tandems of trust and control 
play a central role in the successful execution of CHMI trials and scientific experiments in 
general. We especially elaborate on the distinction between trust in and control of persons, 
machines, and institutions and argue that links between these different domains are crucial 
for the safe and effective execution of clinical trials. We also argue that trust and control are 
not just alternatives, which substitute for each other when one does not suffice, but that they 
actually work in conjunction and coproduce each other, to make scientific research work.
In the review in chapter 3 we raise the hypothesis that chloroquine might be important 
for the efficient induction of immunity by CPS immunization through its known immune 
modulating capacities. In chapter 4 we use the rodent malaria parasite P. berghei to 
investigate this hypothesis, but do not find supportive evidence in this model. In chapter 
5, we explore the option of translating chemoprophylaxis and parasite exposure into a field 
intervention with the aim of inducing protective immune responses. We propose that this 
could be evaluated in an area with a short but intensive transmission season, allowing for 
high exposure to pre-erythrocytic antigens while blood-stage infections are controlled by the 
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drug, and the possibility to evaluate induced protection in the next season. 
Next, we use the CPS model to address two important questions in malaria immunity. 
We first investigate, in chapter 6, towards which stages of the parasite lifecycle the protective 
immune responses are directed. The clinical trial described in this chapter shows that CPS-
immunized subjects are not protected against a challenge with blood-stage parasites. Thus, 
CPS-induced protection is, at least primarily, mediated by immune responses against the 
pre-erythrocytic (sporozoite and liver) stages. We do, however, find evidence that immune 
recognition of blood-stages does occur after CPS immunization, although apparently not 
sufficient to protect against these parasite densities. 
The second question is which immune responses are induced and whether these are 
associated with protection. Both cellular responses and antibodies appear to play a role in 
protection induced by live sporozoite based immunization; in this thesis we focused on cellular 
immune responses. In chapter 7 we perform a dose de-escalation CPS trial, generating a 
differentially protected cohort: protection is dose-dependently induced, with almost 100% 
protection when immunized with bites from three times 15 mosquitoes, reducing to 50% 
protection when immunized with bites from three times five mosquitoes. This study design 
allows us to investigate immune correlates of protection. In vitro restimulation experiments 
reveal two cell types that are associated with protection: CD4 T cells expressing the 
degranulation marker CD107a and CD8 T cells producing granzyme B. In chapter 8 we 
conduct an alternative analysis of CPS-induced immune responses by ex vivo lymphocyte 
phenotyping during immunization. These experiments indicate a role for Th1 responses and 
cytotoxic T cells in CPS-induced immunity, which is in line with the results from chapter 7.
All CPS studies up until now have been performed with the same (homologous) 
NF54 strain for both immunization and challenge. It is, however, of critical importance to 
show protection against heterologous strains, given the huge diversity of strains in the field. 
Chapter 9 describes a clinical trial in which NF54 CPS-immunized and challenged subjects 
were re-challenged with a different strain (NF135.C10). Although less efficient, NF54-
induced CPS immunity also protects against NF135.C10 when tested after a period of more 
than a year. In chapter 10 we show that CPS immunization in humans does not specifically 
depend on the choice of chloroquine for prophylaxis, as CPS with mefloquine is equally safe 
and protective. In addition, induced cellular and humoral immune responses do not differ 
significantly between both drug groups.
For clinical development of whole sporozoite based vaccines, it is obviously necessary 
to replace sporozoite inoculation through mosquito bites by needle and syringe. We show in 
chapter 11 that CHMI can be performed by intradermal injection of aseptic, purified, vialed 
and cryopreserved P. falciparum sporozoites. These results will facilitate application of 
CHMI and accelerate malaria vaccine development, including whole sporozoite approaches.
Finally, in chapter 12, we use the CHMI model for an alternative application by 
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exploring a novel framework derived from population biology. Our objective is to investigate 
tolerance against malaria by using so called “disease maps” to describe the relationship 
between the level of parasitemia and severity of disease. Visualization of the course of 
infection in disease space enables us to distinguish different levels of tolerance against P. 
falciparum malaria. The presented data illustrate the potential of this framework for rational 
monitoring and treatment of malaria on an individual basis. 
In conclusion, this thesis sheds light on several aspects of protective immunity induced 
by whole sporozoite immunization: i) pre-erythrocytic stages as the target of immunity, ii) 
the dose-response relationship between immunization dose and protection, iii) the generation 
of heterologous protection, iv) the induction of cellular immune responses, v) the option to 
use different drugs for CPS and vi) the possibility to use cryopreserved sporozoites instead of 
bites by infected mosquitoes. We hereby aim to set an agenda for future work on the clinical 
development of whole sporozoite vaccines. This will be supported by the reproducibility 
and efficiency of CPS immunization and will include identification of novel target antigens 
and delineation of mechanisms of sterile pre-erythrocytic immunity. Rather than single 
immunological markers or parasitic antigens, we expect the focus of such studies to be on 
identifying immune signatures of protection. Altogether, CHMI and CPS immunization have 
proven to be highly valuable models in malaria vaccine research, and will likely continue to 




Malaria is een belangrijke infectieziekte waaraan meer dan 3 miljard mensen worden 
blootgesteld, met meer dan 200 miljoen ziektegevallen en bijna 600.000 doden per jaar. 
De ziekte wordt veroorzaakt door Plasmodium parasieten die worden overgebracht 
door vrouwelijke Anopheles muggen. Implementatie van effectieve maatregelen zoals 
geïmpregneerde klamboes, het binnenshuis spuiten van insecticiden en gerichte diagnostiek 
en behandeling met artemisinine-combinatie therapie, heeft geleid tot een afname in het 
aantal malariagevallen in de afgelopen jaren. Deze interventies worden echter bedreigd door 
de opkomst van resistentie van parasieten en muggen. Nieuwe strategieën zijn dus nodig 
om malaria te bestrijden, en een effectief vaccin zou een belangrijk onderdeel zijn van een 
dergelijke strategie. Goed begrip van de beschermende afweerreacties is cruciaal om een 
vaccin te ontwerpen en ontwikkelen.
In dit proefschrift gebruiken wij modellen met gezonde vrijwilligers om beschermende 
immuniteit tegen P. falciparum malaria te onderzoeken. In gecontroleerde humane malaria 
infecties (CHMIs) worden gezonde vrijwilligers geïnfecteerd met malaria door hen bloot 
te stellen aan beten van geïnfecteerde muggen, of door intraveneuze toediening van 
bloedstadium parasieten. In het chemoprofylaxe en sporozoïten (CPS) immunisatie model 
worden vrijwilligers blootgesteld aan sporozoïten terwijl ze chloroquine profylaxe nemen. 
CPS immunisatie is zeer effectief gebleken in het opwekken van bescherming tegen een 
malaria infectie onder gecontroleerde omstandigheden. Wij gebruiken deze modellen om ons 
begrip van immuniteit tegen malaria te vergroten en op deze manier klinische ontwikkeling 
van sporozoïten-vaccins te bevorderen.
Dit proefschrift begint met een interdisciplinaire studie waarin we gebruik maken van 
de methodologie en het gedachtegoed van Wetenschap en Technologie studies om de sociale 
constructie van wetenschappelijke kennis in CHMI studies te onderzoeken (hoofdstuk 2). 
We betogen dat tandems van vertrouwen en controle een cruciale rol spelen in de succesvolle 
uitvoering van CHMI studies en wetenschappelijke experimenten in het algemeen. We 
maken onderscheid tussen vertrouwen in en controle van personen, machines en instellingen 
en betogen dat verbindingen tussen deze verschillende domeinen cruciaal zijn voor de veilige 
en effectieve uitvoering van klinische studies. We betogen ook dat vertrouwen en controle 
niet simpele alternatieven zijn die elkaar vervangen als een van beide niet voldoet, maar dat 
ze samen werken en elkaar coproduceren, om wetenschappelijk werk succesvol te laten zijn.
In de literatuurbespreking in hoofdstuk 3 opperen we de hypothese dat chloroquine op 
basis van haar immuun-modulerende eigenschappen belangrijk is voor de efficiënte wijze 
waarop immuniteit door CPS immunisatie wordt opgewekt. In hoofdstuk 4 gebruiken we 
de muizen-malariaparasiet P. berghei om deze hypothese te onderzoeken, maar vinden geen 
bewijs hiervoor in dit model. In hoofdstuk 5 verkennen we de mogelijkheid om CPS te 
vertalen naar een interventie voor endemische gebieden, met als doel het opwekken van een 
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beschermende immuunreactie. We stellen voor om dit te onderzoeken in een gebied waar 
sprake is van een kort maar intensief transmissie-seizoen. Op deze manier vindt blootstelling 
aan een relatieve hoge dosis pre-erytrocytaire antigenen plaats, terwijl bloedstadium infecties 
worden gecontroleerd met hulp van de medicatie, en is er de mogelijkheid om in een 
opeenvolgend seizoen de opgewekte bescherming te evalueren.
Vervolgens gebruiken we het CPS model om twee belangrijke vragen te beantwoorden 
over malaria immuniteit. Ten eerste onderzoeken we, in hoofdstuk 6, tegen welke stadia van 
de parasiet-levenscyclus de beschermende immuunrespons is gericht. De klinische studie 
in dit hoofdstuk laat zien dat CPS-geïmmuniseerde personen niet beschermd zijn tegen een 
infectie met bloedstadium parasieten. Bescherming door CPS is dus primair gebaseerd op 
een afweerreactie tegen pre-erytrocytaire stadia (sporozoïten en leverstadia). We vinden 
wel aanwijzingen voor herkenning van bloedstadium parasieten door het immuunsysteem, 
maar dit is dus niet voldoende om een beschermend effect te bewerkstelligen bij de lage 
parasietenconcentraties waarvan in het CHMI model sprake is.
De tweede vraag is welke immuunresponsen worden opgewekt, en of deze geassocieerd 
zijn met bescherming. Zowel cellulaire immuniteit als antistoffen lijken een rol te spelen in 
bescherming; in dit proefschrift concentreren we ons op de cellulaire responsen. In hoofdstuk 
7 beschrijven we een dosis de-escalatie CPS studie, waarin een gedifferentieerd cohort is 
gecreëerd, met bijna 100% bescherming na immunisatie met beten van driemaal 15 muggen, 
afnemend tot 50% bescherming na immunisatie met beten van driemaal vijf muggen. Deze 
studie stelt ons in de gelegenheid om op zoek te gaan naar cellulaire immuunresponsen 
die geassocieerd zijn met bescherming. Uit in vitro restimulatie experimenten komen twee 
celtypes naar voren die geassocieerd blijken te zijn met bescherming: CD4 T cellen die 
CD107a tot expressie brengen (een teken van degranulatie) en CD8 T cellen die granzyme 
B produceren. In hoofdstuk 8 hebben we een alternatieve analyse van immuunresponsen 
uitgevoerd door middel van ex vivo fenotypering van lymfocyten tijdens CPS immunisatie. 
Deze experimenten wijzen op een rol voor Th1 responsen en cytotoxische T cellen, in lijn 
met de resultaten van hoofdstuk 7.
Tot op heden zijn alle CPS studies uitgevoerd met dezelfde (homologe) NF54 stam 
voor zowel immunisatie als challenge infectie. Het is echter van cruciaal belang dat ook 
bescherming tegen een heterologe stam wordt aangetoond, gezien de enorme variatie tussen 
stammen in endemische gebieden. Hoofdstuk 9 beschrijft een klinische studie waarin 
vrijwilligers die CPS immunisatie en een challenge infectie met NF54 hebben ondergaan, 
worden blootgesteld aan een challenge met de heterologe stam NF135.C10. Uit deze studie 
blijkt dat CPS immunisatie ook bescherming opwekt tegen een heterologe stam, alhoewel 
minder effectief dan homoloog. In hoofdstuk 10 tonen we aan dat de werking van CPS 
immunisatie in mensen niet afhankelijk is van de keuze voor chloroquine als profylaxe: 
CPS immunisatie met mefloquine blijkt even veilig en effectief te zijn. Bovendien zijn ook 
301
Samenvatting
cellulaire en humorale immuunresponsen niet verschillend tussen beide groepen.
Voor de klinische ontwikkeling van sporozoïten-vaccins is het natuurlijk noodzakelijk 
dat het toedienen van sporozoïten door middel van muggenbeten wordt vervangen door een 
injectie met spuit en naald. We laten in hoofdstuk 11 zien dat dit mogelijk is: we voeren 
CHMIs uit door intradermale injectie van aseptische, gezuiverde en bevroren P. falciparum 
sporozoïten. Deze resultaten zullen wereldwijde toepassing van CHMI faciliteren en de 
ontwikkeling van malaria vaccins, inclusief sporozoïten-vaccins, versnellen.
Tot slot gebruiken we in hoofdstuk 12 het CHMI model voor een alternatieve toepassing 
door een nieuw raamwerk, afgeleid van de populatie biologie, te onderzoeken. Ons doel is om 
tolerantie tegen malaria te onderzoeken door de relatie tussen de hoogte van de parasitemie 
en de ernst van de ziekte te beschrijven in zogenaamde “disease maps”. Visualisatie van het 
beloop van de infectie in “disease space” maakt het mogelijk om verschillende niveaus van 
tolerantie tegen P. falciparum te onderscheiden. Deze data illustreren het potentieel van dit 
raamwerk voor rationele monitoring en behandeling van malaria op een individuele basis.
Concluderend werpt dit proefschrift licht op een aantal aspecten van immuniteit tegen 
malaria, opgewekt door immunisatie met sporozoïten: i) de pre-erytrocytaire stadia als 
aangrijpingspunt voor immuunresponsen, ii) de dosis-respons relatie tussen immunisatie 
dosis en bescherming, iii) het opwekken van heterologe bescherming, iv) de opgewekte 
cellulaire responsen, v) de mogelijkheid om andere medicatie voor CPS te gebruiken en vi) 
de mogelijkheid om bevroren parasieten te gebruiken in plaats van beten van geïnfecteerde 
muggen. Hiermee hopen wij bij te dragen aan het ontwikkelingsproces van sporozoïten-
vaccins, waarin CPS immunisatie gezien de reproduceerbaarheid en efficiëntie een 
belangrijke rol zal kunnen spelen. Toekomstige studies zullen onder andere gericht zijn op het 
identificeren van nieuwe antigenen en het uitpluizen van de immunologische mechanismen 
van pre-erytrocytaire bescherming. In plaats van een enkele marker, zullen deze studies zich 
waarschijnlijk richten op het identificeren van een “immunologische handtekening” voor 
bescherming. CHMI en CPS immunisatie hebben bewezen zeer waardevolle modellen te zijn 
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door de pathofysiologie, de grote impact van de ziekte wereldwijd en de complexe 
immunologie. Als snel bleken ook de mensen waarmee ik ging werken een grote inspiratiebron. 
Ik wil daarom de gelegenheid benutten om iedereen hiervoor van harte te bedanken. 
 
Robert, ik ben je ontzettend dankbaar voor de vele kansen die je mij geboden hebt. Niet 
alleen de verschillende trials en experimenten, maar ook alle presentaties op (inter)nationale 
congressen en de subsidieaanvragen die we samen hebben geschreven, hebben mij gevormd 
tot de wetenschapper die ik nu ben. Iemand aannemen die in haar CV de track changes nog 
heeft staan, getuigt van veel vertrouwen, en dat positieve gevoel heb ik gedurende mijn hele 
promotietraject ervaren. 
Leo, ik vind het altijd geweldig om met jou over de opzet of resultaten van experimenten 
te brainstormen. We hebben samen een aantal hele mooie trials neergezet, en ik ben verheugd 
en trots dat je mijn promotor bent. Anja, ik vond het heel fijn om met je samen te werken, 
jouw oog voor detail was van groot belang voor onze gezamenlijke projecten. De vele en 
lange trips naar Leiden lijken al weer een eeuwigheid geleden, maar ik koester de herinnering 
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jullie huis met schuifpui…
Anne, jij bent voor mij hét voorbeeld van het ideale teamlid. De manier waarop jij 
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onvolprezen hoogtepunt. Guido, achterneef! Door jouw aanstekelijke positiviteit was het 
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het CRCN. Krystelle, jij hebt mij wegwijs gemaakt in het doen van muizenstudies en in 
de cellulaire immunologie, dank je wel! Remko, bedankt voor de samenwerking en je 
onmisbare hulp bij de klinische studies in Leiden. Ik bewonder je inzet en je goede zorg voor 
de vrijwilligers. 
Jorien, malaria-mama, bedankt voor je cruciale bijdrage aan de studies. Zowel in de 
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to see where you’re going in the future. Although you have a different focus than our clinical/
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